2862 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp00028 | Enkephalins7 analogue-8 | YA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 14.2% inhibition at 10-6 M |
| dbacp00029 | Enkephalins7 analogue-8 | YA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 19.7% inhibition at 10-5 M |
| dbacp00030 | Enkephalins7 analogue-8 | YA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 24.9% inhibition at 10-4 M |
| dbacp00031 | Enkephalins7 analogue-8 | YA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 30.4% inhibition at 10-3 M |
| dbacp00032 | Enkephalins7 analogue-8 | YA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HeLa | Cervical cancer | 10% inhibition at 10-5 M |
| dbacp00033 | Enkephalins7 analogue-8 | YA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HeLa | Cervical cancer | 8.2% inhibition at 10-4 M |
| dbacp00034 | Enkephalins7 analogue-8 | YA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HeLa | Cervical cancer | 36.1% inhibition at 10-3 M |
| dbacp00035 | Enkephalins7 analogue-8 | YA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HBL | Skin cancer | 6.5% inhibition at 10-6 M |
| dbacp00036 | Enkephalins7 analogue-8 | YA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HBL | Skin cancer | 14% inhibition at 10-5 M |
| dbacp00037 | Enkephalins7 analogue-8 | YA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HBL | Skin cancer | 7.5% inhibition at 10-4 M |
| dbacp00038 | Enkephalins7 analogue-8 | YA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HBL | Skin cancer | 14% inhibition at 10-3 M |
| dbacp00039 | Enkephalins7 analogue-8 | YA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HT-29 | Colon cancer | 9.8% inhibition at 10-6 M |
| dbacp00040 | Enkephalins7 analogue-8 | YA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HT-29 | Colon cancer | 1.6% inhibition at 10-5 M |
| dbacp00041 | Enkephalins7 analogue-8 | YA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HT-29 | Colon cancer | 5.4% inhibition at 10-4 M |
| dbacp00042 | Enkephalins7 analogue-8 | YA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HT-29 | Colon cancer | 26.5% inhibition at 10-3 M |
| dbacp00043 | Enkephalins7 analogue-8 | YA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 12.9% inhibition at 10-6 M |
| dbacp00044 | Enkephalins7 analogue-8 | YA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 16.5% inhibition at 10-5 M |
| dbacp00045 | Enkephalins7 analogue-8 | YA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 28.1% inhibition at 10-4 M |
| dbacp00046 | Enkephalins7 analogue-8 | YA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 58.2% inhibition at 10-3 M |
| dbacp00047 | Enkephalins7 analogue-8 | YA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | CaCo-2 | Colon cancer | 3.5% inhibition at 10-6 M |
| dbacp00048 | Enkephalins7 analogue-8 | YA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | CaCo-2 | Colon cancer | 22.7% inhibition at 10-5 M |
| dbacp00049 | Enkephalins7 analogue-8 | YA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | CaCo-2 | Colon cancer | 18.9% inhibition at 10-4 M |
| dbacp00050 | Enkephalins7 analogue-8 | YA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | CaCo-2 | Colon cancer | 26.4% inhibition at 10-3 M |
| dbacp00051 | Enkephalins7 analogue-8 | YA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | 2.4% inhibition at 10-5 M |
| dbacp00052 | Enkephalins7 analogue-8 | YA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | 7.5% inhibition at 10-4 M |
| dbacp00053 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 6.2% inhibition at 10-6 M |
| dbacp00054 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 6.4% inhibition at 10-5 M |
| dbacp00055 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 8.2% inhibition at 10-4 M |
| dbacp00056 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 21.2% inhibition at 10-3 M |
| dbacp00057 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HeLa | Cervical cancer | 7.5% inhibition at 10-6 M |
| dbacp00058 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HeLa | Cervical cancer | 6.1% inhibition at 10-5 M |
| dbacp00059 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HeLa | Cervical cancer | 3.1% inhibition at 10-4 M |
| dbacp00060 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HeLa | Cervical cancer | 14.8% inhibition at 10-3 M |
| dbacp00061 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HBL | Skin cancer | 3.9% inhibition at 10-5 M |
| dbacp00062 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HBL | Skin cancer | 7.3% inhibition at 10-3 M |
| dbacp00063 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HT-29 | Colon cancer | 4.9% inhibition at 10-6 M |
| dbacp00064 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HT-29 | Colon cancer | 8.9% inhibition at 10-5 M |
| dbacp00065 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HT-29 | Colon cancer | 3.4% inhibition at 10-4 M |
| dbacp00066 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HT-29 | Colon cancer | 20.8% inhibition at 10-3 M |
| dbacp00067 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 10.5% inhibition at 10-6 M |
| dbacp00068 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 21.9% inhibition at 10-5 M |
| dbacp00069 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 11.8% inhibition at 10-4 M |
| dbacp00070 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 17.9% inhibition at 10-3 M |
| dbacp00071 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | CaCo-2 | Colon cancer | 3.7% inhibition at 10-6 M |
| dbacp00072 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | CaCo-2 | Colon cancer | 16.5% inhibition at 10-5 M |
| dbacp00073 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | CaCo-2 | Colon cancer | 8.4% inhibition at 10-4 M |
| dbacp00074 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | CaCo-2 | Colon cancer | 14.5% inhibition at 10-3 M |
| dbacp00075 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | 1.1% inhibition at 10-5 M |
| dbacp00076 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | 1.2% inhibition at 10-4 M |
| dbacp00077 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | 17.8% inhibition at 10-3 M |
| dbacp00078 | Enkephalins7 analogue-10 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 8.5% inhibition at 10-6 M |
| dbacp00079 | Enkephalins7 analogue-10 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 4.9% inhibition at 10-5 M |
| dbacp00080 | Enkephalins7 analogue-10 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 1.9% inhibition at 10-4 M |
| dbacp00081 | Enkephalins7 analogue-10 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 16.2% inhibition at 10-3 M |
| dbacp00082 | Enkephalins7 analogue-10 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HeLa | Cervical cancer | 7.2% inhibition at 10-6 M |
| dbacp00083 | Enkephalins7 analogue-10 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HeLa | Cervical cancer | 17.1% inhibition at 10-5 M |
| dbacp00084 | Enkephalins7 analogue-10 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HeLa | Cervical cancer | 11.0% inhibition at 10-4 M |
| dbacp00085 | Enkephalins7 analogue-10 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HeLa | Cervical cancer | 20.5% inhibition at 10-3 M |
| dbacp00086 | Enkephalins7 analogue-10 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HBL | Skin cancer | 3.0% inhibition at 10-6 M |
| dbacp00087 | Enkephalins7 analogue-10 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HBL | Skin cancer | 4.7% inhibition at 10-5 M |
| dbacp00088 | Enkephalins7 analogue-10 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HBL | Skin cancer | 2.7% inhibition at 10-4 M |
| dbacp00089 | Enkephalins7 analogue-10 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HBL | Skin cancer | 7.3% inhibition at 10-3 M |
| dbacp00090 | Enkephalins7 analogue-10 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HT-29 | Colon cancer | 0.7% inhibition at 10-6 M |
| dbacp00091 | Enkephalins7 analogue-10 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HT-29 | Colon cancer | 8.3% inhibition at 10-5 M |
| dbacp00092 | Enkephalins7 analogue-10 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HT-29 | Colon cancer | 10.5% inhibition at 10-4 M |
| dbacp00093 | Enkephalins7 analogue-10 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HT-29 | Colon cancer | 21.8% inhibition at 10-3 M |
| dbacp00094 | Enkephalins7 analogue-10 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 10.7% inhibition at 10-6 M |
| dbacp00095 | Enkephalins7 analogue-10 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 10.0% inhibition at 10-5 M |
| dbacp00096 | Enkephalins7 analogue-10 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | 7.7% inhibition at 10-4 M |
| dbacp00097 | Enkephalins7 analogue-10 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | 18.7% inhibition at 10-3 M |
| dbacp00125 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 2.7% inhibition at 10-6 M |
| dbacp00126 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 2.0% inhibition at 10-5 M |
| dbacp00127 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 18.8% inhibition at 10-4 M |
| dbacp00128 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 26.7% inhibition at 10-3 M |
| dbacp00129 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HeLa | Cervical cancer | 9.8% inhibition at 10-6 M |
| dbacp00130 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HeLa | Cervical cancer | 7.3% inhibition at 10-5 M |
| dbacp00131 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HeLa | Cervical cancer | 9.9% inhibition at 10-4 M |
| dbacp00132 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HeLa | Cervical cancer | 28.2% inhibition at 10-3 M |
| dbacp00133 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HBL | Skin cancer | 1.6% inhibition at 10-6 M |
| dbacp00134 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HBL | Skin cancer | 2.9% inhibition at 10-5 M |
| dbacp00135 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HBL | Skin cancer | 5.9% inhibition at 10-4 M |
| dbacp00136 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HBL | Skin cancer | 17.9% inhibition at 10-3 M |
| dbacp00137 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HT-29 | Colon cancer | 5.4% inhibition at 10-6 M |
| dbacp00138 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HT-29 | Colon cancer | 7.4% inhibition at 10-5 M |
| dbacp00139 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HT-29 | Colon cancer | 9.5% inhibition at 10-4 M |
| dbacp00140 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HT-29 | Colon cancer | 15.7% inhibition at 10-3 M |
| dbacp00141 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 13.6% inhibition at 10-6 M |
| dbacp00142 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 20.4% inhibition at 10-5 M |
| dbacp00143 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 14.4% inhibition at 10-4 M |
| dbacp00144 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 23.4% inhibition at 10-3 M |
| dbacp00145 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | CaCo-2 | Colon cancer | 2.2% inhibition at 10-6 M |
| dbacp00146 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | CaCo-2 | Colon cancer | 4.2% inhibition at 10-5 M |
| dbacp00147 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | CaCo-2 | Colon cancer | 6.4% inhibition at 10-4 M |
| dbacp00148 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | CaCo-2 | Colon cancer | 6.2% inhibition at 10-3 M |
| dbacp00149 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | 21.2% inhibition at 10-3 M |
| dbacp00159 | Enkephalins7 analogue-16 | YRA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 4.6% inhibition at 10-6 M |
| dbacp00160 | Enkephalins7 analogue-16 | YRA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 4.9% inhibition at 10-5 M |
| dbacp00161 | Enkephalins7 analogue-16 | YRA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 12.6% inhibition at 10-4 M |
| dbacp00162 | Enkephalins7 analogue-16 | YRA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 26.4% inhibition at 10-3 M |
| dbacp00163 | Enkephalins7 analogue-16 | YRA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HeLa | Cervical cancer | 11.0% inhibition at 10-6 M |
| dbacp00164 | Enkephalins7 analogue-16 | YRA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HeLa | Cervical cancer | 11.7% inhibition at 10-5 M |
| dbacp00165 | Enkephalins7 analogue-16 | YRA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HeLa | Cervical cancer | 11.6% inhibition at 10-4 M |
| dbacp00166 | Enkephalins7 analogue-16 | YRA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HeLa | Cervical cancer | 28.2% inhibition at 10-3 M |
| dbacp00167 | Enkephalins7 analogue-16 | YRA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HBL | Skin cancer | 1.2% inhibition at 10-5 M |
| dbacp00168 | Enkephalins7 analogue-16 | YRA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HBL | Skin cancer | 3.3% inhibition at 10-4 M |
| dbacp00169 | Enkephalins7 analogue-16 | YRA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HBL | Skin cancer | 19.4% inhibition at 10-3 M |
| dbacp00170 | Enkephalins7 analogue-16 | YRA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HT-29 | Colon cancer | 7.6% inhibition at 10-6 M |
| dbacp00171 | Enkephalins7 analogue-16 | YRA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HT-29 | Colon cancer | 3.8% inhibition at 10-5 M |
| dbacp00172 | Enkephalins7 analogue-16 | YRA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HT-29 | Colon cancer | 12.4% inhibition at 10-4 M |
| dbacp00173 | Enkephalins7 analogue-16 | YRA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HT-29 | Colon cancer | 22.4% inhibition at 10-3 M |
| dbacp00174 | Enkephalins7 analogue-16 | YRA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 17.0% inhibition at 10-6 M |
| dbacp00175 | Enkephalins7 analogue-16 | YRA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 13.5% inhibition at 10-5 M |
| dbacp00176 | Enkephalins7 analogue-16 | YRA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 13.5% inhibition at 10-4 M |
| dbacp00177 | Enkephalins7 analogue-16 | YRA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 25.3% inhibition at 10-3 M |
| dbacp00178 | Enkephalins7 analogue-16 | YRA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | CaCo-2 | Colon cancer | 8.1% inhibition at 10-6 M |
| dbacp00179 | Enkephalins7 analogue-16 | YRA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | CaCo-2 | Colon cancer | 6.9% inhibition at 10-5 M |
| dbacp00180 | Enkephalins7 analogue-16 | YRA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | CaCo-2 | Colon cancer | 8.1% inhibition at 10-4 M |
| dbacp00181 | Enkephalins7 analogue-16 | YRA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | CaCo-2 | Colon cancer | 8.6% inhibition at 10-3 M |
| dbacp00182 | Enkephalins7 analogue-16 | YRA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | 15.6% inhibition at 10-3 M |
| dbacp00192 | Enkephalins7 analogue-17 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 1.0% inhibition at 10-6 M |
| dbacp00193 | Enkephalins7 analogue-17 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 10.1% inhibition at 10-5 M |
| dbacp00194 | Enkephalins7 analogue-17 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 16.8% inhibition at 10-4 M |
| dbacp00195 | Enkephalins7 analogue-17 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 36.1% inhibition at 10-3 M |
| dbacp00196 | Enkephalins7 analogue-17 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HeLa | Cervical cancer | 4.9% inhibition at 10-6 M |
| dbacp00197 | Enkephalins7 analogue-17 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HeLa | Cervical cancer | 10.2% inhibition at 10-5 M |
| dbacp00198 | Enkephalins7 analogue-17 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HeLa | Cervical cancer | 13.3% inhibition at 10-4 M |
| dbacp00199 | Enkephalins7 analogue-17 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HeLa | Cervical cancer | 28.0% inhibition at 10-3 M |
| dbacp00200 | Enkephalins7 analogue-17 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HBL | Skin cancer | 0.8% inhibition at 10-6 M |
| dbacp00201 | Enkephalins7 analogue-17 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HBL | Skin cancer | 1.4% inhibition at 10-5 M |
| dbacp00202 | Enkephalins7 analogue-17 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HBL | Skin cancer | 2.4% inhibition at 10-4 M |
| dbacp00203 | Enkephalins7 analogue-17 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HBL | Skin cancer | 18.3% inhibition at 10-3 M |
| dbacp00204 | Enkephalins7 analogue-17 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HT-29 | Colon cancer | 3.3% inhibition at 10-6 M |
| dbacp00205 | Enkephalins7 analogue-17 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HT-29 | Colon cancer | 11.0% inhibition at 10-5M |
| dbacp00206 | Enkephalins7 analogue-17 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HT-29 | Colon cancer | 7.9% inhibition at 10-4 M |
| dbacp00207 | Enkephalins7 analogue-17 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HT-29 | Colon cancer | 23.7% inhibition at 10-3 M |
| dbacp00208 | Enkephalins7 analogue-17 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 12.2% inhibition at 10-6 M |
| dbacp00209 | Enkephalins7 analogue-17 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 15.5% inhibition at 10-5 M |
| dbacp00210 | Enkephalins7 analogue-17 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 24.7% inhibition at 10-4 M |
| dbacp00211 | Enkephalins7 analogue-17 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 29.0% inhibition at 10-3 M |
| dbacp00212 | Enkephalins7 analogue-17 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | CaCo-2 | Colon cancer | 3.0% inhibition at 10-6 M |
| dbacp00213 | Enkephalins7 analogue-17 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | CaCo-2 | Colon cancer | 8.4% inhibition at 10-5 M |
| dbacp00214 | Enkephalins7 analogue-17 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | CaCo-2 | Colon cancer | 18.5% inhibition at 10-4 M |
| dbacp00215 | Enkephalins7 analogue-17 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | CaCo-2 | Colon cancer | 10.6% inhibition at 10-3 M |
| dbacp00216 | Enkephalins7 analogue-17 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | 22.8% inhibition at 10-3 M |
| dbacp00226 | Enkephalins7 analogue-18 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 13.7% inhibition at 10-6 M |
| dbacp00227 | Enkephalins7 analogue-18 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 25.8% inhibition at 10-5 M |
| dbacp00228 | Enkephalins7 analogue-18 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 34.7% inhibition at 10-4 M |
| dbacp00229 | Enkephalins7 analogue-18 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 44.5% inhibition at 10-3 M |
| dbacp00230 | Enkephalins7 analogue-18 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HeLa | Cervical cancer | 8.5% inhibition at 10-6 M |
| dbacp00231 | Enkephalins7 analogue-18 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HeLa | Cervical cancer | 9.5% inhibition at 10-5 M |
| dbacp00232 | Enkephalins7 analogue-18 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HeLa | Cervical cancer | 15.4% inhibition at 10-4 M |
| dbacp00233 | Enkephalins7 analogue-18 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HeLa | Cervical cancer | 24.1% inhibition at 10-3 M |
| dbacp00234 | Enkephalins7 analogue-18 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HBL | Skin cancer | 2.4% inhibition at 10-6 M |
| dbacp00235 | Enkephalins7 analogue-18 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HBL | Skin cancer | 4.5% inhibition at 10-5 M |
| dbacp00236 | Enkephalins7 analogue-18 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HBL | Skin cancer | 11.4% inhibition at 10-4 M |
| dbacp00237 | Enkephalins7 analogue-18 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HBL | Skin cancer | 23.2% inhibition at 10-3 M |
| dbacp00238 | Enkephalins7 analogue-18 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HT-29 | Colon cancer | 16.2% inhibition at 10-6 M |
| dbacp00239 | Enkephalins7 analogue-18 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HT-29 | Colon cancer | 6.6% inhibition at 10-5 M |
| dbacp00240 | Enkephalins7 analogue-18 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HT-29 | Colon cancer | 5.1% inhibition at 10-4 M |
| dbacp00241 | Enkephalins7 analogue-18 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HT-29 | Colon cancer | 14.5% inhibition at 10-3 M |
| dbacp00242 | Enkephalins7 analogue-18 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 26.4% inhibition at 10-6 M |
| dbacp00243 | Enkephalins7 analogue-18 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 13.1% inhibition at 10-5 M |
| dbacp00244 | Enkephalins7 analogue-18 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 14.6% inhibition at 10-4 M |
| dbacp00245 | Enkephalins7 analogue-18 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 38.4% inhibition at 10-3 M |
| dbacp00246 | Enkephalins7 analogue-18 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | CaCo-2 | Colon cancer | 17.7% inhibition at 10-6 M |
| dbacp00247 | Enkephalins7 analogue-18 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | CaCo-2 | Colon cancer | 10.9% inhibition at 10-5 M |
| dbacp00248 | Enkephalins7 analogue-18 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | CaCo-2 | Colon cancer | 12.1% inhibition at 10-4 M |
| dbacp00249 | Enkephalins7 analogue-18 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | CaCo-2 | Colon cancer | 8.1% inhibition at 10-3 M |
| dbacp00250 | Enkephalins7 analogue-18 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | 9.6% inhibition at 10-4 M |
| dbacp00251 | Enkephalins7 analogue-18 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | 29.9% inhibition at 10-3 M |
| dbacp00279 | Enkephalins7 analogue-23 | YGGFMA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 3.9% inhibition at 10-5 M |
| dbacp00280 | Enkephalins7 analogue-23 | YGGFMA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 45% inhibition at 10-3 M |
| dbacp00281 | Enkephalins7 analogue-23 | YGGFMA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HeLa | Cervical cancer | 9.3% inhibition at 10-3 M |
| dbacp00282 | Enkephalins7 analogue-23 | YGGFMA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HBL | Skin cancer | 4.1% inhibition at 10-6 M |
| dbacp00283 | Enkephalins7 analogue-23 | YGGFMA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HBL | Skin cancer | 70.7% inhibition at 10-5 M |
| dbacp00284 | Enkephalins7 analogue-23 | YGGFMA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HBL | Skin cancer | 34.4% inhibition at 10-3 M |
| dbacp00285 | Enkephalins7 analogue-23 | YGGFMA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HT-29 | Colon cancer | 9.2% inhibition at 10-3 M |
| dbacp00286 | Enkephalins7 analogue-23 | YGGFMA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | CaCo-2 | Colon cancer | 11.08% inhibition at 10-5 M |
| dbacp00287 | Enkephalins7 analogue-23 | YGGFMA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | CaCo-2 | Colon cancer | 47.0% inhibition at 10-3 M |
| dbacp00288 | Enkephalins7 analogue-23 | YGGFMA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | 2.2% inhibition at 10-6 M |
| dbacp00289 | Enkephalins7 analogue-23 | YGGFMA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | 7.1% inhibition at 10-5 M |
| dbacp00290 | Enkephalins7 analogue-23 | YGGFMA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | 6.9% inhibition at 10-4 M |
| dbacp00291 | Enkephalins7 analogue-23 | YGGFMA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | 25.9% inhibition at 10-3 M |
| dbacp00301 | (cpm)-1285 | KNLWAAQRYGRELRRMSDEFEGSFKGL | BH3-only, Sensizers (BAD, HRK, Noxa) | Apoptosis inducing | Not specified | HL-60 | Various cancers | Not found |
| dbacp00302 | (cpm)-1285 | KNLWAAQRYGRELRRMSDEFEGSFKGL | BH3-only, Sensizers (BAD, HRK, Noxa) | Apoptosis inducing | Not specified | PBL | Various cancers | Not found |
| dbacp00303 | Temporin-SHf | FFFLSRIF* | Sahara frog | Apoptosis inducing | MTT assay | A549 | Not specified | IC50 : 24.03 ± 0.945 µM |
| dbacp00304 | Temporin-SHf | FFFLSRIF* | Sahara frog | Apoptosis inducing | MTT assay | MCF-7 | Not specified | IC50 : 32.76 ± 1.528 µM |
| dbacp00305 | Temporin-SHf | FFFLSRIF* | Sahara frog | Apoptosis inducing | MTT assay | HepG2 | Not specified | IC50 : 32.64 ± 1.350 µM |
| dbacp00306 | Temporin-SHf | FFFLSRIF* | Sahara frog | Apoptosis inducing | MTT assay | PC3 | Not specified | IC50 : 36.67 ± 0.729 µM |
| dbacp00308 | (ATAP) Amphipathic tail-anchoring peptide of Bfl-1 | KFEPKSGWMTFLEVTGKICEMLSLLKQYC | Anti apoptotic (MCL-1, BFL1) | Apoptosis inducing | Not specified | HeLa | Not found | Not found |
| dbacp00309 | (Bl- LAAO) L-amino acid oxidases (L-AAO) | ADDRNPLEECFRETDYEEFLEIAKNGLSTT | Venom base | Apoptosis inducing | MTT assay | MKN-45 | Stomach cancer | Not found |
| dbacp00310 | (Bl- LAAO) L-amino acid oxidases (L-AAO) | ADDRNPLEECFRETDYEEFLEIAKNGLSTT | Venom base | Apoptosis inducing | MTT assay | HUTU | Adenocarcinoma | Not found |
| dbacp00311 | (Bl- LAAO) L-amino acid oxidases (L-AAO) | ADDRNPLEECFRETDYEEFLEIAKNGLSTT | Venom base | Apoptosis inducing | MTT assay | RKO | Colorectal cancer | Not found |
| dbacp00318 | (RGD-4C)-GG-D(KLAKLAK)2 | ACDCRGDCFCGGKLAKLAKKLAKLAK | Synthetic Peptide | Apoptosis inducing | Internalization assay,Mitochondrial swelling assay,Cell-free apoptosis assay,Caspase activation assay | KS1767 | Not specified | LC50 : 10 μM |
| dbacp00701 | 072RB | DMRPEIYI(Aib)QELRRIGDAFN(Aib)YRQIKIWFQNRRMKWKK | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Jurkat | Leukemia | Not found |
| dbacp00702 | 072RB | DMRPEIYI(Aib)QELRRIGDAFN(Aib)YRQIKIWFQNRRMKWKK | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Namalwa | Leukemia | Not found |
| dbacp00703 | 072RB | DMRPEIYI(Aib)QELRRIGDAFN(Aib)YRQIKIWFQNRRMKWKK | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | U937 | Leukemia | Not found |
| dbacp00704 | 10a | NA | Synthetic b2,2-amino acid derivatives | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 28 µM |
| dbacp00705 | 10b | NA | Synthetic b2,2-amino acid derivatives | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 11.4 µM |
| dbacp00706 | 10c | NA | Synthetic b2,2-amino acid derivatives | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 6.6 µM |
| dbacp00707 | 11a | NA | Synthetic b2,2-amino acid derivatives | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 5.2 µM |
| dbacp00708 | 11b | NA | Synthetic b2,2-amino acid derivatives | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 19 µM |
| dbacp00709 | 11c | NA | Synthetic b2,2-amino acid derivatives | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 7.2 µM |
| dbacp00710 | 12a | NA | Synthetic b2,2-amino acid derivatives | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 6.1 µM |
| dbacp00711 | 12b | NA | Synthetic b2,2-amino acid derivatives | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 27 µM |
| dbacp00712 | 12c | NA | Synthetic b2,2-amino acid derivatives | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 14 µM |
| dbacp00718 | 2XAkt-in | VTDHPDRLWAWEKGGGVTDHPDRLWAWEK | Not found | Inducing apoptosis | Cell death assay | T4 | Leukemia | Not found |
| dbacp00719 | 3A | LTAEHYAAQATS | Not found | Cell cycle arrest or apoptosis of cells | Immunoprecipitation assay | HCT-116-p53+/+ | Colon cancer | IC50 : >100 µM |
| dbacp00722 | 5a | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 10.6 µM |
| dbacp00723 | 5b | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 7.1 µM |
| dbacp00724 | 5c | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 4.1 µM |
| dbacp00725 | 6,7-dimethyl-8-ribityllumazine synthase 2 | MNQSCPNKTSFKIAFIQARWHADIVDEARKSFVAELAAKTGGSVEVEIFDVPGAYEIPLHAKTLARTGRYAAIVGAAFVIDGGIYRHDFVATAVINGMMQVQLETEVPVLSVVLTPHHFHESKEHHDFFHAHFKVKGVEAAHAALQIVSERSRIAALV | Not found | Apoptosis inducing | Apoptosis assay | B16 | Melanoma | Not found |
| dbacp00727 | 6a | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 14.4 µM |
| dbacp00728 | 6b | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 11.0 µM |
| dbacp00729 | 6c | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 4.3 µM |
| dbacp00730 | 7a | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : >63 µM |
| dbacp00731 | 7b | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : >78 µM |
| dbacp00732 | 7c | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 79 µM |
| dbacp00733 | 8a | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 136 µM |
| dbacp00734 | 8b | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : >254 µM |
| dbacp00735 | 8c | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 107 µM |
| dbacp00736 | 9a | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 31 µM |
| dbacp00737 | 9b | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 2.3 µM |
| dbacp00738 | 9c | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 3.1 µM |
| dbacp00739 | 9R | RRRRRNWMWC | Not found | Cell membrane disintegration; Apoptosis | MTT/MTS assay | LNCaP | Prostate cancer | IC50 : 44 µM |
| dbacp00740 | 9R | RRRRRNWMWC | Not found | Cell membrane disintegration; Apoptosis | MTT/MTS assay | LNCaP | Prostate cancer | IC50 : 23 µM |
| dbacp00741 | 9R | RRRRRNWMWC | Not found | Cell membrane disintegration; Apoptosis | MTT/MTS assay | LNCaP | Prostate cancer | IC50 : 28 µM |
| dbacp00742 | 9R | RRRRRNWMWC | Not found | Cell membrane disintegration; Apoptosis | MTT/MTS assay | MDA-MB-231 | Breast cancer | IC50 : 39 µM |
| dbacp00743 | 9R | RRRRRNWMWC | Not found | Cell membrane disintegration; Apoptosis | MTT/MTS assay | MDA-MB-231 | Breast cancer | IC50 : 29 µM |
| dbacp00744 | 9R | RRRRRNWMWC | Not found | Cell membrane disintegration; Apoptosis | MTT/MTS assay | MDA-MB-231 | Breast cancer | IC50 : 16 µM |
| dbacp00745 | 9R | RRRRRNWMWC | Not found | Cell membrane disintegration; Apoptosis | MTT/MTS assay | HUT-102 | Lymphoma cancer | IC50 : 93 µM |
| dbacp00746 | 9R | RRRRRNWMWC | Not found | Cell membrane disintegration; Apoptosis | MTT/MTS assay | HUT-102 | Lymphoma cancer | IC50 : 39 µM |
| dbacp00747 | 9R | RRRRRNWMWC | Not found | Cell membrane disintegration; Apoptosis | MTT/MTS assay | HUT-102 | Lymphoma cancer | IC50 : 37 µM |
| dbacp00748 | 9R | RRRRRNWMWC | Not found | Cell membrane disintegration; Apoptosis | MTT/MTS assay | HUT-102 | Lymphoma cancer | IC50 : 36 µM |
| dbacp00749 | 9R | RRRRRNWMWC | Not found | Cell membrane disintegration; Apoptosis | MTT/MTS assay | HUT-102 | Lymphoma cancer | IC50 : 25 µM |
| dbacp00750 | 9R | RRRRRNWMWC | Not found | Cell membrane disintegration; Apoptosis | MTT/MTS assay | J774A.1 | Tumor | IC50 : 47 µM |
| dbacp00751 | 9R | RRRRRNWMWC | Not found | Cell membrane disintegration; Apoptosis | MTT/MTS assay | J774A.1 | Tumor | IC50 : 12 µM |
| dbacp00752 | 9S1R | RRRRRWCMNW | Not found | Cell membrane disintegration; Apoptosis | MTT/MTS assay | LNCaP | Prostate cancer | IC50 : 26 µM |
| dbacp00753 | 9S1R | RRRRRWCMNW | Not found | Cell membrane disintegration; Apoptosis | MTT/MTS assay | LNCaP | Prostate cancer | IC50 : 9 µM |
| dbacp00754 | 9S1R | RRRRRWCMNW | Not found | Cell membrane disintegration; Apoptosis | MTT/MTS assay | LNCaP | Prostate cancer | IC50 : 8 µM |
| dbacp00755 | 9S1R | RRRRRWCMNW | Not found | Cell membrane disintegration; Apoptosis | MTT/MTS assay | MDA-MB-231 | Breast cancer | IC50 : 18 µM |
| dbacp00756 | 9S1R | RRRRRWCMNW | Not found | Cell membrane disintegration; Apoptosis | MTT/MTS assay | MDA-MB-231 | Breast cancer | IC50 : 12 µM |
| dbacp00757 | 9S1R | RRRRRWCMNW | Not found | Cell membrane disintegration; Apoptosis | MTT/MTS assay | MDA-MB-231 | Breast cancer | IC50 : 10 µM |
| dbacp00758 | 9S1R | RRRRRWCMNW | Not found | Cell membrane disintegration; Apoptosis | MTT/MTS assay | HUT-102 | Lymphoma cancer | IC50 : 38 µM |
| dbacp00759 | 9S1R | RRRRRWCMNW | Not found | Cell membrane disintegration; Apoptosis | MTT/MTS assay | HUT-102 | Lymphoma cancer | IC50 : 43 µM |
| dbacp00760 | 9S1R | RRRRRWCMNW | Nullomer derived anticancer peptides (NulloPs) | Cell membrane disintegration; Apoptosis | MTT/MTS assay | HUT-102 | Lymphoma cancer | IC50 : 43 µM |
| dbacp00761 | 9S1R | RRRRRWCMNW | Nullomer derived anticancer peptides (NulloPs) | Cell membrane disintegration; Apoptosis | MTT/MTS assay | HUT-102 | Lymphoma cancer | IC50 : 45 µM |
| dbacp00762 | 9S1R | RRRRRWCMNW | Nullomer derived anticancer peptides (NulloPs) | Cell membrane disintegration; Apoptosis | MTT/MTS assay | HUT-102 | Lymphoma cancer | IC50 : 36 µM |
| dbacp00763 | 9S1R | RRRRRWCMNW | Nullomer derived anticancer peptides (NulloPs) | Cell membrane disintegration; Apoptosis | MTT/MTS assay | J774A.1 | Tumor | IC50 : 26 µM |
| dbacp00764 | 9S1R | RRRRRWCMNW | Nullomer derived anticancer peptides (NulloPs) | Cell membrane disintegration; Apoptosis | MTT/MTS assay | J774A.1 | Tumor | IC50 : 17 µM |
| dbacp00771 | A12 | RPEIWMGQGLRRLGDEINAYYAR | BH3-only, Direct activators, BIM analogues | Apoptosis inducing | Not specified | Mcl-1/Myc 2640 | Not found | Not found |
| dbacp00772 | A12 | RPEIWMGQGLRRLGDEINAYYAR | BH3-only, Direct activators, BIM analogues | Apoptosis inducing | Not specified | Bcl-2/Myc 2924 | Not found | Not found |
| dbacp00813 | A5 | KAQIRAMECNIL | Cyclin B (285-296) | Apoptosis inducing | MTT/MTS assay | HCT-116 | Colon cancer | Not found |
| dbacp00814 | AAD (or Aa-Pri1) | MDSNKDERAYAQWVIIILHNVGSSPFKIANLGLSWGKLYADGNKDKEVYPSDYNGKTVGPDEKIQINSCGRENASSGTEGSFDIVDPNDGNKTIRHFYWECPWGSKRNTWTPSGSNTKWMVEWSGQNLDSGALGTITVDVLRKGN | Purified from chestnut mushroom | Apoptosis inducing | MTT/MTS assay | HepG-2 | Liver cancer | At 2.5 µM concentration,decrease in cell vibility: 35% |
| dbacp00815 | AAD (or Aa-Pri1) | MDSNKDERAYAQWVIIILHNVGSSPFKIANLGLSWGKLYADGNKDKEVYPSDYNGKTVGPDEKIQINSCGRENASSGTEGSFDIVDPNDGNKTIRHFYWECPWGSKRNTWTPSGSNTKWMVEWSGQNLDSGALGTITVDVLRKGN | Purified from chestnut mushroom | Apoptosis inducing | MTT/MTS assay | HeLa | Cervical cancer | At 2.5 µM concentration,decrease in cell vibility: 70% |
| dbacp00816 | AAD (or Aa-Pri1) | MDSNKDERAYAQWVIIILHNVGSSPFKIANLGLSWGKLYADGNKDKEVYPSDYNGKTVGPDEKIQINSCGRENASSGTEGSFDIVDPNDGNKTIRHFYWECPWGSKRNTWTPSGSNTKWMVEWSGQNLDSGALGTITVDVLRKGN | Purified from chestnut mushroom | Apoptosis inducing | MTT/MTS assay | SH-SY5Y | Brain tumor | At 2.5 µM concentration,decrease in cell vibility: 70% |
| dbacp00833 | AAP-H | YVPGP | Marine invertebrates | Apoptosis inducing | MTT assay | DU-145 | Prostate cancer | IC50 : 9.605 mM |
| dbacp00834 | AAP-H | YVPGP | Marine invertebrates | Apoptosis inducing | MTT assay | DU-146 | Prostate cancer | IC50 : 7.910 mM |
| dbacp00835 | AAP-H | YVPGP | Marine invertebrates | Apoptosis inducing | MTT assay | DU-147 | Prostate cancer | IC50 : 2.298 mM |
| dbacp00951 | ABP-dHC-Cecropin A | RWKIFKKIERVGQNVRDGIIKAGPAIQVLGTAKALGK | Synthetic construct | Apoptosis inducing | MTT assay | K562 cells | Leukemia | IC50 : 349.5 μM |
| dbacp00952 | ABP-dHC-Cecropin A | RWKIFKKIERVGQNVRDGIIKAGPAIQVLGTAKALGK | Synthetic construct | Apoptosis inducing | MTT assay | U937 cells | Leukemia | IC50 : 303.2 μM |
| dbacp00953 | ABP-dHC-Cecropin A | RWKIFKKIERVGQNVRDGIIKAGPAIQVLGTAKALGK | Synthetic construct | Apoptosis inducing | MTT assay | THP-1 cells | Leukemia | IC50 : 228.5 μM |
| dbacp00954 | ABP-dHC-Cecropin A-K | RWKIFKKIERVGQNVRDGIIKAGKAIQVLGTAKALGK | Synthetic construct | Apoptosis inducing | MTT assay | K562 cells | Leukemia | IC50 : 349.5 μM |
| dbacp00955 | ABP-dHC-Cecropin A-K | RWKIFKKIERVGQNVRDGIIKAGKAIQVLGTAKALGK | Synthetic construct | Apoptosis inducing | MTT assay | U937 cells | Leukemia | IC50 : 303.2 μM |
| dbacp00956 | ABP-dHC-Cecropin A-K | RWKIFKKIERVGQNVRDGIIKAGKAIQVLGTAKALGK | Synthetic construct | Apoptosis inducing | MTT assay | THP-1 cells | Leukemia | IC50 : 228.5 μM |
| dbacp00962 | ACL LAO L-amino acid oxidase(LAO) | ADSRNPLEEEFRETNYEEF | Venom base | Apoptosis inducing | HL-60 cell culture assay | HL-60 | Not specified | Not found |
| dbacp00991 | AKPF dimer, Smac-1 | (AKPF-NH2)2 | SMAC | Inducing apoptosis | Not specified | MDA-MB-231 | Not specified | IC50 : 3.93 ± 1.1 nM |
| dbacp00992 | Akt-in | AVTDHPDRLWAWEKF | Not found | Inducing apoptosis | Co-immunoprecipitation, GST Pull-down,GST Competition, In Vitro Akt Kinase, PKA Kinase, In Vitro PDK1 Kinase, PtdIns(3,4,5)P3 Lipid-Protein Pull-down, Proliferation assay, Cell Death assay and Mitochondrial Permeability Transition assay | T4 | T-cell Leukemia | Not found |
| dbacp01144 | Ansalvamide A | NA | Marine fungus, Wilt of banana | Apoptosis inducing | Not specified | COLO 205 | Colorectal cancer | IC50 : 3.5 µg/mL |
| dbacp01145 | Ansalvamide A | NA | Marine fungus, Wilt of banana | Apoptosis inducing | Not specified | SKMEL-2 | Melanoma cells | IC50 : 5.9 µg/mL |
| dbacp01146 | Ansalvamide A | NA | Marine fungus, Wilt of banana | Apoptosis inducing | Not specified | HCT-116 | Colon cancer | IC50 : 9.8 µg/mL |
| dbacp01147 | Ant-Bad | RQIKIWFQNRRMKWKKNLWAAQRYGRELRRMSDEFVD | BH3-only, Sensizers (BAD, HRK, Noxa) | Apoptosis inducing | Not specified | 1483 | Head and neck squamous cell carcinomas (HNSCC) | IC50 : 24.8 µM |
| dbacp01148 | Ant-Bad | RQIKIWFQNRRMKWKKNLWAAQRYGRELRRMSDEFVD | BH3-only, Sensizers (BAD, HRK, Noxa) | Apoptosis inducing | Not specified | UM-22A | Head and neck squamous cell carcinomas (HNSCC) | IC50 : 18.3 µM |
| dbacp01149 | Ant-Bad | RQIKIWFQNRRMKWKKNLWAAQRYGRELRRMSDEFVD | BH3-only, Sensizers (BAD, HRK, Noxa) | Apoptosis inducing | Not specified | UM-22B | Head and neck squamous cell carcinomas (HNSCC) | IC50 : 40.2 µM |
| dbacp01150 | Ant-Bak | RQIKIWFQNRRMKWKKMGQVGRQLAIIGDDINRRY | Effectors (BAK, BAX) | Apoptosis inducing | Not specified | 1483 | Head and neck squamous cell carcinomas (HNSCC) | IC50 : 32.9 µM |
| dbacp01151 | Ant-Bak | RQIKIWFQNRRMKWKKMGQVGRQLAIIGDDINRRY | Effectors (BAK, BAX) | Apoptosis inducing | Not specified | UM-22A | Head and neck squamous cell carcinomas (HNSCC) | IC50 : 82 µM |
| dbacp01152 | Ant-Bak | RQIKIWFQNRRMKWKKMGQVGRQLAIIGDDINRRY | Effectors (BAK, BAX) | Apoptosis inducing | Not specified | UM-22B | Head and neck squamous cell carcinomas (HNSCC) | IC50 : > 100 µM |
| dbacp01153 | Ant-Bax | RQIKIWFQNRRMKWKKSTKKLSECLKRIGDELDSnM | Effectors (BAK, BAX) | Apoptosis inducing | Not specified | 1483 | Head and neck squamous cell carcinomas (HNSCC) | IC50 : 18.2 µM |
| dbacp01154 | Ant-Bax | RQIKIWFQNRRMKWKKSTKKLSECLKRIGDELDSnM | Effectors (BAK, BAX) | Apoptosis inducing | Not specified | UM-22A | Head and neck squamous cell carcinomas (HNSCC) | IC50 : 45.5 µM |
| dbacp01155 | Ant-Bax | RQIKIWFQNRRMKWKKSTKKLSECLKRIGDELDSnM | Effectors (BAK, BAX) | Apoptosis inducing | Not specified | UM-22B | Head and neck squamous cell carcinomas (HNSCC) | IC50 : > 100 µM |
| dbacp01156 | Ant-p53pep | GSRAHSSHLKSKKGQSTSRHKKWKMRRNQFWVKVQRG | Not found | Apoptosis inducing | Annexin V-FITC Binding assay | MDA-MB-468 | Breast cancer | IC50 : 30 µM |
| dbacp01157 | Anthopleura anjunae anti-tumor peptide | YVPGP | Sea anemone anti-tumor peptide | Apoptosis inducing | MTT Cell Proliferation and Cytotoxicity assay | DU-145 | Prostate cancer | IC50 : 9.605 μM |
| dbacp01158 | Anticancer bioactive peptide | NA | Goat spleen | Apoptosis inducing | Cell proliferation assay | HCT116 | Human Colorectal cancer | IC50 : 35 μg/mL |
| dbacp01172 | Antp-LP4 | RQIKIWFQNRRMKWKKSWTWEKKLETAVNLAWTAGNSNKWTWK | VDAC1(voltage-dependent anion channel1) | Apoptosis inducing | Not specified | CLL | Leukemia | IC50 : 0.7 ± 0.1 µM |
| dbacp01173 | Antp-LP4 | RQIKIWFQNRRMKWKKSWTWEKKLETAVNLAWTAGNSNKWTWK | VDAC1(voltage-dependent anion channel1) | Apoptosis inducing | Not specified | MEC-1 | Leukemia | IC50 : 2.5 ± 0.1 µM |
| dbacp01193 | ATAP-iRGD peptide-Parental | KFEPKSGWMTFLEVTGKIAEMLSLLKQYCRGDKGPDC | Anti apoptotic (MCL-1, BFL1) | Inducing apoptosis | MTT assay | DU-145 | Prostate cancer | IC50 : 1.6 μM |
| dbacp01194 | ATAP-iRGD-M1 | AFEPKSGWMTFLEVTGKIAEMLSLLKQYCRGDKGPDC | Anti apoptotic (MCL-1, BFL1) | Inducing apoptosis | MTT assay | DU-145 | Prostate cancer | IC50 : 36 μM |
| dbacp01195 | ATAP-iRGD-M2 | LFEPKSGWMTFLEVTGKIAEMLSLLKQYCRGDKGPDC | Anti apoptotic (MCL-1, BFL1) | Inducing apoptosis | MTT assay | DU-145 | Prostate cancer | IC50 : 68 μM |
| dbacp01196 | ATAP-iRGD-M3 | KFEPLSGWMTFLEVTGKIAEMLSLLKQYCRGDKGPDC | Anti apoptotic (MCL-1, BFL1) | Inducing apoptosis | MTT assay | DU-145 | Prostate cancer | IC50 : 25 μM |
| dbacp01197 | ATAP-iRGD-M5 | KFEPKSGWETFLEVTGKIAEMLSLLKQYCRGDKGPDC | Anti apoptotic (MCL-1, BFL1) | Inducing apoptosis | MTT assay | DU-145 | Prostate cancer | IC50 : 6 μM |
| dbacp01198 | ATAP-iRGD-M6 | KKFEPKSGWMTFLEVTGKIAEMLSLLKQYCRGDKGPDC | Anti apoptotic (MCL-1, BFL1) | Inducing apoptosis | MTT assay | DU-145 | Prostate cancer | IC50 : 3.1 μM |
| dbacp01199 | ATAP-iRGD-M7 | KFEPKSGWMTFLEVTGKIAEMLSLLKQYCRGDKGPDC | Anti apoptotic (MCL-1, BFL1) | Inducing apoptosis | MTT assay | DU-145 | Prostate cancer | IC50 : 2.1 μM |
| dbacp01200 | ATAP-iRGD-M8 | KKFEPKSGWMTFLEVTGKIAEMLSLLKQYCRGDKGPDC | Anti apoptotic (MCL-1, BFL1) | Inducing apoptosis | MTT assay | DU-145 | Prostate cancer | IC50 : 2.1 μM |
| dbacp01438 | B3 | RPEIWLGQSLQRLGDEINAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Mcl-1/Myc 2640 | Not found | Not found |
| dbacp01439 | B3 | RPEIWLGQSLQRLGDEINAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Bcl-2/Myc 2924 | Not found | Not found |
| dbacp01441 | BAA-2 | NA | Bovine lactoferrin (Lf-B) | Apoptosis inducing | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 3.8 µg/ml |
| dbacp01442 | Baceridin | cyclo(L-Trp-D-Ala-D-allo-Ile-L-Val-D-Leu-L-Leu-) | Synthetic construct | Apoptosis inducing | MTT assay | HCT116 | Not specified | Not found |
| dbacp01443 | Baceridin | cyclo(L-Trp-D-Ala-D-allo-Ile-L-Val-D-Leu-L-Leu-) | Synthetic construct | Apoptosis inducing | MTT assay | RKO | Not specified | Not found |
| dbacp01444 | Baceridin | cyclo(L-Trp-D-Ala-D-allo-Ile-L-Val-D-Leu-L-Leu-) | Synthetic construct | Apoptosis inducing | MTT assay | HeLa | Not specified | Not found |
| dbacp01445 | Baceridin | WAIVLL | Plant-associated rod-shaped, Gram-positive bacteria | Apoptosis inducing | MTT assay | HCT116 | Not specified | Not found |
| dbacp01446 | Baceridin | WAIVLL | Plant-associated rod-shaped, Gram-positive bacteria | Apoptosis inducing | MTT assay | RKO | Not specified | Not found |
| dbacp01447 | Baceridin | WAIVLL | Plant-associated rod-shaped, Gram-positive bacteria | Apoptosis inducing | MTT assay | HeLa | Not specified | Not found |
| dbacp01448 | Bad | LWAAQRYGRELRRMSDEFEGSFKGL | BH3-only, Sensizers (BAD, HRK, Noxa) | Apoptosis inducing | Not specified | Not found | Not specified | Not found |
| dbacp01449 | Bad | LWAAQRYGRELRRMSDEFVDSFKK | BH3-only, Sensizers (BAD, HRK, Noxa) | Apoptosis inducing | Not specified | Not found | Not found | Not found |
| dbacp01450 | Bad a | NLWAARYGRELRRMSDKFVD | BH3-only, Sensizers (BAD, HRK, Noxa) | Apoptosis inducing | Not specified | Not found | Not found | Not found |
| dbacp01451 | Bassianolide nonribosomal cyclodepsipeptide synthetase | MEPPNNANTGQLGPTLPNGTVDLPTDLSREITRHFGLEQDEIEEILPCTPFQRDVIECASDDKRRAVGHVVYEIPEDVDTERLAAAWKATVRYTPALRTCIFTSETGNAFQVVLRDYFIFARMYCPSAHLKSAIVKDEATAAVAGPRCNRYVLTGEPNSKRRVLVWTFSHSFVDSAFQGRILQQVLAAYKDGHGRVFSLQPTTDLTESENGDHLSTPASERTVVIERATQFWQEKLHGLDASVFPHLPSHKRVPAIDARADHYLPCPPFIQHEWSSTTVCRTALAILLARYTHSSEALFGVVTEQSHEEHPLLLDGPTSTVVPFRVLCALNQSVSKVMEAITTYDHDMRQFAHAGLCNISRIGDDASAACGFQTVLMVTDSRTAGDDEIHQVLEESEKFIPCTDRALLLSCQMTDEGVLLVARYDQSILEPLQMARFLRQLGFLINKLQSTDGSPCVGQLDVLAPEDRTEIEGWNSEPLQTQDCLIHSEVVRNAGDTPNKPAVCAWDGEWTYSELNNVSSRLASYISSLDLGQQLIVPIYLEKSKWVMAAILAVLKAGHAFTLIDPNDPPARTAQIIKQASASIALTSALHQSKMQAVVGRCITVDDDLVQTLTTFEGSQVASAAKPGDLAYVIFTSGSTGDPKGIMIEHRAFYSSVVKFGKALGIRSSTRALQFATHGFGAFLLEVLTTLIHGGCICVPSDHDRMHNIPGFIRQNQINWMMATPSYMTTMKPEDVPGLETLVLVGEQMSSSINDVWLSELQLLDGYGQSESSSICFVGKIDDSSRDPNNLGWAIGAHSWIINPDNPDQLVPIGAIGELLIESPGIARGYLFSQSTETPFLERAPAWYASKQPPYGVKFYRTGDLARYAPDGTVICLGRMDSQVKIRGQRVELDAIENLLRRQFPSDVTVVAEAVKRSDLPSSVVITGFLISSEYVVGAPSTEDTYILDQVVTQEINAKMRQILPAHSIPSFYICMKSLPRTATGKVDRRKLRSIGSSLLALQAQSTAPRSSQAPDASAGVTKLEEVWMDIFNLTPNSHNIGGNFFALGGDSITAIKMVnMARAAGIQLKVSDIFQNPTLASLQAAIGGSSMTVTSIPALALDGPVEQSYSQGRLWFLDQLEIGANWYTIPYAVRLRGPLDVDALNRALLALEKRHETLRTTFEDQDGVGVQIIHETLLDQLRIINADHADYVQLLKQEQTAPFNLASESGWRVSLIRLDDDDNILSIVMHHIISDGWSIDVLRRELGQLYAAALHGADLFGSALSPLPIQYRDFSVWQKQDAQVAEHERQLQYWQKQLADCSPAKLPTDFHRPALLSGKATTVPVTITSELYYRLQEFCSTFNTTSFVVLLATFRAAHYRLTGVDDAVIGTPIANRNRHELENLIGFFVNTQCMRITINEDEDTFESLVRQVRSTTTAAFEHEDVPFERVVSAMLPGSRDLSQNPLAQLVFAIHSHKDLGKFELEALESEPLQNEVYTRFDAEFHFFQAPDGLTGYINFATELFKVETIQNVVSVFLQILRHGLEHPQTLISVVPLTDGLAELRSMGLLEIKKVEYPRDSSVVDVFRTQVASYPDTLAVVDSSSRLTYAELDHQSDLLATWLRQQNLPTEALVVVLAPRSCETIITFLGILKANLAYLPLDIRSPITRMRDVLSTLPGRTIALLCSDEVAPDFQLPSIELVRIADALEEAAGMTSLNGHEHVPVPSPSPTSLAYVLYTSGSTGRPKGVMIEHRAIVRLARSDIIPDYRPACGDTMAHMFNTAFDGATYEIYTMLLNGGTLVCVDYMDTLSPKSLEAVFKKEQVNATIMAPALLKLYLADARDALKGLDVLISGGDRFDPQDAVDAQSLVRGSCYNGYGPTENGVFSTVYKVDKNDPFVNGVPLGRAVNNSGAYVVDRNQQLVGPGIIGELVVTGDGLARGYTERAFDQNRFTQLKVEGQSVRGYRTGDRVRYRVGEGLIEFFGRMDFQFKIRSNRIEAGEVEAAILSHPAVRNAAVILRVEEKLEPEIVGFVVAEHDDTAEQEEAGDQVEGWQAFFESTTYTELDTVSSSEIGKDFKGWTSMYDGNEIDKAEMQEWLDDTIHTLTDGQALGHVLEIGTGSGMVLFNLGSGLQSFVGLEPSKSAAAFVNNAIKSTPALAGKAQVFVGTATDTNKLDDLHPDLVIFNSVLQYFPTRDYLERVVDALVHLRSAKRIFFGDVRSYATNRHFLAARAIYTLGNHTTKDEVRKKMAEMEEREEEFLVEPAFFTTLVNRLPDVRHVEIIPKnMQATNELSAYRYAAVVHLRGSDELTRPVHPIKMDDWVDFQASHMHKDALREYLRLAENTKTVAISNIPYGKTIFERQVVESLDETSEDAPHASLDGAAWISAVRSDAKARSSLSVPDLVLLAKETGFRVEVSAARQWSQSGALDAVFHRYPAEPGVRTLFQFPTDNDVRMSAPLTNQPLQRLQKRRVAVQVREWLQDRIPSYMIPSHIVALDQMPLNTSGKVDRKELSRQAKAIKKVQKSAPPTAPAFPLSEVEVMLCEELTKTFEMDVNITDDFFQLGGHSLLATRLVARISHRLGARLTVKDVFDYPVFSELADIIRQQLASKNTLLPTASAGGGGQDKKESAGVAPTTDMEAMLCEEFANILGMDVGITDNFFDLGGHSLMATRLAARIGHRLNTTISVKDIFSHPVIFQLSAKLEVSQLESSSGGTDIKMPDYTAFQLIPAADAEKFMQDHIYPQINFSQDMVQDVYLATHLQQCFLRDVFGRPKPLVPFYVEFPPDSNPHTLATACTSLVDKYDIFRTIFVEAEGNLYQVVLKHLNLDIDVVETDANVHKTSSDLVDAIAKEPVRLGQPMIQVKVLKQTSSVRVLLWLSHALYDGLSWEHIVRDLHILSKERSLPPATQFSRYMQYVDHTRGPGCDFWRDVLQNAPITNLSDAGSGGRPTKAGDPRVWHAGKVISGPSQAIRSSITQATVFNAACAIVLSKETGTDNVVFGRIVSGRQGLPVRWQNIIGPCTNAVPVRAVVDAHGNHQQMLRDLQEQYLLSLPYETIGFDEIKRSCTDWPDSARNYGCCVTYQNFEYHPESEVDQQRVEMGILAKKAELIKEEPLYNVAIAGEVEPDGVHLQVTVVVDSQLFSQEGATHLMEQVCNTFQALNASL | White muscardine disease fungus | Cell apoptosis | Not specified | PC-3M | Prostate cancer | Not found |
| dbacp01452 | Bassianolide nonribosomal cyclodepsipeptide synthetase | MEPPNNANTGQLGPTLPNGTVDLPTDLSREITRHFGLEQDEIEEILPCTPFQRDVIECASDDKRRAVGHVVYEIPEDVDTERLAAAWKATVRYTPALRTCIFTSETGNAFQVVLRDYFIFARMYCPSAHLKSAIVKDEATAAVAGPRCNRYVLTGEPNSKRRVLVWTFSHSFVDSAFQGRILQQVLAAYKDGHGRVFSLQPTTDLTESENGDHLSTPASERTVVIERATQFWQEKLHGLDASVFPHLPSHKRVPAIDARADHYLPCPPFIQHEWSSTTVCRTALAILLARYTHSSEALFGVVTEQSHEEHPLLLDGPTSTVVPFRVLCALNQSVSKVMEAITTYDHDMRQFAHAGLCNISRIGDDASAACGFQTVLMVTDSRTAGDDEIHQVLEESEKFIPCTDRALLLSCQMTDEGVLLVARYDQSILEPLQMARFLRQLGFLINKLQSTDGSPCVGQLDVLAPEDRTEIEGWNSEPLQTQDCLIHSEVVRNAGDTPNKPAVCAWDGEWTYSELNNVSSRLASYISSLDLGQQLIVPIYLEKSKWVMAAILAVLKAGHAFTLIDPNDPPARTAQIIKQASASIALTSALHQSKMQAVVGRCITVDDDLVQTLTTFEGSQVASAAKPGDLAYVIFTSGSTGDPKGIMIEHRAFYSSVVKFGKALGIRSSTRALQFATHGFGAFLLEVLTTLIHGGCICVPSDHDRMHNIPGFIRQNQINWMMATPSYMTTMKPEDVPGLETLVLVGEQMSSSINDVWLSELQLLDGYGQSESSSICFVGKIDDSSRDPNNLGWAIGAHSWIINPDNPDQLVPIGAIGELLIESPGIARGYLFSQSTETPFLERAPAWYASKQPPYGVKFYRTGDLARYAPDGTVICLGRMDSQVKIRGQRVELDAIENLLRRQFPSDVTVVAEAVKRSDLPSSVVITGFLISSEYVVGAPSTEDTYILDQVVTQEINAKMRQILPAHSIPSFYICMKSLPRTATGKVDRRKLRSIGSSLLALQAQSTAPRSSQAPDASAGVTKLEEVWMDIFNLTPNSHNIGGNFFALGGDSITAIKMVnMARAAGIQLKVSDIFQNPTLASLQAAIGGSSMTVTSIPALALDGPVEQSYSQGRLWFLDQLEIGANWYTIPYAVRLRGPLDVDALNRALLALEKRHETLRTTFEDQDGVGVQIIHETLLDQLRIINADHADYVQLLKQEQTAPFNLASESGWRVSLIRLDDDDNILSIVMHHIISDGWSIDVLRRELGQLYAAALHGADLFGSALSPLPIQYRDFSVWQKQDAQVAEHERQLQYWQKQLADCSPAKLPTDFHRPALLSGKATTVPVTITSELYYRLQEFCSTFNTTSFVVLLATFRAAHYRLTGVDDAVIGTPIANRNRHELENLIGFFVNTQCMRITINEDEDTFESLVRQVRSTTTAAFEHEDVPFERVVSAMLPGSRDLSQNPLAQLVFAIHSHKDLGKFELEALESEPLQNEVYTRFDAEFHFFQAPDGLTGYINFATELFKVETIQNVVSVFLQILRHGLEHPQTLISVVPLTDGLAELRSMGLLEIKKVEYPRDSSVVDVFRTQVASYPDTLAVVDSSSRLTYAELDHQSDLLATWLRQQNLPTEALVVVLAPRSCETIITFLGILKANLAYLPLDIRSPITRMRDVLSTLPGRTIALLCSDEVAPDFQLPSIELVRIADALEEAAGMTSLNGHEHVPVPSPSPTSLAYVLYTSGSTGRPKGVMIEHRAIVRLARSDIIPDYRPACGDTMAHMFNTAFDGATYEIYTMLLNGGTLVCVDYMDTLSPKSLEAVFKKEQVNATIMAPALLKLYLADARDALKGLDVLISGGDRFDPQDAVDAQSLVRGSCYNGYGPTENGVFSTVYKVDKNDPFVNGVPLGRAVNNSGAYVVDRNQQLVGPGIIGELVVTGDGLARGYTERAFDQNRFTQLKVEGQSVRGYRTGDRVRYRVGEGLIEFFGRMDFQFKIRSNRIEAGEVEAAILSHPAVRNAAVILRVEEKLEPEIVGFVVAEHDDTAEQEEAGDQVEGWQAFFESTTYTELDTVSSSEIGKDFKGWTSMYDGNEIDKAEMQEWLDDTIHTLTDGQALGHVLEIGTGSGMVLFNLGSGLQSFVGLEPSKSAAAFVNNAIKSTPALAGKAQVFVGTATDTNKLDDLHPDLVIFNSVLQYFPTRDYLERVVDALVHLRSAKRIFFGDVRSYATNRHFLAARAIYTLGNHTTKDEVRKKMAEMEEREEEFLVEPAFFTTLVNRLPDVRHVEIIPKnMQATNELSAYRYAAVVHLRGSDELTRPVHPIKMDDWVDFQASHMHKDALREYLRLAENTKTVAISNIPYGKTIFERQVVESLDETSEDAPHASLDGAAWISAVRSDAKARSSLSVPDLVLLAKETGFRVEVSAARQWSQSGALDAVFHRYPAEPGVRTLFQFPTDNDVRMSAPLTNQPLQRLQKRRVAVQVREWLQDRIPSYMIPSHIVALDQMPLNTSGKVDRKELSRQAKAIKKVQKSAPPTAPAFPLSEVEVMLCEELTKTFEMDVNITDDFFQLGGHSLLATRLVARISHRLGARLTVKDVFDYPVFSELADIIRQQLASKNTLLPTASAGGGGQDKKESAGVAPTTDMEAMLCEEFANILGMDVGITDNFFDLGGHSLMATRLAARIGHRLNTTISVKDIFSHPVIFQLSAKLEVSQLESSSGGTDIKMPDYTAFQLIPAADAEKFMQDHIYPQINFSQDMVQDVYLATHLQQCFLRDVFGRPKPLVPFYVEFPPDSNPHTLATACTSLVDKYDIFRTIFVEAEGNLYQVVLKHLNLDIDVVETDANVHKTSSDLVDAIAKEPVRLGQPMIQVKVLKQTSSVRVLLWLSHALYDGLSWEHIVRDLHILSKERSLPPATQFSRYMQYVDHTRGPGCDFWRDVLQNAPITNLSDAGSGGRPTKAGDPRVWHAGKVISGPSQAIRSSITQATVFNAACAIVLSKETGTDNVVFGRIVSGRQGLPVRWQNIIGPCTNAVPVRAVVDAHGNHQQMLRDLQEQYLLSLPYETIGFDEIKRSCTDWPDSARNYGCCVTYQNFEYHPESEVDQQRVEMGILAKKAELIKEEPLYNVAIAGEVEPDGVHLQVTVVVDSQLFSQEGATHLMEQVCNTFQALNASL | White muscardine disease fungus | Cell apoptosis | Not specified | MDA-MB-231 | Breast cancer | Not found |
| dbacp01453 | Bassianolide nonribosomal cyclodepsipeptide synthetase | MEPPNNANTGQLGPTLPNGTVDLPTDLSREITRHFGLEQDEIEEILPCTPFQRDVIECASDDKRRAVGHVVYEIPEDVDTERLAAAWKATVRYTPALRTCIFTSETGNAFQVVLRDYFIFARMYCPSAHLKSAIVKDEATAAVAGPRCNRYVLTGEPNSKRRVLVWTFSHSFVDSAFQGRILQQVLAAYKDGHGRVFSLQPTTDLTESENGDHLSTPASERTVVIERATQFWQEKLHGLDASVFPHLPSHKRVPAIDARADHYLPCPPFIQHEWSSTTVCRTALAILLARYTHSSEALFGVVTEQSHEEHPLLLDGPTSTVVPFRVLCALNQSVSKVMEAITTYDHDMRQFAHAGLCNISRIGDDASAACGFQTVLMVTDSRTAGDDEIHQVLEESEKFIPCTDRALLLSCQMTDEGVLLVARYDQSILEPLQMARFLRQLGFLINKLQSTDGSPCVGQLDVLAPEDRTEIEGWNSEPLQTQDCLIHSEVVRNAGDTPNKPAVCAWDGEWTYSELNNVSSRLASYISSLDLGQQLIVPIYLEKSKWVMAAILAVLKAGHAFTLIDPNDPPARTAQIIKQASASIALTSALHQSKMQAVVGRCITVDDDLVQTLTTFEGSQVASAAKPGDLAYVIFTSGSTGDPKGIMIEHRAFYSSVVKFGKALGIRSSTRALQFATHGFGAFLLEVLTTLIHGGCICVPSDHDRMHNIPGFIRQNQINWMMATPSYMTTMKPEDVPGLETLVLVGEQMSSSINDVWLSELQLLDGYGQSESSSICFVGKIDDSSRDPNNLGWAIGAHSWIINPDNPDQLVPIGAIGELLIESPGIARGYLFSQSTETPFLERAPAWYASKQPPYGVKFYRTGDLARYAPDGTVICLGRMDSQVKIRGQRVELDAIENLLRRQFPSDVTVVAEAVKRSDLPSSVVITGFLISSEYVVGAPSTEDTYILDQVVTQEINAKMRQILPAHSIPSFYICMKSLPRTATGKVDRRKLRSIGSSLLALQAQSTAPRSSQAPDASAGVTKLEEVWMDIFNLTPNSHNIGGNFFALGGDSITAIKMVnMARAAGIQLKVSDIFQNPTLASLQAAIGGSSMTVTSIPALALDGPVEQSYSQGRLWFLDQLEIGANWYTIPYAVRLRGPLDVDALNRALLALEKRHETLRTTFEDQDGVGVQIIHETLLDQLRIINADHADYVQLLKQEQTAPFNLASESGWRVSLIRLDDDDNILSIVMHHIISDGWSIDVLRRELGQLYAAALHGADLFGSALSPLPIQYRDFSVWQKQDAQVAEHERQLQYWQKQLADCSPAKLPTDFHRPALLSGKATTVPVTITSELYYRLQEFCSTFNTTSFVVLLATFRAAHYRLTGVDDAVIGTPIANRNRHELENLIGFFVNTQCMRITINEDEDTFESLVRQVRSTTTAAFEHEDVPFERVVSAMLPGSRDLSQNPLAQLVFAIHSHKDLGKFELEALESEPLQNEVYTRFDAEFHFFQAPDGLTGYINFATELFKVETIQNVVSVFLQILRHGLEHPQTLISVVPLTDGLAELRSMGLLEIKKVEYPRDSSVVDVFRTQVASYPDTLAVVDSSSRLTYAELDHQSDLLATWLRQQNLPTEALVVVLAPRSCETIITFLGILKANLAYLPLDIRSPITRMRDVLSTLPGRTIALLCSDEVAPDFQLPSIELVRIADALEEAAGMTSLNGHEHVPVPSPSPTSLAYVLYTSGSTGRPKGVMIEHRAIVRLARSDIIPDYRPACGDTMAHMFNTAFDGATYEIYTMLLNGGTLVCVDYMDTLSPKSLEAVFKKEQVNATIMAPALLKLYLADARDALKGLDVLISGGDRFDPQDAVDAQSLVRGSCYNGYGPTENGVFSTVYKVDKNDPFVNGVPLGRAVNNSGAYVVDRNQQLVGPGIIGELVVTGDGLARGYTERAFDQNRFTQLKVEGQSVRGYRTGDRVRYRVGEGLIEFFGRMDFQFKIRSNRIEAGEVEAAILSHPAVRNAAVILRVEEKLEPEIVGFVVAEHDDTAEQEEAGDQVEGWQAFFESTTYTELDTVSSSEIGKDFKGWTSMYDGNEIDKAEMQEWLDDTIHTLTDGQALGHVLEIGTGSGMVLFNLGSGLQSFVGLEPSKSAAAFVNNAIKSTPALAGKAQVFVGTATDTNKLDDLHPDLVIFNSVLQYFPTRDYLERVVDALVHLRSAKRIFFGDVRSYATNRHFLAARAIYTLGNHTTKDEVRKKMAEMEEREEEFLVEPAFFTTLVNRLPDVRHVEIIPKnMQATNELSAYRYAAVVHLRGSDELTRPVHPIKMDDWVDFQASHMHKDALREYLRLAENTKTVAISNIPYGKTIFERQVVESLDETSEDAPHASLDGAAWISAVRSDAKARSSLSVPDLVLLAKETGFRVEVSAARQWSQSGALDAVFHRYPAEPGVRTLFQFPTDNDVRMSAPLTNQPLQRLQKRRVAVQVREWLQDRIPSYMIPSHIVALDQMPLNTSGKVDRKELSRQAKAIKKVQKSAPPTAPAFPLSEVEVMLCEELTKTFEMDVNITDDFFQLGGHSLLATRLVARISHRLGARLTVKDVFDYPVFSELADIIRQQLASKNTLLPTASAGGGGQDKKESAGVAPTTDMEAMLCEEFANILGMDVGITDNFFDLGGHSLMATRLAARIGHRLNTTISVKDIFSHPVIFQLSAKLEVSQLESSSGGTDIKMPDYTAFQLIPAADAEKFMQDHIYPQINFSQDMVQDVYLATHLQQCFLRDVFGRPKPLVPFYVEFPPDSNPHTLATACTSLVDKYDIFRTIFVEAEGNLYQVVLKHLNLDIDVVETDANVHKTSSDLVDAIAKEPVRLGQPMIQVKVLKQTSSVRVLLWLSHALYDGLSWEHIVRDLHILSKERSLPPATQFSRYMQYVDHTRGPGCDFWRDVLQNAPITNLSDAGSGGRPTKAGDPRVWHAGKVISGPSQAIRSSITQATVFNAACAIVLSKETGTDNVVFGRIVSGRQGLPVRWQNIIGPCTNAVPVRAVVDAHGNHQQMLRDLQEQYLLSLPYETIGFDEIKRSCTDWPDSARNYGCCVTYQNFEYHPESEVDQQRVEMGILAKKAELIKEEPLYNVAIAGEVEPDGVHLQVTVVVDSQLFSQEGATHLMEQVCNTFQALNASL | White muscardine disease fungus | Cell apoptosis | Not specified | HUVEC-2 | Prostate cancer | Not found |
| dbacp01454 | Bassianolide nonribosomal cyclodepsipeptide synthetase (BSLS) | MEPPNNANTGQLGPTLPNGTVDLPTDLSREITRHFGLEQDEIEEILPCTPFQRDVIECASDDKRRAVGHVVYEIPEDVDTERLAAAWKATVRYTPALRTCIFTSETGNAFQVVLRDCFIFARMYCPSAHLKSAIVKDEATAAVAGPRCNRYVLTGEPNSKRRVLVWTFSHSFVDSAFQGRILQQVLAAYKDEHGRVFSLQPTTDLVESENGDCLSTPASERTVGIERATQFWQEKLHGLDASVFPHLPSHKRVPAIDARADHYLPCPPFIQHEWSSTTVCRTALAILLARYTHSSEALFGVVTEQSHEEHPLLLDGPTSTVVPFRVLCAPNQSVSEVMEAITTYDHDMRQFAHAGLCNISRIGDDASAACGFQTVLMVTDSRTASADEIHHVLEEPEKFIPCTDRALLLSCQMTDEGVLLVARYDQSILEPLQMARFLRQLGFLINKLQSTDGSPCVGQLDVLAPEDRTEIEGWNSEPLQTQDCLIHSEVVKNADDTPNKPAVCAWDGEWTYSELNNVSSRLASYISSLDLGQQLIVPIYLEKSKWVMAAILAVLKAGHAFTLIDPNDPPARTAQIIKQASASIALTSALHQSKMQTVVGRCITVDDDLFQTLTTFEGSQVASAAKPGDLAYVIFTSGSTGDPKGIMIEHRAFYSSVVKFGKALGIRSSTRALQFATHGFGAFLLEVLTTLIHGGCICIPSDHDRMHNIPGFIRQSQINWMMATPSYMTTMKPEDVPGLETLVLVGEQMSSSINDVWLSELQLLDGYGQSESSSICFVGKISDSSRDPNNLGRAIGSHSWIVNPDNPDQLVPIGAIGELLIESPGIARGYLFSQSTETPFLERAPAWYASKQPPYGVKFYRTGDLARYAPDGTVICLGRMDSQVKIRGQRVELDAIENLLRRQFPSDVTVVAEAVKRSDLPSSVVITGFLISSEYVVGAPSTEDTYILDQAVTQEINAKMRQILPAHSIPSFYICMKSLPRTATGKVDRRKLRSIGSSLLALQAQSTAPRSSQAPDASAGVTKLEEVWMDIFNLTPNSHNIGGNFFALGGDSITAIKMVnMARAAGIQLKVSDIFQNPTLASLQAAIGGSSMTVTSIPALALDGPVEQSYSQGRLWFLDQLEIGANWYTIPYAVRLRGPLDVDALNRALLALEKRHETLRTTFEDQDGVGVQIIHETLLDQLRIINADHADYVQLLKQEQTAPFNLASESGWRVSLIRLDDDDNILSIVMHHIISDGWSIDVLRRELGQLYAAALHGADLFGSALSPLPIQYRDFSVWQKQDAQVAEHERQLQYWQKQLADCSPAKLPTDFHRPALLSGKATTVPVTITSELYYRLQEFCSTFNTTSFVVLLATFRAAHYRLTGVDDAVIGTPIANRNRHELENLIGFFVNTQCMRITINEDEETFESLVRQVRSTTTAAFEHEDVPFERVVSAMLPGSRDLSQNPLAQLVFAIHSHKDLGKFELEALESEPLQNEVYTRFDAEFHFFQAPDGLTGYINFATELFKVETIQNVVSVFLQILRHGLEHPQTLISVVPLTDGLAELRSMGLLEIKKVEYPRDSSVVDVFATQVASYPDTLAVVDSSSRLTYAELDHQSDLLATWLRQQNLPTEALVVVLAPRSCETIITFLGILKANLAYLPLDIRSPITRMRDVLSTLPGRTIALLCSDEVAPDFQLPSIELVRIADALEEAAGMTSLNGHEHVPVPSPSPTSLAYVLYTSGSTGRPKGVMIEHRAIVRLARSDIIPDYRPACGDTMAHMFNTAFDGATYEIYTMLLNGGTLVCVDYMDTLSPKSLEAVFKKEQVNATIMAPALLKLYLADARDALKGLDVLISGGDRFDPQDAVDAQSLVRGSCYNGYGPTENGVFSTVYKVDKNDPFVNGVPLGRAVNNSGAYVVDRNQQLVGPGIIGELVVTGDGLARGYTERAFDQNRFIQLKIEGQSVRGYRTGDRVRYRVGEGLIEFFGRMDFQFKIRSNRIEAGEVEAAILSHPAVRNAAVILHVQEKLEPEIVGFVVAEHDDTAEQEEAGDQVEGWQAFFESTTYTELDTVSSSEIGKDFKGWTSMYDGNEIDKAEMQEWLDDTIHTLTDGQALGHVLEIGTGSGMVLFNLGSGLQSFVGLEPSKSAAAFVNNAIKSTPALAGKAHVFVGTATDTNKLDDLHPDLVIFNSVLQYFPTRDYLEQVVDALVHLRSAKRIFFGDVRSYATNRHFLAARAIYTLGNHTTKDEVRKKMAEMEEREEEFLVEPAFFTTLVNRLPDVRHVEIIPKnMQATNELSAYRYAAVVHLRGPDELTRPVHLIKMDDWVDFQASHMHKDALREYLRLAENTKTVAISNIPYGKTIFERQVVESLDDTSEDAPHASLDGAAWISAVRSDAKARSSLSVPDLVLLAKETGFRVEVSAARQWSQSGALDAVFHRYHPAEPDVRTLFQFPTDNDVRMSALLTNQPLQRLQKRRVAVQVREWLQDRIPSYMIPSHIVALDQMPLNTSGKVDRKELSRQAKAIKKVQKSAPPTAPAFPLSEVEVMLCEELTKTFEMDVNITDDFFQLGGHSLLATRLVARISHRLGARLTVKDVFDYPVFSELADIIRQQLASKNTLLPTASAGGGGQDKKESAGVAPTTDMEAMLCEEFANILGMDVGITDNFFDLGGHSLMATRLAARIGHRLNTTISVKDIFSHPVIFQLSAKLEVSQLESSSGGTDIKMPDYTAFQLIPAADAEKFMQDHIYPQINFSQDMVQDVYLATHLQQCFLRDVFGRPKPLVPFYVEFPPDSNPHTLATACTSLVDKYDIFRTIFVEAEGNLYQVVLKHLNLDIDVVETDANVHKTSSDLVDAIAKEPVRLGQPMIQVKVLKQTSSVRVLLWLSHALYDGLSWEHIVRDLHILSKERSLPPATQFSRYMQYVDHTRGPGCDFWRDVLQNAPITNLSDAGSGGRPTKAGDPRVWHAGKVISGPSQAIRSSITQATVFNAACAIVLSKETGTDNVVFGRIVSGRQGLPVRWQNIIGPCTNAVPVRAVVDAHGNHQQMLRDLQEQYLLSLPYETIGFDEIKRSCTDWPDSARNYGCCVTYQNFEYHPESEVDQQRVEMGILAKKAELIKEEPLYNVAIAGEVEPDGVHLQVTVVVDSQLFSQEGATHLMEQVCNTFQALNASL | White muscardine disease fungus | Cell apoptosis | Not specified | PC-3M | Prostate cancer | Not found |
| dbacp01455 | Bassianolide nonribosomal cyclodepsipeptide synthetase (BSLS) | MEPPNNANTGQLGPTLPNGTVDLPTDLSREITRHFGLEQDEIEEILPCTPFQRDVIECASDDKRRAVGHVVYEIPEDVDTERLAAAWKATVRYTPALRTCIFTSETGNAFQVVLRDCFIFARMYCPSAHLKSAIVKDEATAAVAGPRCNRYVLTGEPNSKRRVLVWTFSHSFVDSAFQGRILQQVLAAYKDEHGRVFSLQPTTDLVESENGDCLSTPASERTVGIERATQFWQEKLHGLDASVFPHLPSHKRVPAIDARADHYLPCPPFIQHEWSSTTVCRTALAILLARYTHSSEALFGVVTEQSHEEHPLLLDGPTSTVVPFRVLCAPNQSVSEVMEAITTYDHDMRQFAHAGLCNISRIGDDASAACGFQTVLMVTDSRTASADEIHHVLEEPEKFIPCTDRALLLSCQMTDEGVLLVARYDQSILEPLQMARFLRQLGFLINKLQSTDGSPCVGQLDVLAPEDRTEIEGWNSEPLQTQDCLIHSEVVKNADDTPNKPAVCAWDGEWTYSELNNVSSRLASYISSLDLGQQLIVPIYLEKSKWVMAAILAVLKAGHAFTLIDPNDPPARTAQIIKQASASIALTSALHQSKMQTVVGRCITVDDDLFQTLTTFEGSQVASAAKPGDLAYVIFTSGSTGDPKGIMIEHRAFYSSVVKFGKALGIRSSTRALQFATHGFGAFLLEVLTTLIHGGCICIPSDHDRMHNIPGFIRQSQINWMMATPSYMTTMKPEDVPGLETLVLVGEQMSSSINDVWLSELQLLDGYGQSESSSICFVGKISDSSRDPNNLGRAIGSHSWIVNPDNPDQLVPIGAIGELLIESPGIARGYLFSQSTETPFLERAPAWYASKQPPYGVKFYRTGDLARYAPDGTVICLGRMDSQVKIRGQRVELDAIENLLRRQFPSDVTVVAEAVKRSDLPSSVVITGFLISSEYVVGAPSTEDTYILDQAVTQEINAKMRQILPAHSIPSFYICMKSLPRTATGKVDRRKLRSIGSSLLALQAQSTAPRSSQAPDASAGVTKLEEVWMDIFNLTPNSHNIGGNFFALGGDSITAIKMVnMARAAGIQLKVSDIFQNPTLASLQAAIGGSSMTVTSIPALALDGPVEQSYSQGRLWFLDQLEIGANWYTIPYAVRLRGPLDVDALNRALLALEKRHETLRTTFEDQDGVGVQIIHETLLDQLRIINADHADYVQLLKQEQTAPFNLASESGWRVSLIRLDDDDNILSIVMHHIISDGWSIDVLRRELGQLYAAALHGADLFGSALSPLPIQYRDFSVWQKQDAQVAEHERQLQYWQKQLADCSPAKLPTDFHRPALLSGKATTVPVTITSELYYRLQEFCSTFNTTSFVVLLATFRAAHYRLTGVDDAVIGTPIANRNRHELENLIGFFVNTQCMRITINEDEETFESLVRQVRSTTTAAFEHEDVPFERVVSAMLPGSRDLSQNPLAQLVFAIHSHKDLGKFELEALESEPLQNEVYTRFDAEFHFFQAPDGLTGYINFATELFKVETIQNVVSVFLQILRHGLEHPQTLISVVPLTDGLAELRSMGLLEIKKVEYPRDSSVVDVFATQVASYPDTLAVVDSSSRLTYAELDHQSDLLATWLRQQNLPTEALVVVLAPRSCETIITFLGILKANLAYLPLDIRSPITRMRDVLSTLPGRTIALLCSDEVAPDFQLPSIELVRIADALEEAAGMTSLNGHEHVPVPSPSPTSLAYVLYTSGSTGRPKGVMIEHRAIVRLARSDIIPDYRPACGDTMAHMFNTAFDGATYEIYTMLLNGGTLVCVDYMDTLSPKSLEAVFKKEQVNATIMAPALLKLYLADARDALKGLDVLISGGDRFDPQDAVDAQSLVRGSCYNGYGPTENGVFSTVYKVDKNDPFVNGVPLGRAVNNSGAYVVDRNQQLVGPGIIGELVVTGDGLARGYTERAFDQNRFIQLKIEGQSVRGYRTGDRVRYRVGEGLIEFFGRMDFQFKIRSNRIEAGEVEAAILSHPAVRNAAVILHVQEKLEPEIVGFVVAEHDDTAEQEEAGDQVEGWQAFFESTTYTELDTVSSSEIGKDFKGWTSMYDGNEIDKAEMQEWLDDTIHTLTDGQALGHVLEIGTGSGMVLFNLGSGLQSFVGLEPSKSAAAFVNNAIKSTPALAGKAHVFVGTATDTNKLDDLHPDLVIFNSVLQYFPTRDYLEQVVDALVHLRSAKRIFFGDVRSYATNRHFLAARAIYTLGNHTTKDEVRKKMAEMEEREEEFLVEPAFFTTLVNRLPDVRHVEIIPKnMQATNELSAYRYAAVVHLRGPDELTRPVHLIKMDDWVDFQASHMHKDALREYLRLAENTKTVAISNIPYGKTIFERQVVESLDDTSEDAPHASLDGAAWISAVRSDAKARSSLSVPDLVLLAKETGFRVEVSAARQWSQSGALDAVFHRYHPAEPDVRTLFQFPTDNDVRMSALLTNQPLQRLQKRRVAVQVREWLQDRIPSYMIPSHIVALDQMPLNTSGKVDRKELSRQAKAIKKVQKSAPPTAPAFPLSEVEVMLCEELTKTFEMDVNITDDFFQLGGHSLLATRLVARISHRLGARLTVKDVFDYPVFSELADIIRQQLASKNTLLPTASAGGGGQDKKESAGVAPTTDMEAMLCEEFANILGMDVGITDNFFDLGGHSLMATRLAARIGHRLNTTISVKDIFSHPVIFQLSAKLEVSQLESSSGGTDIKMPDYTAFQLIPAADAEKFMQDHIYPQINFSQDMVQDVYLATHLQQCFLRDVFGRPKPLVPFYVEFPPDSNPHTLATACTSLVDKYDIFRTIFVEAEGNLYQVVLKHLNLDIDVVETDANVHKTSSDLVDAIAKEPVRLGQPMIQVKVLKQTSSVRVLLWLSHALYDGLSWEHIVRDLHILSKERSLPPATQFSRYMQYVDHTRGPGCDFWRDVLQNAPITNLSDAGSGGRPTKAGDPRVWHAGKVISGPSQAIRSSITQATVFNAACAIVLSKETGTDNVVFGRIVSGRQGLPVRWQNIIGPCTNAVPVRAVVDAHGNHQQMLRDLQEQYLLSLPYETIGFDEIKRSCTDWPDSARNYGCCVTYQNFEYHPESEVDQQRVEMGILAKKAELIKEEPLYNVAIAGEVEPDGVHLQVTVVVDSQLFSQEGATHLMEQVCNTFQALNASL | White muscardine disease fungus | Cell apoptosis | Not specified | MDA-MB-231 | Breast cancer | Not found |
| dbacp01456 | Bassianolide nonribosomal cyclodepsipeptide synthetase (BSLS) | MEPPNNANTGQLGPTLPNGTVDLPTDLSREITRHFGLEQDEIEEILPCTPFQRDVIECASDDKRRAVGHVVYEIPEDVDTERLAAAWKATVRYTPALRTCIFTSETGNAFQVVLRDCFIFARMYCPSAHLKSAIVKDEATAAVAGPRCNRYVLTGEPNSKRRVLVWTFSHSFVDSAFQGRILQQVLAAYKDEHGRVFSLQPTTDLVESENGDCLSTPASERTVGIERATQFWQEKLHGLDASVFPHLPSHKRVPAIDARADHYLPCPPFIQHEWSSTTVCRTALAILLARYTHSSEALFGVVTEQSHEEHPLLLDGPTSTVVPFRVLCAPNQSVSEVMEAITTYDHDMRQFAHAGLCNISRIGDDASAACGFQTVLMVTDSRTASADEIHHVLEEPEKFIPCTDRALLLSCQMTDEGVLLVARYDQSILEPLQMARFLRQLGFLINKLQSTDGSPCVGQLDVLAPEDRTEIEGWNSEPLQTQDCLIHSEVVKNADDTPNKPAVCAWDGEWTYSELNNVSSRLASYISSLDLGQQLIVPIYLEKSKWVMAAILAVLKAGHAFTLIDPNDPPARTAQIIKQASASIALTSALHQSKMQTVVGRCITVDDDLFQTLTTFEGSQVASAAKPGDLAYVIFTSGSTGDPKGIMIEHRAFYSSVVKFGKALGIRSSTRALQFATHGFGAFLLEVLTTLIHGGCICIPSDHDRMHNIPGFIRQSQINWMMATPSYMTTMKPEDVPGLETLVLVGEQMSSSINDVWLSELQLLDGYGQSESSSICFVGKISDSSRDPNNLGRAIGSHSWIVNPDNPDQLVPIGAIGELLIESPGIARGYLFSQSTETPFLERAPAWYASKQPPYGVKFYRTGDLARYAPDGTVICLGRMDSQVKIRGQRVELDAIENLLRRQFPSDVTVVAEAVKRSDLPSSVVITGFLISSEYVVGAPSTEDTYILDQAVTQEINAKMRQILPAHSIPSFYICMKSLPRTATGKVDRRKLRSIGSSLLALQAQSTAPRSSQAPDASAGVTKLEEVWMDIFNLTPNSHNIGGNFFALGGDSITAIKMVnMARAAGIQLKVSDIFQNPTLASLQAAIGGSSMTVTSIPALALDGPVEQSYSQGRLWFLDQLEIGANWYTIPYAVRLRGPLDVDALNRALLALEKRHETLRTTFEDQDGVGVQIIHETLLDQLRIINADHADYVQLLKQEQTAPFNLASESGWRVSLIRLDDDDNILSIVMHHIISDGWSIDVLRRELGQLYAAALHGADLFGSALSPLPIQYRDFSVWQKQDAQVAEHERQLQYWQKQLADCSPAKLPTDFHRPALLSGKATTVPVTITSELYYRLQEFCSTFNTTSFVVLLATFRAAHYRLTGVDDAVIGTPIANRNRHELENLIGFFVNTQCMRITINEDEETFESLVRQVRSTTTAAFEHEDVPFERVVSAMLPGSRDLSQNPLAQLVFAIHSHKDLGKFELEALESEPLQNEVYTRFDAEFHFFQAPDGLTGYINFATELFKVETIQNVVSVFLQILRHGLEHPQTLISVVPLTDGLAELRSMGLLEIKKVEYPRDSSVVDVFATQVASYPDTLAVVDSSSRLTYAELDHQSDLLATWLRQQNLPTEALVVVLAPRSCETIITFLGILKANLAYLPLDIRSPITRMRDVLSTLPGRTIALLCSDEVAPDFQLPSIELVRIADALEEAAGMTSLNGHEHVPVPSPSPTSLAYVLYTSGSTGRPKGVMIEHRAIVRLARSDIIPDYRPACGDTMAHMFNTAFDGATYEIYTMLLNGGTLVCVDYMDTLSPKSLEAVFKKEQVNATIMAPALLKLYLADARDALKGLDVLISGGDRFDPQDAVDAQSLVRGSCYNGYGPTENGVFSTVYKVDKNDPFVNGVPLGRAVNNSGAYVVDRNQQLVGPGIIGELVVTGDGLARGYTERAFDQNRFIQLKIEGQSVRGYRTGDRVRYRVGEGLIEFFGRMDFQFKIRSNRIEAGEVEAAILSHPAVRNAAVILHVQEKLEPEIVGFVVAEHDDTAEQEEAGDQVEGWQAFFESTTYTELDTVSSSEIGKDFKGWTSMYDGNEIDKAEMQEWLDDTIHTLTDGQALGHVLEIGTGSGMVLFNLGSGLQSFVGLEPSKSAAAFVNNAIKSTPALAGKAHVFVGTATDTNKLDDLHPDLVIFNSVLQYFPTRDYLEQVVDALVHLRSAKRIFFGDVRSYATNRHFLAARAIYTLGNHTTKDEVRKKMAEMEEREEEFLVEPAFFTTLVNRLPDVRHVEIIPKnMQATNELSAYRYAAVVHLRGPDELTRPVHLIKMDDWVDFQASHMHKDALREYLRLAENTKTVAISNIPYGKTIFERQVVESLDDTSEDAPHASLDGAAWISAVRSDAKARSSLSVPDLVLLAKETGFRVEVSAARQWSQSGALDAVFHRYHPAEPDVRTLFQFPTDNDVRMSALLTNQPLQRLQKRRVAVQVREWLQDRIPSYMIPSHIVALDQMPLNTSGKVDRKELSRQAKAIKKVQKSAPPTAPAFPLSEVEVMLCEELTKTFEMDVNITDDFFQLGGHSLLATRLVARISHRLGARLTVKDVFDYPVFSELADIIRQQLASKNTLLPTASAGGGGQDKKESAGVAPTTDMEAMLCEEFANILGMDVGITDNFFDLGGHSLMATRLAARIGHRLNTTISVKDIFSHPVIFQLSAKLEVSQLESSSGGTDIKMPDYTAFQLIPAADAEKFMQDHIYPQINFSQDMVQDVYLATHLQQCFLRDVFGRPKPLVPFYVEFPPDSNPHTLATACTSLVDKYDIFRTIFVEAEGNLYQVVLKHLNLDIDVVETDANVHKTSSDLVDAIAKEPVRLGQPMIQVKVLKQTSSVRVLLWLSHALYDGLSWEHIVRDLHILSKERSLPPATQFSRYMQYVDHTRGPGCDFWRDVLQNAPITNLSDAGSGGRPTKAGDPRVWHAGKVISGPSQAIRSSITQATVFNAACAIVLSKETGTDNVVFGRIVSGRQGLPVRWQNIIGPCTNAVPVRAVVDAHGNHQQMLRDLQEQYLLSLPYETIGFDEIKRSCTDWPDSARNYGCCVTYQNFEYHPESEVDQQRVEMGILAKKAELIKEEPLYNVAIAGEVEPDGVHLQVTVVVDSQLFSQEGATHLMEQVCNTFQALNASL | White muscardine disease fungus | Cell apoptosis | Not specified | HUVEC-2 | Prostate cancer | Not found |
| dbacp01457 | Bax 1 | STKKLSECLKRIGDELDSnM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | Jurkat | Not specified | IC50 : 2.0 μmol/L |
| dbacp01458 | Bax 1 | STKKLSECLKRIGDELDSnM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | HL-60 | Not specified | IC50 : 2.0 μmol/L |
| dbacp01459 | Bax 1 | STKKLSECLKRIGDELDSnM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | U937 | Not specified | IC50 : 2.0 μmol/L |
| dbacp01460 | Bax 1 | STKKLSECLKRIGDELDSnM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | PC-3 | Not specified | IC50 : 2.0 μmol/L |
| dbacp01461 | Bax 10 | KLSECLKRIGDELDS | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | Jurkat | Not specified | IC50 : > 500 μmol/L |
| dbacp01462 | Bax 10 | KLSECLKRIGDELDS | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | HL-60 | Not specified | IC50 : > 500 μmol/L |
| dbacp01463 | Bax 10 | KLSECLKRIGDELDS | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | U937 | Not specified | IC50 : > 500 μmol/L |
| dbacp01464 | Bax 10 | KLSECLKRIGDELDS | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | PC-3 | Not specified | IC50 : > 500 μmol/L |
| dbacp01465 | Bax 11 | LSECLKRIGDELDSN | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | Jurkat | Not specified | IC50 : > 500 μmol/L |
| dbacp01466 | Bax 11 | LSECLKRIGDELDSN | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | HL-60 | Not specified | IC50 : > 500 μmol/L |
| dbacp01467 | Bax 11 | LSECLKRIGDELDSN | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | U937 | Not specified | IC50 : > 500 μmol/L |
| dbacp01468 | Bax 11 | LSECLKRIGDELDSN | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | PC-3 | Not specified | IC50 : > 500 μmol/L |
| dbacp01469 | Bax 12 | STKKLECLKRIGDELDSnM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | Jurkat | Not specified | IC50 : > 500 μmol/L |
| dbacp01470 | Bax 12 | STKKLECLKRIGDELDSnM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | HL-60 | Not specified | IC50 : > 500 μmol/L |
| dbacp01471 | Bax 12 | STKKLECLKRIGDELDSnM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | U937 | Not specified | IC50 : > 500 μmol/L |
| dbacp01472 | Bax 12 | STKKLECLKRIGDELDSnM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | PC-3 | Not specified | IC50 : > 500 μmol/L |
| dbacp01473 | Bax 13 | STKKLCLKRIGDELDSnM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | Jurkat | Not specified | IC50 : > 500 μmol/L |
| dbacp01474 | Bax 13 | STKKLCLKRIGDELDSnM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | HL-60 | Not specified | IC50 : > 500 μmol/L |
| dbacp01475 | Bax 13 | STKKLCLKRIGDELDSnM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | U937 | Not specified | IC50 : > 500 μmol/L |
| dbacp01476 | Bax 13 | STKKLCLKRIGDELDSnM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | PC-3 | Not specified | IC50 : > 500 μmol/L |
| dbacp01477 | Bax 14 | STKKLLKRIGDELDSnM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | Jurkat | Not specified | IC50 : > 500 μmol/L |
| dbacp01478 | Bax 14 | STKKLLKRIGDELDSnM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | HL-60 | Not specified | IC50 : > 500 μmol/L |
| dbacp01479 | Bax 14 | STKKLLKRIGDELDSnM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | U937 | Not specified | IC50 : > 500 μmol/L |
| dbacp01480 | Bax 14 | STKKLLKRIGDELDSnM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | PC-3 | Not specified | IC50 : > 500 μmol/L |
| dbacp01481 | Bax 15 | STKKLSECLGDELDSnM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | Jurkat | Not specified | IC50 : > 500 μmol/L |
| dbacp01482 | Bax 15 | STKKLSECLGDELDSnM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | HL-60 | Not specified | IC50 : > 500 μmol/L |
| dbacp01483 | Bax 15 | STKKLSECLGDELDSnM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | U937 | Not specified | IC50 : > 500 μmol/L |
| dbacp01484 | Bax 15 | STKKLSECLGDELDSnM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | PC-3 | Not specified | IC50 : > 500 μmol/L |
| dbacp01485 | Bax 16 | STKKLSECLKRIGDEL | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | Jurkat | Not specified | IC50 : 20 μmol/L |
| dbacp01486 | Bax 16 | STKKLSECLKRIGDEL | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | HL-60 | Not specified | IC50 : 20 μmol/L |
| dbacp01487 | Bax 16 | STKKLSECLKRIGDEL | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | U937 | Not specified | IC50 : 20 μmol/L |
| dbacp01488 | Bax 16 | STKKLSECLKRIGDEL | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | PC-3 | Not specified | IC50 : 20 μmol/L |
| dbacp01489 | Bax 17 | TKKLSECLKRIGDEL | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | Jurkat | Not specified | IC50 : 79 μmol/L |
| dbacp01490 | Bax 17 | TKKLSECLKRIGDEL | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | HL-60 | Not specified | IC50 : 79 μmol/L |
| dbacp01491 | Bax 17 | TKKLSECLKRIGDEL | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | U937 | Not specified | IC50 : 79 μmol/L |
| dbacp01492 | Bax 17 | TKKLSECLKRIGDEL | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | PC-3 | Not specified | IC50 : 79 μmol/L |
| dbacp01493 | Bax 18 | TKKLSECLKRIGDE | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | Jurkat | Not specified | IC50 : > 500 μmol/L |
| dbacp01494 | Bax 18 | TKKLSECLKRIGDE | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | HL-60 | Not specified | IC50 : > 500 μmol/L |
| dbacp01495 | Bax 18 | TKKLSECLKRIGDE | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | U937 | Not specified | IC50 : > 500 μmol/L |
| dbacp01496 | Bax 18 | TKKLSECLKRIGDE | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | PC-3 | Not specified | IC50 : > 500 μmol/L |
| dbacp01497 | Bax 2 | AAKKLSECLKRIGDELDSnM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | Jurkat | Not specified | IC50 : 2.3 μmol/L |
| dbacp01498 | Bax 2 | AAKKLSECLKRIGDELDSnM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | HL-60 | Not specified | IC50 : 2.3 μmol/L |
| dbacp01499 | Bax 2 | AAKKLSECLKRIGDELDSnM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | U937 | Not specified | IC50 : 2.3 μmol/L |
| dbacp01500 | Bax 2 | AAKKLSECLKRIGDELDSnM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | PC-3 | Not specified | IC50 : 2.3 μmol/L |
| dbacp01501 | Bax 3 | STKKLSECLKRIGDELDS | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | Jurkat | Not specified | IC50 : 18.3 μmol/L |
| dbacp01502 | Bax 3 | STKKLSECLKRIGDELDS | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | HL-60 | Not specified | IC50 : 18.3 μmol/L |
| dbacp01503 | Bax 3 | STKKLSECLKRIGDELDS | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | U937 | Not specified | IC50 : 18.3 μmol/L |
| dbacp01504 | Bax 3 | STKKLSECLKRIGDELDS | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | PC-3 | Not specified | IC50 : 18.3 μmol/L |
| dbacp01505 | Bax 4 | STKKLSECLKRIGDELDSM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | Jurkat | Not specified | IC50 : 7.6 μmol/L |
| dbacp01506 | Bax 4 | STKKLSECLKRIGDELDSM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | HL-60 | Not specified | IC50 : 7.6 μmol/L |
| dbacp01507 | Bax 4 | STKKLSECLKRIGDELDSM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | U937 | Not specified | IC50 : 7.6 μmol/L |
| dbacp01508 | Bax 4 | STKKLSECLKRIGDELDSM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | PC-3 | Not specified | IC50 : 7.6 μmol/L |
| dbacp01509 | Bax 5 | STKKLSECLKRIGDELDM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | Jurkat | Not specified | IC50 : 2.1 μmol/L |
| dbacp01510 | Bax 5 | STKKLSECLKRIGDELDM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | HL-60 | Not specified | IC50 : 2.1 μmol/L |
| dbacp01511 | Bax 5 | STKKLSECLKRIGDELDM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | U937 | Not specified | IC50 : 2.1 μmol/L |
| dbacp01512 | Bax 5 | STKKLSECLKRIGDELDM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | PC-3 | Not specified | IC50 : 2.1 μmol/L |
| dbacp01513 | Bax 6 | STKKLSECLKRIGDELM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | Jurkat | Not specified | IC50 : 8.0 μmol/L |
| dbacp01514 | Bax 6 | STKKLSECLKRIGDELM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | HL-60 | Not specified | IC50 : 8.0 μmol/L |
| dbacp01515 | Bax 6 | STKKLSECLKRIGDELM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | U937 | Not specified | IC50 : 8.0 μmol/L |
| dbacp01516 | Bax 6 | STKKLSECLKRIGDELM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | PC-3 | Not specified | IC50 : 8.0 μmol/L |
| dbacp01517 | Bax 7 | STKKLSECLKRIGDEM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | Jurkat | Not specified | IC50 : 7.4 μmol/L |
| dbacp01518 | Bax 7 | STKKLSECLKRIGDEM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | HL-60 | Not specified | IC50 : 7.4 μmol/L |
| dbacp01519 | Bax 7 | STKKLSECLKRIGDEM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | U937 | Not specified | IC50 : 7.4 μmol/L |
| dbacp01520 | Bax 7 | STKKLSECLKRIGDEM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | PC-3 | Not specified | IC50 : 7.4 μmol/L |
| dbacp01521 | Bax 8 | STKKLSECLKRIGDM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | Jurkat | Not specified | IC50 : > 500 μmol/L |
| dbacp01522 | Bax 8 | STKKLSECLKRIGDM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | HL-60 | Not specified | IC50 : > 500 μmol/L |
| dbacp01523 | Bax 8 | STKKLSECLKRIGDM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | U937 | Not specified | IC50 : > 500 μmol/L |
| dbacp01524 | Bax 8 | STKKLSECLKRIGDM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | PC-3 | Not specified | IC50 : > 500 μmol/L |
| dbacp01525 | Bax 9 | KKLSECLKRIGDELDSnM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | Jurkat | Not specified | IC50 : 148.0 μmol/L |
| dbacp01526 | Bax 9 | KKLSECLKRIGDELDSnM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | HL-60 | Not specified | IC50 : 148.0 μmol/L |
| dbacp01527 | Bax 9 | KKLSECLKRIGDELDSnM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | U937 | Not specified | IC50 : 148.0 μmol/L |
| dbacp01528 | Bax 9 | KKLSECLKRIGDELDSnM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | PC-3 | Not specified | IC50 : 148.0 μmol/L |
| dbacp01529 | BC46 | c[(bA)(bA)RKD] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Breast cancer | Not found |
| dbacp01530 | BC46 | c[(bA)(bA)RKD] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Prostate cancer | Not found |
| dbacp01531 | BC46 | c[(bA)(bA)RKD] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Lung cancer | Not found |
| dbacp01532 | BC46 | c[(bA)(bA)RKD] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Ovarian cancer | Not found |
| dbacp01533 | BC46 | c[(bA)(bA)RKD] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Skin cancer | Not found |
| dbacp01534 | BC48 | c[(bA)GRKD] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Breast cancer | Not found |
| dbacp01535 | BC48 | c[(bA)GRKD] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Prostate cancer | Not found |
| dbacp01536 | BC48 | c[(bA)GRKD] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Lung cancer | Not found |
| dbacp01537 | BC48 | c[(bA)GRKD] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Ovarian cancer | Not found |
| dbacp01538 | BC48 | c[(bA)GRKD] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Skin cancer | Not found |
| dbacp01539 | BC49 | c[(bA)(4aba)RKD] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Breast cancer | Not found |
| dbacp01540 | BC49 | c[(bA)(4aba)RKD] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Prostate cancer | Not found |
| dbacp01541 | BC49 | c[(bA)(4aba)RKD] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Lung cancer | Not found |
| dbacp01542 | BC49 | c[(bA)(4aba)RKD] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Ovarian cancer | Not found |
| dbacp01543 | BC49 | c[(bA)(4aba)RKD] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Skin cancer | Not found |
| dbacp01544 | BC50 | c[(4aba)(bA)RKD] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Breast cancer | Not found |
| dbacp01545 | BC50 | c[(4aba)(bA)RKD] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Prostate cancer | Not found |
| dbacp01546 | BC50 | c[(4aba)(bA)RKD] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Lung cancer | Not found |
| dbacp01547 | BC50 | c[(4aba)(bA)RKD] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Ovarian cancer | Not found |
| dbacp01548 | BC50 | c[(4aba)(bA)RKD] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Skin cancer | Not found |
| dbacp01549 | BC70 | c[(bA)(k)RKD(1-D-NAl)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Breast cancer | Not found |
| dbacp01550 | BC70 | c[(bA)(k)RKD(1-D-NAl)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Prostate cancer | Not found |
| dbacp01551 | BC70 | c[(bA)(k)RKD(1-D-NAl)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Lung cancer | Not found |
| dbacp01552 | BC70 | c[(bA)(k)RKD(1-D-NAl)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Ovarian cancer | Not found |
| dbacp01553 | BC70 | c[(bA)(k)RKD(1-D-NAl)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Skin cancer | Not found |
| dbacp01554 | BC71 | c[(bA)(k)RKD(2-D-NAl)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Breast cancer | Not found |
| dbacp01555 | BC71 | c[(bA)(k)RKD(2-D-NAl)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Prostate cancer | Not found |
| dbacp01556 | BC71 | c[(bA)(k)RKD(2-D-NAl)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Lung cancer | Not found |
| dbacp01557 | BC71 | c[(bA)(k)RKD(2-D-NAl)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Ovarian cancer | Not found |
| dbacp01558 | BC71 | c[(bA)(k)RKD(2-D-NAl)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Skin cancer | Not found |
| dbacp01559 | BC72 | c[(bA)(o)RKD(f)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Breast cancer | Not found |
| dbacp01560 | BC72 | c[(bA)(o)RKD(f)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Prostate cancer | Not found |
| dbacp01561 | BC72 | c[(bA)(o)RKD(f)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Lung cancer | Not found |
| dbacp01562 | BC72 | c[(bA)(o)RKD(f)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Ovarian cancer | Not found |
| dbacp01563 | BC72 | c[(bA)(o)RKD(f)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Skin cancer | Not found |
| dbacp01564 | BC74 | c[(bA)(k)(Fguan)KD(f)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Breast cancer | Not found |
| dbacp01565 | BC74 | c[(bA)(k)(Fguan)KD(f)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Prostate cancer | Not found |
| dbacp01566 | BC74 | c[(bA)(k)(Fguan)KD(f)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Lung cancer | Not found |
| dbacp01567 | BC74 | c[(bA)(k)(Fguan)KD(f)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Ovarian cancer | Not found |
| dbacp01568 | BC74 | c[(bA)(k)(Fguan)KD(f)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Skin cancer | Not found |
| dbacp01569 | BC75 | c[(bA)(k)RKD(D-Bip)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Breast cancer | Not found |
| dbacp01570 | BC75 | c[(bA)(k)RKD(D-Bip)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Prostate cancer | Not found |
| dbacp01571 | BC75 | c[(bA)(k)RKD(D-Bip)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Lung cancer | Not found |
| dbacp01572 | BC75 | c[(bA)(k)RKD(D-Bip)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Ovarian cancer | Not found |
| dbacp01573 | BC75 | c[(bA)(k)RKD(D-Bip)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Skin cancer | Not found |
| dbacp01574 | BC81 | c[(2233tmpa)(k)RKD(2-D-NAl)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Breast cancer | Not found |
| dbacp01575 | BC81 | c[(2233tmpa)(k)RKD(2-D-NAl)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Prostate cancer | Not found |
| dbacp01576 | BC81 | c[(2233tmpa)(k)RKD(2-D-NAl)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Lung cancer | Not found |
| dbacp01577 | BC81 | c[(2233tmpa)(k)RKD(2-D-NAl)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Ovarian cancer | Not found |
| dbacp01578 | BC81 | c[(2233tmpa)(k)RKD(2-D-NAl)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Skin cancer | Not found |
| dbacp01579 | BC83 | c[(bA)(k)RKD(D-2Anth)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Breast cancer | Not found |
| dbacp01580 | BC83 | c[(bA)(k)RKD(D-2Anth)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Prostate cancer | Not found |
| dbacp01581 | BC83 | c[(bA)(k)RKD(D-2Anth)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Lung cancer | Not found |
| dbacp01582 | BC83 | c[(bA)(k)RKD(D-2Anth)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Ovarian cancer | Not found |
| dbacp01583 | BC83 | c[(bA)(k)RKD(D-2Anth)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Skin cancer | Not found |
| dbacp01584 | BC84 | c[(bA)(k)RKD(w)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Breast cancer | Not found |
| dbacp01585 | BC84 | c[(bA)(k)RKD(w)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Prostate cancer | Not found |
| dbacp01586 | BC84 | c[(bA)(k)RKD(w)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Lung cancer | Not found |
| dbacp01587 | BC84 | c[(bA)(k)RKD(w)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Ovarian cancer | Not found |
| dbacp01588 | BC84 | c[(bA)(k)RKD(w)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Skin cancer | Not found |
| dbacp01589 | BCP-A | WPP | Marine invertebrates | Inducing apoptosis | Not specified | PC-3 | Not specified | IC50 : 1.99 mg/ml |
| dbacp01590 | BCP-A | WPP | Marine invertebrates | Inducing apoptosis | Not specified | DU-145 | Not specified | IC50 : 2.80 mg/ml |
| dbacp01591 | BCP-A | WPP | Marine invertebrates | Inducing apoptosis | Not specified | H1299 | Not specified | IC50 : 3.3 mg/ml |
| dbacp01592 | BCP-A | WPP | Marine invertebrates | Inducing apoptosis | Not specified | HeLa | Not specified | IC50 : 2.54 mg/ml |
| dbacp01601 | BH3 peptide spanned amino acids (53-86) BAX | DASTKKLSECLKRIGDELDSnMELQRMIAAVDTD | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | GT1-7 | Not specified | Not found |
| dbacp01602 | BH3 peptide spanned amino acids (53-86) BAX | DASTKKLSECLKRIGDELDSnMELQRMIAAVDTD | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | PC12S | Not specified | Not found |
| dbacp01604 | BiLAO L-amino acid oxidase | ADDKNPLEECFREDDYEGFLEIAKNGLSTTSNPKRVVIVGAGMSGLAAY | Venom base | Inducing apoptosis | Not specified | Not found | Not specified | Not found |
| dbacp01605 | BIM | RPEIWIAQELRRIGDEFNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Leukemia | Not found |
| dbacp01606 | BIM | RPEIWIAQELRRIGDEFNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Breast cancer | Not found |
| dbacp01607 | Bim | EIWIAQELRRIGDEFNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | EL4 | Mouse T cell lymphoma | Not found |
| dbacp01608 | Bim | EIWIAQELRRIGDEFNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Panc-02 | Pancreatic cancer | Not found |
| dbacp01609 | Bim | EIWIAQELRRIGDEFNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | B16 | Melanoma | Not found |
| dbacp01610 | BIM 2A | DMRPEIWIAQEARRIGDEANAYYARR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not specified | Not found |
| dbacp01611 | Bim A2eD | MRPEIWIDQELRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01612 | Bim A2eE | MRPEIWIEQELRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01613 | Bim A2eF | MRPEIWIFQELRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01614 | Bim A2eG | MRPEIWIGQELRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01615 | Bim A2eH | MRPEIWIHQELRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01616 | Bim A2eI | MRPEIWIIQELRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01617 | Bim A2eK | MRPEIWIKQELRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01618 | Bim A2eL | MRPEIWILQELRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01619 | Bim A2eN | MRPEIWINQELRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01620 | Bim A2eP | MRPEIWIPQELRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01621 | Bim A2eQ | MRPEIWIQQELRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01622 | Bim A2eR | MRPEIWIRQELRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01623 | Bim A2eS | MRPEIWISQELRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01624 | Bim A2eT | MRPEIWITQELRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01625 | Bim A2eV | MRPEIWIVQELRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01626 | Bim A2eW | MRPEIWIWQELRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01627 | Bim A2eY | MRPEIWIYQELRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01628 | BIM BH3 (E158S) | EIWIAQELRRIGDSFNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | MTT assay | Not found | Prostate cancer | Not found |
| dbacp01629 | BIM BH3 (I155R, E158A) | EIWIAQELRRRGDAFNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | MTT assay | Not found | Prostate cancer | Not found |
| dbacp01630 | BIM BH3 (I155R, E158S) | EIWIAQELRRRGDSFNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | MTT assay | Not found | Prostate cancer | Not found |
| dbacp01631 | BIM BH3 (R154S, I155R, E158S) | EIWIAQELRSRGDSFNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | MTT assay | Not found | Prostate cancer | Not found |
| dbacp01632 | Bim D3fA | MRPEIWIAQELRRIGAEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01633 | Bim D3fE | MRPEIWIAQELRRIGEEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01634 | Bim D3fF | MRPEIWIAQELRRIGFEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01635 | Bim D3fG | MRPEIWIAQELRRIGGEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01636 | Bim D3fH | MRPEIWIAQELRRIGHEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01637 | Bim D3fI | MRPEIWIAQELRRIGIEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01638 | Bim D3fK | MRPEIWIAQELRRIGKEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01639 | Bim D3fL | MRPEIWIAQELRRIGLEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01640 | Bim D3fN | MRPEIWIAQELRRIGNEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01641 | Bim D3fP | MRPEIWIAQELRRIGPEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01642 | Bim D3fQ | MRPEIWIAQELRRIGQEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01643 | Bim D3fR | MRPEIWIAQELRRIGREFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01644 | Bim D3fS | MRPEIWIAQELRRIGSEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01645 | Bim D3fT | MRPEIWIAQELRRIGTEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01646 | Bim D3fV | MRPEIWIAQELRRIGVEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01647 | Bim D3fW | MRPEIWIAQELRRIGWEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01648 | Bim D3fY | MRPEIWIAQELRRIGYEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01649 | Bim E2gA | MRPEIWIAQALRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01650 | Bim E2gD | MRPEIWIAQDLRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01651 | Bim E2gF | MRPEIWIAQFLRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01652 | Bim E2gG | MRPEIWIAQGLRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01653 | Bim E2gH | MRPEIWIAQHLRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01654 | Bim E2gI | MRPEIWIAQILRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01655 | Bim E2gK | MRPEIWIAQKLRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01656 | Bim E2gL | MRPEIWIAQLLRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01657 | Bim E2gN | MRPEIWIAQNLRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01658 | Bim E2gP | MRPEIWIAQPLRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01659 | Bim E2gQ | MRPEIWIAQQLRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01660 | Bim E2gR | MRPEIWIAQRLRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01661 | Bim E2gS | MRPEIWIAQSLRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01662 | Bim E2gT | MRPEIWIAQTLRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01663 | Bim E2gW | MRPEIWIAQWLRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01664 | Bim E2gY | MRPEIWIAQYLRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01665 | Bim E3gA | MRPEIWIAQELRRIGDAFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01666 | Bim E3gD | MRPEIWIAQELRRIGDDFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01667 | Bim E3gF | MRPEIWIAQELRRIGDFFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01668 | Bim E3gG | MRPEIWIAQELRRIGDGFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01669 | Bim E3gH | MRPEIWIAQELRRIGDHFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01670 | Bim E3gI | MRPEIWIAQELRRIGDIFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01671 | Bim E3gK | MRPEIWIAQELRRIGDKFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01672 | BIM E3gK | MRPEIWIAQELRRIGDKFNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01673 | Bim E3gL | MRPEIWIAQELRRIGDLFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01674 | Bim E3gN | MRPEIWIAQELRRIGDNFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01675 | Bim E3gP | MRPEIWIAQELRRIGDPFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01676 | Bim E3gQ | MRPEIWIAQELRRIGDQFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01677 | Bim E3gR | MRPEIWIAQELRRIGDRFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01678 | Bim E3gS | MRPEIWIAQELRRIGDSFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01679 | Bim E3gT | MRPEIWIAQELRRIGDTFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01680 | Bim E3gV | MRPEIWIAQELRRIGDVFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01681 | Bim E3gW | MRPEIWIAQELRRIGDWFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01682 | Bim E3gY | MRPEIWIAQELRRIGDYFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01683 | Bim EgV | MRPEIWIAQVLRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01684 | BIM EL - I146Y | LRPEIRYAQELRRIGDEFNE | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Breast cancer | Not found |
| dbacp01685 | BIM EL -CST-2A | PQMVILQLLAFIFALVWRRH | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Breast cancer | Not found |
| dbacp01686 | BIM EL -I153M | LRPEIRIAQELRRMGDEFNE | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Breast cancer | Not found |
| dbacp01687 | BIM EL -Q148R | LRPEIRIARELRRIGDEFNE | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Breast cancer | Not found |
| dbacp01688 | BIM EL -V192E | PQMVILQLLRFIFRLEWRRH | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Breast cancer | Not found |
| dbacp01689 | BIM EL I146Y-I153M | LRPEIRYAQELRRMGDEFNE | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Breast cancer | Not found |
| dbacp01690 | BIM EL- I181E | PQMVELQLLRFIFRLVWRRH | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Breast cancer | Not found |
| dbacp01691 | BIM EL- I188E | PQMVILQLLRFEFRLVWRRH | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Breast cancer | Not found |
| dbacp01692 | BIM EL-CTS | PQMVILQLLRFIFRLVWRRH | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Breast cancer | Not found |
| dbacp01693 | BIM EL-L185E | PQMVILQLERFIFRLVWRRH | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Breast cancer | Not found |
| dbacp01694 | Bim F4aA | MRPEIWIAQELRRIGDEANAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01695 | Bim F4aD | MRPEIWIAQELRRIGDEDNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01696 | Bim F4aE | MRPEIWIAQELRRIGDEENAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01697 | BIM F4aE | MRPEIWIAQELRRIGDEENAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01698 | Bim F4aG | MRPEIWIAQELRRIGDEGNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01699 | Bim F4aH | MRPEIWIAQELRRIGDEHNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01700 | Bim F4aI | MRPEIWIAQELRRIGDEINAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01701 | Bim F4aK | MRPEIWIAQELRRIGDEKNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01702 | Bim F4aL | MRPEIWIAQELRRIGDELNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01703 | Bim F4aN | MRPEIWIAQELRRIGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01704 | Bim F4aP | MRPEIWIAQELRRIGDEPNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01705 | Bim F4aQ | MRPEIWIAQELRRIGDEQNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01706 | Bim F4aR | MRPEIWIAQELRRIGDERNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01707 | Bim F4aS | MRPEIWIAQELRRIGDESNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01708 | Bim F4aT | MRPEIWIAQELRRIGDETNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01709 | Bim F4aV | MRPEIWIAQELRRIGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01710 | Bim F4aW | MRPEIWIAQELRRIGDEWNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01711 | Bim F4aY | MRPEIWIAQELRRIGDEYNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01712 | BIM FA1 | RPEIWIAQELRRAGDVLNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Leukemia | Not found |
| dbacp01713 | BIM FA1 | RPEIWIAQELRRAGDVLNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Breast cancer | Not found |
| dbacp01714 | BIM FD1 | RPEIWLAQYLRRLGDQINAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Leukemia | Not found |
| dbacp01715 | BIM FD1 | RPEIWLAQYLRRLGDQINAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Breast cancer | Not found |
| dbacp01716 | BIM FD2 | RPEIWMAQVLRRFGDLLNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Leukemia | Not found |
| dbacp01717 | BIM FD2 | RPEIWMAQVLRRFGDLLNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Breast cancer | Not found |
| dbacp01718 | BIM FW1 | RPEIWIAQGLRRIGDTWNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Leukemia | Not found |
| dbacp01719 | BIM FW1 | RPEIWIAQGLRRIGDTWNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Breast cancer | Not found |
| dbacp01720 | Bim G3eA | MRPEIWIAQELRRIADEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01721 | Bim G3eD | MRPEIWIAQELRRIDDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01722 | Bim G3eE | MRPEIWIAQELRRIEDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01723 | Bim G3eF | MRPEIWIAQELRRIFDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01724 | Bim G3eH | MRPEIWIAQELRRIHDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01725 | Bim G3eI | MRPEIWIAQELRRIIDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01726 | Bim G3eK | MRPEIWIAQELRRIKDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01727 | Bim G3eL | MRPEIWIAQELRRILDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01728 | Bim G3eN | MRPEIWIAQELRRINDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01729 | Bim G3eP | MRPEIWIAQELRRIPDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01730 | Bim G3eQ | MRPEIWIAQELRRIQDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01731 | Bim G3eR | MRPEIWIAQELRRIRDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01732 | Bim G3eS | MRPEIWIAQELRRISDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01733 | Bim G3eT | MRPEIWIAQELRRITDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01734 | Bim G3eV | MRPEIWIAQELRRIVDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01735 | Bim G3eW | MRPEIWIAQELRRIWDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01736 | Bim G3eY | MRPEIWIAQELRRIYDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01737 | BIM I2dA | MRPEIWAAQELRRIGDEFNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01738 | Bim I2dA | MRPEIWAAQELRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01739 | Bim I2dD | MRPEIWDAQELRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01740 | Bim I2dE | MRPEIWEAQELRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01741 | Bim I2dF | MRPEIWFAQELRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01742 | Bim I2dG | MRPEIWGAQELRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01743 | Bim I2dH | MRPEIWHAQELRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01744 | Bim I2dK | MRPEIWKAQELRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01745 | Bim I2dL | MRPEIWLAQELRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01746 | Bim I2dN | MRPEIWNAQELRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01747 | Bim I2dP | MRPEIWPAQELRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01748 | Bim I2dQ | MRPEIWQAQELRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01749 | Bim I2dR | MRPEIWRAQELRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01750 | Bim I2dS | MRPEIWSAQELRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01751 | Bim I2dT | MRPEIWTAQELRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01752 | Bim I2dV | MRPEIWVAQELRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01753 | Bim I2dW | MRPEIWWAQELRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01754 | BIM I2dY | MRPEIWYAQELRRIGDEFNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01755 | Bim I2dY | MRPEIWYAQELRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01756 | Bim I3dA | MRPEIWIAQELRRAGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01757 | Bim I3dD | MRPEIWIAQELRRDGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01758 | Bim I3dE | MRPEIWIAQELRREGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01759 | Bim I3dF | MRPEIWIAQELRRFGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01760 | BIM I3dF | MRPEIWIAQELRRFGDEFNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01761 | Bim I3dG | MRPEIWIAQELRRGGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01762 | Bim I3dH | MRPEIWIAQELRRHGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01763 | Bim I3dK | MRPEIWIAQELRRKGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01764 | Bim I3dL | MRPEIWIAQELRRLGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01765 | Bim I3dN | MRPEIWIAQELRRNGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01766 | Bim I3dP | MRPEIWIAQELRRPGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01767 | Bim I3dQ | MRPEIWIAQELRRQGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01768 | Bim I3dR | MRPEIWIAQELRRRGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01769 | Bim I3dS | MRPEIWIAQELRRSGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01770 | Bim I3dT | MRPEIWIAQELRRTGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01771 | Bim I3dV | MRPEIWIAQELRRVGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01772 | Bim I3dW | MRPEIWIAQELRRWGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01773 | Bim I3dY | MRPEIWIAQELRRYGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01774 | Bim L3aA | MRPEIWIAQEARRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01775 | Bim L3aD | MRPEIWIAQEDRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01776 | Bim L3aE | MRPEIWIAQEERRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01777 | Bim L3aF | MRPEIWIAQEFRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01778 | Bim L3aG | MRPEIWIAQEGRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01779 | Bim L3aH | MRPEIWIAQEHRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01780 | Bim L3aI | MRPEIWIAQEIRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01781 | Bim L3aK | MRPEIWIAQEKRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01782 | Bim L3aN | MRPEIWIAQENRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01783 | Bim L3aP | MRPEIWIAQEPRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01784 | Bim L3aQ | MRPEIWIAQEQRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01785 | Bim L3aR | MRPEIWIAQERRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01786 | Bim L3aS | MRPEIWIAQESRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01787 | Bim L3aT | MRPEIWIAQETRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01788 | Bim L3aV | MRPEIWIAQEVRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01789 | Bim L3aW | MRPEIWIAQEWRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01790 | Bim L3aY | MRPEIWIAQEYRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01791 | Bim R3bA | MRPEIWIAQELARIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01792 | Bim R3bD | MRPEIWIAQELDRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01793 | Bim R3bE | MRPEIWIAQELERIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01794 | Bim R3bF | MRPEIWIAQELFRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01795 | Bim R3bG | MRPEIWIAQELGRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01796 | Bim R3bH | MRPEIWIAQELHRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01797 | Bim R3bI | MRPEIWIAQELIRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01798 | Bim R3bK | MRPEIWIAQELKRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01799 | Bim R3bL | MRPEIWIAQELLRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01800 | Bim R3bN | MRPEIWIAQELNRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01801 | Bim R3bP | MRPEIWIAQELPRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01802 | Bim R3bQ | MRPEIWIAQELQRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01803 | Bim R3bS | MRPEIWIAQELSRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01804 | Bim R3bT | MRPEIWIAQELTRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01805 | Bim R3bV | MRPEIWIAQELVRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01806 | Bim R3bW | MRPEIWIAQELWRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01807 | Bim R3bY | MRPEIWIAQELYRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01808 | BIM SM-1 | IWIAQELRRIGDEFNA | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01809 | BIM SM-2 | IWIAQELRRIGDEF | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01810 | BIM SM-3 | IAQELRRIGDEFNA | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01811 | BIM SM-4 | WIAQELRRIGDEFN | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01812 | BIM SM-5 | IAQELRRIGDEF | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01813 | BIM SM-6 | IAQELRRIGDEF | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01814 | BIM SM-7 | IAQELRRIGDEF | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp01815 | BIM XXA1 | RPEIWYAQGLKRFGDEFNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | MTT assay | Not found | Prostate cancer | Not found |
| dbacp01816 | BIM XXA1 F3dI | RPEIWYAQGLKRIGDEFNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not specified | Not found |
| dbacp01817 | BIM XXA1 G2gE | RPEIWYAQELKRFGDEFNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not specified | Not found |
| dbacp01818 | BIM XXA1 K3bR | RPEIWYAQGLRRFGDEFNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not specified | Not found |
| dbacp01819 | BIM XXA1 Y2dI | RPEIWIAQGLKRFGDEFNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not specified | Not found |
| dbacp01820 | BIM XXA1 Y4eK | RPEIWYAQGLKRFGDEFNAYKAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not specified | Not found |
| dbacp01821 | BIM XXA4 | RPEIWYAQWLKRFGDQFNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not specified | Not found |
| dbacp01822 | BIM Y4eK- 18 | IWYAQGLKRFGDEFNAYK | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not specified | Not found |
| dbacp01823 | BIM Y4eK- 21 | RPEIWYAQGLKRFGDEFNAYK | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not specified | Not found |
| dbacp01824 | BIM- A2eT | RPEIWITQELRRIGDEFNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Mcl-1/Myc 2640 | Not found | Not found |
| dbacp01825 | BIM- A2eT | RPEIWITQELRRIGDEFNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Bcl-2/Myc 2924 | Not found | Not found |
| dbacp01826 | BIM- A2eT-E2gG | RPEIWITQGLRRIGDEFNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Mcl-1/Myc 2640 | Not found | Not found |
| dbacp01827 | BIM- A2eT-E2gG | RPEIWITQGLRRIGDEFNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Bcl-2/Myc 2924 | Not found | Not found |
| dbacp01828 | BIM- A2eT-F4aI | RPEIWITQELRRIGDEINAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Mcl-1/Myc 2640 | Not found | Not found |
| dbacp01829 | BIM- A2eT-F4aI | RPEIWITQELRRIGDEINAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Bcl-2/Myc 2924 | Not found | Not found |
| dbacp01830 | BIM- A2eT-I2dM | RPEIWMTQELRRIGDEFNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Mcl-1/Myc 2640 | Not found | Not found |
| dbacp01831 | BIM- A2eT-I2dM | RPEIWMTQELRRIGDEFNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Bcl-2/Myc 2924 | Not found | Not found |
| dbacp01832 | BIM- A2eT-I3dL | RPEIWITQELRRLGDEFNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Mcl-1/Myc 2640 | Not found | Not found |
| dbacp01833 | BIM- A2eT-I3dL | RPEIWITQELRRLGDEFNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Bcl-2/Myc 2924 | Not found | Not found |
| dbacp01834 | Bim-BH3W89Y | DMRPEIYIAQELRRIGDEFNAY | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Jurkat | Leukemia | Not found |
| dbacp01835 | Bim-BH3W89Y | DMRPEIYIAQELRRIGDEFNAY | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Namalwa | Leukemia | Not found |
| dbacp01836 | Bim-BH3W89Y | DMRPEIYIAQELRRIGDEFNAY | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | U937 | Leukemia | Not found |
| dbacp01837 | Bim-BH3YA2Aib | DMRPEIYI(Aib)QELRRIGDAFN(Aib)Y | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Jurkat | Leukemia | Not found |
| dbacp01838 | Bim-BH3YA2Aib | DMRPEIYI(Aib)QELRRIGDAFN(Aib)Y | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Namalwa | Leukemia | Not found |
| dbacp01839 | Bim-BH3YA2Aib | DMRPEIYI(Aib)QELRRIGDAFN(Aib)Y | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | U937 | Leukemia | Not found |
| dbacp01840 | BIRD-2 (Bcl-2 IP3R disrupter 2) | RKKRRQRRRGGNVYTEIKCNSLLPLAAIVRV | Not found | Inducing apoptosis | MTT assay | DLBCL | Leukemia | Not found |
| dbacp01841 | BIRD-2 (Bcl-2 IP3R disrupter 2) | RKKRRQRRRGGNVYTEIKCNSLLPLAAIVRV | Not found | Inducing apoptosis | MTT assay | CLL | Leukemia | Not found |
| dbacp01842 | BjarLAAO,L-amino-acid oxidase (BjarLAAO-I; LAAO; LAO; Snakes, reptils, animals) | ADDKNPLEECFRETDYEEFLEIARNGLKATSNPKRVV | Venom base | Inducing apoptosis | Not specified | EAT | Gastric cancer | Not found |
| dbacp01892 | BPC194 | KKLKKFKKLQ | Synthetic Peptide | Inducing apoptosis | MTT assay | MDA-MB-231 | Cervical cancer | IC50 : 32.5 ± 0.5 μM |
| dbacp01893 | BPC194 | KKLKKFKKLQ | Synthetic Peptide | Inducing apoptosis | MTT assay | HeLa | Cervical cancer | IC50 : 29.5 ± 2 μM |
| dbacp01894 | BPC194 | KKLKKFKKLQ | Synthetic Peptide | Inducing apoptosis | MTT assay | HepG2 | Cervical cancer | IC50 : 46.0 ± 3 μM |
| dbacp01895 | BPC194 | KKLKKFKKLQ | Synthetic Peptide | Inducing apoptosis | MTT assay | A431 | Cervical cancer | IC50 : 50.0 ± 10 μM |
| dbacp01896 | BPC194 | KKLKKFKKLQ | Synthetic Peptide | Inducing apoptosis | MTT assay | Panc-1 | Cervical cancer | IC50 : 40.0 ± 3 Μm |
| dbacp01897 | BPC88 | KKLLKFKKLQ | Synthetic Peptide | Inducing apoptosis | MTT assay | MDA-MB-231 | Cervical cancer | IC50 : 31.2 ± 5 μM |
| dbacp01898 | BPC88 | KKLLKFKKLQ | Synthetic Peptide | Inducing apoptosis | MTT assay | HeLa | Cervical cancer | IC50 : 22.5 ± 0 μM |
| dbacp01899 | BPC88 | KKLLKFKKLQ | Synthetic Peptide | Inducing apoptosis | MTT assay | HepG2 | Cervical cancer | IC50 : 32.5 ± 4 μM |
| dbacp01900 | BPC88 | KKLLKFKKLQ | Synthetic Peptide | Inducing apoptosis | MTT assay | A431 | Cervical cancer | IC50 : 28.0 ± 3 μM |
| dbacp01901 | BPC88 | KKLLKFKKLQ | Synthetic Peptide | Inducing apoptosis | MTT assay | Panc-1 | Cervical cancer | IC50 : 32.5 ± 11 μM |
| dbacp01902 | BPC96 | LKLKKFKKLQ | Synthetic Peptide | Inducing apoptosis | MTT assay | MDA-MB-231 | Cervical cancer | IC50 : 40.0 ± 7 μM |
| dbacp01903 | BPC96 | LKLKKFKKLQ | Synthetic Peptide | Inducing apoptosis | MTT assay | HeLa | Cervical cancer | IC50 : 24.5 ± 0.7 μM |
| dbacp01904 | BPC96 | LKLKKFKKLQ | Synthetic Peptide | Inducing apoptosis | MTT assay | HepG2 | Cervical cancer | IC50 : 34.5 ± 2 μM |
| dbacp01905 | BPC96 | LKLKKFKKLQ | Synthetic Peptide | Inducing apoptosis | MTT assay | A431 | Cervical cancer | IC50 : 35.0 ± 7 μM |
| dbacp01906 | BPC96 | LKLKKFKKLQ | Synthetic Peptide | Inducing apoptosis | MTT assay | Panc-1 | Cervical cancer | IC50 : 51.0 ± 6 Μm |
| dbacp01907 | BPC98 | LLKKKFKKLQ | Synthetic Peptide | Inducing apoptosis | MTT assay | MDA-MB-231 | Cervical cancer | IC50 : 40.7 ± 3 μM |
| dbacp01908 | BPC98 | LLKKKFKKLQ | Synthetic Peptide | Inducing apoptosis | MTT assay | HeLa | Cervical cancer | IC50 : 38.5 ± 4 μM |
| dbacp01909 | BPC98 | LLKKKFKKLQ | Synthetic Peptide | Inducing apoptosis | MTT assay | HepG2 | Cervical cancer | IC50 : 44.0 ± 3 μM |
| dbacp01910 | BPC98 | LLKKKFKKLQ | Synthetic Peptide | Inducing apoptosis | MTT assay | A431 | Cervical cancer | IC50 : 47.5 ± 4 μM |
| dbacp01911 | BPC98 | LLKKKFKKLQ | Synthetic Peptide | Inducing apoptosis | MTT assay | Panc-1 | Cervical cancer | IC50 : 44.5 ± 0.7 Μm |
| dbacp01912 | BpirLAAO-I | ADDKNPLEEFRETNYEVFLEIAKNGLKATSNPKRVVIVGAGMAGLSAAY | Venom base | Inducing apoptosis | MTT assay | SKBR-3 | Breast cancer | Not found |
| dbacp01913 | BpirLAAO-I | ADDKNPLEEFRETNYEVFLEIAKNGLKATSNPKRVVIVGAGMAGLSAAY | Venom base | Inducing apoptosis | MTT assay | Jurkat | Acute T cell Leukemia | Not found |
| dbacp01914 | BpirLAAO-I | ADDKNPLEEFRETNYEVFLEIAKNGLKATSNPKRVVIVGAGMAGLSAAY | Venom base | Inducing apoptosis | MTT assay | EAT | Erlich ascitic tumor | Not found |
| dbacp01915 | BpirLAAO-I | ADDKNPLEEFRETNYEVFLEIAKNGLKATSNPKRVVIVGAGMAGLSAAY | Venom base | Inducing apoptosis | MTT assay | S180 | Tumor | Not found |
| dbacp01916 | BPP-II | MTLTG | Immunomodulatory bursal-derived Pentapeptide-II | Inducing apoptosis | MTT/MTS assay | CEF | Tumor | Not found |
| dbacp01917 | BPP-II | MTLTG | Immunomodulatory bursal-derived Pentapeptide-II | Inducing apoptosis | MTT/MTS assay | Vero | Renal cancer | Not found |
| dbacp01918 | BPP-II | MTLTG | Immunomodulatory bursal-derived Pentapeptide-II | Inducing apoptosis | MTT/MTS assay | MDBK | Renal cancer | Not found |
| dbacp01919 | BR-C | CKLKNFAKGVAQSLLNKASKLSGQC | Not found | Inducing apoptosis | Not specified | MCF-7 | Not specified | IC50 : 45.72 μg/ml |
| dbacp01920 | BR-C | CKLKNFAKGVAQSLLNKASKLSGQC | Not found | Inducing apoptosis | Not specified | A549 | Not specified | IC50 : 75.44 μg/ml |
| dbacp01921 | BR-D | KLKNFAKGVAQSLLNKASCKLSGQC | Not found | Inducing apoptosis | Not specified | MCF-7 | Not specified | IC50 : 67.52 μg/ml |
| dbacp01922 | BR-D | KLKNFAKGVAQSLLNKASCKLSGQC | Not found | Inducing apoptosis | Not specified | A549 | Not specified | IC50 : 94.74 μg/ml |
| dbacp01946 | Brevinin-1RL1 | FFPLIAGLAARFLPKIFCSITKRC | Not found | Inducing apoptosis | Cell death assay | HCT116 | Not specified | IC50 : 5.87 ± 0.15 μM |
| dbacp01947 | Brevinin-1RL1 | FFPLIAGLAARFLPKIFCSITKRC | Not found | Inducing apoptosis | Cell death assay | MDA-MB-231 | Not specified | IC50 : 5.44 ± 0.33 μM |
| dbacp01948 | Brevinin-1RL1 | FFPLIAGLAARFLPKIFCSITKRC | Not found | Inducing apoptosis | Cell death assay | SW480 | Not specified | IC50 : 10.37 ± 0.40 μM |
| dbacp01949 | Brevinin-1RL1 | FFPLIAGLAARFLPKIFCSITKRC | Not found | Inducing apoptosis | Cell death assay | A549 | Not specified | IC50 : 5.81 ± 0.23 μM |
| dbacp01950 | Brevinin-1RL1 | FFPLIAGLAARFLPKIFCSITKRC | Not found | Inducing apoptosis | Cell death assay | SMMC-7721 | Not specified | IC50 : 6.87 ± 0.51 μM |
| dbacp01951 | Brevinin-1RL1 | FFPLIAGLAARFLPKIFCSITKRC | Not found | Inducing apoptosis | Cell death assay | B16F10 | Not specified | IC50 : 6.65 ± 0.33 μM |
| dbacp01952 | Brevinin-1RL1 | FFPLIAGLAARFLPKIFCSITKRC | Not found | Inducing apoptosis | Cell death assay | NCM460 | Not specified | IC50 : 16.84 ± 0.56 μM |
| dbacp01953 | Brevinin-1RL1 | FFPLIAGLAARFLPKIFCSITKRC | Not found | Inducing apoptosis | Cell death assay | BEAS-2B | Not specified | IC50 : 16.57 ± 0.29 μM |
| dbacp01954 | Brevinin-1RL1 | FFPLIAGLAARFLPKIFCSITKRC | Not found | Inducing apoptosis | Cell death assay | HaCaT | Not specified | IC50 : 28.67 ± 0.36 μM |
| dbacp01984 | Brevinin-2R (BR-2R) | KLKNFAKGVAQSLLNKASCKLSGQC | Not found | Inducing apoptosis | Not specified | MCF-7 | Not specified | IC50 : 24.11 μg/ml |
| dbacp01985 | Brevinin-2R (BR-2R) | KLKNFAKGVAQSLLNKASCKLSGQC | Not found | Inducing apoptosis | Not specified | A549 | Not specified | IC50 : 47.39 μg/ml |
| dbacp01987 | Buforin 2 | TRSSRAGLQFPVGRVHRLLRK | Asiatic toad | Disruption of electric potential of the cell membrane; Necrosis, Membranolytic activity leading to apoptosis | MTT/MTS assay | U-937 | Lymphoma cancer | IC50 : 90-95 µg/ml |
| dbacp01989 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 14.7 µg/ml |
| dbacp01990 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | HL-60 | Leukemia cancer | IC50 : 11.3 µg/ml |
| dbacp01991 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | K-562 | Leukemia cancer | IC50 : 8.2 µg/ml |
| dbacp01992 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | MOLT-4 | Leukemia cancer | IC50 : 17 µg/ml |
| dbacp01993 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | RPMI-8226 | Leukemia cancer | IC50 : 10.5 µg/ml |
| dbacp01994 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | SR | Leukemia cancer | IC50 : 20.2 µg/ml |
| dbacp01995 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 15.1 µg/ml |
| dbacp01996 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | NCI/ADR-RES | Breast cancer | IC50 : 11.5 µg/ml |
| dbacp01997 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | MDA-MB-231 | Breast cancer | IC50 : 11.3 µg/ml |
| dbacp01998 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | HS578T | Breast cancer | IC50 : 11.7 µg/ml |
| dbacp01999 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | MDA-MB-435 | Breast cancer | IC50 : 11.3 µg/ml |
| dbacp02000 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | MDA-N | Breast cancer | IC50 : 10.6 µg/ml |
| dbacp02001 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | BT-549 | Breast cancer | IC50 : 12.9 µg/ml |
| dbacp02002 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | T-47D | Breast cancer | IC50 : 23.9 µg/ml |
| dbacp02003 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | A-549 | Lung cancer | IC50 : 11.7 µg/ml |
| dbacp02004 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | EKVX | Lung cancer | IC50 : 12.1 µg/ml |
| dbacp02005 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | HOP-62 | Lung cancer | IC50 : 12.6 µg/ml |
| dbacp02006 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | HOP-92 | Lung cancer | IC50 : 7.2 µg/ml |
| dbacp02007 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | NCI-H226 | Lung cancer | IC50 : 13.3 µg/ml |
| dbacp02008 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | NCI-H23 | Lung cancer | IC50 : 10.8 µg/ml |
| dbacp02009 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | NCI-H322M | Lung cancer | IC50 : 10.7 µg/ml |
| dbacp02010 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | NCI-H460 | Lung cancer | IC50 : 12.1 µg/ml |
| dbacp02011 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | NCI-H522 | Lung cancer | IC50 : 11.2 µg/ml |
| dbacp02012 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | SF-268 | Brain tumor | IC50 : 12.4 µg/ml |
| dbacp02013 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | SF-295 | Brain tumor | IC50 : 12.9 µg/ml |
| dbacp02014 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | SF-539 | Brain tumor | IC50 : 9.5 µg/ml |
| dbacp02015 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | SNB-19 | Brain tumor | IC50 : 13.8 µg/ml |
| dbacp02016 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | SNB-75 | Brain tumor | IC50 : 15.5 µg/ml |
| dbacp02017 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | U-251 | Brain tumor | IC50 : 10.6 µg/ml |
| dbacp02018 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | LOXIMVI | Skin cancer | IC50 : 9.5 µg/ml |
| dbacp02019 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | MALME-3M | Skin cancer | IC50 : 10.9 µg/ml |
| dbacp02020 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | M14 | Skin cancer | IC50 : 15.1 µg/ml |
| dbacp02021 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | SK-MEL-2 | Skin cancer | IC50 : 11.1 µg/ml |
| dbacp02022 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | SK-MEL-5 | Skin cancer | IC50 : 8.9 µg/ml |
| dbacp02023 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | UACC-257 | Skin cancer | IC50 : 12.5 µg/ml |
| dbacp02024 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | UACC-62 | Skin cancer | IC50 : 10.6 µg/ml |
| dbacp02025 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | 786-0 | Renal cancer | IC50 : 12.2 µg/ml |
| dbacp02026 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | A-498 | Renal cancer | IC50 : 10 µg/ml |
| dbacp02027 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | ACHN | Renal cancer | IC50 : 12 µg/ml |
| dbacp02028 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | CAKI-1 | Renal cancer | IC50 : 14.1 µg/ml |
| dbacp02029 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | RFX393 | Renal cancer | IC50 : 11 µg/ml |
| dbacp02030 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | SN-12C | Renal cancer | IC50 : 11.4 µg/ml |
| dbacp02031 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | TK-10 | Renal cancer | IC50 : 13.1 µg/ml |
| dbacp02032 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | UO-31 | Renal cancer | IC50 : 10.6 µg/ml |
| dbacp02033 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | IGROV1 | Ovarian cancer | IC50 : 9 µg/ml |
| dbacp02034 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | OVRCAR-3 | Ovarian cancer | IC50 : 15.2 µg/ml |
| dbacp02035 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | OVRCAR-4 | Ovarian cancer | IC50 : 17.6 µg/ml |
| dbacp02036 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | OVRCAR-5 | Ovarian cancer | IC50 : 13.8 µg/ml |
| dbacp02037 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | OVRCAR-8 | Ovarian cancer | IC50 : 13 µg/ml |
| dbacp02038 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | SK-OV-3 | Ovarian cancer | IC50 : 12.6 µg/ml |
| dbacp02039 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | COLO-205 | Colon cancer | IC50 : 11.2 µg/ml |
| dbacp02040 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | HCT-116 | Colon cancer | IC50 : 14.6 µg/ml |
| dbacp02041 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | HCT-15 | Colon cancer | IC50 : 13.2 µg/ml |
| dbacp02042 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | HT-29 | Colon cancer | IC50 : 17.6 µg/ml |
| dbacp02043 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | KM12 | Colon cancer | IC50 : 12 µg/ml |
| dbacp02044 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | SW-620 | Colon cancer | IC50 : 12.7 µg/ml |
| dbacp02045 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 12 µg/ml |
| dbacp02046 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | DU-145 | Prostate cancer | IC50 : 15.3 µg/ml |
| dbacp02047 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | CCRF-CEM | Not specified | IC50 : 14.7 µg/ml |
| dbacp02048 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | HL-60 | Not specified | IC50 : 11.3 µg/ml |
| dbacp02049 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | K562 | Not specified | IC50 : 8.2 µg/ml |
| dbacp02050 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | MOLT4 | Not specified | IC50 : 17.0 µg/ml |
| dbacp02051 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | RPMI-8226 | Not specified | IC50 : 10.5 µg/ml |
| dbacp02052 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | SR | Not specified | IC50 : 20.2 µg/ml |
| dbacp02053 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | MCF-7 | Not specified | IC50 : 15.1 µg/ml |
| dbacp02054 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | NCI/ADR-RES | Not specified | IC50 : 11.5 µg/ml |
| dbacp02055 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | MDA-MB-231 | Not specified | IC50 : 11.3 µg/ml |
| dbacp02056 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | HS 578T | Not specified | IC50 : 11.7 µg/ml |
| dbacp02057 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | MDA-MB-435 | Not specified | IC50 : 11.3 µg/ml |
| dbacp02058 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | MDA-N | Not specified | IC50 : 10.6 µg/ml |
| dbacp02059 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | BT-549 | Not specified | IC50 : 12.9 µg/ml |
| dbacp02060 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | T-47D | Not specified | IC50 : 23.9 µg/ml |
| dbacp02061 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | A549 | Not specified | IC50 : 11.7 µg/ml |
| dbacp02062 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | EKVX | Not specified | IC50 : 12.1 µg/ml |
| dbacp02063 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | HOP-62 | Not specified | IC50 : 12.6 µg/ml |
| dbacp02064 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | HOP-92 | Not specified | IC50 : 7.2 µg/ml |
| dbacp02065 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | NCI-H226 | Not specified | IC50 : 13.3µg/ml |
| dbacp02066 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | NCI-H23 | Not specified | IC50 : 10.8 µg/ml |
| dbacp02067 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | NCI-H322M | Not specified | IC50 : 10.7 µg/ml |
| dbacp02068 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | NCI-H460 | Not specified | IC50 : 12.1 µg/ml |
| dbacp02069 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | NCI-H522 | Not specified | IC50 : 11.2 µg/ml |
| dbacp02070 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | SF-268 | Not specified | IC50 : 12.4 µg/ml |
| dbacp02071 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | SF-295 | Not specified | IC50 : 12.9 µg/ml |
| dbacp02072 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | SF-539 | Not specified | IC50 : 9.5 µg/ml |
| dbacp02073 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | SNB-19 | Not specified | IC50 : 13.8 µg/ml |
| dbacp02074 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | SNB-75 | Not specified | IC50 : 15.5 µg/ml |
| dbacp02075 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | U251 | Not specified | IC50 : 10.6 µg/ml |
| dbacp02076 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | LOX IMVI | Not specified | IC50 : 9.5 µg/ml |
| dbacp02077 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | MALME-3M | Not specified | IC50 : 10.9 µg/ml |
| dbacp02078 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | M14 | Not specified | IC50 : 15.1 µg/ml |
| dbacp02079 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | SK-MEL-2 | Not specified | IC50 : 11.1 µg/ml |
| dbacp02080 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | SK-MEL-5 | Not specified | IC50 : 8.9 µg/ml |
| dbacp02081 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | UACC-257 | Not specified | IC50 : 12.5µg/ml |
| dbacp02082 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | UACC-62 | Not specified | IC50 : 10.6 µg/ml |
| dbacp02083 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | 786-0 | Not specified | IC50 : 12.2 µg/ml |
| dbacp02084 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | A498 | Not specified | IC50 : 10 µg/ml |
| dbacp02085 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | ACHN | Not specified | IC50 : 12 µg/ml |
| dbacp02086 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | CAKI-1 | Not specified | IC50 : 14.1 µg/ml |
| dbacp02087 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | RFX 393 | Not specified | IC50 : 11 µg/ml |
| dbacp02088 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | SN12C | Not specified | IC50 : 11.1 µg/ml |
| dbacp02089 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | TK-10 | Not specified | IC50 : 13.1 µg/ml |
| dbacp02090 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | UO-31 | Not specified | IC50 : 10.6 µg/ml |
| dbacp02091 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | IGROV 1 | Not specified | IC50 : 9 µg/ml |
| dbacp02092 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | OVRCAR-3 | Not specified | IC50 : 15.2 µg/ml |
| dbacp02093 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | OVRCAR-4 | Not specified | IC50 : 17.6 µg/ml |
| dbacp02094 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | OVRCAR-5 | Not specified | IC50 : 13.8 µg/ml |
| dbacp02095 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | OVRCAR-8 | Not specified | IC50 : 13 µg/ml |
| dbacp02096 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | SKOV3 | Not specified | IC50 : 12.6 µg/ml |
| dbacp02097 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | COLO-205 | Not specified | IC50 : 11.2 µg/ml |
| dbacp02098 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | HCT116 | Not specified | IC50 : 14.6 µg/ml |
| dbacp02099 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | HT-29 | Not specified | IC50 : 13.2 µg/ml |
| dbacp02100 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | HCT-15 | Not specified | IC50 : 12 µg/ml |
| dbacp02101 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | KM12 | Not specified | IC50 : 12 µg/ml |
| dbacp02102 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | SW-620 | Not specified | IC50 : 12.7 µg/ml |
| dbacp02103 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | HCT-15 | Not specified | IC50 : 17.6 µg/ml |
| dbacp02104 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | DU-145 | Not specified | IC50 : 15.3 µg/ml |
| dbacp02105 | Buforin2 | TRSSRAGLQFPVGRVHRLLRK | Asiatic toad | Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis | MTT/MTS assay | U-937 | Lymphoma cancer | 5% Cytotoxicity at 0.5 µg/ml |
| dbacp02108 | cMastoparan-C(cMP-C) | CLNLKALLAVAKKILC | Synthetic construct | Apoptosis | MTT assay | H157 | Non-small cell Lung cancer | IC50 : 7.02 μM |
| dbacp02109 | cMastoparan-C(cMP-C) | CLNLKALLAVAKKILC | Synthetic construct | Apoptosis | MTT assay | MBD-MB-435S | Melanocyte | IC50 : 13.87 μM |
| dbacp02110 | cMastoparan-C(cMP-C) | CLNLKALLAVAKKILC | Synthetic construct | Apoptosis | MTT assay | PC-3 | Human prostate carcinoma | IC50 : 13.87 μM |
| dbacp02111 | cMastoparan-C(cMP-C) | CLNLKALLAVAKKILC | Synthetic construct | Apoptosis | MTT assay | U251-MG | Human glioblastoma astrocytoma | IC50 : 8.56 μM |
| dbacp02112 | cMastoparan-C(cMP-C) | CLNLKALLAVAKKILC | Synthetic construct | Apoptosis | MTT assay | MCF-7 | Human breast cancer | IC50 : 13.66 μM |
| dbacp02168 | C7A | KILRGVAKKIMRTFLRRISKDILTGKK | NK-2 peptide based derivatives | Apoptosis; Necrosis | Cell viability assay | HCT-116 | Colorectal cancer | Cell viability : >50% at 25μM approx. |
| dbacp02169 | C7A | KILRGVAKKIMRTFLRRISKDILTGKK | NK-2 peptide based derivatives | Apoptosis; Necrosis | Cell viability assay | HROC24 | Colorectal cancer | Cell viability : >60% at 25μM approx. |
| dbacp02170 | C7A | KILRGVAKKIMRTFLRRISKDILTGKK | NK-2 peptide based derivatives | Apoptosis; Necrosis | Cell viability assay | HROC40 | Colorectal cancer | Cell viability : >60% at 25μM approx. |
| dbacp02171 | C7A | KILRGVAKKIMRTFLRRISKDILTGKK | NK-2 peptide based derivatives | Apoptosis; Necrosis | Cell viability assay | HROC60 | Colorectal cancer | Cell viability : >50% at 25μM approx. |
| dbacp02172 | C7A | KILRGVAKKIMRTFLRRISKDILTGKK | NK-2 peptide based derivatives | Apoptosis; Necrosis | Cell viability assay | HROC32 | Colorectal cancer | Cell viability : >60% at 25μM approx. |
| dbacp02173 | C7A | KILRGVAKKIMRTFLRRISKDILTGKK | NK-2 peptide based derivatives | Apoptosis; Necrosis | Cell viability assay | HCT-116 | Colorectal cancer | Cell viability : >40% at 12.5μM approx. |
| dbacp02174 | C7A | KILRGVAKKIMRTFLRRISKDILTGKK | NK-2 peptide based derivatives | Apoptosis; Necrosis | Cell viability assay | HROC18 | Colorectal cancer | Cell viability : >55% at 12.5μM approx. |
| dbacp02175 | C7A | KILRGVAKKIMRTFLRRISKDILTGKK | NK-2 peptide based derivatives | Apoptosis; Necrosis | Cell viability assay | HROC24 | Colorectal cancer | Cell viability : >55% at 12.5μM approx. |
| dbacp02176 | C7A | KILRGVAKKIMRTFLRRISKDILTGKK | NK-2 peptide based derivatives | Apoptosis; Necrosis | Cell viability assay | HROC40 | Colorectal cancer | Cell viability : >45% at 12.5μM approx. |
| dbacp02177 | C7A | KILRGVAKKIMRTFLRRISKDILTGKK | NK-2 peptide based derivatives | Apoptosis; Necrosis | Cell viability assay | HROC60 | Colorectal cancer | Cell viability : >70% at 12.5μM approx. |
| dbacp02178 | C7A | KILRGVAKKIMRTFLRRISKDILTGKK | NK-2 peptide based derivatives | Apoptosis; Necrosis | Cell viability assay | HROC113 | Colorectal cancer | Cell viability : >80% at 12.5μM approx. |
| dbacp02179 | C7A | KILRGVAKKIMRTFLRRISKDILTGKK | NK-2 peptide based derivatives | Apoptosis; Necrosis | Cell viability assay | HROC32 | Colorectal cancer | Cell viability : >55% at 12.5μM approx. |
| dbacp02180 | C7A | KILRGVAKKIMRTFLRRISKDILTGKK | NK-2 peptide based derivatives | Apoptosis; Necrosis | Cell viability assay | HROC107 | Colorectal cancer | Cell viability : >50% at 12.5μM approx. |
| dbacp02189 | C7A-D21K | KILRGVAKKIMRTFLRRISKKILTGKK | NK-2 peptide based derivatives | Apoptosis; Necrosis | Cell viability assay | HCT-116 | Colorectal cancer | Cell viability : 50% at 12.5μM approx. |
| dbacp02190 | C7A-D21K | KILRGVAKKIMRTFLRRISKKILTGKK | NK-2 peptide based derivatives | Apoptosis; Necrosis | Cell viability assay | HROC24 | Colorectal cancer | Cell viability : >50% at 25μM approx. |
| dbacp02191 | C7A-D21K | KILRGVAKKIMRTFLRRISKKILTGKK | NK-2 peptide based derivatives | Apoptosis; Necrosis | Cell viability assay | HROC40 | Colorectal cancer | Cell viability : >50% at 25μM approx.. |
| dbacp02192 | C7A-D21K | KILRGVAKKIMRTFLRRISKKILTGKK | NK-2 peptide based derivatives | Apoptosis; Necrosis | Cell viability assay | HROC60 | Colorectal cancer | Cell viability : >50% at 25μM approx. |
| dbacp02193 | C7A-D21K | KILRGVAKKIMRTFLRRISKKILTGKK | NK-2 peptide based derivatives | Apoptosis; Necrosis | Cell viability assay | HROC32 | Colorectal cancer | Cell viability : 50% at 12.5μM approx. |
| dbacp02194 | C7A-D21K | KILRGVAKKIMRTFLRRISKKILTGKK | NK-2 peptide based derivatives | Apoptosis; Necrosis | Cell viability assay | HCT-116 | Colorectal cancer | Cell viability : >40% at 12.5μM approx. |
| dbacp02195 | C7A-D21K | KILRGVAKKIMRTFLRRISKKILTGKK | NK-2 peptide based derivatives | Apoptosis; Necrosis | Cell viability assay | HROC18 | Colorectal cancer | Cell viability : >55% at 12.5μM approx. |
| dbacp02196 | C7A-D21K | KILRGVAKKIMRTFLRRISKKILTGKK | NK-2 peptide based derivatives | Apoptosis; Necrosis | Cell viability assay | HROC24 | Colorectal cancer | Cell viability : >55% at 12.5μM approx. |
| dbacp02197 | C7A-D21K | KILRGVAKKIMRTFLRRISKKILTGKK | NK-2 peptide based derivatives | Apoptosis; Necrosis | Cell viability assay | HROC40 | Colorectal cancer | Cell viability : >80% at 12.5μM approx. |
| dbacp02198 | C7A-D21K | KILRGVAKKIMRTFLRRISKKILTGKK | NK-2 peptide based derivatives | Apoptosis; Necrosis | Cell viability assay | HROC60 | Colorectal cancer | Cell viability : >60% at 12.5μM approx. |
| dbacp02199 | C7A-D21K | KILRGVAKKIMRTFLRRISKKILTGKK | NK-2 peptide based derivatives | Apoptosis; Necrosis | Cell viability assay | HROC113 | Colorectal cancer | Cell viability : >65% at 12.5μM approx. |
| dbacp02200 | C7A-D21K | KILRGVAKKIMRTFLRRISKKILTGKK | NK-2 peptide based derivatives | Apoptosis; Necrosis | Cell viability assay | HROC32 | Colorectal cancer | Cell viability : >80% at 12.5μM approx. |
| dbacp02201 | C7A-D21K | KILRGVAKKIMRTFLRRISKKILTGKK | NK-2 peptide based derivatives | Apoptosis; Necrosis | Cell viability assay | HROC107 | Colorectal cancer | Cell viability : >65% at 12.5μM approx. |
| dbacp02209 | C7A-Δ | KILRGVAKKIMRTFLRRISKDILTGKK | NK-2 peptide based derivatives | Apoptosis; Necrosis | Cell viability assay | HCT-116 | Colorectal cancer | Cell viability : >50% at 12.5μM approx. |
| dbacp02210 | C7A-Δ | KILRGVAKKIMRTFLRRISKDILTGKK | NK-2 peptide based derivatives | Apoptosis; Necrosis | Cell viability assay | HROC24 | Colorectal cancer | Cell viability : >60% at 25μM approx. |
| dbacp02211 | C7A-Δ | KILRGVAKKIMRTFLRRISKDILTGKK | NK-2 peptide based derivatives | Apoptosis; Necrosis | Cell viability assay | HROC40 | Colorectal cancer | Cell viability : >50% at 25μM approx. |
| dbacp02212 | C7A-Δ | KILRGVAKKIMRTFLRRISKDILTGKK | NK-2 peptide based derivatives | Apoptosis; Necrosis | Cell viability assay | HROC60 | Colorectal cancer | Cell viability : >50% at 25μM approx. |
| dbacp02213 | C7A-Δ | KILRGVAKKIMRTFLRRISKDILTGKK | NK-2 peptide based derivatives | Apoptosis; Necrosis | Cell viability assay | HROC32 | Colorectal cancer | Cell viability : 50% at 12.5μM approx. |
| dbacp02214 | C7A-Δ | KILRGVAKKIMRTFLRRISKDILTGKK | NK-2 peptide based derivatives | Apoptosis; Necrosis | Cell viability assay | HCT-116 | Colorectal cancer | Cell viability : >50% at 12.5μM approx. |
| dbacp02215 | C7A-Δ | KILRGVAKKIMRTFLRRISKDILTGKK | NK-2 peptide based derivatives | Apoptosis; Necrosis | Cell viability assay | HROC18 | Colorectal cancer | Cell viability : >75% at 12.5μM approx. |
| dbacp02216 | C7A-Δ | KILRGVAKKIMRTFLRRISKDILTGKK | NK-2 peptide based derivatives | Apoptosis; Necrosis | Cell viability assay | HROC24 | Colorectal cancer | Cell viability : >70% at 12.5μM approx. |
| dbacp02217 | C7A-Δ | KILRGVAKKIMRTFLRRISKDILTGKK | NK-2 peptide based derivatives | Apoptosis; Necrosis | Cell viability assay | HROC40 | Colorectal cancer | Cell viability : >85% at 12.5μM approx. |
| dbacp02218 | C7A-Δ | KILRGVAKKIMRTFLRRISKDILTGKK | NK-2 peptide based derivatives | Apoptosis; Necrosis | Cell viability assay | HROC60 | Colorectal cancer | Cell viability : >70% at 12.5μM approx. |
| dbacp02219 | C7A-Δ | KILRGVAKKIMRTFLRRISKDILTGKK | NK-2 peptide based derivatives | Apoptosis; Necrosis | Cell viability assay | HROC113 | Colorectal cancer | Cell viability : >70% at 12.5μM approx. |
| dbacp02220 | C7A-Δ | KILRGVAKKIMRTFLRRISKDILTGKK | NK-2 peptide based derivatives | Apoptosis; Necrosis | Cell viability assay | HROC32 | Colorectal cancer | Cell viability : >85% at 12.5μM approx. |
| dbacp02221 | C7A-Δ | KILRGVAKKIMRTFLRRISKDILTGKK | NK-2 peptide based derivatives | Apoptosis; Necrosis | Cell viability assay | HROC107 | Colorectal cancer | Cell viability : >70% at 12.5μM approx. |
| dbacp02235 | CA-MA | KWKLFKKIGIGKFLHSAKKF | Ceropin A-African clawed frog | Apoptosis | MTT/MTS assay | NCI-H69 | Lung cancer | IC50 : 15.8 µM |
| dbacp02236 | CA-MA | KWKLFKKIGIGKFLHSAKKF | Ceropin A-African clawed frog | Apoptosis | MTT/MTS assay | NCI-H128 | Lung cancer | IC50 : 16.1 µM |
| dbacp02237 | CA-MA | KWKLFKKIGIGKFLHSAKKF | Ceropin A-African clawed frog | Apoptosis | MTT/MTS assay | NCI-H146 | Lung cancer | IC50 : 15.8 µM |
| dbacp02253 | CA-ME | KWKLFKKIGIGAVLKVLTTG | Ceropin A-African clawed frog | Apoptosis | MTT/MTS assay | NCI-H69 | Lung cancer | IC50 : 32.2 µM |
| dbacp02254 | CA-ME | KWKLFKKIGIGAVLKVLTTG | Ceropin A-African clawed frog | Apoptosis | MTT/MTS assay | NCI-H128 | Lung cancer | IC50 : 28.6 µM |
| dbacp02255 | CA-ME | KWKLFKKIGIGAVLKVLTTG | Ceropin A-African clawed frog | Apoptosis | MTT/MTS assay | NCI-H146 | Lung cancer | IC50 : 28.6 µM |
| dbacp02304 | Cartilage protein hydrolysate peptide | FIMGPY | Skate | Cell proliferation inhibition; Apoptosis inducing | MTT assay | HeLa | Cervical cancer | IC50 : 4.81 mg/mL |
| dbacp02305 | Caseinphosphopeptides | PPPEE | Bovine milk | Regulation of immune response; Apoptosis inducing | MTT/MTS assay | AZ-97 | Colon cancer | Inhibition at 24-28g/l |
| dbacp02314 | Cathepsin B | MWWSLILLSCLLALTSAHDKPSFHPLSDDLINYINKQNTTWQAGRNFYNVDISYLKKLCGTVLGGPKLPGRVAFGEDIDLPETFDAREQWSNCPTIGQIRDQGSCGSCWAFGAVEAISDRTCIHTNGRVNVEVSAEDLLTCCGIQCGDGCNGGYPSGAWSFWTKKGLVSGGVYNSHVGCLPYTIPPCEHHVNGSRPPCTGEGDTPRCNKSCEAGYSPSYKEDKHFGYTSYSVSNSVKEIMAEIYKNGPVEGAFTVFSDFLTYKSGVYKHEAGDMMGGHAIRILGWGVENGVPYWLAANSWNLDWGDNGFFKILRGENHCGIESEIVAGIPRTDQYWGRF | Mouse | Apoptosis; Cell proliferation | Not specified | Not found | Not found | Not found |
| dbacp02378 | Cercopin D | GNFFKDLEKMGQRVRDAVISAAPAVDTLAKAKALGQ | Domestic silk moth | Apoptosis inducing | Not specified | Not found | Not found | Not found |
| dbacp02379 | Ceropin | MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG | House fly | Apoptosis inducing | Trypan blue assay | BEL-7402 | Liver cancer | 91.8% cell viability at 12.5 µM |
| dbacp02380 | Ceropin | MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG | House fly | Apoptosis inducing | Trypan blue assay | BEL-7402 | Liver cancer | 84.1% cell viability at 25 µM |
| dbacp02381 | Ceropin | MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG | House fly | Apoptosis inducing | Trypan blue assay | BEL-7402 | Liver cancer | 76.3% cell viability at 50 µM |
| dbacp02382 | Ceropin | MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG | House fly | Apoptosis inducing | Trypan blue assay | BEL-7402 | Liver cancer | 71.5 % cell viability at 75 µM |
| dbacp02383 | Ceropin | MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG | House fly | Apoptosis inducing | Trypan blue assay | BEL-7402 | Liver cancer | 54.2 % cell viability at 100 µM |
| dbacp02384 | Ceropin | MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG | House fly | Apoptosis inducing | Trypan blue assay | BEL-7402 | Liver cancer | 87.3 % cell viability at 25 µM |
| dbacp02385 | Ceropin | MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG | House fly | Apoptosis inducing | Trypan blue assay | BEL-7402 | Liver cancer | 75.6 % cell viability at 50 µM |
| dbacp02386 | Ceropin | MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG | House fly | Apoptosis inducing | Trypan blue assay | BEL-7402 | Liver cancer | 62.8 % cell viability at 75 µM |
| dbacp02387 | Ceropin | MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG | House fly | Apoptosis inducing | Trypan blue assay | BEL-7402 | Liver cancer | 54.3 % cell viability at 100 µM |
| dbacp02388 | Ceropin | MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG | House fly | Apoptosis inducing | Trypan blue assay | BEL-7402 | Liver cancer | 48.6 % cell viability at 100 µM |
| dbacp02389 | Ceropin | MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG | House fly | Apoptosis inducing | Trypan blue assay | BEL-7402 | Liver cancer | 72.1 % cell viability at 12.5 µM |
| dbacp02390 | Ceropin | MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG | House fly | Apoptosis inducing | Trypan blue assay | BEL-7402 | Liver cancer | 63.3 % cell viability at 25 µM |
| dbacp02391 | Ceropin | MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG | House fly | Apoptosis inducing | Trypan blue assay | BEL-7402 | Liver cancer | 49.7 % cell viability at 50 µM |
| dbacp02392 | Ceropin | MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG | House fly | Apoptosis inducing | Trypan blue assay | BEL-7402 | Liver cancer | 41.1 % cell viability at 75 µM |
| dbacp02393 | Ceropin | MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG | House fly | Apoptosis inducing | Trypan blue assay | BEL-7402 | Liver cancer | 35.2 % cell viability at 100 µM |
| dbacp02458 | Chartergellus-CP1 peptide | IIGTILGLLKSLNH2 | Social wasp | Apoptosis inducing | MTT assay | A375 | Human melanoma | IC50 : 40.5 µg/mL |
| dbacp02459 | Chartergellus-CP1 peptide | IIGTILGLLKSLNH2 | Social wasp | Apoptosis inducing; Intracellular ROS formation | MTT assay | MNT-1 | Human melanoma | IC50 : 51.6 µg/mL |
| dbacp02472 | Chickpea peptide | ADLPGLK | Plant sources | Inducing apoptosis | SRB assay | A-549 | Human endometrial cancer | IC50 : 126.4 ± 1.98 µM |
| dbacp02473 | Chickpea peptide | ADLPGLK | Plant sources | Inducing apoptosis | SRB assay | HepG-2 | Human endometrial cancer | IC50 : 113.7 ± 0.99 µM |
| dbacp02474 | Chickpea peptide | ADLPGLK | Plant sources | Inducing apoptosis | SRB assay | Ishikawa | Human endometrial cancer | IC50 : 101.5 ± 1.83 µM |
| dbacp02475 | Chickpea peptide | ADLPGLK | Plant sources | Inducing apoptosis | SRB assay | MCF-7 | Human endometrial cancer | IC50 : 110.3 ± 2.97µM |
| dbacp02476 | Chickpea peptide | ADLPGLK | Plant sources | Inducing apoptosis | SRB assay | MDA-MB-231 | Human endometrial cancer | IIC50 : 107.2 ± 1.62µM |
| dbacp02477 | Chickpea peptide | ADLPGLK | Plant sources | Inducing apoptosis | SRB assay | PA-1 | Human endometrial cancer | IC50 : 133.4 ± 0.70µM |
| dbacp02483 | Chrysophsin-1 | FFGWLIKGAIHAGKAIHGLI | The pyloric caeca and gills; Red sea bream | Disruption of cancer cell membranes; Apoptosis | MTS assay, Lactate dehydrogenase (LDH) detection assay | HT-1080 | Human fibrosarcoma | MIC : 7 µg/ml |
| dbacp02484 | Chrysophsin-1 | FFGWLIKGAIHAGKAIHGLI | The pyloric caeca and gills; Red sea bream | Disruption of cancer cell membranes; Apoptosis | MTS assay, Lactate dehydrogenase (LDH) detection assay | U937 | Histiocytic lymphoma | MIC : 7 µg/ml |
| dbacp02485 | Chrysophsin-1 | FFGWLIKGAIHAGKAIHGLI | The pyloric caeca and gills; Red sea bream | Disruption of cancer cell membranes; Apoptosis | MTS assay, Lactate dehydrogenase (LDH) detection assay | HeLa | Epithelial carcinoma | MIC : 7 µg/ml |
| dbacp02487 | Citropin 1.1 | GLFDVIKKVASVIGGL | Australian blue mountains tree frog | Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis | MTT/MTS assay | U-938 | Lymphoma cancer | IC50 :40 µg/ml |
| dbacp02512 | Citropin1.1 | GLFDVIKKVASVIGGL | Australian blue mountains tree frog | Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis | MTT/MTS assay | U-937 | Lymphoma cancer | 60% Cytotoxicity at 0.5 µg/ml |
| dbacp02513 | Citropin1.1 | GLFDVIKKVASVIGGL | Australian blue mountains tree frog | Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis | MTT/MTS assay | U-937 | Lymphoma cancer | 60% Cytotoxicity at 0.5 µg/ml |
| dbacp02534 | CNGRC-GG-D(KLAKLAK)2 | CNGRCGGKLAKLAKKLAKLAK | Not found | Inducing apoptosis | Internalization assay, Mitochondrial swelling assay, Cell-free apoptosis assay, Caspase activation assay | KS1767 | Not specified | LC50 : 42 μM |
| dbacp02535 | CNGRC-GG-D(KLAKLAK)3 | CNGRCGGKLAKLAKKLAKLAK | Not found | Inducing apoptosis | Internalization assay, Mitochondrial swelling assay, Cell-free apoptosis assay, Caspase activation assay | MDA-MB-435 | Not specified | LC50 : 415 Μm |
| dbacp02541 | Conotoxin Cl14.1a (Conotoxin Cal14.1a) | MNVTAMFIVLLLTMPLTDGFNIRAINGGELFGLVQRDAGNALDHGFYRRGDCPPWCVGARCRAEKC | California cone | Apoptosis | MTT assay | H1299 | Non-small cell Lung cancer | Not found |
| dbacp02542 | Conotoxin Cl14.1a (Conotoxin Cal14.1a) | MNVTAMFIVLLLTMPLTDGFNIRAINGGELFGLVQRDAGNALDHGFYRRGDCPPWCVGARCRAEKC | California cone | Apoptosis | MTT assay | H1437 | Non-small cell Lung cancer | Not found |
| dbacp02543 | Conotoxin Cl14.1a (Conotoxin Cal14.1a) | MNVTAMFIVLLLTMPLTDGFNIRAINGGELFGLVQRDAGNALDHGFYRRGDCPPWCVGARCRAEKC | California cone | Apoptosis | MTT assay | H1975 | Non-small cell Lung cancer | Not found |
| dbacp02544 | Conotoxin Cl14.1a (Conotoxin Cal14.1a) | MNVTAMFIVLLLTMPLTDGFNIRAINGGELFGLVQRDAGNALDHGFYRRGDCPPWCVGARCRAEKC | California cone | Apoptosis | MTT assay | H661 | Non-small cell Lung cancer | Not found |
| dbacp02545 | Conotoxin Cl14.1a (Conotoxin Cal14.1a) | MNVTAMFIVLLLTMPLTDGFNIRAINGGELFGLVQRDAGNALDHGFYRRGDCPPWCVGARCRAEKC | California cone | Apoptosis | Not specified | SK-BR-3 | Breast cancer | Not found |
| dbacp02546 | Conotoxin Cl14.1a (Conotoxin Cal14.1a) | MNVTAMFIVLLLTMPLTDGFNIRAINGGELFGLVQRDAGNALDHGFYRRGDCPPWCVGARCRAEKC | California cone | Apoptosis | Not specified | MCF-7 | Breast cancer | Not found |
| dbacp02552 | Cpm-1285 | KNLWAAQRYGRELRRMSDEFEGSFKGL | BH3-only, Sensizers (BAD, HRK, Noxa) | Inducing apoptosis | Not specified | HL-60 | Not specified | IC50 : 130 nM |
| dbacp02553 | Cpm-1285 | KNLWAAQRYGRELRRMSDEFEGSFKGL | BH3-only, Sensizers (BAD, HRK, Noxa) | Inducing apoptosis | Not specified | PBL | Not specified | IC50 : 130 nM |
| dbacp02554 | Cpm-1285m | KNLWAAQRYGREARRMSDEFEGSFKGL | BH3-only, Sensizers (BAD, HRK, Noxa) | Inducing apoptosis | Not specified | HL-60 | Not specified | Not found |
| dbacp02555 | Cpm-1285m | KNLWAAQRYGREARRMSDEFEGSFKGL | BH3-only, Sensizers (BAD, HRK, Noxa) | Inducing apoptosis | Not specified | PBL | Not specified | Not found |
| dbacp02560 | Cr-AcACP1 | AW(Ac)KLFDDGV | Not found | Inducing apoptosis | MTT assay | Not found | Colon carcinoma | Not found |
| dbacp02561 | Cr-ACP1 | AWKLFDDGV | Seeds, sago palm | Apoptosis inducing | Not specified | Not found | Not found | Not found |
| dbacp02562 | Cr-ACP1 | AWKLFDDGV | Not found | Inducing apoptosis | MTT assay | Hep2 | Human epidermoid cancer | IC50 : 1.5 mM |
| dbacp02580 | CS5931 | MVVCPDGQSECPDGN | Marine invertebrates | Inducing apoptosis | Not specified | HCT-8 | Colorectal cancer | Not found |
| dbacp02599 | Cyclosaplin | RLGDGCTR | Not found | Apoptosis | DNA fragmentation assay | MDA-MB-231 | Breast cancer | IC50 : 2.06 µg/mL |
| dbacp02608 | Cytotoxin drCT-1 | LKCNKLVPLFYKTCPAGKNL | Not found | Inducing apoptosis | MTT assay | U937 | Leukemia | IC50 : 8.9 µg/ml |
| dbacp02609 | Cytotoxin drCT-1 | LKCNKLVPLFYKTCPAGKNL | Not found | Inducing apoptosis | MTT assay | K562 | Leukemia | IC50 : 6.7 µg/ml |
| dbacp02611 | D (KLAKLAK) 2-TAT | KLAKLAKKLAKLAKGGRKKRRQRRR | Not found | Inducing apoptosis | Not specified | A549 | Not specified | IC50 : 5.3 μM |
| dbacp02618 | D-Antp-LP4 | RQIKIWFQNRRMKWKKSWTWEKKLETAVNLAWTAGNSNKWTWK | Not found | Inducing apoptosis | Not specified | CLL | Leukemia | IC50 : 0.7 ± 0.4 µM |
| dbacp02619 | D-Antp-LP4 | RQIKIWFQNRRMKWKKSWTWEKKLETAVNLAWTAGNSNKWTWK | Not found | Inducing apoptosis | Not specified | MEC-1 | Leukemia | IC50 : 1.6 ± 0.3 µM |
| dbacp02623 | D-MinAntp-LP4 | KRRMKWKKSWTWEKKLETAVNLAWTAGNSNKWTWK | Not found | Inducing apoptosis | Not specified | CLL | Leukemia | IC50 : 0.6 ± 0.2 µM |
| dbacp02624 | D-MinAntp-LP4 | KRRMKWKKSWTWEKKLETAVNLAWTAGNSNKWTWK | Not found | Inducing apoptosis | Not specified | MEC-1 | Leukemia | IC50 : 1.4 ± 0.1 µM |
| dbacp02625 | D-N-Ter-Antp | MAVPPTYADLGKSARDVFTKGYGFGLRQIKIWFQNRRMKWKK | VDAC1(voltage-dependent anion channel1) | Inducing apoptosis | Not specified | CLL | Leukemia | IC50 : 1.5 ± 0.6 µM |
| dbacp02626 | D-N-Ter-Antp | MAVPPTYADLGKSARDVFTKGYGFGLRQIKIWFQNRRMKWKK | VDAC1(voltage-dependent anion channel1) | Inducing apoptosis | Not specified | MEC-1 | Leukemia | IC50 : 2.2 ± 1.6 µM |
| dbacp02631 | DC1 | GAFLKCGESCVYLPCLTTVVGCSCQNSVCYRD | Snake-needle grass | Apoptosis inducing | Colorimetric Cell viability assay,Migration assay ,Wound healing assay and Human prostate cancer xenograft assay | DC3 | Prostate cancer | Not found |
| dbacp02632 | DC1 | GAFLKCGESCVYLPCLTTVVGCSCQNSVCYRD | Snake-needle grass | Apoptosis inducing | Colorimetric Cell viability assay,Migration assay ,Wound healing assay and Human prostate cancer xenograft assay | LNCap | Prostate cancer | Not found |
| dbacp02633 | DC2 | GAVPCGETCVYLPCITPDIGCSCQNKVCYRD | Snake-needle grass | Apoptosis inducing | Colorimetric Cell viability assay,Migration assay ,Wound healing assay and Human prostate cancer xenograft assay | DC3 | Prostate cancer | Not found |
| dbacp02634 | DC2 | GAVPCGETCVYLPCITPDIGCSCQNKVCYRD | Snake-needle grass | Apoptosis inducing | Colorimetric Cell viability assay,Migration assay ,Wound healing assay and Human prostate cancer xenograft assay | LNCap | Prostate cancer | Not found |
| dbacp02635 | DC3 | GTSCGETCVLLPCLSSVLGCTCQNKRCYKD | Snake-needle grass | Apoptosis inducing | Colorimetric Cell viability assay,Migration assay ,Wound healing assay and Human prostate cancer xenograft assay | DC3 | Prostate cancer | Not found |
| dbacp02636 | DC3 | GTSCGETCVLLPCLSSVLGCTCQNKRCYKD | Snake-needle grass | Apoptosis inducing | Colorimetric Cell viability assay,Migration assay ,Wound healing assay and Human prostate cancer xenograft assay | LNCap | Prostate cancer | Not found |
| dbacp02640 | Defensin coprisin | MAKLIAFALVASLCLSMVLCNPLPEEVQEEGLVRQKRVTCDVLSFEAKGIAVNHSACALHCIALRKKGGSCQNGVCVCRN | Dung beetle | Induces apoptosis and necrosis | Radial diffusion assay, MIC assay | SNU-484 | Gastric cancer | MIC : ≤ 50 μM |
| dbacp02641 | Defensin coprisin | MAKLIAFALVASLCLSMVLCNPLPEEVQEEGLVRQKRVTCDVLSFEAKGIAVNHSACALHCIALRKKGGSCQNGVCVCRN | Dung beetle | Induces apoptosis and necrosis | Radial diffusion assay, MIC assay | SNU-601 | Gastric cancer | MIC : ≤ 50 μM |
| dbacp02642 | Defensin coprisin | MAKLIAFALVASLCLSMVLCNPLPEEVQEEGLVRQKRVTCDVLSFEAKGIAVNHSACALHCIALRKKGGSCQNGVCVCRN | Dung beetle | Induces apoptosis and necrosis | Radial diffusion assay, MIC assay | SNU-638 | Gastric cancer | MIC : ≤ 50 μM |
| dbacp02643 | Defensin coprisin | MAKLIAFALVASLCLSMVLCNPLPEEVQEEGLVRQKRVTCDVLSFEAKGIAVNHSACALHCIALRKKGGSCQNGVCVCRN | Dung beetle | Induces apoptosis and necrosis | Radial diffusion assay, MIC assay | SNU-668 | Gastric cancer | MIC : ≤ 50 μM |
| dbacp02646 | Demegen P-113 | AKRHHGYKRKFH | Thrush | Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis | MTT/MTS assay | U-939 | Lymphoma cancer | IC50 : 85-90 µg/ml |
| dbacp02647 | Demegen P-113 | AKRHHGYKRKFH | Amphibian skin peptide | Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis | MTT/MTS assay | U-937 | Lymphoma cancer | 15% Cytotoxicity at 0.5 µg/ml |
| dbacp02648 | DepA | MYSSSDVASRRISAADKFGPHHAFPHREALSIARQLLWRAEASPDRLAYASADPVKNIALSYAGLCERASGIAARLAQATETGDRVMLVYQEPLDFLPAFFGCCLAGVIPVPVAPRHGRDTMLAIAEDCGAVIALTAEARDALPGLRWMRTDETEGAAPFLRAAGEGSPVLLQYTSGSTRTPQGVVVTQTGLWATIEDLDRGAMHDADSVMISWLPYFHDMGLVYGILTPLQCGFPAYLMAPEKFVAQPMSWLRAIEARRGTHTAAPNFAYALCADRAADLAPGTDLSSLRYALNGAEPVRCDTVRRFEAAFAPFGLKPSVVAPGYGLAEATLKVTAGRCGEGTRGVRFGRDALARGRVSPEADGVELAACGSSLIDTRVRIVNPDTREPCEADVVGEIWVSGSTVADSYWRRPEESREIFGARLADDNGVWLRTGDLGFLYDGDLFVTSRLKDLIIVGGRNFYSHDLEDTVSACHPSIRMGRVFAAAVDGEEGEGVLIGAEVRGGCEEADAREILPVIRAALAREHGVAPARVALLRRGSILRTSSGKTRRSATRDALLRGELSIIADDAADMSDDAILAEISSFVPGAAATSDARLIDLGLDSLSAARLAAMARARHGVELSFATLFALSAEQLRREIVAARARHDGSAAPVSVRGYAAGEPFELSEMQQAYWIGQQGGVPLGSVSPHIRVDFEIDAARAPELGRRLASLVARHPSLRMTVGADGRGVFDALAYDPLLPPQDLRGLDAAEAAERLEATRASLAERDGPPVVAAVTRLTDSTAILHMRLGLLAGDLRSFLQLMAELARGAAGDVPAQLITPMTPATPTGEQREAWLRRVEAIAPAPELPMKMALADVAEPRFAGRRRELPAALSAALAARAQGLGVTLTSLCIAAFADTLRLWTAAHAFTLNVTCNTRAEQAGQAIGDYTSNALLSLSERHESFAAFAREVQRQVWADLDAPWCSGVSILRELSRRNGAPVLMPVVLTSLLSGDPADDLSILDGIGRVVDMANPTPQVSLHAVLGRRGDRLLVMWEFVAQLFPEGMIDAMFDAFLGALETMATEAAALERPTVARLAPEQAARREAVNATEAERAPRRLETPIIRQALTTPEAVAVRQGAATLSYGELLRQAEDIAGALRQSGVARGDVVAAIVAPGPRAVAALLGIVMAGAVYLSIEPSWPAARIEELLGEAGARHAVVSEGGWTLPVQALRLDLPLPPGDAGPAPDLEAGDAAYVIFTSGSTGRPKGVLIAHEAAANTIDDINERFAVGPADRTLCVSSLAFDLSVYDIFGLLAVGGEVVFPERARDPDAMAQALCDGRITIWNSVPAVLELLLDVAAPRSPDLRLALLSGDWIAPGLAGRLRDAFPALRPISLGGATEVSIWSVVHPIAPEDAALASIPYGRPLSNQQCFVRAPDGRERPDGVVGELLLGGRGLALAYLGNEAETQRRFFIDAEGRRLYRTGDLARWQPDGELELLGRMDGQVKVQGYRIELGEIEAAAMRAGCLARAVASVVRRNNATAIQLHVVARPDYDGDIVAAVRAKLVLHLPAYMQPHHVTVLDALPLTANGKVDRARLAALAAPAPASAKPAATARRDDSLEATMLAAFAEVVGVEIDPQQGFFDAGATSMHVVRLRALLASRGVVVPPLVDFFSLATIRALAERADSGDADLSPMIDVDGARAYRQRVRARKEAL | Gram-negative bacillus | Inducing apoptosis | GFP assay | NIH 3T3 | Cutaneous T-cell lymphoma | Not found |
| dbacp02649 | DepD | MTMARLMTDLADAGVTLRRRGDQLQVQAPQGALDAALVARLREAKEELLRVLDDEGARAAPLAPAQPGEAGDAAALSPGQARLVAATRLGDPAMYNEQAAIELADAVDAEAVARAFAALARRHDILRTVFSDGEPVRQTVLPEPIVTLQAWTVDGDDALRARAADLARLPFAAGAPMWRVDLFSTPERAAVLVLTIHHAIFDRWSMSVLIRDFSAYLALPDAAEAPASGLSYRDYSAWQRRWMASPDYAAQLDAWVDDLAEVDEVPAIRGDRPRPPAMSGRGGTERFEIPADCMDAAAAFSRSRNTTLFTTLFSAFALLQHRYTGEARALTLTPAANRPFQAAEEIAGYFVNLVALATEVGEGDSFGALVDRARDASARAFARQGVPLDAIVERLRARGGPRHEQFAQTVFAFQNVRLPAVRTASGAAVPFDLDSPFARFDLYLSIEGDERGTFAVWQYNTDLYEAATIRQLGEHYLALLRAALASPDADARALPILSAEEEARLRGWGRHELPYRADAAIDRLFRERAADHPGRVALEQGGVRWTYAELDQWSDRAAGALRAAGVEAGAVVGVAGERSPRLLAAFLAVLKAGAAYLPLDPTYPAARLRAMTADAAPALMIIADGLDAGWLGDYAGPVLSLADCEAGVARPLQSEARPAEAESLAYVMYTSGSTGQPKGVAVPHRAVARLATGGGYARLDASTVMLQQSPLGFDASTFEIWGCWLNGGRLVVAEPGMPFLDAASRDGVTTMWLTADLFRMAVEEEPAALGGLRELLTGGDALPVASCRAFLEACPGVALINGYGPTENTTFTCSHRVTAGDARRGSIPIGRPIGNTEVRVVDAGGRLVPVGVPGELWAGGDGLALGYLGRADLTAERFVAAPPPDGGRWYRTGDRVRWRRDGVLEFLGRIDEQIKLRGYRIELGEIEATLGHYPGLSGCAVALRRSAADEKQLVGYLVARPDSGEAADSAAVQAWLEARLPGYMVPRVWVWLDALPQSANGKVDRKRLPDPVVETGAAAAETEAEAALVEIWQGLLGLERVGVRDNFFALGGDSILSIQMASRAAERGLRLSPQQVFRYPTIAELAAEGCAAEEAGAQAEQGEVVGEVRPGPIQAWYLDWPGTDWEQFNQGAYLGLDGVVDAESLIGALQAVAQRHDALRIGWRRDGERWIQASGAGEPVEVKAVDLRGLADAEAALERDAAALQSSLRLGGASLWAARLYRLDEGWRLLWLAHHASVDGVSWRILLEDLWRAYAALSRGEAAAWPAKTVSYQAWSQRLWEWAETLPDSTLSYWREMDAPGMPLPGFNAAEDTVAAESRVSLQWEPETTERWLRQAGEAYRMRPEELLVTALARALRQWTGAEECVLDLEGHGRDGLAGVDVSRTVGWFTSLYPLRLPLSGELSGDLKRVKERMRSVPDGGLAYHALRYGGRGSALGGHARTVCFNYLGQWRLEEGGEPRSTWLGEPPGGTRGAGMTRRYGLDVVAQVHEGRLRVDWLYSAARQREDAIKALAEGFRAELDAVLAHCQSPESGGLTPSDLPLAHLDQSEIDAIEREHPRLEALYGLTPLQQGILFHSIADDGAPLYVEQLHWKMSGAFDAERFRQAWFDVAAAHAALRTTFRWRGLKSAVQIVHPRLDPDWETLDWGDVSADACASRFAALCELHRERGFDLERGPLLRGTLVREPGDAWRFLWSYHHAVVDGWSVPLILKQVLGRYAELGAGEAAPLPGSRFLPFVNWLAARDAREQAEYWKQVLEGIEEPTPIGFASPARGPQAQGQGRRAFVFDAALREQVDRAARRAGVTRASLLTGAWALTLGYAGGGRDVVFGTTLSGRPATLPGVERMVGLFINTVPVRVGMDDDASVSQWLRQLHEQQSERARLGAASLTDIQRWAGYEGGELLSSLFVVENYPVDRTLARGDAGFDVSEFAAAETRTNYPLVGQLIPGEETVLYVDFDASRYDEESIGRLGASFMHLLSQLAAQPDARLGDLTLVDDDEARRLIHDWNATPPVGEGYLLHASIERHAELTPLAPAIIGVDEAMNYRELADETLRTARAVAAAGAKREPVAVLLPRSARAVAAYSGVMRAGCAYVPADPAMPPGRLRDLLATVGYVLTTREHLPMLDGVAARAILIDETPPADVALPDAAPDDLAYVMFTSGSTGKPKGVMITHRAASLTIEVFLRRYEIGASDRLMCVSAAGFDLSVFDFFGAFAAGAAVLLAPESSTIAPAVWLELMTREGATVWESVPAVMELLLLECRQSGRALPPSLKLAMLSGDRVPVGLPAQIRAAATSDPEVLALGGATEGAIWSCWYDTRELASDAAFVPYGRHLPGQRLYVLSSSLQAVPVGVPGDLWIAGAGVALGYLGQPDLTAYRFVDNPFVPGERMYRTGDRARVLADGNLEFLGRVDDQVKIGGFRIEIGEIEAALAAAPGVERGVASVVERDGRRIIAGYVLLLPGASLDLAAVRDALARRLPPYMLPASIMALDSLPLSANGKVDRKRLPDPVVETGAAAAETEAEAALVEIWQGLLGLERVGVRDNFFALGGDSILSIQMASRAAERGLRLSPQQVFRYPTIAELAAEGCAAEEAGAQAEQGEVVGEVRPGPIQAWYLDWPGTDWEQFNQGAYLGLDGVVDAESLIGALQAVAQRHDALRIGWRRDGERWIQASGAGEPVEVKAVDLRGLADAEAALERDAAALQSSLRLGGASLWAARLYRLDEGWRLLWLAHHASVDGVSWRILLEDLWRAYAALSRGEAAAWPAKTVSYQAWSQRLWEWAETLPDSTLSYWREMDAPGMPLPGFNAAEDTVAAESRVSLQWEPETTERWLRQAGEAYRMRPEELLVTALARALRQWTGAKECVLDLEGHGRDGLAGVDVSRTVGWFTSLYPLRLPLSGELSGDLKRVKERMRSVPDGGLAYHALRYGGRGSELGGHARTVCFNYLGQWRLEEGGEPRSTWLGEPPGGTRGAGMTRRYGLDVVAQVHEGRLRVDWLYSAARQREDAIKALAEGFRAELDAVLAHCQSPESGGLTPSDLPLAHLDQNDIDEVLQLLNEQL | Gram-negative bacillus | Inducing apoptosis | GFP assay | NIH 3T3 | Cutaneous T-cell lymphoma | Not found |
| dbacp02650 | DepE | MNQTLSNTAQQARSKVETMLPLTPTQQGLLFHTLKAPESGVYYEQVACSFHAALNAADYRRALEAVVARHGVLRTGFLWDGPSKPVQVVFRDVALPWVEEDWRAFDQEEQQRRLAAYRDADRRPGFHLSRAPLMRCALFRTGEERYEFVWSYHHLLLDGWSVQIVLGEALAFYDAYRRSAVPAMPPPQPYSAFLRWLDEQDGAEAEAFWRARLGDVRSATPLPFADDARPDRAPGHGLIERELDARTSEGLQRLARECELTQSTVIQAAWALLLARASGRDDVVFGTTVSGRPAALRGVEQMVGLFVNALPTRASVDLELRLGDWLRRLHRQHVDAEAYAYTPLHAIPGWSGVAPGAPLFESLVVFENYPARADAKRYREQLGVSDVEVVEQTNYPLTVVAIPGERLSLRLHFDRQRISAASAERVVEMLTGVLGQFERGGPALSVARVSLLGDEAGGALAARWNAAARRADDAERQCLHRRFEAQARSRPDAVALKCDGETLTYAELDRRANRLAWRLDAAGVRGNAPVALAFGRGMDSVVAILAVLKAGAFYVPLDLDHPSERLAWMLDDIGAGALICGEEARDRFGDFGGVLIGMGDAAAPGEREDAPPPRDTSPADLCYVIYTSGSTGQPKGVCVEHRNADHLFAATRRSYGIGPSDVWTLFHSYAFDFSVWEIWGALLHGGRLEIVPYRCSRTPDEFLALLEREGVTMLSQTPSAFKQLLRALDDARRPLPAGLRYVFFGGEATIPSQFAACLNDAGGVALVNLYGITETTVHVTERVLGPGDAQSSRSPVGRPLPGYRVYLLDAAGHPVPPGVPGEIHVGGEGVARGYHNRPELDRERFIADPFLPGERLYRSGDLGRFDARGELDYLGRIDDQVKIRGFRIELGEVEATLARHPDVAAAAVMVDDATIDGHAQLAGFVVARGSARVSGSALRDWLAQRLPPHAVPARVVEMDAIPLTSNGKLDRRRLAGALAADADAARPRIAPRNTVEQALVGVFESVLKRSPIGVTDNFFELGGDSILSIQILSAAHKVNIDFSLDDLMRSLTIERLAPRVRQAGSAPPTASAPPLDAVHEDAYPLSAMQMAMLANEMRHGQDSAYHNVNGQRLALPFDAAALEAALRGAFERHPALRTAFDLAADEEPLQYVHRQVPLPLTVSDWRGLDPERQDERIRDWREAERRRRFDVERPPLIRFAVHRLSEKAMHIGVTKHHAILDGWSFNLLLSELISDYSARLAGRPLTLAAPASRFRDFVEREREAARSESLRDWWRARLQSLPVTRLAREPGGDAEPVDVPISAAQSAGLEALAASAGASVKSVLLTAHLLALSRIAGASSVTSGVVFNGRSEGVDGDRVLGLFLNSLPLGFDFPAGAFDAVALVRAVQSAELEVFSRRRYPLIELHRQAGTVFDALFNFTHFRALEEAVRDIEVSDGYASDMTNVPLVVQSSFDGRQRALRITLVPSRGYFSMATVNRFAALYADALRTLLGEPAAEGAGAVGAIRADGGERRSGASTAATPAAAGRAAAARPSGAALRRELRALWAAVLKREPPSDDSDFVALGGDSLLMLRICSRAGRAFGLNSAVVARLLTAQTVAEQARVIETDGAGEDGARVGSLVALSAQGDAPPLFFAPGAGGHVPYLRALAAELPNAFSVWGMTLPGDAGSVEAMATALIADIRRAQPYGPYRLGGHSFGGWVAFEVARQLAGQGEAVDWVAVVDSLPPGPAAQSRKQDWQGGRWVAEIGNSFARLADAELAFDEGEFDALDDARRVEHLRERLVEAGAVPEALGLPEFAARVRAFIAHSLTDYTPATPYAGALHVIVAADGDGEALISGWRQAASGAATAVRLAGDHIGIMRRPFVNGLAAALRAAEAAARRSVSVKQTEEEQ | Gram-negative bacillus | Inducing apoptosis | GFP assay | NIH 3T3 | Cutaneous T-cell lymphoma | Not found |
| dbacp02660 | Dermaseptin-B3 | ALWKnMLKGIGKLAGQAALGAVKTLVGA | South American frog, Giant leaf frog | Apoptosis inducing | Thymidine Incorporation assay | MCF-7 | Breast cancer | Not found |
| dbacp02661 | Dermaseptin-B4 | ALWKDILKNVGKAAGKAVLNTVTDMVNQ | Giant leaf frog | Apoptosis inducing | Thymidine Incorporation assay | MCF-7 | Breast cancer | Not found |
| dbacp02723 | Dermaseptin-PS1 | ALWKTMLKKLGTVALHAGKAALGAVADTISQ | Rock Kribensis Cichlid | Disrupting cell membranes; Apoptosis | Lactate dehydrogenase (LDH) assay, MTT cell proliferation assay | U251MG | Human glioblastoma | MIC : 10−5 M and above |
| dbacp02746 | DI | LTFEHYWAQLTS | E3 ubiquitin-protein ligase | Cell cycle arrest or apoptosis of cells | Immunoprecipitation assay | HCT-116-p53+/+ | Colon cancer | IC50 : 0.29 µM |
| dbacp02747 | DI | LTFEHYWAQLTS | E3 ubiquitin-protein ligase | Cell cycle arrest or apoptosis of cells | Immunoprecipitation assay | HCT-116-p53+/+ | Colon cancer | IC50 : 1.6 µM |
| dbacp02760 | Dimeric Smac Mature Smac (1-4) | AVPIAQKKQAIPVA | SMAC | Inducing apoptosis | Not specified | HeLa | Not specified | Not found |
| dbacp02801 | Dolastatin 10 | 2-[[2-(dimethylamino)-3-methylbutanoyl]amino]-N-[3-methoxy-1-[2-[1-methoxy-2-methyl-3-oxo-3-[[2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N,3-dimethylbutaNAmide | Wedge sea hare | Apoptosis inducing | TUNEL assay | DU-145 | Prostate cancer | IC50 : 0.5 nM |
| dbacp02802 | Dolastatin 10 | 2-[[2-(dimethylamino)-3-methylbutanoyl]amino]-N-[3-methoxy-1-[2-[1-methoxy-2-methyl-3-oxo-3-[[2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N,3-dimethylbutaNAmide | Wedge sea hare | Apoptosis inducing | Cell viability assay | DB | Lymphoma cancer | IC50 : 0.0013 - 0.013 nM |
| dbacp02803 | Dolastatin 10 | 2-[[2-(dimethylamino)-3-methylbutanoyl]amino]-N-[3-methoxy-1-[2-[1-methoxy-2-methyl-3-oxo-3-[[2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N,3-dimethylbutaNAmide | Wedge sea hare | Apoptosis inducing | Cell viability assay | HT | Lymphoma cancer | IC50 : 0.0013 - 0.013 nM |
| dbacp02804 | Dolastatin 10 | 2-[[2-(dimethylamino)-3-methylbutanoyl]amino]-N-[3-methoxy-1-[2-[1-methoxy-2-methyl-3-oxo-3-[[2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N,3-dimethylbutaNAmide | Wedge sea hare | Apoptosis inducing | Cell viability assay | RL | Lymphoma cancer | IC50 : 0.0013 - 0.013 nM |
| dbacp02805 | Dolastatin 10 | 2-[[2-(dimethylamino)-3-methylbutanoyl]amino]-N-[3-methoxy-1-[2-[1-methoxy-2-methyl-3-oxo-3-[[2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N,3-dimethylbutaNAmide | Wedge sea hare | Apoptosis inducing | Cell viability assay | SR | Leukemia cancer | IC50 : 0.0013 - 0.013 nM |
| dbacp02806 | Dolastatin 15 | VV-nMe-VPP-2hydroxyisovaleryl-2-oxo-4-methoxy-5-benzyl-3-pyrroline | Wedge sea hare | Apoptosis inducing | Cell viability assay | DB | Lymphoma cancer | IC50 : 0.0013 - 0.013 nM |
| dbacp02807 | Dolastatin 15 | VV-nMe-VPP-2hydroxyisovaleryl-2-oxo-4-methoxy-5-benzyl-3-pyrroline | Wedge sea hare | Apoptosis inducing | Cell viability assay | HT | Lymphoma cancer | IC50 : 0.0013 - 0.013 nM |
| dbacp02808 | Dolastatin 15 | VV-nMe-VPP-2hydroxyisovaleryl-2-oxo-4-methoxy-5-benzyl-3-pyrroline | Wedge sea hare | Apoptosis inducing | Cell viability assay | RL | Lymphoma cancer | IC50 : 0.0013 - 0.013 nM |
| dbacp02809 | Dolastatin 15 | VV-nMe-VPP-2hydroxyisovaleryl-2-oxo-4-methoxy-5-benzyl-3-pyrroline | Wedge sea hare | Apoptosis inducing | Cell viability assay | SR | Leukemia cancer | IC50 : 0.0013 - 0.013 nM |
| dbacp02810 | DP1 | KLAKLAKKLAKLAK | Protein transduction domain | Induction of apoptosis | MTT/MTS assay | MCA205 | Renal cancer | LC50 : < 50 µM |
| dbacp02811 | DP1 | KLAKLAKKLAKLAK | KLA sequence repeats, motif-based design | Induction of apoptosis | MTT/MTS assay | MCA205 | Renal cancer | LC50 : < 50 µM |
| dbacp02812 | DR-5 binding peptide | YCKVILTHRCY | Not found | Inducing apoptosis | Not specified | COLO-205 | Not found | Not found |
| dbacp02815 | DRS B3 | ALWKnMLKGIGKLAGQAALGAVKTLVGA | Dermaseptins B | Apoptosis inducing | Thymidine incorporation assay | MCF-7 | Breast cancer | Cytotoxicity :12 µM |
| dbacp02816 | DRS B4 | ALWKDILKNVGKAAGKAVLNTVTDMVNQ | Dermaseptins B | Apoptosis inducing | Thymidine incorporation assay | MCF-7 | Breast cancer | Cytotoxicity :15 µM |
| dbacp02817 | DRS S1 | ALWKTMLKKLGTMALHAGKAALGAAADTISQGTQ | Dermaseptins B | Apoptosis inducing | Thymidine incorporation assay | MCF-7 | Breast cancer | Not found |
| dbacp02818 | DRS-DU-1 | ALWKSLLKNVGKAAGKAALNAVTDMVNQ | Purple and orange leaf frog | Apoptosis inducing | Not specified | Not found | Not found | Not found |
| dbacp02819 | Dual-functional peptide LPLTPLP | LPLTPLP | Not found | Inducing apoptosis | CCK-8 assay | A549 | Lung cancer | IC50 : 0.00022 M |
| dbacp02820 | Dual-functional peptide LPLTPLP | LPLTPLP | Not found | Inducing apoptosis | CCK-8 assay | WI-38 | Lung cancer | IC50 : 0.035 M |
| dbacp02821 | DV3-RI-TATp53C’ | LGASWHRPDKGRRRQRRKKRGKKHRSTSQGKKSKLHSSHARSG | Not found | Inducing apoptosis | Not specified | 293T | Not specified | IC50 (Binding for the CXCR4 receptor) <0.01 µMol/L |
| dbacp02822 | DV3-RI-TATp53C’ | LGASWHRPDKGRRRQRRKKRGKKHRSTSQGKKSKLHSSHARSG | Not found | Inducing apoptosis | Not specified | H1299 | Not specified | IC50 (Binding for the CXCR4 receptor) <0.01 µMol/L |
| dbacp02828 | EGFR-related peptide | ERRP | EGFR-related peptide | Apoptosis | MTT/MTS assay | PC-3 | Prostate cancer | 30% Cell viability at 5 µg/ml |
| dbacp02829 | Elastin derived peptide | VGVAPG | Elastin derived | Apoptosis inducing | Cell viability assay | MCF-7 | Breast cancer | Not found |
| dbacp02830 | Elastin derived peptide | VGVAPG | Elastin derived | Apoptosis inducing | Cell viability assay | A549 | Lung cancer | Not found |
| dbacp02836 | Emericellipsin A | PQAAIVASG | **Emericellopsis alkaline** VKPM F1428, Alkalophile, extremophile | Disrupt cell membrane structures; Apoptosis | MTT assay | HeLa | Cervical cancer | EC50 : < 0.5 µM |
| dbacp02837 | Emericellipsin A | PQAAIVASG | **Emericellopsis alkaline** VKPM F1428, Alkalophile, extremophile | Disrupt cell membrane structures; Apoptosis | MTT assay | Hep G2 | Liver cancer | EC50 : 2.8 µM |
| dbacp02838 | EP3 | AMVGT | Not found | Inducing apoptosis | Not specified | HeLa | Not specified | Not found |
| dbacp02839 | EP3 | AMVGT | Earthworm | Apoptosis | Not specified | HeLa | Not found | Not found |
| dbacp02840 | EP3 | AMVGT | Earthworm | Apoptosis | Not specified | MGC803 | Not found | Not found |
| dbacp02841 | EP5 | ACSAG | Not found | Inducing apoptosis | Not specified | HeLa | Not specified | Not found |
| dbacp02871 | Epinecidin-1 | GFIFHIIKGLFHAGKMIHGLV | Not found | Inducing apoptosis | MTT assay | U937 | Leukemia | Not found |
| dbacp02949 | Figainin 2 | FLGAILKIGHALAKTVLPMVTNAFKPKQ | Skin secretions, Chaco tree frog, South America | Cell membrane interaction; Necrosis; Apoptosis | MTT/MTS assay | B16F10 | Murien melanoma | IC50 : 12.8 µM |
| dbacp02950 | Figainin 2 | FLGAILKIGHALAKTVLPMVTNAFKPKQ | Skin secretions, Chaco tree frog, South America | Cell membrane interaction; Necrosis; Apoptosis | MTT/MTS assay | MCF-7 | Murien melanoma | IC50 : 15.3 µM |
| dbacp02951 | Figainin 2 | MAFLKKSLFLVLFLGIVSLSVCEEEKREGEEKEEKREEEEGKEENEDGNEEHKEKRFLGAILKIGHALAKTVLPMVTNAFKPKQ | Chaco tree frog | Necrosis; Apoptosis | MTT/MTS assay | B16F10 | Skin cancer | IC50 : 12.8 µM |
| dbacp02952 | Figainin 2 | MAFLKKSLFLVLFLGIVSLSVCEEEKREGEEKEEKREEEEGKEENEDGNEEHKEKRFLGAILKIGHALAKTVLPMVTNAFKPKQ | Chaco tree frog | Necrosis; Apoptosis | MTT/MTS assay | B16F10 | Breast cancer | IC50 : 12.8 µM |
| dbacp02953 | Figainin 2 | MAFLKKSLFLVLFLGIVSLSVCEEEKREGEEKEEKREEEEGKEENEDGNEEHKEKRFLGAILKIGHALAKTVLPMVTNAFKPKQ | Chaco tree frog | Necrosis; Apoptosis | MTT/MTS assay | MCF-7 | Skin cancer | IC50 : 15.3 µM |
| dbacp02954 | Figainin 2 | MAFLKKSLFLVLFLGIVSLSVCEEEKREGEEKEEKREEEEGKEENEDGNEEHKEKRFLGAILKIGHALAKTVLPMVTNAFKPKQ | Chaco tree frog | Necrosis; Apoptosis | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 15.3 µM |
| dbacp02961 | FIMGPY | FIMGPY | Not found | Inducing apoptosis | MTT assay | HeLa | Cervical cancer | IC50 : 4.81 mg/mL |
| dbacp02962 | FK-16 | FKRIVQRIKDFLRNLV | Not found | Inducing apoptosis | MTT assay | LoVo, HCT116 | Colon cancer | Not found |
| dbacp02968 | FRAP-4 | WEWT | Not found | Inducing apoptosis | Not specified | NOS4 | Ovarian cancer | IC50 : 7 µM |
| dbacp03034 | Galaxamide derivative (Compound 3) | cyclo(WnMLLLnML) | Marine invertebrates | Inducing apoptosis | MTT assay | HepG2 | Breast cancer | IC50 : 3.98 ± 0.71 μg/mL |
| dbacp03035 | Galaxamide derivative (Compound 3) | cyclo(WnMLLLnML) | Marine invertebrates | Inducing apoptosis | MTT assay | MCF-7 | Breast cancer | IC50 : 1.72 ± 0.85 μg/mL |
| dbacp03036 | Galaxamide derivative (Compound 3) | cyclo(WnMLLLnML) | Marine invertebrates | Inducing apoptosis | MTT assay | HeLa | Breast cancer | IC50 : 5.32 ± 0.42 μg/mL |
| dbacp03037 | Galaxamide derivative (Compound 3) | cyclo(WnMLLLnML) | Marine invertebrates | Inducing apoptosis | MTT assay | MD-MBA-231 | Breast cancer | IC50 :3.51 ± 1.32 μg/Ml |
| dbacp03038 | Galaxamide derivative Compound 1 | cyclo(FnMLLLnML) | Marine invertebrates | Inducing apoptosis | MTT assay | HepG2 | Breast cancer | IC50 : 6.25 ± 1.03 μg/mL |
| dbacp03039 | Galaxamide derivative Compound 1 | cyclo(FnMLLLnML) | Marine invertebrates | Inducing apoptosis | MTT assay | MCF-7 | Breast cancer | IC50 : 4.76 ± 1.36 μg/mL |
| dbacp03040 | Galaxamide derivative Compound 1 | cyclo(FnMLLLnML) | Marine invertebrates | Inducing apoptosis | MTT assay | HeLa | Breast cancer | IC50 : 13.22 ± 1.12 μg/mL |
| dbacp03041 | Galaxamide derivative Compound 1 | cyclo(FnMLLLnML) | Marine invertebrates | Inducing apoptosis | MTT assay | MD-MBA-231 | Breast cancer | IC50 : 5.83 ± 0.45 μg/M |
| dbacp03042 | Galaxamide derivative Compound 2 | cyclo(NAl-nMLLLnML) | Marine invertebrates | Inducing apoptosis | MTT assay | HepG2 | Breast cancer | IC50 : 8.42 ± 1.82 μg/mL |
| dbacp03043 | Galaxamide derivative Compound 2 | cyclo(NAl-nMLLLnML) | Marine invertebrates | Inducing apoptosis | MTT assay | MCF-7 | Breast cancer | IC50 : 3.16 ± 0.92 μg/mL |
| dbacp03044 | Galaxamide derivative Compound 2 | cyclo(NAl-nMLLLnML) | Marine invertebrates | Inducing apoptosis | MTT assay | HeLa | Breast cancer | IC50 : 6.43 ± 1.20 μg/mL |
| dbacp03045 | Galaxamide derivative Compound 2 | cyclo(NAl-nMLLLnML) | Marine invertebrates | Inducing apoptosis | MTT assay | MD-MBA-231 | Breast cancer | IC50 : 4.48 ± 2.24 μg/mL |
| dbacp03057 | GGN6 | FLPLLAGLAANFLPTIICKISYKC | Skin of a Korean frog, wrinkled frog | Induce apoptosis | MTT/MTS assay | A-549 | Lung cancer | IC50 : 6.49 µg/ml |
| dbacp03058 | GGN6 | FLPLLAGLAANFLPTIICKISYKC | Skin of a Korean frog, wrinkled frog | Induce apoptosis | MTT/MTS assay | HEK293 | Renal cancer | IC50 : 5.62 µg/ml |
| dbacp03059 | GGN6 | FLPLLAGLAANFLPTIICKISYKC | Skin of a Korean frog, wrinkled frog | Induce apoptosis | MTT/MTS assay | HEK301 | Renal cancer | IC50 : 5.75 µg/ml |
| dbacp03060 | GGN6 | FLPLLAGLAANFLPTIICKISYKC | Skin of a Korean frog, wrinkled frog | Induce apoptosis | MTT/MTS assay | Hep3B | Liver cancer | IC50 : 4.91 µg/ml |
| dbacp03061 | GGN6 | FLPLLAGLAANFLPTIICKISYKC | Skin of a Korean frog, wrinkled frog | Induce apoptosis | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 4.88 µg/ml |
| dbacp03105 | GM15 | GGTCVIRGCVPKKLM | Not found | Inducing apoptosis | MTT assay | KB | Oral cancer | Not found |
| dbacp03121 | GO-203 | RRRRRRRRRCQCRRKN | Not found | Inducing apoptosis | Not specified | COLO-205 | Colorectal cancer | Not found |
| dbacp03155 | GR01 | c[CRKDC]Disulfidebridge | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Breast cancer | Not found |
| dbacp03156 | GR01 | c[CRKDC]Disulfidebridge | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Prostate cancer | Not found |
| dbacp03157 | GR01 | c[CRKDC]Disulfidebridge | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Lung cancer | Not found |
| dbacp03158 | GR01 | c[CRKDC]Disulfidebridge | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Ovarian cancer | Not found |
| dbacp03159 | GR01 | c[CRKDC]Disulfidebridge | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Skin cancer | Not found |
| dbacp03160 | GR16 | c[KRKDF] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Breast cancer | Not found |
| dbacp03161 | GR16 | c[KRKDF] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Prostate cancer | Not found |
| dbacp03162 | GR16 | c[KRKDF] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Lung cancer | Not found |
| dbacp03163 | GR16 | c[KRKDF] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Ovarian cancer | Not found |
| dbacp03164 | GR16 | c[KRKDF] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Skin cancer | Not found |
| dbacp03165 | GR35 | c[KRAAF] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Breast cancer | Not found |
| dbacp03166 | GR35 | c[KRAAF] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Prostate cancer | Not found |
| dbacp03167 | GR35 | c[KRAAF] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Lung cancer | Not found |
| dbacp03168 | GR35 | c[KRAAF] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Ovarian cancer | Not found |
| dbacp03169 | GR35 | c[KRAAF] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Skin cancer | Not found |
| dbacp03174 | H-0, Hymenochirin-1B | IKLSPETKDNLKKVLKGAIKGAIAVAKMV | Congo dwarf clawed frog | Inducing apoptosis | MTT assay | A549 | Not found | IC50 : 15.22 ± 0.21 μM |
| dbacp03175 | H-0, Hymenochirin-1B | IKLSPETKDNLKKVLKGAIKGAIAVAKMV | Congo dwarf clawed frog | Inducing apoptosis | MTT assay | HCT116 | Not found | IC50 : 12.76 ± 0.43 μM |
| dbacp03176 | H-0, Hymenochirin-1B | IKLSPETKDNLKKVLKGAIKGAIAVAKMV | Congo dwarf clawed frog | Inducing apoptosis | MTT assay | HepG2 | Not found | IC50 : 8.07 ± 0.21 μM |
| dbacp03177 | H-11 | IKLSPETKKNLKKVLKGAIKGAIAVAKMV | Synthetic construct | Inducing apoptosis | MTT assay | A549 | Not found | IC50 : 1.82 ± 0.23 μM |
| dbacp03178 | H-11 | IKLSPETKKNLKKVLKGAIKGAIAVAKMV | Synthetic construct | Inducing apoptosis | MTT assay | HCT116 | Not found | IC50 : 6.50 ± 0.32 μM |
| dbacp03179 | H-11 | IKLSPETKKNLKKVLKGAIKGAIAVAKMV | Synthetic construct | Inducing apoptosis | MTT assay | HepG2 | Not found | IC50 : 4.96 ± 0.43 μM |
| dbacp03180 | H-12 | IKLSKETKDNLKKVLKGAIKGAIAVAKMV | Synthetic construct | Inducing apoptosis | MTT assay | A549 | Not found | IC50 : 2.35 ± 0.31 μM |
| dbacp03181 | H-12 | IKLSKETKDNLKKVLKGAIKGAIAVAKMV | Synthetic construct | Inducing apoptosis | MTT assay | HCT116 | Not found | IC50 : 8.09 ± 0.40 μM |
| dbacp03182 | H-12 | IKLSKETKDNLKKVLKGAIKGAIAVAKMV | Synthetic construct | Inducing apoptosis | MTT assay | HepG2 | Not found | IC50 : 4.28 ± 0.38 μM |
| dbacp03183 | H-13 | IKLSKETKKNLKKVLKGAIKGAIAVAKMV | Synthetic construct | Inducing apoptosis | MTT assay | A549 | Not found | IC50 : 1.17 ± 0.23 μM |
| dbacp03184 | H-13 | IKLSKETKKNLKKVLKGAIKGAIAVAKMV | Synthetic construct | Inducing apoptosis | MTT assay | HCT116 | Not found | IC50 : 4.93 ± 0.51 μM |
| dbacp03185 | H-13 | IKLSKETKKNLKKVLKGAIKGAIAVAKMV | Synthetic construct | Inducing apoptosis | MTT assay | HepG2 | Not found | IC50 : 2.46 ± 0.32 μM |
| dbacp03186 | H-14 | IKLSKKTKKNLKKVLKGAIKGAIAVAKMV | Synthetic construct | Inducing apoptosis | MTT assay | A549 | Not found | IC50 : 0.98 ± 0.11 μM |
| dbacp03187 | H-14 | IKLSKKTKKNLKKVLKGAIKGAIAVAKMV | Synthetic construct | Inducing apoptosis | MTT assay | HCT116 | Not found | IC50 : 1.841 ± 0.34 μM |
| dbacp03188 | H-14 | IKLSKKTKKNLKKVLKGAIKGAIAVAKMV | Synthetic construct | Inducing apoptosis | MTT assay | HepG2 | Not found | IC50 : 4.54 ± 0.25 μM |
| dbacp03289 | HCAP18(109-135) | FRKSKEKIGKEFKRIVQRIKDFLRNLV | HCAP18 synthetic peptide | Apoptosis inducing | Not specified | SAS-H1 | Oral cancer | Not found |
| dbacp03305 | HIV-TAT48-57 | GRKKRRQRRR | Not found | Apoptosis inducing | LDH leakage assay | HeLa | Cervical cancer | 7% apoptosis at 10 µM |
| dbacp03306 | HIV-TAT48-57 | GRKKRRQRRR | Not found | Apoptosis inducing | LDH leakage assay | HeLa | Cervical cancer | 15% apoptosis at 20 µM |
| dbacp03307 | HIV-TAT48-57 | GRKKRRQRRR | Not found | Apoptosis inducing | LDH leakage assay | HeLa | Cervical cancer | 35% apoptosis at 30 µM |
| dbacp03308 | HIV-TAT48-57 | GRKKRRQRRR | Not found | Apoptosis inducing | LDH leakage assay | HeLa | Cervical cancer | 65% apoptosis at 50 µM |
| dbacp03327 | Hrk | WSSAAQLTAARLKALGDELHQ | BH3-only, Sensizers (BAD, HRK, Noxa) | Inducing apoptosis | Not specified | Not found | Not specified | Not found |
| dbacp03329 | Human A-defensin-1 (HNP1) | ACYCRIPACIAGERRYGTCIYQGRLWAFCC | Not found | Inducing apoptosis | MTT assay | A549 | Lung cancer | Not found |
| dbacp03330 | Human A-defensin-1 (HNP1) | ACYCRIPACIAGERRYGTCIYQGRLWAFCC | Not found | Inducing apoptosis | MTT assay | COS-7 | Lung cancer | Not found |
| dbacp03331 | Human BAD peptide | NLWAAQRYGRELRRMSDEFVDSFKK | BH3-only, Sensizers (BAD, HRK, Noxa) | Inducing apoptosis | Not specified | EGY191 | Not specified | Not found |
| dbacp03332 | Human BAD peptide | NLWAAQRYGRELRRMSDEFVDSFKK | BH3-only, Sensizers (BAD, HRK, Noxa) | Inducing apoptosis | Not specified | GM701 | Not specified | Not found |
| dbacp03356 | Hymenochirin-1B | IKLSPETKDNLKKVLKGAIKGAIAVAKMV-NH2 | Zaire dwarf clawed frog | Induce apoptosis and cell cycle arrest | LDH release assay, MTT assay | NCI-H1299 | Lung cancer | MIC : 0 - 50 μM |
| dbacp03357 | Hymenochirin-1B | IKLSPETKDNLKKVLKGAIKGAIAVAKMV-NH3 | Zaire dwarf clawed frog | Induce apoptosis and cell cycle arrest | LDH release assay, MTT assay | A549 | Lung cancer | MIC : 0 - 50 μM |
| dbacp03358 | Hymenochirin-1B | IKLSPETKDNLKKVLKGAIKGAIAVAKMV-NH4 | Zaire dwarf clawed frog | Induce apoptosis and cell cycle arrest | LDH release assay, MTT assay | H460 | Lung cancer | MIC : 0 - 50 μM |
| dbacp03359 | Hymenochirin-1B | IKLSPETKDNLKKVLKGAIKGAIAVAKMV-NH5 | Zaire dwarf clawed frog | Induce apoptosis and cell cycle arrest | LDH release assay, MTT assay | HepG2 | Human hepatocellular carcinoma | MIC : 0 - 50 μM |
| dbacp03360 | Hymenochirin-1B | IKLSPETKDNLKKVLKGAIKGAIAVAKMV-NH6 | Zaire dwarf clawed frog | Induce apoptosis and cell cycle arrest | LDH release assay, MTT assay | PLC | Human hepatocellular carcinoma | MIC : 0 - 50 μM |
| dbacp03366 | IbACP | AASTPVGGGRRLDRGQ | Sweet potato leaves | Apoptosis | MTT/MTS assay | H1299 | Lung cancer | MIC : 5 mg/ml |
| dbacp03367 | Ichthyophthirius multifiliis (strain G5) B4 | LKKLFKKILKYL | White spot disease (strain G5) B4 | Apoptosis inducing; Penetration of the cell membrane | MTT assay | MCF-7 | Breast cancer | MIC : 5 μM |
| dbacp03368 | Ichthyophthirius multifiliis (strain G5) B4 | LKKLFKKILKYL | White spot disease (strain G5) B4 | Apoptosis inducing; Penetration of the cell membrane | MTT assay | K562 | Breast cancer | MIC : 5 μM |
| dbacp03369 | Ichthyophthirius multifiliis (strain G5) B8 | LKKLFKKILKY | White spot disease (strain G5) B8 | Apoptosis inducing; Penetration of the cell membrane | MTT assay | MCF-7 | Breast cancer | MIC : 7 μM |
| dbacp03370 | Ichthyophthirius multifiliis (strain G5) B8 | LKKLFKKILKY | White spot disease (strain G5) B8 | Apoptosis inducing; Penetration of the cell membrane | MTT assay | K562 | Breast cancer | MIC : 7 μM |
| dbacp03371 | Ichthyophthirius multifiliis BP100 | KKLFKKILKYL | White spot disease BP100 | Apoptosis inducing; Penetration of the cell membrane | MTT assay | MCF-7 | Breast cancer | MIC : 25 μM |
| dbacp03372 | Ichthyophthirius multifiliis BP100 | KKLFKKILKYL | White spot disease BP100 | Apoptosis inducing; Penetration of the cell membrane | MTT assay | K562 | Breast cancer | MIC : 25 μM |
| dbacp03373 | IL-4Rα-lytic hybrid peptide | KQLIRFLKRLDRNGGGKLlLKlLkkLLKlLKKK | Interleukin-4 receptor a (IL-4Ra) chain | Induction of apoptosis | WST-1 assay | BXPC-3 | Pancreatic cancer | IC50 : 6.8 µMol/L |
| dbacp03374 | IL-4Rα-lytic hybrid peptide | KQLIRFLKRLDRNGGGKLlLKlLkkLLKlLKKK | Interleukin-4 receptor a (IL-4Ra) chain | Induction of apoptosis | WST-1 assay | SU.86.86 | Pancreatic cancer | IC50 : 7.5 µMol/L |
| dbacp03375 | IL-4Rα-lytic hybrid peptide | KQLIRFLKRLDRNGGGKLlLKlLkkLLKlLKKK | Bovine lactoferrin (Lf-B) | Induction of apoptosis | WST-1 assay | KB | Oral cancer | IC50 : 13.2 µMol/L |
| dbacp03376 | IL-4Rα-lytic hybrid peptide | KQLIRFLKRLDRNGGGKLlLKlLkkLLKlLKKK | Interleukin-4 receptor a (IL-4Ra) chain | Induction of apoptosis | WST-1 assay | T98G | Brain tumor | IC50 : 18.5 µMol/L |
| dbacp03377 | IL-4Rα-lytic hybrid peptide | KQLIRFLKRLDRNGGGKLlLKlLkkLLKlLKKK | Interleukin-4 receptor a (IL-4Ra) chain | Induction of apoptosis | WST-1 assay | A-172 | Brain tumor | IC50 : 6.8 µMol/L |
| dbacp03378 | IL-4Rα-lytic hybrid peptide | KQLIRFLKRLDRNGGGKLlLKlLkkLLKlLKKK | Interleukin-4 receptor a (IL-4Ra) chain | Induction of apoptosis | WST-1 assay | H-322 | Lung cancer | IC50 : 3.6 µMol/L |
| dbacp03379 | IL-4Rα-lytic hybrid peptide | KQLIRFLKRLDRNGGGKLlLKlLkkLLKlLKKK | Interleukin-4 receptor a (IL-4Ra) chain | Induction of apoptosis | WST-1 assay | MDA-MB-231 | Breast cancer | IC50 : 5.7 µMol/L |
| dbacp03395 | Interferon gamma (IFN-gamma) | MKYTSYILAFQLCIVLGSLGCYCQDPYVKEAENLKKYFNAGHSDVADNGTLFLGILKNWKEESDRKIMQSQIVSFYFKLFKNFKDDQSIQKSVETIKEDMNVKFFNSNKKKRDDFEKLTNYSVTDLNVQRKAIHELIQVMAELSPAVKTGKRKRSQMLFRGRRASQ | Chimpanzee | Apoptosis; Immunomodulatory activity | Not specified | Not found | Colorectal cancer | Not found |
| dbacp03396 | Interferon gamma (IFN-gamma) | MKYTSYILAFQLCIVLGSLGCYCQDPYVKEAENLKKYFNAGHSDVADNGTLFLGILKNWKEESDRKIMQSQIVSFYFKLFKNFKDDQSIQKSVETIKEDMNVKFFNSNKKKRDDFEKLTNYSVTDLNVQRKAIHELIQVMAELSPAVKTGKRKRSQMLFRGRRASQ | Chimpanzee | Apoptosis; Immunomodulatory activity | Not specified | Not found | Oral cancer | Not found |
| dbacp03397 | Interferon gamma (IFN-gamma) | MKYTSYILAFQLCIVLGSLGCYCQDPYVKEAENLKKYFNAGHSDVADNGTLFLGILKNWKEESDRKIMQSQIVSFYFKLFKNFKDDQSIQKSVETIKEDMNVKFFNSNKKKRDDFEKLTNYSVTDLNVQRKAIHELIQVMAELSPAVKTGKRKRSQMLFRGRRASQ | Chimpanzee | Apoptosis; Immunomodulatory activity | Not specified | Not found | Prostate cancer | Not found |
| dbacp03458 | Interferon gamma (IFN-gamma) | MMNYTSYILAFQLCVILGSSSCYCQATFLKEIENLKEYFNASNSNVADGGNLFLDILKNWREESDKKIIQSQIVSFYFKLFENLKDNPIIQSSVQIIKEDLRVKFFNSNNSKLEDFKKVIQIPVNNQTVQRKAISELFKVMTDLSPKSNQRKRKRSQSLFRGWKA | Black flying fox | Immune response regulation, apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03471 | IP3R-derived peptide (IDP) | NVYTEIKCNSLLPLDDIVRV | Not found | Inducing apoptosis | Not specified | CLL | Leukemia | Not found |
| dbacp03473 | K4R2-Nal2-S1 | Ac-KKKKRR-NAl-NAl-KKWRKWLAKK-NH2 | Not found | Necrosis or apoptosis | MTT assay | PC9 | Human lung cancer | MIC : 25 μM |
| dbacp03474 | K4R2-Nal2-S1 | Ac-KKKKRR-NAl-NAl-KKWRKWLAKK-NH2 | Not found | Necrosis or apoptosis | MTT assay | PC9-G | Oral cancer | MIC : 25 μM |
| dbacp03475 | K4R2-Nal2-S1 | Ac-KKKKRR-NAl-NAl-KKWRKWLAKK-NH2 | Not found | Necrosis or apoptosis | MTT assay | A549 | Human lung cancer | MIC : 25 μM |
| dbacp03476 | K4R2-Nal2-S1 | Ac-KKKKRR-NAl-NAl-KKWRKWLAKK-NH2 | Not found | Necrosis or apoptosis | MTT assay | C9 | Oral cancer | MIC : 25 μM |
| dbacp03477 | K4R2-Nal2-S1 | Ac-KKKKRR-NAl-NAl-KKWRKWLAKK-NH2 | Not found | Necrosis or apoptosis | MTT assay | OECM-1 | Human lung cancer | MIC : 25 μM |
| dbacp03478 | K4R2-Nal2-S1 | Ac-KKKKRR-NAl-NAl-KKWRKWLAKK-NH2 | Not found | Necrosis or apoptosis | MTT assay | SAS | Oral cancer | MIC : 25 μM |
| dbacp03479 | K6-Nal2-S1 | Ac-KKKKKK-NAl-NAl-KKWRKWLAKK-NH2 | Not found | Necrosis or apoptosis | MTT assay | PC9 | Human lung cancer | MIC : 3.1 μM |
| dbacp03480 | K6-Nal2-S1 | Ac-KKKKKK-NAl-NAl-KKWRKWLAKK-NH2 | Not found | Necrosis or apoptosis | MTT assay | PC9-G | Oral cancer | MIC : 3.1 μM |
| dbacp03481 | K6-Nal2-S1 | Ac-KKKKKK-NAl-NAl-KKWRKWLAKK-NH2 | Not found | Necrosis or apoptosis | MTT assay | A549 | Human lung cancer | MIC : 3.1 μM |
| dbacp03482 | K6-Nal2-S1 | Ac-KKKKKK-NAl-NAl-KKWRKWLAKK-NH2 | Not found | Necrosis or apoptosis | MTT assay | C9 | Oral cancer | MIC : 3.1 μM |
| dbacp03483 | K6-Nal2-S1 | Ac-KKKKKK-NAl-NAl-KKWRKWLAKK-NH2 | Not found | Necrosis or apoptosis | MTT assay | OECM-1 | Human lung cancer | MIC : 3.1 μM |
| dbacp03484 | K6-Nal2-S1 | Ac-KKKKKK-NAl-NAl-KKWRKWLAKK-NH2 | Not found | Necrosis or apoptosis | MTT assay | SAS | Oral cancer | MIC : 3.1 μM |
| dbacp03523 | KLAK peptide | KLAKLAKKLAKLAK | Not found | Inducing apoptosis | Internalization assay,Mitochondrial swelling assay,Cell-free apoptosis assay,Caspase activation assay | KS1767 | Not specified | LC50 : 387 μM |
| dbacp03524 | KLAK peptide | KLAKLAKKLAKLAK | Not found | Inducing apoptosis | Internalization assay,Mitochondrial swelling assay,Cell-free apoptosis assay,Caspase activation assay | MDA-MB-435 | Not specified | LC50 : 333 Μm |
| dbacp03525 | KT2 | NGVQPKYKWWKWWKKWW-NH2 | Siamese freshwater crocodile leukocyte | Inducing apoptosis | Sulforhodamine B colorimetric assay | CaSki | Cervical cancer | IC50 : 17.3 – 30.8 μM |
| dbacp03526 | KT2 | NGVQPKYKWWKWWKKWW-NH2 | Siamese freshwater crocodile leukocyte | Apoptosis inducing | Sulforhodamine B colorimetric assay | CaSki | Cervical cancer | IC50 : 17.3 – 30.8 μM |
| dbacp03527 | KT2 | NGVQPKYKWWKWWKKWW-NH2 | Siamese freshwater crocodile leukocyte | Apoptosis inducing | Sulforhodamine B colorimetric assay | CaSki | Cervical cancer | IC50 : 17.3 – 30.8 μM |
| dbacp03535 | L-amino oxidase (CP-LAAO) (LAO) (EC 1.4.3.2) | MNVFFMFSLLFLAALGSCADDRNPLEECFRETDYEEFLEIARXXXXTSNPKHVVRVGAGMSGLSAAYVLAGAGHQVTVLEASERPGGRXXXXXXXXEGWYANLGPMRXXXXXXXXXXXXXKFGLNLNEFSQENDNAWYFIKXXXXXXXXXXDPGLLKYPVKPSEAGKSAGQLYEESLGKXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXFDEIVDGMDKLPTSMYQAIXXXXXXXXXXXXXXXXXXKVTVTYQTPAKXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXIFLTCTKKFWEDDGIHGGKSTTDLPSRXXXXXXXXXXXXXXVIIAYGIGDDANFFQALDFKDCADIVFNDLSLIHQLPKEEIPSFCYPSMIQKXXXXXXXXXXITTFFTPYQFQHFSEAXXXXXXXIYFAGEYTAQAHGWIDSTIK | Mangrove pit viper | Cytotoxic; Anti-proliferative; Apoptosis | Not specified | SW480 | Colon cancer | EC50 : 29.43 ± 0.48 |
| dbacp03536 | L-amino oxidase (CP-LAAO) (LAO) (EC 1.4.3.2) | MNVFFMFSLLFLAALGSCADDRNPLEECFRETDYEEFLEIARXXXXTSNPKHVVRVGAGMSGLSAAYVLAGAGHQVTVLEASERPGGRXXXXXXXXEGWYANLGPMRXXXXXXXXXXXXXKFGLNLNEFSQENDNAWYFIKXXXXXXXXXXDPGLLKYPVKPSEAGKSAGQLYEESLGKXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXFDEIVDGMDKLPTSMYQAIXXXXXXXXXXXXXXXXXXKVTVTYQTPAKXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXIFLTCTKKFWEDDGIHGGKSTTDLPSRXXXXXXXXXXXXXXVIIAYGIGDDANFFQALDFKDCADIVFNDLSLIHQLPKEEIPSFCYPSMIQKXXXXXXXXXXITTFFTPYQFQHFSEAXXXXXXXIYFAGEYTAQAHGWIDSTIK | Mangrove pit viper | Cytotoxic; Anti-proliferative; Apoptosis | Not specified | SW620 | Colon cancer | EC50 : 23.19 ± 1.57 |
| dbacp03537 | L-amino oxidase (CP-LAAO) (LAO) (EC 1.4.3.2) | MNVFFMFSLLFLAALGSCADDRNPLEECFRETDYEEFLEIARXXXXTSNPKHVVRVGAGMSGLSAAYVLAGAGHQVTVLEASERPGGRXXXXXXXXEGWYANLGPMRXXXXXXXXXXXXXKFGLNLNEFSQENDNAWYFIKXXXXXXXXXXDPGLLKYPVKPSEAGKSAGQLYEESLGKXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXFDEIVDGMDKLPTSMYQAIXXXXXXXXXXXXXXXXXXKVTVTYQTPAKXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXIFLTCTKKFWEDDGIHGGKSTTDLPSRXXXXXXXXXXXXXXVIIAYGIGDDANFFQALDFKDCADIVFNDLSLIHQLPKEEIPSFCYPSMIQKXXXXXXXXXXITTFFTPYQFQHFSEAXXXXXXXIYFAGEYTAQAHGWIDSTIK | Mangrove pit viper | Cytotoxic; Anti-proliferative; Apoptosis | Not specified | CCD-18co | Colon cancer | EC50 : 15.99 ± 1.20 |
| dbacp03538 | L-amino-acid oxidase (BatroxLAAO) (LAO) (EC 1.4.3.2) | MNVFFTFSLLFLAALGSCADDRNPLEECFRETDYEEFLEIAKNGLSTTSNPKRVVIVGAGMSGLSAAYVLANAGHQVTVLEASERAGGRVKTYRNEKEGWYANLGPMRLPEKHRIVREYIRKFDLQLNEFSQENENAWYFIKNIRKRVGEVNKDPGVLEYPVKPSEVGKSAGQLYEESLQKAVEELRRTNCSYMLNKYDTYSTKEYLLKEGNLSPGAVDMIGDLLNEDSGYYVSFIESLKHDDIFAYEKRFDEIVGGMDKLPTSMYQAIQEKVHLNARVIKIQQDVKEVTVTYQTSEKETLSVTADYVIVCTTSRAARRIKFEPPLPPKKAHALRSVHYRSGTKIFLTCTKKFWEDDGIHGGKSTTDLPSRFIYYPNHNFPNGVGVIIAYGIGDDANYFQALDFEDCGDIVINDLSLIHQLPKEEIQAICRPSMIQRWSLDKYAMGGITTFTPYQFQHFSEALTAPVDRIYFAGEYTAQAHGWIDSTIKSGLRAARDVNRASEIKK | Common lancehead | Inducing apoptosis | MTT assay | PC12 | Not found | Not found |
| dbacp03539 | L-amino-acid oxidase (BatroxLAAO) (LAO) (EC 1.4.3.2) | MNVFFTFSLLFLAALGSCADDRNPLEECFRETDYEEFLEIAKNGLSTTSNPKRVVIVGAGMSGLSAAYVLANAGHQVTVLEASERAGGRVKTYRNEKEGWYANLGPMRLPEKHRIVREYIRKFDLQLNEFSQENENAWYFIKNIRKRVGEVNKDPGVLEYPVKPSEVGKSAGQLYEESLQKAVEELRRTNCSYMLNKYDTYSTKEYLLKEGNLSPGAVDMIGDLLNEDSGYYVSFIESLKHDDIFAYEKRFDEIVGGMDKLPTSMYQAIQEKVHLNARVIKIQQDVKEVTVTYQTSEKETLSVTADYVIVCTTSRAARRIKFEPPLPPKKAHALRSVHYRSGTKIFLTCTKKFWEDDGIHGGKSTTDLPSRFIYYPNHNFPNGVGVIIAYGIGDDANYFQALDFEDCGDIVINDLSLIHQLPKEEIQAICRPSMIQRWSLDKYAMGGITTFTPYQFQHFSEALTAPVDRIYFAGEYTAQAHGWIDSTIKSGLRAARDVNRASEIKK | Common lancehead | Inducing apoptosis | MTT assay | B16F10 | Not found | Not found |
| dbacp03540 | L-amino-acid oxidase (BatroxLAAO) (LAO) (EC 1.4.3.2) | MNVFFTFSLLFLAALGSCADDRNPLEECFRETDYEEFLEIAKNGLSTTSNPKRVVIVGAGMSGLSAAYVLANAGHQVTVLEASERAGGRVKTYRNEKEGWYANLGPMRLPEKHRIVREYIRKFDLQLNEFSQENENAWYFIKNIRKRVGEVNKDPGVLEYPVKPSEVGKSAGQLYEESLQKAVEELRRTNCSYMLNKYDTYSTKEYLLKEGNLSPGAVDMIGDLLNEDSGYYVSFIESLKHDDIFAYEKRFDEIVGGMDKLPTSMYQAIQEKVHLNARVIKIQQDVKEVTVTYQTSEKETLSVTADYVIVCTTSRAARRIKFEPPLPPKKAHALRSVHYRSGTKIFLTCTKKFWEDDGIHGGKSTTDLPSRFIYYPNHNFPNGVGVIIAYGIGDDANYFQALDFEDCGDIVINDLSLIHQLPKEEIQAICRPSMIQRWSLDKYAMGGITTFTPYQFQHFSEALTAPVDRIYFAGEYTAQAHGWIDSTIKSGLRAARDVNRASEIKK | Common lancehead | Inducing apoptosis | MTT assay | HL-60 | Not found | Not found |
| dbacp03541 | L-amino-acid oxidase (BatroxLAAO) (LAO) (EC 1.4.3.2) | MNVFFTFSLLFLAALGSCADDRNPLEECFRETDYEEFLEIAKNGLSTTSNPKRVVIVGAGMSGLSAAYVLANAGHQVTVLEASERAGGRVKTYRNEKEGWYANLGPMRLPEKHRIVREYIRKFDLQLNEFSQENENAWYFIKNIRKRVGEVNKDPGVLEYPVKPSEVGKSAGQLYEESLQKAVEELRRTNCSYMLNKYDTYSTKEYLLKEGNLSPGAVDMIGDLLNEDSGYYVSFIESLKHDDIFAYEKRFDEIVGGMDKLPTSMYQAIQEKVHLNARVIKIQQDVKEVTVTYQTSEKETLSVTADYVIVCTTSRAARRIKFEPPLPPKKAHALRSVHYRSGTKIFLTCTKKFWEDDGIHGGKSTTDLPSRFIYYPNHNFPNGVGVIIAYGIGDDANYFQALDFEDCGDIVINDLSLIHQLPKEEIQAICRPSMIQRWSLDKYAMGGITTFTPYQFQHFSEALTAPVDRIYFAGEYTAQAHGWIDSTIKSGLRAARDVNRASEIKK | Common lancehead | Inducing apoptosis | MTT assay | Jurkat | Acute T-cell Leukemia | Not found |
| dbacp03544 | L-amino-acid oxidase ACTX-8 | ADDRNPLEEFRENNYEEFL | Venom base | Inducing apoptosis | MTT assay | HeLa | Cervical cancer | MIC : 20 μg/ml |
| dbacp03545 | L-amino-acid oxidase ACTX-8 (LAAO) (LAO) (EC 1.4.3.2) | ADDRNPLEEFRENNYEEFL | Hundred-pace Snake | Inducing apoptosis | MTT assay | HeLa | Cervical cancer | MIC : 20 μg/ml |
| dbacp03638 | Lactoferricin B | FKCRRWQWRMKKLGA | Temporins family | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | Kelly | Brain tumor | IC50 : 15.5 µM |
| dbacp03639 | Lactoferricin B | FKCRRWQWRMKKLGA | Temporins family | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | IMR-32 | Brain tumor | IC50 : 29 µM |
| dbacp03640 | Lactoferricin B | FKCRRWQWRMKKLGA | Temporins family | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | SK-N-DZ | Brain tumor | IC50 : 37 µM |
| dbacp03641 | Lactoferricin B | FKCRRWQWRMKKLGA | Temporins family | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | SHEP-12 | Brain tumor | IC50 : 45 µM |
| dbacp03642 | Lactoferricin B | FKCRRWQWRMKKLGA | Temporins family | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | SH-SY-5Y2 | Brain tumor | IC50 : 60 µM |
| dbacp03719 | LB-DR5-1 | QEVCMTSCDKLMKCNWMAAM | Not found | Inducing apoptosis | Not specified | SK-MES-1 | Not specified | IC50 : 6 nM |
| dbacp03720 | LCP-3 | WLHV | Plant sources | Inducing apoptosis | Not specified | Caco-2 | Not specified | Not found |
| dbacp03721 | LFB | GLFSVVKGVLKGVGKNVSGSLLDQLKCKISGGC | The Fujian Large Headed Frog | Cell Apoptosis | MTT assay | H460 | Colon cancer | IC50 : 3.47 μM |
| dbacp03722 | LFB | GLFSVVKGVLKGVGKNVSGSLLDQLKCKISGGC | The Fujian Large Headed Frog | Cell Apoptosis | MTT assay | MB435 | Melanocyte | IC50 : 18.99 μM |
| dbacp03723 | LFB | GLFSVVKGVLKGVGKNVSGSLLDQLKCKISGGC | The Fujian Large Headed Frog | Cell Apoptosis | MTT assay | U251MG | Breast cancer | IC50 : 2.32 μM |
| dbacp03724 | LFB | GLFSVVKGVLKGVGKNVSGSLLDQLKCKISGGC | The Fujian Large Headed Frog | Cell Apoptosis | MTT assay | HCT116 | Lung cancer | IC50 : 2.02 μM |
| dbacp03725 | LFB | GLFSVVKGVLKGVGKNVSGSLLDQLKCKISGGC | The Fujian Large Headed Frog, China, Asia | Cell Apoptosis | MTT assay | H460 | Colon cancer | IC50 : 3.47 μM |
| dbacp03726 | LFB | GLFSVVKGVLKGVGKNVSGSLLDQLKCKISGGC | The Fujian Large Headed Frog, China, Asia | Cell Apoptosis | MTT assay | MB435 | Melanocyte | IC50 : 18.99 μM |
| dbacp03727 | LFB | GLFSVVKGVLKGVGKNVSGSLLDQLKCKISGGC | The Fujian Large Headed Frog, China, Asia | Cell Apoptosis | MTT assay | U251MG | Breast cancer | IC50 : 2.32 μM |
| dbacp03728 | LFB | GLFSVVKGVLKGVGKNVSGSLLDQLKCKISGGC | The Fujian Large Headed Frog, China, Asia | Cell Apoptosis | MTT assay | HCT116 | Lung cancer | IC50 : 2.02 μM |
| dbacp03729 | LfcinB | FKCRRWQWRMKK | Bovine milk | Regulation of immune response; Apoptosis | MTT/MTS assay | AZ-97 | Colon cancer | Inhibition at 0.1g/l |
| dbacp03730 | LfcinB | FKCRRWQWRMKK | Bovine lactoferrin (Lf-B) | Cell membrane disintegration; Regulation of immune response; Apoptosis | MTT/MTS assay | HT-29 | Colon cancer | IC50 : > 160 µM |
| dbacp03731 | LfcinB | FKCRRWQWRMKK | Bovine lactoferrin (Lf-B) | Cell membrane disintegration; Regulation of immune response; Apoptosis | MTT/MTS assay | MT-1 | Breast cancer | IC50 : > 160 µM |
| dbacp03732 | LfcinB | FKCRRWQWRMKK | Bovine lactoferrin (Lf-B) | Cell membrane disintegration; Regulation of immune response; Apoptosis | MTT/MTS assay | Kelly | Brain tumor | IC50 : 141 ± 3 µM |
| dbacp03733 | LfcinB | FKCRRWQWRMKK | Bovine lactoferrin (Lf-B) | Cell membrane disintegration; Regulation of immune response; Apoptosis | MTT/MTS assay | FEMX | Skin cancer | IC50 : 40 ± 7 µM |
| dbacp03734 | LfcinB | FKCRRWQWRMKK | Bovine lactoferrin (Lf-B) | Cell membrane disintegration; Regulation of immune response; Apoptosis | MTT/MTS assay | HT-29 | Colon cancer | IC50 : 148 ± 8 µM |
| dbacp03735 | LfcinB | FKCRRWQWRMKK | Bovine lactoferrin (Lf-B) | Cell membrane disintegration; Regulation of immune response; Apoptosis | MTT/MTS assay | KMS-5 | Skin cancer | IC50 : 38 µM |
| dbacp03736 | LfcinB | FKCRRWQWRMKK | Bovine lactoferrin (Lf-B) | Cell membrane disintegration; Regulation of immune response; Apoptosis | MTT/MTS assay | U-266 | Lymphoma cancer | IC50 : 55 µM |
| dbacp03737 | LfcinB | FKCRRWQWRMKK | Bovine lactoferrin (Lf-B) | Cell membrane disintegration; Regulation of immune response; Apoptosis | MTT/MTS assay | KMM-1 | Skin cancer | IC50 : 57 µM |
| dbacp03738 | LfcinB | FKCRRWQWRMKK | Bovine lactoferrin (Lf-B) | Cell membrane disintegration; Regulation of immune response; Apoptosis | MTT/MTS assay | Sudhl-4 | Skin cancer | IC50 : 16 µM |
| dbacp03739 | LfcinB | FKCRRWQWRMKK | Bovine lactoferrin (Lf-B) | Cell membrane disintegration; Regulation of immune response; Apoptosis | MTT/MTS assay | Raji | Lymphoma cancer | IC50 : 13 µM |
| dbacp03740 | LfcinB | FKCRRWQWRMKK | Bovine lactoferrin (Lf-B) | Cell membrane disintegration; Regulation of immune response; Apoptosis | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 10 µM |
| dbacp03741 | LfcinB (Bovine lactoferricin) | FKCRRWQWRM | Not found | Inducing apoptosis | MTT assay | Jurkat | Leukemia | Not found |
| dbacp03742 | LfcinB (Bovine lactoferricin) | FKCRRWQWRM | Not found | Inducing apoptosis | MTT assay | MCF-7 | Leukemia | Not found |
| dbacp03743 | LfcinB (Bovine lactoferricin) | FKCRRWQWRM | Not found | Inducing apoptosis | MTT assay | Colo-35 | Leukemia | Not found |
| dbacp03744 | LfcinB (Bovine lactoferricin) | FKCRRWQWRM | Not found | Inducing apoptosis | MTT assay | MDA-MB-435 | Leukemia | Not found |
| dbacp03745 | LfcinB (Bovine lactoferricin) | FKCRRWQWRM | Not found | Inducing apoptosis | MTT assay | SKov3 | Leukemia | Not found |
| dbacp03746 | LfcinB (Bovine lactoferricin) | FKCRRWQWRM | Not found | Inducing apoptosis | MTT assay | CAov3 | Leukemia | Not found |
| dbacp03747 | LfcinB (Bovine lactoferricin) | FKCRRWQWRM | Not found | Inducing apoptosis | MTT assay | HT-29 | Leukemia | Not found |
| dbacp03748 | LfcinB (Bovine lactoferricin) | FKCRRWQWRM | Not found | Inducing apoptosis | MTT assay | T-47D | Leukemia | Not found |
| dbacp03749 | LfcinB (Bovine lactoferricin) | FKCRRWQWRM | Not found | Inducing apoptosis | MTT assay | CCRF-CEM | Leukemia | Not found |
| dbacp03750 | LfcinB (Bovine lactoferricin) | FKCRRWQWRM | Not found | Inducing apoptosis | MTT assay | K562 | Leukemia | Not found |
| dbacp03751 | LfcinB (Bovine lactoferricin) | FKCRRWQWRM | Not found | Inducing apoptosis | MTT assay | Raji | Leukemia | Not found |
| dbacp03752 | LHRH–BH3 peptide luteinizing hormone-releasing hormone (LHRH) | QHWSYGLRPGMGQVGRQLAIIGDDINRRY | Effectors (BAK, BAX) | Inducing apoptosis | Cytotoxicity assay, MTT assay | A2780 | Ovarian carcinoma | Not found |
| dbacp03753 | LHRH–BH3 peptide luteinizing hormone-releasing hormone (LHRH) | QHWSYGLRPGMGQVGRQLAIIGDDINRRY | Effectors (BAK, BAX) | Inducing apoptosis | Cytotoxicity assay, MTT assay | MCF-7 | Human breast cancer | Not found |
| dbacp03754 | LHRH–BH3 peptide luteinizing hormone-releasing hormone (LHRH) | QHWSYGLRPGMGQVGRQLAIIGDDINRRY | Effectors (BAK, BAX) | Inducing apoptosis | Cytotoxicity assay, MTT assay | PC-3 | Prostate cancer | Not found |
| dbacp03755 | LHRH–BH3 peptide luteinizing hormone-releasing hormone (LHRH) | QHWSYGLRPGMGQVGRQLAIIGDDINRRY | Effectors (BAK, BAX) | Inducing apoptosis | Cytotoxicity assay, MTT assay | SKOV-3 | LHRH negative ovarian cancer | Not found |
| dbacp03756 | LIB10 | MRPEIWIAQELRRNGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03757 | LIB100 | MRPEIWIAQEARRNGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03758 | LIB101 | MRPEIWIAQEARRNGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03759 | LIB102 | MRPEIWIAQEARRNGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03760 | LIB103 | MRPEIWIAQEARRAGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03761 | LIB104 | MRPEIWIAQEARRAGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03762 | LIB105 | MRPEIWIAQEARRAGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03763 | LIB106 | MRPEIWIAQEADRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03764 | LIB107 | MRPEIWIAQEADRIGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03765 | LIB108 | MRPEIWIAQEADRIGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03766 | LIB109 | MRPEIWIAQEADRFGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03767 | LIB11 | MRPEIWIAQELRRNGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03768 | LIB110 | MRPEIWIAQEADRFGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03769 | LIB111 | MRPEIWIAQEADRFGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03770 | LIB112 | MRPEIWIAQEADRDGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03771 | LIB113 | MRPEIWIAQEADRDGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03772 | LIB114 | MRPEIWIAQEADRDGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03773 | LIB115 | MRPEIWIAQEADRNGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03774 | LIB116 | MRPEIWIAQEADRNGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03775 | LIB117 | MRPEIWIAQEADRNGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03776 | LIB118 | MRPEIWIAQEADRAGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03777 | LIB119 | MRPEIWIAQEADRAGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03778 | LIB12 | MRPEIWIAQELRRNGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03779 | LIB120 | MRPEIWIAQEADRAGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03780 | LIB122 | MRPEIWAAQELRRIGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03781 | LIB123 | MRPEIWAAQELRRIGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03782 | LIB124 | MRPEIWAAQELRRFGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03783 | LIB125 | MRPEIWAAQELRRFGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03784 | LIB126 | MRPEIWAAQELRRFGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03785 | LIB127 | MRPEIWAAQELRRDGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03786 | LIB128 | MRPEIWAAQELRRDGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03787 | LIB129 | MRPEIWAAQELRRDGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03788 | LIB130 | MRPEIWAAQELRRNGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03789 | LIB131 | MRPEIWAAQELRRNGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03790 | LIB132 | MRPEIWAAQELRRNGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03791 | LIB133 | MRPEIWAAQELRRAGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03792 | LIB134 | MRPEIWAAQELRRAGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03793 | LIB135 | MRPEIWAAQELRRAGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03794 | LIB136 | MRPEIWAAQELDRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03795 | LIB137 | MRPEIWAAQELDRIGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03796 | LIB138 | MRPEIWAAQELDRIGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03797 | LIB139 | MRPEIWAAQELDRFGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03798 | LIB14 | MRPEIWIAQELRRAGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03799 | LIB140 | MRPEIWAAQELDRFGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03800 | LIB141 | MRPEIWAAQELDRFGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03801 | LIB142 | MRPEIWAAQELDRDGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03802 | LIB143 | MRPEIWAAQELDRDGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03803 | LIB144 | MRPEIWAAQELDRDGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03804 | LIB145 | MRPEIWAAQELDRNGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03805 | LIB146 | MRPEIWAAQELDRNGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03806 | LIB147 | MRPEIWAAQELDRNGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03807 | LIB148 | MRPEIWAAQELDRAGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03808 | LIB149 | MRPEIWAAQELDRAGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03809 | LIB15 | MRPEIWIAQELRRAGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03810 | LIB150 | MRPEIWAAQELDRAGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03811 | LIB151 | MRPEIWAAQEIRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03812 | LIB152 | MRPEIWAAQEIRRIGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03813 | LIB153 | MRPEIWAAQEIRRIGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03814 | LIB154 | MRPEIWAAQEIRRFGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03815 | LIB155 | MRPEIWAAQEIRRFGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03816 | LIB156 | MRPEIWAAQEIRRFGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03817 | LIB157 | MRPEIWAAQEIRRDGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03818 | LIB158 | MRPEIWAAQEIRRDGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03819 | LIB159 | MRPEIWAAQEIRRDGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03820 | LIB160 | MRPEIWAAQEIRRNGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03821 | LIB161 | MRPEIWAAQEIRRNGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03822 | LIB162 | MRPEIWAAQEIRRNGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03823 | LIB163 | MRPEIWAAQEIRRAGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03824 | LIB164 | MRPEIWAAQEIRRAGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03825 | LIB165 | MRPEIWAAQEIRRAGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03826 | LIB166 | MRPEIWAAQEIDRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03827 | LIB167 | MRPEIWAAQEIDRIGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03828 | LIB168 | MRPEIWAAQEIDRIGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03829 | LIB169 | MRPEIWAAQEIDRFGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03830 | LIB17 | MRPEIWIAQELDRIGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03831 | LIB170 | MRPEIWAAQEIDRFGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03832 | LIB171 | MRPEIWAAQEIDRFGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03833 | LIB172 | MRPEIWAAQEIDRDGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03834 | LIB173 | MRPEIWAAQEIDRDGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03835 | LIB174 | MRPEIWAAQEIDRDGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03836 | LIB175 | MRPEIWAAQEIDRNGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03837 | LIB176 | MRPEIWAAQEIDRNGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03838 | LIB177 | MRPEIWAAQEIDRNGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03839 | LIB178 | MRPEIWAAQEIDRAGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03840 | LIB179 | MRPEIWAAQEIDRAGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03841 | LIB18 | MRPEIWIAQELDRIGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03842 | LIB180 | MRPEIWAAQEIDRAGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03843 | LIB181 | MRPEIWAAQEFRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03844 | LIB182 | MRPEIWAAQEFRRIGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03845 | LIB183 | MRPEIWAAQEFRRIGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03846 | LIB184 | MRPEIWAAQEFRRFGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03847 | LIB185 | MRPEIWAAQEFRRFGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03848 | LIB186 | MRPEIWAAQEFRRFGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03849 | LIB187 | MRPEIWAAQEFRRDGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03850 | LIB188 | MRPEIWAAQEFRRDGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03851 | LIB189 | MRPEIWAAQEFRRDGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03852 | LIB19 | MRPEIWIAQELDRFGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03853 | LIB190 | MRPEIWAAQEFRRNGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03854 | LIB191 | MRPEIWAAQEFRRNGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03855 | LIB192 | MRPEIWAAQEFRRNGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03856 | LIB193 | MRPEIWAAQEFRRAGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03857 | LIB194 | MRPEIWAAQEFRRAGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03858 | LIB195 | MRPEIWAAQEFRRAGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03859 | LIB196 | MRPEIWAAQEFDRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03860 | LIB197 | MRPEIWAAQEFDRIGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03861 | LIB198 | MRPEIWAAQEFDRIGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03862 | LIB199 | MRPEIWAAQEFDRFGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03863 | LIB20 | MRPEIWIAQELDRFGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03864 | LIB200 | MRPEIWAAQEFDRFGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03865 | LIB201 | MRPEIWAAQEFDRFGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03866 | LIB202 | MRPEIWAAQEFDRDGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03867 | LIB203 | MRPEIWAAQEFDRDGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03868 | LIB204 | MRPEIWAAQEFDRDGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03869 | LIB205 | MRPEIWAAQEFDRNGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03870 | LIB206 | MRPEIWAAQEFDRNGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03871 | LIB207 | MRPEIWAAQEFDRNGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03872 | LIB208 | MRPEIWAAQEFDRAGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03873 | LIB209 | MRPEIWAAQEFDRAGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03874 | LIB21 | MRPEIWIAQELDRFGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03875 | LIB210 | MRPEIWAAQEFDRAGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03876 | LIB211 | MRPEIWAAQEARRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03877 | LIB212 | MRPEIWAAQEARRIGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03878 | LIB213 | MRPEIWAAQEARRIGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03879 | LIB214 | MRPEIWAAQEARRFGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03880 | LIB215 | MRPEIWAAQEARRFGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03881 | LIB216 | MRPEIWAAQEARRFGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03882 | LIB217 | MRPEIWAAQEARRDGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03883 | LIB218 | MRPEIWAAQEARRDGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03884 | LIB219 | MRPEIWAAQEARRDGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03885 | LIB22 | MRPEIWIAQELDRDGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03886 | LIB220 | MRPEIWAAQEARRNGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03887 | LIB221 | MRPEIWAAQEARRNGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03888 | LIB222 | MRPEIWAAQEARRNGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03889 | LIB223 | MRPEIWAAQEARRAGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03890 | LIB224 | MRPEIWAAQEARRAGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03891 | LIB225 | MRPEIWAAQEARRAGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03892 | LIB226 | MRPEIWAAQEADRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03893 | LIB227 | MRPEIWAAQEADRIGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03894 | LIB228 | MRPEIWAAQEADRIGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03895 | LIB229 | MRPEIWAAQEADRFGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03896 | LIB23 | MRPEIWIAQELDRDGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03897 | LIB230 | MRPEIWAAQEADRFGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03898 | LIB231 | MRPEIWAAQEADRFGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03899 | LIB232 | MRPEIWAAQEADRDGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03900 | LIB233 | MRPEIWAAQEADRDGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03901 | LIB234 | MRPEIWAAQEADRDGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03902 | LIB235 | MRPEIWAAQEADRNGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03903 | LIB236 | MRPEIWAAQEADRNGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03904 | LIB237 | MRPEIWAAQEADRNGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03905 | LIB238 | MRPEIWAAQEADRAGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03906 | LIB239 | MRPEIWAAQEADRAGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03907 | LIB24 | MRPEIWIAQELDRDGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03908 | LIB240 | MRPEIWAAQEADRAGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03909 | LIB242 | MRPEIWFAQELRRIGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03910 | LIB243 | MRPEIWFAQELRRIGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03911 | LIB244 | MRPEIWFAQELRRFGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03912 | LIB245 | MRPEIWFAQELRRFGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03913 | LIB246 | MRPEIWFAQELRRFGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03914 | LIB247 | MRPEIWFAQELRRDGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03915 | LIB248 | MRPEIWFAQELRRDGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03916 | LIB249 | MRPEIWFAQELRRDGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03917 | LIB25 | MRPEIWIAQELDRNGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03918 | LIB250 | MRPEIWFAQELRRNGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03919 | LIB251 | MRPEIWFAQELRRNGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03920 | LIB252 | MRPEIWFAQELRRNGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03921 | LIB253 | MRPEIWFAQELRRAGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03922 | LIB254 | MRPEIWFAQELRRAGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03923 | LIB255 | MRPEIWFAQELRRAGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03924 | LIB256 | MRPEIWFAQELDRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03925 | LIB257 | MRPEIWFAQELDRIGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03926 | LIB258 | MRPEIWFAQELDRIGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03927 | LIB259 | MRPEIWFAQELDRFGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03928 | LIB26 | MRPEIWIAQELDRNGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03929 | LIB260 | MRPEIWFAQELDRFGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03930 | LIB261 | MRPEIWFAQELDRFGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03931 | LIB262 | MRPEIWFAQELDRDGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03932 | LIB263 | MRPEIWFAQELDRDGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03933 | LIB264 | MRPEIWFAQELDRDGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03934 | LIB265 | MRPEIWFAQELDRNGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03935 | LIB266 | MRPEIWFAQELDRNGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03936 | LIB267 | MRPEIWFAQELDRNGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03937 | LIB268 | MRPEIWFAQELDRAGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03938 | LIB269 | MRPEIWFAQELDRAGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03939 | LIB27 | MRPEIWIAQELDRNGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03940 | LIB270 | MRPEIWFAQELDRAGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03941 | LIB271 | MRPEIWFAQEIRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03942 | LIB272 | MRPEIWFAQEIRRIGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03943 | LIB273 | MRPEIWFAQEIRRIGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03944 | LIB274 | MRPEIWFAQEIRRFGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03945 | LIB275 | MRPEIWFAQEIRRFGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03946 | LIB276 | MRPEIWFAQEIRRFGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03947 | LIB277 | MRPEIWFAQEIRRDGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03948 | LIB278 | MRPEIWFAQEIRRDGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03949 | LIB279 | MRPEIWFAQEIRRDGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03950 | LIB28 | MRPEIWIAQELDRAGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03951 | LIB280 | MRPEIWFAQEIRRNGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03952 | LIB281 | MRPEIWFAQEIRRNGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03953 | LIB282 | MRPEIWFAQEIRRNGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03954 | LIB283 | MRPEIWFAQEIRRAGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03955 | LIB284 | MRPEIWFAQEIRRAGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03956 | LIB285 | MRPEIWFAQEIRRAGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03957 | LIB286 | MRPEIWFAQEIDRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03958 | LIB287 | MRPEIWFAQEIDRIGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03959 | LIB288 | MRPEIWFAQEIDRIGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03960 | LIB289 | MRPEIWFAQEIDRFGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03961 | LIB29 | MRPEIWIAQELDRAGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03962 | LIB290 | MRPEIWFAQEIDRFGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03963 | LIB291 | MRPEIWFAQEIDRFGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03964 | LIB292 | MRPEIWFAQEIDRDGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03965 | LIB293 | MRPEIWFAQEIDRDGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03966 | LIB294 | MRPEIWFAQEIDRDGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03967 | LIB295 | MRPEIWFAQEIDRNGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03968 | LIB296 | MRPEIWFAQEIDRNGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03969 | LIB297 | MRPEIWFAQEIDRNGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03970 | LIB298 | MRPEIWFAQEIDRAGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03971 | LIB299 | MRPEIWFAQEIDRAGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03972 | LIB30 | MRPEIWIAQELDRAGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03973 | LIB300 | MRPEIWFAQEIDRAGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03974 | LIB301 | MRPEIWFAQEFRRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03975 | LIB302 | MRPEIWFAQEFRRIGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03976 | LIB303 | MRPEIWFAQEFRRIGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03977 | LIB304 | MRPEIWFAQEFRRFGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03978 | LIB305 | MRPEIWFAQEFRRFGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03979 | LIB306 | MRPEIWFAQEFRRFGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03980 | LIB307 | MRPEIWFAQEFRRDGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03981 | LIB308 | MRPEIWFAQEFRRDGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03982 | LIB309 | MRPEIWFAQEFRRDGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03983 | LIB310 | MRPEIWFAQEFRRNGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03984 | LIB311 | MRPEIWFAQEFRRNGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03985 | LIB312 | MRPEIWFAQEFRRNGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03986 | LIB313 | MRPEIWFAQEFRRAGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03987 | LIB314 | MRPEIWFAQEFRRAGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03988 | LIB315 | MRPEIWFAQEFRRAGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03989 | LIB316 | MRPEIWFAQEFDRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03990 | LIB317 | MRPEIWFAQEFDRIGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03991 | LIB318 | MRPEIWFAQEFDRIGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03992 | LIB319 | MRPEIWFAQEFDRFGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03993 | LIB32 | MRPEIWIAQEIRRIGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03994 | LIB320 | MRPEIWFAQEFDRFGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03995 | LIB321 | MRPEIWFAQEFDRFGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03996 | LIB322 | MRPEIWFAQEFDRDGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03997 | LIB323 | MRPEIWFAQEFDRDGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03998 | LIB324 | MRPEIWFAQEFDRDGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp03999 | LIB325 | MRPEIWFAQEFDRNGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04000 | LIB326 | MRPEIWFAQEFDRNGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04001 | LIB327 | MRPEIWFAQEFDRNGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04002 | LIB328 | MRPEIWFAQEFDRAGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04003 | LIB329 | MRPEIWFAQEFDRAGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04004 | LIB33 | MRPEIWIAQEIRRIGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04005 | LIB330 | MRPEIWFAQEFDRAGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04006 | LIB331 | MRPEIWFAQEARRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04007 | LIB332 | MRPEIWFAQEARRIGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04008 | LIB333 | MRPEIWFAQEARRIGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04009 | LIB334 | MRPEIWFAQEARRFGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04010 | LIB335 | MRPEIWFAQEARRFGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04011 | LIB336 | MRPEIWFAQEARRFGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04012 | LIB337 | MRPEIWFAQEARRDGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04013 | LIB338 | MRPEIWFAQEARRDGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04014 | LIB339 | MRPEIWFAQEARRDGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04015 | LIB34 | MRPEIWIAQEIRRFGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04016 | LIB340 | MRPEIWFAQEARRNGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04017 | LIB341 | MRPEIWFAQEARRNGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04018 | LIB342 | MRPEIWFAQEARRNGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04019 | LIB343 | MRPEIWFAQEARRAGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04020 | LIB344 | MRPEIWFAQEARRAGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04021 | LIB345 | MRPEIWFAQEARRAGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04022 | LIB346 | MRPEIWFAQEADRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04023 | LIB347 | MRPEIWFAQEADRIGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04024 | LIB348 | MRPEIWFAQEADRIGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04025 | LIB349 | MRPEIWFAQEADRFGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04026 | LIB35 | MRPEIWIAQEIRRFGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04027 | LIB350 | MRPEIWFAQEADRFGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04028 | LIB351 | MRPEIWFAQEADRFGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04029 | LIB352 | MRPEIWFAQEADRDGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04030 | LIB353 | MRPEIWFAQEADRDGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04031 | LIB354 | MRPEIWFAQEADRDGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04032 | LIB355 | MRPEIWFAQEADRNGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04033 | LIB356 | MRPEIWFAQEADRNGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04034 | LIB357 | MRPEIWFAQEADRNGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04035 | LIB358 | MRPEIWFAQEADRAGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04036 | LIB359 | MRPEIWFAQEADRAGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04037 | LIB36 | MRPEIWIAQEIRRFGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04038 | LIB37 | MRPEIWIAQEIRRDGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04039 | LIB38 | MRPEIWIAQEIRRDGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04040 | LIB39 | MRPEIWIAQEIRRDGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04041 | LIB40 | MRPEIWIAQEIRRNGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04042 | LIB41 | MRPEIWIAQEIRRNGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04043 | LIB42 | MRPEIWIAQEIRRNGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04044 | LIB43 | MRPEIWIAQEIRRAGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04045 | LIB44 | MRPEIWIAQEIRRAGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04046 | LIB45 | MRPEIWIAQEIRRAGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04047 | LIB46 | MRPEIWIAQEIDRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04048 | LIB47 | MRPEIWIAQEIDRIGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04049 | LIB48 | MRPEIWIAQEIDRIGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04050 | LIB49 | MRPEIWIAQEIDRFGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04051 | LIB5 | MRPEIWIAQELRRFGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04052 | LIB50 | MRPEIWIAQEIDRFGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04053 | LIB51 | MRPEIWIAQEIDRFGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04054 | LIB52 | MRPEIWIAQEIDRDGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04055 | LIB53 | MRPEIWIAQEIDRDGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04056 | LIB54 | MRPEIWIAQEIDRDGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04057 | LIB55 | MRPEIWIAQEIDRNGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04058 | LIB56 | MRPEIWIAQEIDRNGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04059 | LIB57 | MRPEIWIAQEIDRNGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04060 | LIB58 | MRPEIWIAQEIDRAGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04061 | LIB59 | MRPEIWIAQEIDRAGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04062 | LIB6 | MRPEIWIAQELRRFGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04063 | LIB60 | MRPEIWIAQEIDRAGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04064 | LIB62 | MRPEIWIAQEFRRIGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04065 | LIB63 | MRPEIWIAQEFRRIGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04066 | LIB64 | MRPEIWIAQEFRRFGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04067 | LIB65 | MRPEIWIAQEFRRFGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04068 | LIB66 | MRPEIWIAQEFRRFGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04069 | LIB67 | MRPEIWIAQEFRRDGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04070 | LIB68 | MRPEIWIAQEFRRDGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04071 | LIB69 | MRPEIWIAQEFRRDGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04072 | LIB70 | MRPEIWIAQEFRRNGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04073 | LIB71 | MRPEIWIAQEFRRNGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04074 | LIB72 | MRPEIWIAQEFRRNGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04075 | LIB73 | MRPEIWIAQEFRRAGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04076 | LIB74 | MRPEIWIAQEFRRAGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04077 | LIB75 | MRPEIWIAQEFRRAGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04078 | LIB76 | MRPEIWIAQEFDRIGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04079 | LIB77 | MRPEIWIAQEFDRIGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04080 | LIB78 | MRPEIWIAQEFDRIGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04081 | LIB79 | MRPEIWIAQEFDRFGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04082 | LIB8 | MRPEIWIAQELRRDGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04083 | LIB80 | MRPEIWIAQEFDRFGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04084 | LIB81 | MRPEIWIAQEFDRFGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04085 | LIB82 | MRPEIWIAQEFDRDGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04086 | LIB83 | MRPEIWIAQEFDRDGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04087 | LIB84 | MRPEIWIAQEFDRDGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04088 | LIB85 | MRPEIWIAQEFDRNGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04089 | LIB86 | MRPEIWIAQEFDRNGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04090 | LIB87 | MRPEIWIAQEFDRNGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04091 | LIB88 | MRPEIWIAQEFDRAGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04092 | LIB89 | MRPEIWIAQEFDRAGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04093 | LIB9 | MRPEIWIAQELRRDGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04094 | LIB90 | MRPEIWIAQEFDRAGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04095 | LIB92 | MRPEIWIAQEARRIGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04096 | LIB93 | MRPEIWIAQEARRIGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04097 | LIB94 | MRPEIWIAQEARRFGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04098 | LIB95 | MRPEIWIAQEARRFGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04099 | LIB96 | MRPEIWIAQEARRFGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04100 | LIB97 | MRPEIWIAQEARRDGDEFNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04101 | LIB98 | MRPEIWIAQEARRDGDEVNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04102 | LIB99 | MRPEIWIAQEARRDGDENNAYYARRV | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04128 | LK-L1C/K6W/L8C | CKKLLWLCKKLLKLAG | Not found | Inducing apoptosis | MTS assay | HeLa | Not specified | Not found |
| dbacp04129 | LK-L1C/K6W/L8C | CKKLLWLCKKLLKLAG | Not found | Inducing apoptosis | MTS assay | MCF-7 | Not specified | Not found |
| dbacp04152 | LL-37 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | Not found | Inducing apoptosis | Not specified | SAS-H1 | Not specified | Not found |
| dbacp04153 | LL-37 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | Not found | Inducing apoptosis | Not specified | HCT116 | Not specified | Not found |
| dbacp04255 | LNV-LAO L-amino acid oxidase (LAO) | ADDKNPLEEAFREADYEVFLEIAKNGL | Venom base | Inducing apoptosis | MM6 cell culture assay | MM6 | Not specified | IC50 : < 35 ng/ml |
| dbacp04256 | Loading module of NRPS-PKS | MCLPEDSSPLSGHRPVPAPRVSADRTFSCFLIGGNSLVATCAELLLSHGHRVLGLVSPDAGIRDWARQRRLPALDFGPGLTERLAATPFDYLFSIANLRMLPAALLDLPRELPVNFHDGPLPRHAGLNATTWAVLEREVSHGVTWHVMTEGADEGDVLVQRPVTVTDQDTSHTLNVKCFEAGYASFAELVGLLESGAVRRTAQDLSARSYHGRFDRPAGGGFLSWDRPAALLHAAVRAADHGPYPNEFGTAKFAAGDGAVLVSGLSPLPGPSQGPPGTVLRAGEDGLVVAVADGAVRLTGLTTPMGEPLTGTGLAGYGIRPGHRLPVPGPALLAAATDAQARHLRQERHWRRRLTDLVPADLTGADSTARGGHLAVPVPVPPGAAEAAARAGLRRDQWLLAAHLAFLTRTGVEEGTDVHWRLAHPPTGHRSVDALYASFVPLRIPPVDGADMAAFGSRVVTGTDEANRRGSHPHDLWLRDPRLRDRRPSAAGLPIAVEICDDTTAPATPADGTKLLIRIPAGEDPGPCRWLVREGTYDPGTLAALAGYAAAFLTAAATAEGGRDLSGIPLGTEAQRRGAHGEAIPADDPSPDACVHQLVTRRARLRPDAPAVSGAGQTLSYAELDRRSSALAGYLRARGIGAGHLVGVFLGRSVQLPVVLLGVMKSGAAYVPLDPVYPADRIGYMLRDTALRLVVTESGLATRLPAGHGETLVLDRSWPEVESAVPEPGARVTDEQDAYVLYTSGSTGRPKGVRIGHRALTNLIRSMCRTPGVTEDDTLLAVTTVCFDIAGLELYAPLVAGGRVEVAPEQATADGPALRDLLERVRPTVMQATPATWRMLLDAGWPRGADSPVPRVLCGGEALSDDLAGRLLAHGARLWNLYGPTETTIWSAVKRVRPEEPVTLGRPIANTVFHVVDRRLRPVPPGIPGELLIGGAGVARGYLNRPELTAERFVPDVYGGGDGTVYRTGDLVRLRPDGELEYLGRLDDQVKLHGYRIEPGEVEQALGRHPGVAEAVVVVREDRPGDRRLVAYLVPRTPGLRPAELRAHLLATLPAYMVPTAFVELDAIPLTGNGKTDRRALPRPAGVLGTRTAPTDLLERAVAGIWREVLVLDAVGAEDNFFEAGGTSLLLMRLMARINAEMDASLSRVEMFMYPTVRSMTRHLRSRRSGRTGPGPAVPQSRGTRPSRTGLADLRRRRQQVRTADETGR | Streptomyces conglobatus | Induce apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04287 | LP-4 peptide | SWTWEKKLETAVNLAWTAGNSNKWTWK | VDAC1(voltage-dependent anion channel1) | Inducing apoptosis | Not specified | CLL | Leukemia | Not found |
| dbacp04288 | LP-4 peptide | SWTWEKKLETAVNLAWTAGNSNKWTWK | VDAC1(voltage-dependent anion channel1) | Inducing apoptosis | Not specified | MEC-1 | Leukemia | Not found |
| dbacp04309 | Lunasin | SKWQHQQDSCRKQLQGVNLTPCEKHIMEKIQGRDDDDDDDDDD | Plant sources | Inducing apoptosis | MTT assay | HCT116-derived spheres | Colorectal cancer | IC50 : 161.0 ± 2.4 μM |
| dbacp04310 | Lunasin | SKWQHQQDSCRKQLQGVNLTPCEKHIMEKIQGRDDDDDDDDDD | Plant sources | Inducing apoptosis | MTT assay | HCT-116 parentl | Colorectal cancer | IC50 : 107.5 ± 1.9 μM |
| dbacp04312 | Lunasin | SKWQHQQDSCRKQLQGVNLTPCEKHIMEKIQGRGDDDDDDDDD | Soyabean | Apoptosis inducing; Anti-proliferative | MTT/MTS | HT-29 | Not specified | IC50 : 61.7 µM |
| dbacp04313 | Lunasin | SKWQHQQDSCRKQLQGVNLTPCEKHIMEKIQGRGDDDDDDDDD | Soyabean | Apoptosis inducing; Anti-proliferative | MTT/MTS | HCT-116 | Not specified | IC50 : 31.6 µM |
| dbacp04314 | Lunasin | SKWQHQQDSCRKQLQGVNLTPCEKHIMEKIQGRGDDDDDDDDD | Soyabean | Apoptosis inducing; Anti-proliferative | MTT/MTS | MCF-7 | Not specified | IC50 : 431.9 µM |
| dbacp04317 | LvHemB1 | DVNFLLHKIYGNIRY | Marine invertebrates | Inducing apoptosis | MTT assay | HeLa | Cervical cancer | Not found |
| dbacp04318 | LvHemB1 | DVNFLLHKIYGNIRY | Marine invertebrates | Inducing apoptosis | MTT assay | HeLa | Esophageal cancer | Not found |
| dbacp04319 | LvHemB1 | DVNFLLHKIYGNIRY | Marine invertebrates | Inducing apoptosis | MTT assay | HeLa | Liver cancer | Not found |
| dbacp04320 | LvHemB1 | DVNFLLHKIYGNIRY | Marine invertebrates | Inducing apoptosis | MTT assay | HeLa | Bladder cancer | Not found |
| dbacp04321 | LvHemB1 | DVNFLLHKIYGNIRY | Marine invertebrates | Inducing apoptosis | MTT assay | EC109 | Cervical cancer | Not found |
| dbacp04322 | LvHemB1 | DVNFLLHKIYGNIRY | Marine invertebrates | Inducing apoptosis | MTT assay | EC109 | Esophageal cancer | Not found |
| dbacp04323 | LvHemB1 | DVNFLLHKIYGNIRY | Marine invertebrates | Inducing apoptosis | MTT assay | EC109 | Liver cancer | Not found |
| dbacp04324 | LvHemB1 | DVNFLLHKIYGNIRY | Marine invertebrates | Inducing apoptosis | MTT assay | EC109 | Bladder cancer | Not found |
| dbacp04325 | LvHemB1 | DVNFLLHKIYGNIRY | Marine invertebrates | Inducing apoptosis | MTT assay | HepG2 | Cervical cancer | Not found |
| dbacp04326 | LvHemB1 | DVNFLLHKIYGNIRY | Marine invertebrates | Inducing apoptosis | MTT assay | HepG2 | Esophageal cancer | Not found |
| dbacp04327 | LvHemB1 | DVNFLLHKIYGNIRY | Marine invertebrates | Inducing apoptosis | MTT assay | HepG2 | Liver cancer | Not found |
| dbacp04328 | LvHemB1 | DVNFLLHKIYGNIRY | Marine invertebrates | Inducing apoptosis | MTT assay | HepG2 | Bladder cancer | Not found |
| dbacp04329 | LvHemB1 | DVNFLLHKIYGNIRY | Marine invertebrates | Inducing apoptosis | MTT assay | EJ | Cervical cancer | Not found |
| dbacp04330 | LvHemB1 | DVNFLLHKIYGNIRY | Marine invertebrates | Inducing apoptosis | MTT assay | EJ | Esophageal cancer | Not found |
| dbacp04331 | LvHemB1 | DVNFLLHKIYGNIRY | Marine invertebrates | Inducing apoptosis | MTT assay | EJ | Liver cancer | Not found |
| dbacp04332 | LvHemB1 | DVNFLLHKIYGNIRY | Marine invertebrates | Inducing apoptosis | MTT assay | EJ | Bladder cancer | Not found |
| dbacp04333 | LvHemB1 | DVNFLLHKIYGNIRY | Marine invertebrates | Inducing apoptosis | MTT assay | THLE-3 | Cervical cancer | Not found |
| dbacp04334 | LvHemB1 | DVNFLLHKIYGNIRY | Marine invertebrates | Inducing apoptosis | MTT assay | THLE-3 | Esophageal cancer | Not found |
| dbacp04335 | LvHemB1 | DVNFLLHKIYGNIRY | Marine invertebrates | Inducing apoptosis | MTT assay | THLE-3 | Liver cancer | Not found |
| dbacp04336 | LvHemB1 | DVNFLLHKIYGNIRY | Marine invertebrates | Inducing apoptosis | MTT assay | THLE-3 | Bladder cancer | Not found |
| dbacp04337 | LVTX-8 | IWLTALKFLGKNLGKHLAKQQLSKL-NH2 | True tarantula | Promote apoptosis; Inhibits the proliferation and migration of lung cancer cells both in vitro and in vivo | CCK-8 assay, Flow cytometry, Colony formation assay, Transwell invasion and migration assay | A549 | Lung cancer | IC50 : approx. 8 µM |
| dbacp04338 | LVTX-8 | IWLTALKFLGKNLGKHLAKQQLSKL-NH2 | True tarantula | Promote apoptosis; Inhibits the proliferation and migration of lung cancer cells both in vitro and in vivo | CCK-8 assay, Flow cytometry, Colony formation assay, Transwell invasion and migration assay | H461 | Lung cancer | IC50 : approx. 8 µM |
| dbacp04339 | LVTX-9 | ASIGALIQKAIALIKAKAA-NH2 | True tarantula | Promote apoptosis; Inhibits the proliferation and migration of lung cancer cells both in vitro and in vivo | CCK-8 assay, Flow cytometry, Colony formation assay, Transwell invasion and migration assay | A549 | Lung cancer | IC50 : approx. 8 µM |
| dbacp04340 | LVTX-9 | ASIGALIQKAIALIKAKAA-NH2 | True tarantula | Promote apoptosis; Inhibits the proliferation and migration of lung cancer cells both in vitro and in vivo | CCK-8 assay, Flow cytometry, Colony formation assay, Transwell invasion and migration assay | H460 | Lung cancer | IC50 : approx. 8 µM |
| dbacp04341 | Lycosin-1 | Ac-KGWFKAMKSIAKFIAKEKLKEHL-amide | Tarantula wolf spider | Inhibit the migration of prostate cancer cell; Induce apoptosis | MTT assay | DU-145 | Prostate cancer | MIC : 10 μM |
| dbacp04342 | Lycosin-1 | Ac-KGWFKAMKSIAKFIAKEKLKEHL-amide | Tarantula wolf spider | Inhibit the migration of prostate cancer cell; Induce apoptosis | MTT assay | PC-3 | Prostate cancer | MIC : 20 μM |
| dbacp04343 | Lycosin-I | RKGWFKAMKSIAKFIAKEKLKEHL-OH | Venom, wolf spider | Apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04344 | Lycosin-I | RKGWFKAMKSIAKFIAKEKLKEHL-OH | Wolf spider | Apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04347 | Lytic | KLlLKlLkkLLKlLKKK | Interleukin-4 receptor a (IL-4Ra) chain | Induction of apoptosis | WST-1 assay | BXPC-3 | Pancreatic cancer | IC50 : 37.1 µMol/L |
| dbacp04348 | Lytic | KLlLKlLkkLLKlLKKK | Interleukin-4 receptor a (IL-4Ra) chain | Induction of apoptosis | WST-1 assay | SU.86.86 | Pancreatic cancer | IC50 : 28.0 µMol/L |
| dbacp04349 | Lytic | KLlLKlLkkLLKlLKKK | Bovine lactoferrin (Lf-B) | Induction of apoptosis | WST-1 assay | KB | Oral cancer | IC50 : 37.4 µMol/L |
| dbacp04350 | Lytic | KLlLKlLkkLLKlLKKK | Interleukin-4 receptor a (IL-4Ra) chain | Induction of apoptosis | WST-1 assay | T98G | Brain tumor | IC50 : 77.3 µMol/L |
| dbacp04351 | Lytic | KLlLKlLkkLLKlLKKK | Interleukin-4 receptor a (IL-4Ra) chain | Induction of apoptosis | WST-1 assay | A-172 | Brain tumor | IC50 : 30.5 µMol/L |
| dbacp04352 | Lytic | KLlLKlLkkLLKlLKKK | Interleukin-4 receptor a (IL-4Ra) chain | Induction of apoptosis | WST-1 assay | H-322 | Lung cancer | IC50 : 27.1 µMol/L |
| dbacp04353 | Lytic | KLlLKlLkkLLKlLKKK | Interleukin-4 receptor a (IL-4Ra) chain | Induction of apoptosis | WST-1 assay | MDA-MB-231 | Breast cancer | IC50 : 18.5 µMol/L |
| dbacp04541 | Malanin chain A | DYPKLTFTTS | Plant sources | Inducing apoptosis | MTT assay | HeLa | Cervical cancer | IC50 : 0.15 ± 0.08 nM |
| dbacp04542 | Malanin chain A | DYPKLTFTTS | Plant sources | Inducing apoptosis | MTT assay | PC-12 | Breast cancer | IC50 : 7.71 ± 0.24 nM |
| dbacp04543 | Malanin chain A | DYPKLTFTTS | Plant sources | Inducing apoptosis | MTT assay | MCF-7 | Leukemia | IC50 : 11.20 ± 0.02 nM |
| dbacp04544 | Malanin chain A | DYPKLTFTTS | Plant sources | Inducing apoptosis | MTT assay | K562 | Not found | IC50 : 15.80 ± 0.09 nM |
| dbacp04545 | Malanin chain A | DYPKLTFTTS | Plant sources | Inducing apoptosis | MTT assay | Vero | Not found | IC50 : 2.79 ± 0.05 nM |
| dbacp04546 | Malanin chain A | DYPKLTFTTS | Plant sources | Inducing apoptosis | MTT assay | MDCK | Not found | IC50 : 3.92 ± 0.01 nM |
| dbacp04547 | Malanin chain B | DETCTDEEFN | Plant sources | Inducing apoptosis | MTT assay | HeLa | Cervical cancer | IC50 : 0.15 ± 0.08 nM |
| dbacp04548 | Malanin chain B | DETCTDEEFN | Plant sources | Inducing apoptosis | MTT assay | PC-12 | Breast cancer | IC50 : 7.71 ± 0.24 nM |
| dbacp04549 | Malanin chain B | DETCTDEEFN | Plant sources | Inducing apoptosis | MTT assay | MCF-7 | Leukemia | IC50 : 11.20 ± 0.02 nM |
| dbacp04550 | Malanin chain B | DETCTDEEFN | Plant sources | Inducing apoptosis | MTT assay | K562 | Not found | IC50 : 15.80 ± 0.09 nM |
| dbacp04551 | Malanin chain B | DETCTDEEFN | Plant sources | Inducing apoptosis | MTT assay | Vero | Not found | IC50 : 2.79 ± 0.05 nM |
| dbacp04552 | Malanin chain B | DETCTDEEFN | Plant sources | Inducing apoptosis | MTT assay | MDCK | Not found | IC50 : 3.92 ± 0.01 nM |
| dbacp04562 | Mastoparan | INLKALAALAKKIL | Venom base | Inducing apoptosis | Not specified | A2058 | Not specified | IC50 : 140 ± 9.2 µM |
| dbacp04563 | Mastoparan | INLKALAALAKKIL | Venom base | Inducing apoptosis | Not specified | MCF-7 | Not specified | IC50 : 432.5 ± 10.9 µM |
| dbacp04564 | Mastoparan | INLKALAALAKKIL | Venom base | Inducing apoptosis | Not specified | MDA-MB-231 | Not specified | IC50 : 251.25 ± 11.5 µM |
| dbacp04565 | Mastoparan | INLKALAALAKKIL | Venom base | Inducing apoptosis | Not specified | SiHa | Not specified | IC50 : 172.1 ± 8.8 µM |
| dbacp04566 | Mastoparan | INLKALAALAKKIL | Venom base | Inducing apoptosis | Not specified | SK-BR3 | Not specified | IC50 : 320.3 ± 12.5 µM |
| dbacp04567 | Mastoparan | INLKALAALAKKIL | Venom base | Inducing apoptosis | Not specified | U87 | Not specified | IC50 : 311.7 ± 8.9 µM |
| dbacp04568 | Mastoparan | INLKALAALAKKIL | Venom base | Inducing apoptosis | Not specified | Jurkat | Not specified | IC50 : 77.9 ± 6.7 µM |
| dbacp04569 | Mastoparan | INLKALAALAKKIL-NH2 | Eusocial wasp | Induction of apoptosis; Alteration of mitochondrial permeability | MTS assay | A549 | Lung cancer | IC50 : 34.3 ± 1.6 µg/mL |
| dbacp04573 | Mastoparan-C | LNLKALLAVAKKIL | European hornet | Apoptosis | MTT assay | H157 | Non-small cell Lung cancer | IC50 : 13.57 μM |
| dbacp04574 | Mastoparan-C | LNLKALLAVAKKIL | European hornet | Apoptosis | MTT assay | MBD-MB-435S | Melanocyte | IC50 : 1.4 μM |
| dbacp04575 | Mastoparan-C | LNLKALLAVAKKIL | European hornet | Apoptosis | MTT assay | PC-3 | Human prostate carcinoma | IC50 : 1.4 μM |
| dbacp04576 | Mastoparan-C | LNLKALLAVAKKIL | European hornet | Apoptosis | MTT assay | U251-MG | Human glioblastoma astrocytoma | IC50 : 1.4 μM |
| dbacp04577 | Mastoparan-C | LNLKALLAVAKKIL | European hornet | Apoptosis | MTT assay | MCF-7 | Human Breast cancer | IC50 : 1.4 μM |
| dbacp04578 | Mastoparan-Cimals. XXA; UCLL1c) | LNLKALLAVAKKIL | Venom, the European Hornet | Inducing apoptosis | MTT cell viability assay and Lactate dehydrogenase (LDH) leakage assay | H157 | Lung cancer | MIC : 6.26 - 36.65 μM |
| dbacp04579 | Mastoparan-Cimals. XXA; UCLL1c) | LNLKALLAVAKKIL | Venom, the European Hornet | Inducing apoptosis | MTT cell viability assay and Lactate dehydrogenase (LDH) leakage assay | MDA-MB-435S | Breast cancer | MIC : 6.26 - 36.65 μM |
| dbacp04580 | Mastoparan-Cimals. XXA; UCLL1c) | LNLKALLAVAKKIL | Venom, the European Hornet | Inducing apoptosis | MTT cell viability assay and Lactate dehydrogenase (LDH) leakage assay | PC-3 | Human prostate carcinoma | MIC : 6.26 - 36.65 μM |
| dbacp04581 | Mastoparan-Cimals. XXA; UCLL1c) | LNLKALLAVAKKIL | Venom, the European Hornet | Inducing apoptosis | MTT cell viability assay and Lactate dehydrogenase (LDH) leakage assay | U251-MG | Glioma | MIC : 6.26 - 36.65 μM |
| dbacp04582 | Mastoparan-Cimals. XXA; UCLL1c) | LNLKALLAVAKKIL | Venom, the European Hornet | Inducing apoptosis | MTT cell viability assay and Lactate dehydrogenase (LDH) leakage assay | MCF-7 | Breast cancer | MIC : 6.26 - 36.65 μM |
| dbacp04583 | Mastoparan-Cimals. XXA; UCLL1c) | LNLKALLAVAKKIL | Venom, the European Hornet | Inducing apoptosis | MTT cell viability assay and Lactate dehydrogenase (LDH) leakage assay | HMEC-1 | Glioma | MIC : 6.26 - 36.65 μM |
| dbacp04584 | Mastoparan-Cimals. XXA; UCLL1c) | LNLKALLAVAKKIL | Venom, the European Hornet | Inducing apoptosis | MTT cell viability assay and Lactate dehydrogenase (LDH) leakage assay | H157 | Lung cancer | IC50 : < 4 μM |
| dbacp04585 | Mastoparan-Cimals. XXA; UCLL1c) | LNLKALLAVAKKIL | Venom, the European Hornet | Inducing apoptosis | MTT cell viability assay and Lactate dehydrogenase (LDH) leakage assay | MDA-MB-435S | Breast cancer | IC50 : < 4 μM |
| dbacp04586 | Mastoparan-Cimals. XXA; UCLL1c) | LNLKALLAVAKKIL | Venom, the European Hornet | Inducing apoptosis | MTT cell viability assay and Lactate dehydrogenase (LDH) leakage assay | PC-3 | Human prostate carcinoma | IC50 : < 4 μM |
| dbacp04587 | Mastoparan-Cimals. XXA; UCLL1c) | LNLKALLAVAKKIL | Venom, the European Hornet | Inducing apoptosis | MTT cell viability assay and Lactate dehydrogenase (LDH) leakage assay | U251-MG | Glioma | IC50 : < 4 μM |
| dbacp04588 | Mastoparan-Cimals. XXA; UCLL1c) | LNLKALLAVAKKIL | Venom, the European Hornet | Inducing apoptosis | MTT cell viability assay and Lactate dehydrogenase (LDH) leakage assay | MCF-7 | Breast cancer | IC50 : < 4 μM |
| dbacp04589 | Mastoparan-Cimals. XXA; UCLL1c) | LNLKALLAVAKKIL | Venom, the European Hornet | Inducing apoptosis | MTT cell viability assay and Lactate dehydrogenase (LDH) leakage assay | HMEC-1 | Glioma | IC50 : < 4 μM |
| dbacp04591 | Mature Smac (1-4) | AVPI | SMAC | Inducing apoptosis | Not specified | Not found | Not specified | Not found |
| dbacp04592 | Mauriporin | MNKKTLLVIFFITMLIVDEVNSFKIGGFIKKLWRSKLAKKLRAKGRELLKDYANRVINGGPEEEAAVPAERRR | Fat-tailed scorpion | Induce cell apoptosis; Targets on the cell membranes and caused membrane lysis | MTT assay, Lactate dehydrogenase (LDH) Release assay | Hela | Human cervical cancer | IC50 : 27.9 μM - 283.3 μM |
| dbacp04593 | Mauriporin | MNKKTLLVIFFITMLIVDEVNSFKIGGFIKKLWRSKLAKKLRAKGRELLKDYANRVINGGPEEEAAVPAERRR | Fat-tailed scorpion | Induce cell apoptosis; Targets on the cell membranes and caused membrane lysis | MTT assay, Lactate dehydrogenase (LDH) Release assay | SACC-83 | Human salivary adenoid cystic carcinoma | IC50 : 27.9 μM - 283.3 μM |
| dbacp04594 | Mauriporin | MNKKTLLVIFFITMLIVDEVNSFKIGGFIKKLWRSKLAKKLRAKGRELLKDYANRVINGGPEEEAAVPAERRR | Fat-tailed scorpion | Induce cell apoptosis; Targets on the cell membranes and caused membrane lysis | MTT assay, Lactate dehydrogenase (LDH) Release assay | HepG2 | Human liver cancer | IC50 : 27.9 μM - 283.3 μM |
| dbacp04595 | Mauriporin | MNKKTLLVIFFITMLIVDEVNSFKIGGFIKKLWRSKLAKKLRAKGRELLKDYANRVINGGPEEEAAVPAERRR | Fat-tailed scorpion | Induce cell apoptosis; Targets on the cell membranes and caused membrane lysis | MTT assay, Lactate dehydrogenase (LDH) Release assay | PC-3 | Human Prostate cancer | IC50 : 27.9 μM - 283.3 μM |
| dbacp04623 | MB1 | RPEIWIAQEIDRIGDEVNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04624 | MB2 | RPEIWFAQEIDRIGDEVNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04625 | MB7 | RPEIWAAQEIRRIGDENNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04629 | MCL-1, BH3 (208-228) | KALETLRRVGDGVQRNHETAF | Anti apoptotic (MCL-1, BFL1) | Inducing apoptosis | Not specified | Not found | Blood cancer | Not found |
| dbacp04630 | MCL-1, BH3 (208-228) | KALETLRRVGDGVQRNHETAF | Anti apoptotic (MCL-1, BFL1) | Inducing apoptosis | Not specified | Not found | Leukemia | Not found |
| dbacp04631 | MCL-1, BH3 (208-228) | KALETLRRVGDGVQRNHETAF | Anti apoptotic (MCL-1, BFL1) | Inducing apoptosis | Not specified | Not found | Skin cancer | Not found |
| dbacp04632 | MCL-1, BH3 (208-228) | KALETLRRVGDGVQRNHETAF | Anti apoptotic (MCL-1, BFL1) | Inducing apoptosis | Not specified | Not found | Breast cancer | Not found |
| dbacp04642 | MEL-dKLA | GIGAVLKVLTTGLPALISWIKRKRQQGGGGSKLAKLAKKLAKLAK | Venom base | Inducing apoptosis | MTS assay | RAW264.7 | Lung cancer | IC50 : 0.85 μM |
| dbacp04653 | Melittin | GIGAVLKVLTTGLPALISWIKRKRQQ | Venom base | Inducing apoptosis | MTT assay | SGC-7901 | Gastric cancer | Not found |
| dbacp04665 | MF11 | RPEIWVAQELERIGEEVNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04676 | MG1 | RPEIWFAQEFSRIGDEVNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04683 | Min-Antp-LP4 | KRRMKWKKSWTWEKKLETAVNLAWTAGNSNKWTWK | VDAC1(voltage-dependent anion channel1) | Inducing apoptosis | Not specified | CLL | Leukemia | IC50 : 0.3 ± 0.1 µM |
| dbacp04684 | Min-Antp-LP4 | KRRMKWKKSWTWEKKLETAVNLAWTAGNSNKWTWK | VDAC1(voltage-dependent anion channel1) | Inducing apoptosis | Not specified | MEC-1 | Leukemia | IC50 : 1.7 ± 0.4 µM |
| dbacp04685 | MIP | PRFWEYWLRLME | E3 ubiquitin-protein ligase | Cell cycle arrest or apoptosis of cells | Immunoprecipitation assay | HCT-116-p53+/+ | Colon cancer | IC50 : 0.01 µM |
| dbacp04686 | MIP | PRFWEYWLRLME | E3 ubiquitin-protein ligase | Cell cycle arrest or apoptosis of cells | Immunoprecipitation assay | HCT-116-p53+/+ | Colon cancer | IC50 : 0.12 µM |
| dbacp04687 | MIP(F3A) | PRAWEYWLRLME | E3 ubiquitin-protein ligase | Cell cycle arrest or apoptosis of cells | Immunoprecipitation assay | HCT-116-p53+/+ | Colon cancer | IC50 : 0.57 µM |
| dbacp04688 | MIP(L10A) | PRFWEYWLRAME | E3 ubiquitin-protein ligase | Cell cycle arrest or apoptosis of cells | Immunoprecipitation assay | HCT-116-p53+/+ | Colon cancer | IC50 : 1.14 µM |
| dbacp04689 | MIP(M11A) | PRFWEYWLRLAE | E3 ubiquitin-protein ligase | Cell cycle arrest or apoptosis of cells | Immunoprecipitation assay | HCT-116-p53+/+ | Colon cancer | IC50 : 0.4 µM |
| dbacp04690 | MIP(R9A) | PRFWEYWLALME | E3 ubiquitin-protein ligase | Cell cycle arrest or apoptosis of cells | Immunoprecipitation assay | HCT-116-p53+/+ | Colon cancer | IC50 : 0.02 µM |
| dbacp04691 | MIP(W7A) | PRFWEYALRLME | E3 ubiquitin-protein ligase | Cell cycle arrest or apoptosis of cells | Immunoprecipitation assay | HCT-116-p53+/+ | Colon cancer | IC50 : >100 µM |
| dbacp04692 | MIP(Y6A) | PRFWEAWLRLME | E3 ubiquitin-protein ligase | Cell cycle arrest or apoptosis of cells | Immunoprecipitation assay | HCT-116-p53+/+ | Colon cancer | IC50 : >100 µM |
| dbacp04693 | MIPP | SLSLSVAR | Plant sources | Inducing apoptosis | SRB assay | HeLa | Human endometrial cancer | Not found |
| dbacp04694 | MK58911 (a peptide Analog from the mastoparan class of wasps) | INWLKIAKKVKGML | Greater wax moth | Apoptosis; Necrosis | Cytotoxicity test | MRC5 | Not found | IC50 : > 500 µg/mL |
| dbacp04695 | MK58911 (a peptide Analog from the mastoparan class of wasps) | INWLKIAKKVKGML | Greater wax moth | Apoptosis; Necrosis | Cytotoxicity test | U87 | Not found | IC50 : > 500 µg/mL |
| dbacp04698 | MP06 | LAVISWKCQEWNSLWKKRKRKT | Green algae | Apoptosis inducing | CCK-8 assay | MRC5 | Lung cancer | IC50 : 10 μM |
| dbacp04699 | MP12 | MDNHVCIPLCPP | Not found | Inducing apoptosis | MTT assay | Hep-2 | Laryngeal cancer | IC50 : 24.7 ± 0.34 Μm |
| dbacp04705 | MS1 | RPEIWMTQGLRRLGDEINAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Mcl-1/Myc 2640 | Not found | Not found |
| dbacp04706 | MS1 | RPEIWMTQGLRRLGDEINAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Bcl-2/Myc 2924 | Not found | Not found |
| dbacp04707 | MS2 | RPEIWLTQSLQRLGDEINAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Mcl-1/Myc 2640 | Not found | Not found |
| dbacp04708 | MS2 | RPEIWLTQSLQRLGDEINAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Bcl-2/Myc 2924 | Not found | Not found |
| dbacp04709 | MS3 | RPEIWLTQHLQRLGDEINAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Mcl-1/Myc 2640 | Not found | Not found |
| dbacp04710 | MS3 | RPEIWLTQHLQRLGDEINAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Bcl-2/Myc 2924 | Not found | Not found |
| dbacp04713 | mt_E17L/L22 W/P27A | LTFSDWWKLLAE | MDM3 | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 15.1 µM |
| dbacp04714 | mt_L22 W/P27A | ETFSDWWKLLAE | MDM2 | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 16.3 µM |
| dbacp04715 | mt_S20A/L22 W/P27A | ETFADWWKLLAE | MDM5 | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 8.7 µM |
| dbacp04716 | mt_T18S/L22 W/P27A | ESFSDWWKLLAE | MDM4 | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 27 µM |
| dbacp04717 | Multivalent DR5 binding peptides, TRAILmim/DR5 (1m) | WDCLDNRIGRRQCVKL | Not found | Inducing apoptosis | Not specified | HCT 116 | Colon cancer | Kd (Binding constants of TRAIL mimics): 129 ± 3.68 nMol/L |
| dbacp04718 | Multivalent DR5 binding peptides, TRAILmim/DR5 (2m) | WDCLDNRIGKRQCVRL | Not found | Inducing apoptosis | Not specified | HCT 116 | Colon cancer | Kd (Binding constants of TRAIL mimics): 664 ± 18 nMol/L |
| dbacp04719 | Multivalent DR5 binding peptides, TRAILmim/DR5 (3m) | WDCLDNKIGRRQCVRL | Not found | Inducing apoptosis | Not specified | HCT 116 | Colon cancer | Kd (Binding constants of TRAIL mimics): 226 ± 5.64 nMol/L |
| dbacp04790 | N-Ter | RDVFTKGYGFGL | VDAC1(voltage-dependent anion channel1) | Inducing apoptosis | SRB assay | A375 | Human endometrial cancer | IC50 : > 50.0 μM |
| dbacp04791 | N-Ter-Antp | N-Ter-RQIKIWFQNRRMKWKK | VDAC1(voltage-dependent anion channel1) | Inducing apoptosis | Not specified | CLL | Leukemia | IC50 : 3.2 ± 0.5 µM |
| dbacp04792 | N-Ter-Antp | N-Ter-RQIKIWFQNRRMKWKK | VDAC1(voltage-dependent anion channel1) | Inducing apoptosis | Not specified | MEC-1 | Leukemia | IC50 : 4.2 ± 0.2 µM |
| dbacp04793 | N-Ter-TAT | RDVFTKGYGFGLGRKKRRQRRRPQ | VDAC1(voltage-dependent anion channel1) | Inducing apoptosis | SRB assay | A375 | Human endometrial cancer | IC50 : > 50.0 μM |
| dbacp04820 | Nal2-S1 | Ac-KKWRKWLAKK-NH2 | Not found | Necrosis; Apoptosis | MTT assay | PC9 | Human Lung cancer | MIC : 25 μM |
| dbacp04821 | Nal2-S1 | Ac-KKWRKWLAKK-NH2 | Not found | Necrosis; Apoptosis | MTT assay | PC9-G | Oral cancer | MIC : 25 μM |
| dbacp04822 | Nal2-S1 | Ac-KKWRKWLAKK-NH2 | Not found | Necrosis; Apoptosis | MTT assay | A549 | Human Lung cancer | MIC : 25 μM |
| dbacp04823 | Nal2-S1 | Ac-KKWRKWLAKK-NH2 | Not found | Necrosis; Apoptosis | MTT assay | C9 | Oral cancer | MIC : 25 μM |
| dbacp04824 | Nal2-S1 | Ac-KKWRKWLAKK-NH2 | Not found | Necrosis; Apoptosis | MTT assay | OECM-1 | Human Lung cancer | MIC : 25 μM |
| dbacp04825 | Nal2-S1 | Ac-KKWRKWLAKK-NH2 | Not found | Necrosis; Apoptosis | MTT assay | SAS | Oral cancer | MIC : 25 μM |
| dbacp04826 | neo-N-methylSansalvamide A | NA | Marine fungus | Apoptosis induction | Not specified | MES-SA | Uterus cancer | 1.00 ± 0.20 nM/L |
| dbacp04827 | neo-N-methylSansalvamide A | NA | Marine fungus | Apoptosis induction | Not specified | HCT15 | Colon cancer | 0.85 ± 0.63 nM/L |
| dbacp04849 | Nisin ZP | ITSISLCTPGCKTGALMGCnMKTATCNCSIHVSK | Not found | Inducing apoptosis | Not specified | HUVEC | Not specified | Not found |
| dbacp04850 | Nisin ZP | ITSISLCTPGCKTGALMGCnMKTATCNCSIHVSK | Not found | Inducing apoptosis | Not specified | HNSCC | Not specified | Not found |
| dbacp04884 | Non-digestible fraction peptide | GLTSK | Common bean | Cell proliferation inhibition; Apoptosis inducing | MTS assay | HCT116 | Colorectal cancer | IC50 : 0.51 mg/ml |
| dbacp04885 | Non-digestible fraction peptide | LSGNK | Common bean | Cell proliferation inhibition; Apoptosis inducing | MTS assay | HCT116 | Colorectal cancer | IC50 : 0.51 mg/ml |
| dbacp04886 | Non-digestible fraction peptide | GEGSGA | Common bean | Cell proliferation inhibition; Apoptosis inducing | MTS assay | HCT116 | Colorectal cancer | IC50 : 0.51 mg/ml |
| dbacp04887 | Non-digestible fraction peptide | MPACGSS | Common bean | Cell proliferation inhibition; Apoptosis inducing | MTS assay | HCT116 | Colorectal cancer | IC50 : 0.51 mg/ml |
| dbacp04888 | Non-digestible fraction peptide | MTEEY | Common bean | Cell proliferation inhibition; Apoptosis inducing | MTS assay | HCT116 | Colorectal cancer | IC50 : 0.51 mg/ml |
| dbacp04905 | Noxa | AELEVECATQLRRFGDKLNFRQKL | BH3-only, Sensizers (BAD, HRK, Noxa) | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04906 | Noxa C2dY | AELEVEYATQLRRFGDKLNFRQKL | BH3-only, Sensizers (BAD, HRK, Noxa) | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp04907 | NoxaA | AELPPEFAAQLRKIGDKVYC | BH3-only, Sensizers (BAD, HRK, Noxa) | Inducing apoptosis | Not specified | Mcl-1/Myc 2640 | Not found | Not found |
| dbacp04908 | NoxaA | AELPPEFAAQLRKIGDKVYC | BH3-only, Sensizers (BAD, HRK, Noxa) | Inducing apoptosis | Not specified | Bcl-2/Myc 2924 | Not found | Not found |
| dbacp04998 | NuBCP-9 | FSRSLHSLL | Not found | Inducing apoptosis | Not specified | MCF-7 | Not specified | Not found |
| dbacp04999 | NuBCP-9 | FSRSLHSLL | Not found | Inducing apoptosis | Not specified | HepG2 | Not specified | Not found |
| dbacp05000 | NuBCP-9 (DR8) | FSRSLHSLLRRRRRRRR | Not found | Inducing apoptosis | XTT assat | MCF-7 | Breast cancer | IC50 : 7.11 μM |
| dbacp05001 | NuBCP-9 (DR8) | FSRSLHSLLRRRRRRRR | Not found | Inducing apoptosis | XTT assat | HepG2 | Liver cancer | IC50 : 9.10 μM |
| dbacp05009 | Okinawa Habu apoxin protein-1(OHAP-1) | ADDRNPLEECFRETDYEEFLEIARNGLKKT | Venom base | Inducing apoptosis | DNA gel electrophoresis assay,TUNEL assay, MTT assay | RBR17T | Glioma | IC50 : 2.1 ± 0.58 µg/ml |
| dbacp05010 | Okinawa Habu apoxin protein-1(OHAP-1) | ADDRNPLEECFRETDYEEFLEIARNGLKKT | Venom base | Inducing apoptosis | DNA gel electrophoresis assay,TUNEL assay, MTT assay | OHAP-1 | Glioma | IC50 : 1.9 ± 0.31 µg/ml |
| dbacp05011 | Okinawa Habu apoxin protein-1(OHAP-1) | ADDRNPLEECFRETDYEEFLEIARNGLKKT | Venom base | Inducing apoptosis | DNA gel electrophoresis assay,TUNEL assay, MTT assay | C6 | Glioma | IC50 : 2.48 ± 0.26 µg/ml |
| dbacp05012 | Omiganan MBI-226 | ILRWPWWPWRRK | Cattle neutrophils | Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis | MTT/MTS assay | U-937 | Lymphoma cancer | IC50 : 80 - 85 µg/ml |
| dbacp05013 | Omiganan MBI-226 | ILRWPWWPWRRK | Helical peptide with a predominance of one or more amino acids tryptophane-rich | Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis | MTT/MTS assay | U-937 | Lymphoma cancer | 27% Cytotoxicity at 0.5 µg/ml |
| dbacp05029 | p-BIM BH3 (I155R, E158S) | EIWIAQELRRRGDpSFNAYYAR‘pS’standsforthephosphorylatedserine | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | MTT assay | Not found | Prostate cancer | Not found |
| dbacp05030 | p-BIM BH3 (R154S, I155R, E158S) | EIWIAQELRSRGDpSFNAYYAR‘pS’standsforthephosphorylatedserine | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | MTT assay | Not found | Prostate cancer | Not found |
| dbacp05031 | P04 | IGEHTPSALAIMENANVLAR | Aldolase A derived | Apoptosis inducing | MTT assay | PDAC | Pancreatic ductal adenocarcinoma | MIC : 25 µg/mL |
| dbacp05032 | P1 | KWKLFKKIGIGAVLKVLKKG | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H69 | Lung cancer | IC50 :3.4 µM |
| dbacp05033 | P1 | KWKLFKKIGIGAVLKVLKKG | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H128 | Lung cancer | IC50 :3.5 µM |
| dbacp05034 | P1 | KWKLFKKIGIGAVLKVLKKG | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H146 | Lung cancer | IC50 :4.5 µM |
| dbacp05035 | p120RasGAP (317-326) | WMWVTNLRTD | Not found | Inducing apoptosis | Luciferase assay | HeLa | Breast cancer | Not found |
| dbacp05036 | p120RasGAP (317-326) | WMWVTNLRTD | Not found | Inducing apoptosis | Luciferase assay | MCF-7 | Human malignant mesothelomia | Not found |
| dbacp05037 | P160 | VPWMEPAYQRFL | Not found | Apoptosis inducing | MTT cytotoxicity assay | MCF-7 | Breast cancer | IC50 : 14.2 ± 1.5 μM |
| dbacp05052 | P2 | KWKLFKKIGIGKFLHSATTF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H69 | Lung cancer | IC50 : 36.2 µM |
| dbacp05053 | P2 | KWKLFKKIGIGKFLHSATTF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H128 | Lung cancer | IC50 : 37.9 µM |
| dbacp05054 | P2 | KWKLFKKIGIGKFLHSATTF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H146 | Lung cancer | IC50 : 47.7 µM |
| dbacp05055 | P2 | RALGWSCL | Plant sources | Inducing apoptosis | MTS assay | NB4 | Not specified | IC50 : 600 μg/mL |
| dbacp05056 | P2 | RALGWSCL | Plant sources | Inducing apoptosis | MTS assay | MOLT4 | Not specified | IC50 : 700 μg/mL |
| dbacp05057 | P2 | RALGWSCL | Plant sources | Inducing apoptosis | MTS assay | Raji | Not specified | IC50 : 700 μg/Ml |
| dbacp05058 | P3 | KWKLFKKIGIGAFLHSAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H69 | Lung cancer | IC50 : 9.3 µM |
| dbacp05059 | P3 | KWKLFKKIGIGAFLHSAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H128 | Lung cancer | IC50 : 9.3 µM |
| dbacp05060 | P3 | KWKLFKKIGIGAFLHSAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H146 | Lung cancer | IC50 : 10.9 µM |
| dbacp05071 | P3Bax | MDGSGEQLGSGGPTSSEQIMKTGAFLLQGFIQ | Effectors (BAK, BAX) | Inducing apoptosis | Cell survival assay | NRP-154 | Prostate cancer | Not found |
| dbacp05072 | P4 | KWKLFKKIGIGKFLHLAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H69 | Lung cancer | IC50 : 1.9 µM |
| dbacp05073 | P4 | KWKLFKKIGIGKFLHLAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H128 | Lung cancer | IC50 : 1.3 µM |
| dbacp05074 | P4 | KWKLFKKIGIGKFLHLAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H146 | Lung cancer | IC50 : 2.8 µM |
| dbacp05075 | P5 | KWKLFKKIGIGAFLHLAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H69 | Lung cancer | IC50 : 2.9 µM |
| dbacp05076 | P5 | KWKLFKKIGIGAFLHLAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H128 | Lung cancer | IC50 : 2.9 µM |
| dbacp05077 | P5 | KWKLFKKIGIGAFLHLAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H146 | Lung cancer | IC50 : 3.2 µM |
| dbacp05078 | p53-C terminal peptide | GSRAHSSHLKSKKGQSTSRHKK | Not found | Inducing apoptosis | Annexin V-FITC Binding assay | MDA-MB-468 | Breast cancer | Not found |
| dbacp05079 | p53-C terminal peptide | GSRAHSSHLKSKKGQSTSRHKK | Not found | Inducing apoptosis | Annexin V-FITC Binding assay | MDA-MB-231 | Breast cancer | Not found |
| dbacp05080 | p53-C terminal peptide | GSRAHSSHLKSKKGQSTSRHKK | Not found | Inducing apoptosis | Annexin V-FITC Binding assay | MCF-7 | Breast cancer | Not found |
| dbacp05081 | p53-C terminal peptide | GSRAHSSHLKSKKGQSTSRHKK | Not found | Inducing apoptosis | Annexin V-FITC Binding assay | MCF10-2A | Breast cancer | Not found |
| dbacp05082 | P5317-28 | QETFSDLWKLLP | E3 ubiquitin-protein ligase | Cell cycle arrest or apoptosis of cells | Immunoprecipitation assay | HCT-116-p53+/+ | Colon cancer | IC50 : 4.7 µM |
| dbacp05083 | P5317-28 | QETFSDLWKLLP | E3 ubiquitin-protein ligase | Cell cycle arrest or apoptosis of cells | Immunoprecipitation assay | HCT-116-p53+/+ | Colon cancer | IC50 : 30 µM |
| dbacp05084 | p53C | KKHRSTSQGKKSKLHSSHARSG | Not found | Inducing apoptosis | Not specified | 293T | Not specified | Not found |
| dbacp05085 | p53C | KKHRSTSQGKKSKLHSSHARSG | Not found | Inducing apoptosis | Not specified | H1299 | Not specified | Not found |
| dbacp05086 | P6 | KWKLFKKIGIGKFKLAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H69 | Lung cancer | IC50 : 1.7 µM |
| dbacp05087 | P6 | KWKLFKKIGIGKFKLAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H128 | Lung cancer | IC50 : 2 µM |
| dbacp05088 | P6 | KWKLFKKIGIGKFKLAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H146 | Lung cancer | IC50 : 3.1 µM |
| dbacp05089 | P6 | WYIRKIRRFFKWLKKKLKKK | Marine invertebrates | Inducing apoptosis | MTT assay | HT-29 | Colorectal cancer | Not found |
| dbacp05090 | P6 | WYIRKIRRFFKWLKKKLKKK | Marine invertebrates | Inducing apoptosis | MTT assay | DLD-1 | Colorectal cancer | Not found |
| dbacp05091 | P6 | WYIRKIRRFFKWLKKKLKKK | Marine invertebrates | Inducing apoptosis | MTT assay | HCT116 | Colorectal cancer | Not found |
| dbacp05092 | P6 | WYIRKIRRFFKWLKKKLKKK | Marine invertebrates | Inducing apoptosis | MTT assay | SW-620 | Colorectal cancer | Not found |
| dbacp05093 | P6 | WYIRKIRRFFKWLKKKLKKK | Marine invertebrates | Inducing apoptosis | MTT assay | L02 | Colorectal cancer | Not found |
| dbacp05094 | P7 | PLLQATLGGGS | Not found | Apoptosis inducing | WST-1 assay | B16-F10 | Skin cancer | IC50 : 1 µM |
| dbacp05095 | P7 | KWKLFAKIGIGKFLHLAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H69 | Lung cancer | IC50 : 3.1 µM |
| dbacp05096 | P7 | KWKLFAKIGIGKFLHLAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H128 | Lung cancer | IC50 : 2.4 µM |
| dbacp05097 | P7 | KWKLFAKIGIGKFLHLAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H146 | Lung cancer | IC50 : 2.4 µM |
| dbacp05098 | p776 | GVGSPYVSRLLGICL | Synthetic Peptide | Inducing apoptosis | ELISPOT assay | Not found | Tumor | Not found |
| dbacp05099 | P8 | KWKKFLKIGIGKFLHLAKKF | Ceropin A-African clawed frog | Apoptosis | MTT/MTS assay | NCI-H69 | Lung cancer | IC50 : 2.6 µM |
| dbacp05100 | P8 | KWKKFLKIGIGKFLHLAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H128 | Lung cancer | IC50 : 2.3 µM |
| dbacp05101 | P8 | KWKKFLKIGIGKFLHLAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H146 | Lung cancer | IC50 : 1.8 µM |
| dbacp05102 | p85 | LIAHNQVRQV | Synthetic Peptide | Inducing apoptosis | ELISPOT assay | Not found | Tumor | Not found |
| dbacp05103 | PA10 | RQIKIWFQNRRMKWKKGGGGNNETTSIQIAGSLHHHHHH | Synthetic construct | Cell proliferation inhibition; Cell penetration; Apoptosis | Cell viability assay | MDA-MB231 | Breast cancer | MIC : 10 μM |
| dbacp05104 | PA10 | RQIKIWFQNRRMKWKKGGGGNNETTSIQIAGSLHHHHHH | Synthetic construct | Cell proliferation inhibition; Cell penetration; Apoptosis | Cell viability assay | HCC1806 | Breast cancer | MIC : 10 μM |
| dbacp05105 | PA10 | RQIKIWFQNRRMKWKKGGGGNNETTSIQIAGSLHHHHHH | Synthetic construct | Cell proliferation inhibition; Cell penetration; Apoptosis | Cell viability assay | 184B5 | Breast cancer | MIC : 10 μM |
| dbacp05106 | PA10 | RQIKIWFQNRRMKWKKGGGGNNETTSIQIAGSLHHHHHH | Synthetic construct | Cell proliferation inhibition; Cell penetration; Apoptosis | Cell viability assay | MCF10A | Breast cancer | MIC : 10 μM |
| dbacp05107 | PA15 | RQIKIWFQNRRMKWKKGGSLSAACHEQWSLGAQHHHHHH | Synthetic construct | Cell proliferation inhibition; Cell penetration; Apoptosis | Cell viability assay | MDA-MB231 | Breast cancer | MIC : 10 μM |
| dbacp05108 | PA15 | RQIKIWFQNRRMKWKKGGSLSAACHEQWSLGAQHHHHHH | Synthetic construct | Cell proliferation inhibition; Cell penetration; Apoptosis | Cell viability assay | HCC1806 | Breast cancer | MIC : 10 μM |
| dbacp05109 | PA15 | RQIKIWFQNRRMKWKKGGSLSAACHEQWSLGAQHHHHHH | Synthetic construct | Cell proliferation inhibition; Cell penetration; Apoptosis | Cell viability assay | 184B5 | Breast cancer | MIC : 10 μM |
| dbacp05110 | PA15 | RQIKIWFQNRRMKWKKGGSLSAACHEQWSLGAQHHHHHH | Synthetic construct | Cell proliferation inhibition; Cell penetration; Apoptosis | Cell viability assay | MCF10A | Breast cancer | MIC : 10 μM |
| dbacp05111 | PA2 | RQIKIWFQNRRMKWKKGGATRPRVDTQPELCGMHHHHHH | Synthetic construct | Cell proliferation inhibition; Cell penetration; Apoptosis | Cell viability assay | MDA-MB231 | Breast cancer | MIC : 10 μM |
| dbacp05112 | PA2 | RQIKIWFQNRRMKWKKGGATRPRVDTQPELCGMHHHHHH | Synthetic construct | Cell proliferation inhibition; Cell penetration; Apoptosis | Cell viability assay | HCC1806 | Breast cancer | MIC : 10 μM |
| dbacp05113 | PA2 | RQIKIWFQNRRMKWKKGGATRPRVDTQPELCGMHHHHHH | Synthetic construct | Cell proliferation inhibition; Cell penetration; Apoptosis | Cell viability assay | 184B5 | Breast cancer | MIC : 10 μM |
| dbacp05114 | PA2 | RQIKIWFQNRRMKWKKGGATRPRVDTQPELCGMHHHHHH | Synthetic construct | Cell proliferation inhibition; Cell penetration; Apoptosis | Cell viability assay | MCF10A | Breast cancer | MIC : 10 μM |
| dbacp05115 | PA3 | RQIKIWFQNRRMKWKKGGDCLCISRRARLLRATHHHHHH | Synthetic construct | Cell proliferation inhibition; Cell penetration; Apoptosis | Cell viability assay | MDA-MB231 | Breast cancer | MIC : 10 μM |
| dbacp05116 | PA3 | RQIKIWFQNRRMKWKKGGDCLCISRRARLLRATHHHHHH | Synthetic construct | Cell proliferation inhibition; Cell penetration; Apoptosis | Cell viability assay | HCC1806 | Breast cancer | MIC : 10 μM |
| dbacp05117 | PA3 | RQIKIWFQNRRMKWKKGGDCLCISRRARLLRATHHHHHH | Synthetic construct | Cell proliferation inhibition; Cell penetration; Apoptosis | Cell viability assay | 184B5 | Breast cancer | MIC : 10 μM |
| dbacp05118 | PA3 | RQIKIWFQNRRMKWKKGGDCLCISRRARLLRATHHHHHH | Synthetic construct | Cell proliferation inhibition; Cell penetration; Apoptosis | Cell viability assay | MCF10A | Breast cancer | MIC : 10 μM |
| dbacp05119 | PA38 | RQIKIWFQNRRMKWKKGGKYNGRFTTHHLLHLLNHHHHHH | Synthetic construct | Cell proliferation inhibition; Cell penetration; Apoptosis | Cell viability assay | MDA-MB231 | Breast cancer | MIC : 10 μM |
| dbacp05120 | PA38 | RQIKIWFQNRRMKWKKGGKYNGRFTTHHLLHLLNHHHHHH | Synthetic construct | Cell proliferation inhibition; Cell penetration; Apoptosis | Cell viability assay | HCC1806 | Breast cancer | MIC : 10 μM |
| dbacp05121 | PA38 | RQIKIWFQNRRMKWKKGGKYNGRFTTHHLLHLLNHHHHHH | Synthetic construct | Cell proliferation inhibition; Cell penetration; Apoptosis | Cell viability assay | 184B5 | Breast cancer | MIC : 10 μM |
| dbacp05122 | PA38 | RQIKIWFQNRRMKWKKGGKYNGRFTTHHLLHLLNHHHHHH | Synthetic construct | Cell proliferation inhibition; Cell penetration; Apoptosis | Cell viability assay | MCF10A | Breast cancer | MIC : 10 μM |
| dbacp05123 | PA49 | RQIKIWFQNRRMKWKKGGAGVYTFLVGADNRGWEHHHHHH | Synthetic construct | Cell proliferation inhibition; Cell penetration; Apoptosis | Cell viability assay | MDA-MB231 | Breast cancer | MIC : 10 μM |
| dbacp05124 | PA49 | RQIKIWFQNRRMKWKKGGAGVYTFLVGADNRGWEHHHHHH | Synthetic construct | Cell proliferation inhibition; Cell penetration; Apoptosis | Cell viability assay | HCC1806 | Breast cancer | MIC : 10 μM |
| dbacp05125 | PA49 | RQIKIWFQNRRMKWKKGGAGVYTFLVGADNRGWEHHHHHH | Synthetic construct | Cell proliferation inhibition; Cell penetration; Apoptosis | Cell viability assay | 184B5 | Breast cancer | MIC : 10 μM |
| dbacp05126 | PA49 | RQIKIWFQNRRMKWKKGGAGVYTFLVGADNRGWEHHHHHH | Synthetic construct | Cell proliferation inhibition; Cell penetration; Apoptosis | Cell viability assay | MCF10A | Breast cancer | MIC : 10 μM |
| dbacp05127 | PaDef | ATCETPSKHFNGLCIRSSNCASVCHGEHFTDGRCQGVRRRCMCLKPC | Plant sources | Inducing apoptosis | MTT assay | Jurkat | Leukemia | Not found |
| dbacp05129 | Pal-N-Ter-TAT | RDVFTKGYGFGLGRKKRRQRRRPQ | VDAC1(voltage-dependent anion channel1) | Inducing apoptosis | SRB assay | A375 | Human endometrial cancer | IC50 : 15.2 ± 0.7 μM |
| dbacp05130 | Pal-pFL-N-Ter-TAT | FPWWWPFLRDVFTKGYGFGLGRKKRRQRRRPQ | VDAC1(voltage-dependent anion channel1) | Inducing apoptosis | MTT assay | A375 | Leukemia | IC50 : 5.5 ± 1.1 μM |
| dbacp05134 | Pardaxin | GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE | Red sea moses sole | Inducing apoptosis | MTT/MTS assay | HT-1080 | Fibrosarcoma | IC50 : 15.74 µg/ml |
| dbacp05135 | Pardaxin | GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE | Red sea moses sole | Inducing apoptosis | MTT/MTS assay | HT-1080 | Fibrosarcoma | IC50 : 15.40 µg/ml |
| dbacp05136 | Pardaxin | GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE | Red sea moses sole | Inducing apoptosis | MTT/MTS assay | HT-1080 | Fibrosarcoma | IC50 : 14.51 µg/ml |
| dbacp05137 | Pardaxin | GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE | Red sea moses sole | Inducing apoptosis | MTT/MTS assay | HT-1080 | Fibrosarcoma | IC50 : 14.52 µg/ml |
| dbacp05216 | PD-L1ip3 | GTRLKPLIICVQWPGL | Not found | Inducing apoptosis | MTT assay | CT26 | Colon cacer | Not found |
| dbacp05222 | Penaeidin-2 | YRGGYTGPIPRPPPIGRPPLPRVVCACYRLSVSDARNCCIKFGSCCHLVK | Pacific white shrimp | Induction of apoptosis | MTT assay | HK-2 | Kidney cancer | MIC : 100 μg/mL |
| dbacp05223 | Penaeidin-2 | YRGGYTGPIPRPPPIGRPPLPRVVCACYRLSVSDARNCCIKFGSCCHLVK | Pacific white shrimp | Induction of apoptosis | MTT assay | ACHN | Kidney cancer | MIC : 100 μg/mL |
| dbacp05224 | Penaeidin-2 | YRGGYTGPIPRPPPIGRPPLPRVVCACYRLSVSDARNCCIKFGSCCHLVK | Pacific white shrimp | Induction of apoptosis | MTT assay | A498 | Kidney cancer | MIC : 100 μg/mL |
| dbacp05241 | pentadactylin | GLLDTLKGAAKNVVGSLASKVMEKL | Not found | Inducing apoptosis | MTT assay | B16F10 | Melanoma | IC50 : 25.7 µM |
| dbacp05242 | pentadactylin | GLLDTLKGAAKNVVGSLASKVMEKL | Not found | Inducing apoptosis | MTT assay | FHN | Melanoma | IC50 : 35.9 µM |
| dbacp05244 | Pentapeptide (ILYMP) | ILYMP | Marine invertebrates | Inducing apoptosis | MTT assay | DU-145 | Prostate cancer | IC50 :11.25 mM |
| dbacp05245 | pep1 | FKCRRWQWRMKKLGAPSITCVR | Bovine lactoferrin (Lf-B) | Activating an apoptosis-inducing pathway | MTT/MTS assay | HL-60 | Prostate cancer | IC50 :77 µM |
| dbacp05246 | Pep27 | MRKEFHNVLSSGQLLADKRPARDYNRK | Pneumococcus | Apoptosis inducing | MTT/MTS assay | AML-2 | Leukemia cancer | Not found |
| dbacp05247 | Pep27 | MRKEFHNVLSSGQLLADKRPARDYNRK | Pneumococcus | Apoptosis inducing | MTT/MTS assay | HL-60 | Leukemia cancer | IC50 : > 70 µM |
| dbacp05248 | Pep27 | MRKEFHNVLSSGQLLADKRPARDYNRK | Pneumococcus | Apoptosis inducing | MTT/MTS assay | Jurkat | Blood cancer | IC50 : > 70 µM |
| dbacp05249 | Pep27 | MRKEFHNVLSSGQLLADKRPARDYNRK | Pneumococcus | Apoptosis inducing | MTT/MTS assay | SNU-601 | Gastric cancer | IC50 : > 70 µM |
| dbacp05250 | Pep27 | MRKEFHNVLSSGQLLADKRPARDYNRK | Pneumococcus | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : > 70 µM |
| dbacp05251 | Pep27 | MRKEFHNVLSSGQLLADKRPARDYNRK | Not found | Inducing apoptosis | MTT assay | AML-2 | Acute myelogenous leukemia | IC50 : > 70 µM |
| dbacp05252 | Pep27 | MRKEFHNVLSSGQLLADKRPARDYNRK | Not found | Inducing apoptosis | MTT assay | HL-60 | Acute promyelocytic leukemia | IC50 : > 70 µM |
| dbacp05253 | Pep27 | MRKEFHNVLSSGQLLADKRPARDYNRK | Not found | Inducing apoptosis | MTT assay | Jurkat | T-cell leukemia | IC50 : > 70 µM |
| dbacp05254 | Pep27 | MRKEFHNVLSSGQLLADKRPARDYNRK | Not found | Inducing apoptosis | MTT assay | SNU-601 | Gastric cancer | IC50 : > 70 µM |
| dbacp05255 | Pep27 | MRKEFHNVLSSGQLLADKRPARDYNRK | Not found | Inducing apoptosis | MTT assay | MCF-7 | Breast cancer | IC50 : > 70 µM |
| dbacp05256 | Pep27 | MRKEFHNVLSSGQLLADKRPARDYNRK | Pneumococcus | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : > 70 µM |
| dbacp05257 | Pep27 anal1 | MWKWFHNVLSSWQLLADKRPARDYNRK | Not found | Inducing apoptosis | MTT assay | AML-2 | Acute myelogenous leukemia | IC50 : 50 µM |
| dbacp05258 | Pep27 anal1 | MWKWFHNVLSSWQLLADKRPARDYNRK | Not found | Inducing apoptosis | MTT assay | HL-60 | Acute promyelocytic leukemia | IC50 : 53 µM |
| dbacp05259 | Pep27 anal1 | MWKWFHNVLSSWQLLADKRPARDYNRK | Not found | Inducing apoptosis | MTT assay | Jurkat | T-cell leukemia | IC50 : 47 µM |
| dbacp05260 | Pep27 anal1 | MWKWFHNVLSSWQLLADKRPARDYNRK | Not found | Inducing apoptosis | MTT assay | SNU-601 | Gastric cancer | IC50 : 37 µM |
| dbacp05261 | Pep27 anal1 | MWKWFHNVLSSWQLLADKRPARDYNRK | Not found | Inducing apoptosis | MTT assay | MCF-7 | Breast cancer | IC50 : 55 µM |
| dbacp05262 | Pep27 anal2 | MWKWFHNVLSWWWLLADKRPARDYNRK | Not found | Inducing apoptosis | MTT assay | AML-2 | Acute myelogenous leukemia | IC50 : 29 µM |
| dbacp05263 | Pep27 anal2 | MWKWFHNVLSWWWLLADKRPARDYNRK | Not found | Inducing apoptosis | MTT assay | HL-60 | Acute promyelocytic leukemia | IC50 : 20 µM |
| dbacp05264 | Pep27 anal2 | MWKWFHNVLSWWWLLADKRPARDYNRK | Not found | Inducing apoptosis | MTT assay | Jurkat | T cell leukemia | IC50 : 23 µM |
| dbacp05265 | Pep27 anal2 | MWKWFHNVLSWWWLLADKRPARDYNRK | Not found | Inducing apoptosis | MTT assay | SNU-601 | Gastric cancer | IC50 : 25 µM |
| dbacp05266 | Pep27 anal2 | MWKWFHNVLSWWWLLADKRPARDYNRK | Not found | Inducing apoptosis | MTT assay | MCF-7 | Breast cancer | IC50 : < 10 µM |
| dbacp05267 | Pep27 anal3 | MRKWFHNVLSSGQLLADKWPAWDYNRK | Not found | Inducing apoptosis | MTT assay | AML-2 | Acute myelogenous leukemia | IC50 : 67 µM |
| dbacp05268 | Pep27 anal3 | MRKWFHNVLSSGQLLADKWPAWDYNRK | Not found | Inducing apoptosis | MTT assay | HL-60 | Acute promyelocytic leukemia | IC50 : 52 µM |
| dbacp05269 | Pep27 anal3 | MRKWFHNVLSSGQLLADKWPAWDYNRK | Not found | Inducing apoptosis | MTT assay | Jurkat | T cell leukemia | IC50 : 50 µM |
| dbacp05270 | Pep27 anal3 | MRKWFHNVLSSGQLLADKWPAWDYNRK | Not found | Inducing apoptosis | MTT assay | SNU-601 | Gastric cancer | IC50 : 50 µM |
| dbacp05271 | Pep27 anal3 | MRKWFHNVLSSGQLLADKWPAWDYNRK | Not found | Inducing apoptosis | MTT assay | MCF-7 | Breast cancer | IC50 : 38 µM |
| dbacp05272 | Pep27 anal4 | MWKEFHNVLSSGQLLADKRWARWYNRW | Not found | Inducing apoptosis | MTT assay | AML-2 | Acute myelogenous leukemia | IC50 : 50 µM |
| dbacp05273 | Pep27 anal4 | MWKEFHNVLSSGQLLADKRWARWYNRW | Not found | Inducing apoptosis | MTT assay | HL-60 | Acute promyelocytic leukemia | IC50 : 51 µM |
| dbacp05274 | Pep27 anal4 | MWKEFHNVLSSGQLLADKRWARWYNRW | Not found | Inducing apoptosis | MTT assay | Jurkat | T-cell Leukemia | IC50 : 46 µM |
| dbacp05275 | Pep27 anal4 | MWKEFHNVLSSGQLLADKRWARWYNRW | Not found | Inducing apoptosis | MTT assay | SNU-601 | Gastric cancer | IC50 : 46 µM |
| dbacp05276 | Pep27 anal4 | MWKEFHNVLSSGQLLADKRWARWYNRW | Not found | Inducing apoptosis | MTT assay | MCF-7 | Breast cancer | IC50 : 29 µM |
| dbacp05277 | Pep27 anal5 | MWKWFHNVLSSGQLLADKWWAWWYNWW | Not found | Inducing apoptosis | MTT assay | AML-2 | Acute myelogenous leukemia | IC50 : > 70 µM |
| dbacp05278 | Pep27 anal5 | MWKWFHNVLSSGQLLADKWWAWWYNWW | Not found | Inducing apoptosis | MTT assay | HL-60 | Acute promyelocytic leukemia | IC50 : > 70 µM |
| dbacp05279 | Pep27 anal5 | MWKWFHNVLSSGQLLADKWWAWWYNWW | Not found | Inducing apoptosis | MTT assay | Jurkat | T cell leukemia | IC50 : > 70 µM |
| dbacp05280 | Pep27 anal5 | MWKWFHNVLSSGQLLADKWWAWWYNWW | Not found | Inducing apoptosis | MTT assay | SNU-601 | Gastric cancer | IC50 : > 70 µM |
| dbacp05281 | Pep27 anal5 | MWKWFHNVLSSGQLLADKWWAWWYNWW | Not found | Inducing apoptosis | MTT assay | MCF-7 | Breast cancer | IC50 : > 70 µM |
| dbacp05282 | Pep27anal1 | MWKWFHNVLSSWQLLADKRPARDYNRK | Pneumococcus | Apoptosis inducing | MTT/MTS assay | AML-2 | Leukemia cancer | IC50 : 50 µM |
| dbacp05283 | Pep27anal1 | MWKWFHNVLSSWQLLADKRPARDYNRK | Pneumococcus | Apoptosis inducing | MTT/MTS assay | HL-60 | Leukemia cancer | IC50 : 53 µM |
| dbacp05284 | Pep27anal1 | MWKWFHNVLSSWQLLADKRPARDYNRK | Pneumococcus | Apoptosis inducing | MTT/MTS assay | Jurkat | Blood cancer | IC50 : 47 µM |
| dbacp05285 | Pep27anal1 | MWKWFHNVLSSWQLLADKRPARDYNRK | Pneumococcus | Apoptosis inducing | MTT/MTS assay | SNU-601 | Gastric cancer | IC50 : 37 µM |
| dbacp05286 | Pep27anal1 | MWKWFHNVLSSWQLLADKRPARDYNRK | Pneumococcus | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 55 µM |
| dbacp05287 | Pep27anal2 | MWKWFHNVLSWWWLLADKRPARDYNRK | Pneumococcus | Apoptosis inducing | MTT/MTS assay | AML-2 | Leukemia cancer | IC50 : 29 µM |
| dbacp05288 | Pep27anal2 | MWKWFHNVLSWWWLLADKRPARDYNRK | Pneumococcus | Apoptosis inducing | MTT/MTS assay | HL-60 | Leukemia cancer | IC50 : 20 µM |
| dbacp05289 | Pep27anal2 | MWKWFHNVLSWWWLLADKRPARDYNRK | Pneumococcus | Apoptosis inducing | MTT/MTS assay | Jurkat | Blood cancer | IC50 : 23 µM |
| dbacp05290 | Pep27anal2 | MWKWFHNVLSWWWLLADKRPARDYNRK | Pneumococcus | Apoptosis inducing | MTT/MTS assay | SNU-601 | Gastric cancer | IC50 : 25 µM |
| dbacp05291 | Pep27anal2 | MWKWFHNVLSWWWLLADKRPARDYNRK | Pneumococcus | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : < 10 µM |
| dbacp05292 | Pep27anal3 | MRKWFHNVLSSGQLLADKWPAWDYNRK | Pneumococcus | Apoptosis inducing | MTT/MTS assay | AML-2 | Leukemia cancer | IC50 : 67 µM |
| dbacp05293 | Pep27anal3 | MRKWFHNVLSSGQLLADKWPAWDYNRK | Pneumococcus | Apoptosis inducing | MTT/MTS assay | HL-60 | Leukemia cancer | IC50 : 52 µM |
| dbacp05294 | Pep27anal3 | MRKWFHNVLSSGQLLADKWPAWDYNRK | Pneumococcus | Apoptosis inducing | MTT/MTS assay | Jurkat | Blood cancer | IC50 : 50 µM |
| dbacp05295 | Pep27anal3 | MRKWFHNVLSSGQLLADKWPAWDYNRK | Pneumococcus | Apoptosis inducing | MTT/MTS assay | SNU-601 | Gastric cancer | IC50 : 50 µM |
| dbacp05296 | Pep27anal3 | MRKWFHNVLSSGQLLADKWPAWDYNRK | Pneumococcus | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 38 µM |
| dbacp05297 | Pep27anal4 | MWKEFHNVLSSGQLLADKRWARWYNRW | Pneumococcus | Apoptosis inducing | MTT/MTS assay | AML-2 | Leukemia cancer | IC50 : 50 µM |
| dbacp05298 | Pep27anal4 | MWKEFHNVLSSGQLLADKRWARWYNRW | Pneumococcus | Apoptosis inducing | MTT/MTS assay | HL-60 | Leukemia cancer | IC50 : 51 µM |
| dbacp05299 | Pep27anal4 | MWKEFHNVLSSGQLLADKRWARWYNRW | Pneumococcus | Apoptosis inducing | MTT/MTS assay | Jurkat | Blood cancer | IC50 : 46 µM |
| dbacp05300 | Pep27anal4 | MWKEFHNVLSSGQLLADKRWARWYNRW | Pneumococcus | Apoptosis inducing | MTT/MTS assay | SNU-601 | Gastric cancer | IC50 : 37 µM |
| dbacp05301 | Pep27anal4 | MWKEFHNVLSSGQLLADKRWARWYNRW | Pneumococcus | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 29 µM |
| dbacp05302 | Pep27anal5 | MWKWFHNVLSSGQLLADKWWAWWYNWW | Pneumococcus | Apoptosis inducing | MTT/MTS assay | AML-2 | Leukemia cancer | IC50 : >70 µM |
| dbacp05303 | Pep27anal5 | MWKWFHNVLSSGQLLADKWWAWWYNWW | Pneumococcus | Apoptosis inducing | MTT/MTS assay | HL-60 | Leukemia cancer | IC50 : >70 µM |
| dbacp05304 | Pep27anal5 | MWKWFHNVLSSGQLLADKWWAWWYNWW | Pneumococcus | Apoptosis inducing | MTT/MTS assay | Jurkat | Blood cancer | IC50 : >70 µM |
| dbacp05305 | Pep27anal5 | MWKWFHNVLSSGQLLADKWWAWWYNWW | Pneumococcus | Apoptosis inducing | MTT/MTS assay | SNU-601 | Gastric cancer | IC50 : >70 µM |
| dbacp05306 | Pep27anal5 | MWKWFHNVLSSGQLLADKWWAWWYNWW | Pneumococcus | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : >70 µM |
| dbacp05371 | peptide containing the BH3 regions from Bad | NLWAAQRYGRELRRMSDEFEGSFKGL | BH3-only, Sensizers (BAD, HRK, Noxa) | Inducing apoptosis | Cell viability assay | FL5.12 | Not specified | Not found |
| dbacp05372 | peptide containing the BH3 regions from Bad(145-160) | QRYGRELRRMSDEFEG | BH3-only, Sensizers (BAD, HRK, Noxa) | Inducing apoptosis | Cell viability assay | FL5.12 | Not specified | Not found |
| dbacp05373 | peptide containing the BH3 regions from Bak(72-87) | GQVGRQLAIIGDDINR | Effectors (BAK, BAX) | Inducing apoptosis | Cell viability assay | FL5.12 | Not specified | Not found |
| dbacp05374 | peptide containing the BH3 regions from Bak(72-94) | GQVGRQLAIIGDDINRRYDSEFQ | Effectors (BAK, BAX) | Inducing apoptosis | Cell viability assay | FL5.12 | Not specified | Not found |
| dbacp05375 | peptide containing the BH3 regions from Bax(57-72) | KKLSECLKRIGDELDS | Effectors (BAK, BAX) | Inducing apoptosis | Cell viability assay | FL5.12 | Not specified | Not found |
| dbacp05376 | peptide containing the BH3 regions from Bid | RNIARHLAQVGDSMDR | BH3-only, Direct activators (PUMA, Bid) | Inducing apoptosis | Agarose gel electrophoresis assay | Not found | Not specified | Not found |
| dbacp05400 | Peptide from Lentinus Squarrosulus | RYGFTEVAGNFQQHNFGRG | Plant sources | Inducing apoptosis | MTT assay | H460 | Breast cancer | Not found |
| dbacp05401 | Peptide from Lentinus Squarrosulus | RYGFTEVAGNFQQHNFGRG | Plant sources | Inducing apoptosis | MTT assay | DPCs | Breast cancer | Not found |
| dbacp05402 | Peptide from Lentinus Squarrosulus | RYGFTEVAGNFQQHNFGRG | Plant sources | Inducing apoptosis | MTT assay | HK-2 | Breast cancer | Not found |
| dbacp05403 | Peptide Glycyrrhetinic Acid Based Derivatives (compound 5) | GGGG | Not found | Inducing apoptosis | Not specified | MCF-7 | Cervical cancer | IC50 : 5.0 ± 0.3 µg/mL |
| dbacp05404 | Peptide Glycyrrhetinic Acid Based Derivatives (compound 5) | GGGG | Not found | Inducing apoptosis | Not specified | HCT116 | Cervical cancer | IC50 : 5.2 ± 0.8 µg/mL |
| dbacp05438 | Peptide-20 | CSSRTMHHC | Synthetic Peptide | Inducing apoptosis | MTT/MTS assay | HL-60 | Leukemia cancer | At 100 µM 90% viablity |
| dbacp05439 | Peptide-20 | CSSRTMHHC | Synthetic Peptide | Inducing apoptosis | MTT/MTS assay | MDA-MB-231 | Breast cancer | At 100 µM 55% viablity |
| dbacp05440 | Peptide-20 | CSSRTMHHC | Synthetic Peptide | Inducing apoptosis | MTT/MTS assay | HeLa | Cervical cancer | At 100 µM 50% viablity |
| dbacp05441 | Peptide-20 | CSSRTMHHC | Synthetic Peptide | Inducing apoptosis | MTT/MTS assay | B16F10-Nex 2 | Skin cancer | At 100 µM 50% viablity |
| dbacp05442 | Peptide-20 | CSSRTMHHC | Synthetic Peptide | Inducing apoptosis | MTT/MTS assay | A-2058 | Skin cancer | At100 µM 30% viablity |
| dbacp05443 | Peptide-20 | CSSRTMHHC | Synthetic Peptide | Inducing apoptosis | MTT/MTS assay | Skmel-25 | Skin cancer | At 100 µM 55 - 60% viablity |
| dbacp05444 | Peptide-20 | CSSRTMHHC | Synthetic Peptide | Inducing apoptosis | MTT/MTS assay | Skmel-28 | Skin cancer | At 100 µM 35 - 40% viablity |
| dbacp05462 | Peptidoglycan recognition protein 1 | MLFAWAPFPALLGLADSCCFVVPRSEWKALPSECSKGLKKPVRYVVISHTAGSFCSSPDSCEQQARNVQLYQMKQLGWCDVAYNFLIGEDGHVYEGRGWTIKGDHTGPIWNPMSIGITFMGDYSHRVPAKRALRAALNLLKCGVSEGFLRSNYEVKGHRDVQSTLSPGDQLYEIIQSWDHYRE | Rat | Apoptosis inducing | Not specified | L929 | Not found | Not found |
| dbacp05463 | Peptidoglycan recognition protein 1 | MSRRSMLLAWALPSLLRLGAAQETEDPACCSPIVPRNEWKALASECAQHLSLPLRYVVVSHTAGSSCNTPASCQQQARNVQHYHMKTLGWCDVGYNFLIGEDGLVYEGRGWNFTGAHSGHLWNPMSIGISFMGNYMDRVPTPQAIRAAQGLLACGVAQGALRSNYVLKGHRDVQRTLSPGNQLYHLIQNWPHYRSP | Human | Apoptosis inducing; Necrotic cell death | Enzyme inhibition assay | K562 | Not specified | Not found |
| dbacp05464 | Peptidoglycan recognition protein 1 | MSRRSMLLAWALPSLLRLGAAQETEDPACCSPIVPRNEWKALASECAQHLSLPLRYVVVSHTAGSSCNTPASCQQQARNVQHYHMKTLGWCDVGYNFLIGEDGLVYEGRGWNFTGAHSGHLWNPMSIGISFMGNYMDRVPTPQAIRAAQGLLACGVAQGALRSNYVLKGHRDVQRTLSPGNQLYHLIQNWPHYRSP | Human | Apoptosis inducing; Necrotic cell death | Enzyme inhibition assay | Molt4 | Not specified | Not found |
| dbacp05465 | Peptidoglycan recognition protein 1 | MSRRSMLLAWALPSLLRLGAAQETEDPACCSPIVPRNEWKALASECAQHLSLPLRYVVVSHTAGSSCNTPASCQQQARNVQHYHMKTLGWCDVGYNFLIGEDGLVYEGRGWNFTGAHSGHLWNPMSIGISFMGNYMDRVPTPQAIRAAQGLLACGVAQGALRSNYVLKGHRDVQRTLSPGNQLYHLIQNWPHYRSP | Human | Apoptosis inducing; Necrotic cell death | Enzyme inhibition assay | HeLa | Not specified | Not found |
| dbacp05466 | Peptidoglycan recognition protein 1 | MSRRSMLLAWALPSLLRLGAAQETEDPACCSPIVPRNEWKALASECAQHLSLPLRYVVVSHTAGSSCNTPASCQQQARNVQHYHMKTLGWCDVGYNFLIGEDGLVYEGRGWNFTGAHSGHLWNPMSIGISFMGNYMDRVPTPQAIRAAQGLLACGVAQGALRSNYVLKGHRDVQRTLSPGNQLYHLIQNWPHYRSP | Human | Apoptosis inducing; Necrotic cell death | Enzyme inhibition assay | L929 | Not specified | Not found |
| dbacp05467 | Peptidoglycan recognition protein 1 | MLFACALLALLGLATSCSFIVPRSEWRALPSECSSRLGHPVRYVVISHTAGSFCNSPDSCEQQARNVQHYHKNELGWCDVAYNFLIGEDGHVYEGRGWNIKGDHTGPIWNPMSIGITFMGNFMDRVPAKRALRAALNLLECGVSRGFLRSNYEVKGHRDVQSTLSPGDQLYQVIQSWEHYRE | Mouse | Necrosis; Apoptosis | Cytotoxicity assay | VMR-0 | Mammary adenocarcinoma | Not found |
| dbacp05468 | Peptidoglycan recognition protein 1 | MLFACALLALLGLATSCSFIVPRSEWRALPSECSSRLGHPVRYVVISHTAGSFCNSPDSCEQQARNVQHYHKNELGWCDVAYNFLIGEDGHVYEGRGWNIKGDHTGPIWNPMSIGITFMGNFMDRVPAKRALRAALNLLECGVSRGFLRSNYEVKGHRDVQSTLSPGDQLYQVIQSWEHYRE | Mouse | Necrosis; Apoptosis | Cytotoxicity assay | VMR-L | Mammary adenocarcinoma | Not found |
| dbacp05469 | Peptidoglycan recognition protein 1 | MLFACALLALLGLATSCSFIVPRSEWRALPSECSSRLGHPVRYVVISHTAGSFCNSPDSCEQQARNVQHYHKNELGWCDVAYNFLIGEDGHVYEGRGWNIKGDHTGPIWNPMSIGITFMGNFMDRVPAKRALRAALNLLECGVSRGFLRSNYEVKGHRDVQSTLSPGDQLYQVIQSWEHYRE | Mouse | Necrosis; Apoptosis | Cytotoxicity assay | CSML-0 | Mammary adenocarcinoma | Not found |
| dbacp05470 | Peptidoglycan recognition protein 1 | MLFACALLALLGLATSCSFIVPRSEWRALPSECSSRLGHPVRYVVISHTAGSFCNSPDSCEQQARNVQHYHKNELGWCDVAYNFLIGEDGHVYEGRGWNIKGDHTGPIWNPMSIGITFMGNFMDRVPAKRALRAALNLLECGVSRGFLRSNYEVKGHRDVQSTLSPGDQLYQVIQSWEHYRE | Mouse | Necrosis; Apoptosis | Cytotoxicity assay | CSML-100 | Mammary adenocarcinoma | Not found |
| dbacp05488 | Pexiganan MSI-78 | GIGKFLKKAKKFGKAFVKILKK | Analog of African clawed frog | Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis | MTT/MTS assay | U-941 | Lymphoma cancer | IC50 : 20-30 µg/ml |
| dbacp05490 | PFL-N-Ter-TAT | FPWWWPFLRDVFTKGYGFGLGRKKRRQRRRPQ | VDAC1 | Inducing apoptosis | SRB assay | A375 | Human endometrial cancer | IC50 : 5.5 ± 1.1 μM |
| dbacp05502 | PHP | ITCPQVTQSLAPCVPYLISG | Plant sources | Inducing apoptosis | MTT assay | Eca-109 | Not found | IC50 : 0.7 µM |
| dbacp05503 | PHP | ITCPQVTQSLAPCVPYLISG | Plant sources | Inducing apoptosis | MTT assay | HeLa | Not found | IC50 : 2.74 µM |
| dbacp05504 | PHP | ITCPQVTQSLAPCVPYLISG | Plant sources | Inducing apoptosis | MTT assay | MGC-7 | Not found | IC50 : 3.13 µM |
| dbacp05505 | PHP | ITCPQVTQSLAPCVPYLISG | Plant sources | Inducing apoptosis | MTT assay | B16 | Not found | IC50 : 1.47 µM |
| dbacp05506 | Phthiocerol/phthiodiolone dimycocerosyl transferase (EC 2.3.1.282) (Acyltransferase PapA5) (Phthiocerol/phthiodiolone O-acyltransferase) (Polyketide synthase-associated protein A5) | MALQRRHPLLRAKIVAGTPPRFTSQGVPPIALEVVERKAEESWQQHVEAELDRPFNSDPGPLVRFILVRGEHRSELLCSYDHLIGDAHSGIFALRDLLQVMASQDQHLPELAPRPAYEELIGPMVPGTRLLGAAVRRGSSALLRLSPTLNTLTERLVAPRGMARSSAEGQALYSHRILEPEQLARLLARCREQGSSVHAALGAALLIARAESQGAKKRVTLTLTSALDARERFGVGEDFGLFTTGKTDFFRARGSTPFWELAHRLRSPLQAARKKRSHLRLFRLILEISALTVDISSQPWMERATRLGLHSMLALSNVGRVEIAARYGNLTLEGLGFTGTTAAQFDVVLTAITFAQRLEASFLFNTAHMQREQVEQLASRTWELLAEATR | Aeromonads | Apoptosis; Cell nucleus fragmentation | Toxicity assay, Cell nucleus fragmentation assay(cnf) | L929 | Not specified | MIC : 50 ng/ml |
| dbacp05565 | piscidin-1 | FFHHIFRGIVHVGKTIHRLVTG | Striped bass fish | Apoptosis inducing; Elevation of ROS | MTT/MTS assay | SCC4 | Oral squamous cell carcinoma | IC50 : 10.82 – 13.77 μM |
| dbacp05566 | piscidin-1 | FFHHIFRGIVHVGKTIHRLVTG | Striped bass fish | Inhibits angiogenesis; Apoptosis inducing; Elevation of ROS | MTT/MTS assay | OC2 | Oral cancer | IC50 : 16.94 – 19.20 μM |
| dbacp05567 | Piscidin-1 | FFHHIFRGIVHVGKTIHRLVTG | Striped bass x White bass | Induce apoptosis; Necrotic activity | MTS assay and soft-agar colony-formation assay | HT1080 | Not specified | MIC : 20 μg/ml |
| dbacp05568 | Piscidin-1 | FFHHIFRGIVHVGKTIHRLVTG | Striped bass x White bass | Induce apoptosis; Necrotic activity | MTS assay and soft-agar colony-formation assay | HeLa | Not specified | MIC : 25 μg/ml |
| dbacp05576 | Pleurocidin | GWGSFFKKAAHVGKHVGKAALTHYL | Winter flounder | Apoptosis inducing; Anti-proliferative activity | MTT assay | J5 | Hepatocellular carcinoma | IC50 : 54.9 µM |
| dbacp05577 | Pleurocidin | GWGSFFKKAAHVGKHVGKAALTHYL | Winter flounder | Apoptosis inducing; Anti-proliferative activity | MTT assay | Hep3B | Hepatocellular carcinoma | IC50 : 340.9 µM |
| dbacp05578 | Pleurocidin | GWGSFFKKAAHVGKHVGKAALTHYL | Winter flounder | Apoptosis inducing; Anti-proliferative activity | MTT assay | A549 | Non-small cell lung adenocarcinoma | IC50 : 300.8 µM |
| dbacp05579 | Pleurocidin | GWGSFFKKAAHVGKHVGKAALTHYL | Winter flounder | Apoptosis inducing; Anti-proliferative activity | MTT assay | AGS | Stomach adenocarcinoma | IC50 : 186.5 µM |
| dbacp05580 | Pleurocidin-a | GWGSFFKKAAHVGKHVGKAALTHYL-NH2 | Winter flounder | Apoptosis inducing; Anti-proliferative activity | MTT assay | J5 | Hepatocellular carcinoma | IC50 :1 1 µM |
| dbacp05581 | Pleurocidin-a | GWGSFFKKAAHVGKHVGKAALTHYL-NH3 | Winter flounder | Apoptosis inducing; Anti-proliferative activity | MTT assay | Huh7 | Hepatocellular carcinoma | IC50 : 60 µM |
| dbacp05582 | Pleurocidin-a | GWGSFFKKAAHVGKHVGKAALTHYL-NH4 | Winter flounder | Apoptosis inducing; Anti-proliferative activity | MTT assay | Hep3B | Hepatocellular carcinoma | IC50 : 77.5 µM |
| dbacp05583 | Pleurocidin-a | GWGSFFKKAAHVGKHVGKAALTHYL-NH5 | Winter flounder | Apoptosis inducing; Anti-proliferative activity | MTT assay | A549 | Non-small cell lung adenocarcinoma | IC50 : 42.1 µM |
| dbacp05584 | Pleurocidin-a | GWGSFFKKAAHVGKHVGKAALTHYL-NH6 | Winter flounder | Apoptosis inducing; Anti-proliferative activity | MTT assay | AGS | Stomach adenocarcinoma | IC50 : 29.8 µM |
| dbacp05585 | Pleurocidin-a | GWGSFFKKAAHVGKHVGKAALTHYL-NH7 | Winter flounder | Apoptosis inducing; Anti-proliferative activity | MTT assay | WiDr | Colon adenocarcinoma | IC50 : 197.3 µM |
| dbacp05586 | Pleurocidin-a | GWGSFFKKAAHVGKHVGKAALTHYL-NH8 | Winter flounder | Apoptosis inducing; Anti-proliferative activity | MTT assay | NIH-3T3 | Mouse fibroblast | IC50 : 313 µM |
| dbacp05626 | Precursor C-1 | CRRRRFΦECΔDPPLHSpTA | Not found | Inducing apoptosis | Not specified | HeLa | Not specified | Not found |
| dbacp05649 | Protegrin 1 | RGGRLCYCRRRFCVCVGR | Alpha helical peptide without cysteines | Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis | MTT/MTS assay | U-942 | Lymphoma cancer | IC50 : 30-40 µg/ml |
| dbacp05674 | Protein S100-A8 | MLTELEKALNSIIDVYHKYSLIKGNFHAVYRDDLKKLLETECPQYIRKKGADVWFKELDINTDGAVNFQEFLILVIKMGVAAHKKSHEESHKE | Human | Apoptosis inducing | MTT/MTS assay | MM46 | Breast cancer | IC50 : 10 µM |
| dbacp05684 | Pseudosubstrate Peptides Inhibit Akt | FEPRARERTYAFGH | Human FOXO3, AKTide-2T | Inducing apoptosis | Not specified | HeLa | Not specified | Not found |
| dbacp05685 | Pseudosubstrate Peptides Inhibit Akt | DPEFEPRARERTYAFGH | Human FOXO3, AKTide-2T | Inducing apoptosis | Not specified | HeLa | Not specified | Not found |
| dbacp05686 | Pseudosubstrate Peptides Inhibit Akt | VELDPEFEPRARERTYAFGH | Human FOXO3, AKTide-2T | Inducing apoptosis | Not specified | HeLa | Not specified | Not found |
| dbacp05687 | Pseudosubstrate Peptides Inhibit Akt | VELDPEFEPRARERTYSFGH | Human FOXO3, AKTide-2T | Inducing apoptosis | Not specified | HeLa | Not specified | Not found |
| dbacp05688 | Pseudosubstrate Peptides Inhibit Akt | VELDPEFEPRARERDYAFGH | Human FOXO3, AKTide-2T | Inducing apoptosis | Akt kinase | HeLa | Not specified | Not found |
| dbacp05689 | Pseudosubstrate Peptides Inhibit Akt | VELDPEFEPRARERAYAFGH | Human FOXO3, AKTide-2T | Inducing apoptosis | Akt kinase | HeLa | Not specified | Not found |
| dbacp05690 | Pseudosubstrate Peptides Inhibit Akt | ERTYAFGH | Human FOXO3, AKTide-2T | Inducing apoptosis | Not specified | HeLa | Not specified | Not found |
| dbacp05691 | Pseudosubstrate Peptides Inhibit Akt | RARERTYAFGH | Human FOXO3, AKTide-2T | Inducing apoptosis | Not specified | HeLa | Not specified | Not found |
| dbacp05692 | Pseudosubstrate Peptides Inhibit Akt | VELDPEFEPRARERTYAFGH | Human FOXO3, AKTide-2T | Inducing apoptosis | Not specified | HeLa | Not specified | Not found |
| dbacp05693 | Pseudosubstrate Peptides Inhibit Akt ) | VELDPEFEPRARERTYDFGH | Human FOXO3, AKTide-2T | Inducing apoptosis | Akt kinase | HeLa | Not specified | Not found |
| dbacp05708 | PTP1 | LLAGLAANFLPTIICKISYKC | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | A-549 | Lung cancer | IC50 : >100 µg/ml |
| dbacp05709 | PTP1 | LLAGLAANFLPTIICKISYKC | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | HEK294 | Renal cancer | IC50 : >100 µg/ml |
| dbacp05710 | PTP1 | LLAGLAANFLPTIICKISYKC | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | HEK302 | Renal cancer | IC50 : >100 µg/ml |
| dbacp05711 | PTP1 | LLAGLAANFLPTIICKISYKC | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | Hep3B | Liver cancer | IC50 : >100 µg/ml |
| dbacp05712 | PTP1 | LLAGLAANFLPTIICKISYKC | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : >100 µg/ml |
| dbacp05713 | PTP2 | FAGLAANFLPTIICKISYKC | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | A-549 | Lung cancer | IC50 : >100 µg/ml |
| dbacp05714 | PTP2 | FAGLAANFLPTIICKISYKC | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | HEK295 | Renal cancer | IC50 : >100 µg/ml |
| dbacp05715 | PTP2 | FAGLAANFLPTIICKISYKC | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | HEK303 | Renal cancer | IC50 : >100 µg/ml |
| dbacp05716 | PTP2 | FAGLAANFLPTIICKISYKC | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | Hep3B | Liver cancer | IC50 : >100 µg/ml |
| dbacp05717 | PTP2 | FAGLAANFLPTIICKISYKC | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : >100 µg/ml |
| dbacp05718 | PTP4 | FLKLLKKLAAKFLPTIICKISYKC | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | A-549 | Lung cancer | IC50 : 13.71 µg/ml |
| dbacp05719 | PTP4 | FLKLLKKLAAKFLPTIICKISYKC | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | HEK296 | Renal cancer | IC50 : 26.15 µg/ml |
| dbacp05720 | PTP4 | FLKLLKKLAAKFLPTIICKISYKC | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 18.63 µg/ml |
| dbacp05721 | PTP4 | FLKLLKKLAAKFLPTIICKISYKC | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | Hep3B | Liver cancer | IC50 : 18.18 µg/ml |
| dbacp05722 | PTP4 | FLKLLKKLAAKFLPTIICKISYKC | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 18.1 µg/ml |
| dbacp05723 | PTP5 | FLKLLKKLAAKLF | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | A-549 | Lung cancer | IC50 : 9.09 µg/ml |
| dbacp05724 | PTP5 | FLKLLKKLAAKLF | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | HEK297 | Renal cancer | IC50 : 15.11 µg/ml |
| dbacp05725 | PTP5 | FLKLLKKLAAKLF | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | PC-3 | Prostate cancer | Not found |
| dbacp05726 | PTP5 | FLKLLKKLAAKLF | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | Hep3B | Liver cancer | Not found |
| dbacp05727 | PTP5 | FLKLLKKLAAKLF | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 5.43 µg/ml |
| dbacp05728 | PTP6 | FLKLLKKLAAKLF | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | A-549 | Lung cancer | IC50 : 13.94 µg/ml |
| dbacp05729 | PTP6 | FLKLLKKLAAKLF | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | HEK298 | Renal cancer | IC50 : 14 µg/ml |
| dbacp05730 | PTP6 | FLKLLKKLAAKLF | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 13.27 µg/ml |
| dbacp05731 | PTP6 | FLKLLKKLAAKLF | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | Hep3B | Liver cancer | IC50 : 15.07 µg/ml |
| dbacp05732 | PTP6 | FLKLLKKLAAKLF | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 17.56 µg/ml |
| dbacp05733 | PTP7 | FLGALFKALSKLL | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | A-549 | Lung cancer | IC50 : 8.01 µg/ml |
| dbacp05734 | PTP7 | FLGALFKALSKLL | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | HEK299 | Renal cancer | IC50 : 6.71 µg/ml |
| dbacp05735 | PTP7 | FLGALFKALSKLL | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 5.01 µg/ml |
| dbacp05736 | PTP7 | FLGALFKALSKLL | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | Hep3B | Liver cancer | IC50 : 5.4 µg/ml |
| dbacp05737 | PTP7 | FLGALFKALSKLL | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 5.25 µg/ml |
| dbacp05738 | PTP8 | FLKLLAGLLKNFA | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | A-549 | Lung cancer | IC50 : 24.58 µg/ml |
| dbacp05739 | PTP8 | FLKLLAGLLKNFA | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | HEK300 | Renal cancer | IC50 : 26.8 µg/ml |
| dbacp05740 | PTP8 | FLKLLAGLLKNFA | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 28.9 µg/ml |
| dbacp05741 | PTP8 | FLKLLAGLLKNFA | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | Hep3B | Liver cancer | IC50 : 30.79 µg/ml |
| dbacp05742 | PTP8 | FLKLLAGLLKNFA | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 32.23 µg/ml |
| dbacp05743 | PTPRJ-pep19 | CHHNLTHAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 4.5 ± 0.1.4% cell growth inhibition at 160 µM |
| dbacp05744 | PTPRJ-pep19 | CHHNLTHAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 19 ± 2.82% cell growth inhibition at 160 µM |
| dbacp05745 | PTPRJ-pep19.0 | CHHNLTHAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 4 ± 1.4% cell growth inhibition at 160 µM |
| dbacp05746 | PTPRJ-pep19.2 | CAHNLTHAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 16.5 ± 2.12% cell growth inhibition at 160 µM |
| dbacp05747 | PTPRJ-pep19.2 | CAHNLTHAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 30 ± 2.82% cell growth inhibition at 160 µM |
| dbacp05748 | PTPRJ-pep19.2 | CAHNLTHAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 32.0 ± 4.2% cell growth inhibition at 160 µM |
| dbacp05749 | PTPRJ-pep19.3 | CHANLTHAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 28 ± 5.5% cell growth inhibition at 160 µM |
| dbacp05750 | PTPRJ-pep19.3 | CHANLTHAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 46 ± 4.2% cell growth inhibition at 160 µM |
| dbacp05751 | PTPRJ-pep19.3 | CHANLTHAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 51 ± 1.4% cell growth inhibition at 160 µM |
| dbacp05752 | PTPRJ-pep19.4 | CHHALTHAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 48.0 ± 2.82% cell growth inhibition at 160 µM |
| dbacp05753 | PTPRJ-pep19.4 | CHHALTHAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 62.5 ± 4.9% cell growth inhibition at 160 µM |
| dbacp05754 | PTPRJ-pep19.4 | CHHALTHAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 66.5 ± 2.12% cell growth inhibition at 160 µM |
| dbacp05755 | PTPRJ-pep19.5 | CHHNATHAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 2 ± 1.5% cell growth inhibition at 160 µM |
| dbacp05756 | PTPRJ-pep19.5 | CHHNATHAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 19 ± 4.2% cell growth inhibition at 160 µM |
| dbacp05757 | PTPRJ-pep19.6 | CHHNLAHAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 19 ± 4.2% cell growth inhibition at 160 µM |
| dbacp05758 | PTPRJ-pep19.7 | CHHNLTAAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 4.5 ± 2.13% cell growth inhibition at 160 µM |
| dbacp05759 | PTPRJ-pep19.7 | CHHNLTAAC | PTPRJ agonist peptides | Cell growth inhibition and apoptosis | Trypan blue assay | HeLa | Cervical cancer | 20 ± 1.4% cell growth inhibition at 160 µM |
| dbacp05760 | PUMA BH3 | EQWAREIGAQLRRMADDLNA | BH3-only, Direct activators (PUMA, Bid) | Inducing apoptosis | Not specified | Not found | Not specified | Not found |
| dbacp05761 | PUMA BH3 | LRRMADDLN | BH3-only, Direct activators (PUMA, Bid) | Inducing apoptosis | Not specified | MDA-MB-231 | Colon cancer | Not found |
| dbacp05762 | PUMA BH4 | LRRMADDLN | BH3-only, Direct activators (PUMA, Bid) | Inducing apoptosis | Not specified | HCT116p53–/– | Colon cancer | Not found |
| dbacp05763 | PUMA BH5 | LRRMADDLN | BH3-only, Direct activators (PUMA, Bid) | Inducing apoptosis | Not specified | HCT116p53+/+ | Colon cancer | Not found |
| dbacp05764 | PUMA BH6 | LRRMADDLN | BH3-only, Direct activators (PUMA, Bid) | Inducing apoptosis | Not specified | GLC-82 | Colon cancer | Not found |
| dbacp05765 | PUMA BH7 | LRRMADDLN | BH3-only, Direct activators (PUMA, Bid) | Inducing apoptosis | Not specified | SGC-7901 | Colon cancer | Not found |
| dbacp05766 | PUMA BH8 | LRRMADDLN | BH3-only, Direct activators (PUMA, Bid) | Inducing apoptosis | Not specified | HEK293 | Colon cancer | Not found |
| dbacp05767 | PUMA BH9 | LRRMADDLN | BH3-only, Direct activators (PUMA, Bid) | Inducing apoptosis | Not specified | 2BS | Colon cancer | Not found |
| dbacp05781 | Putative nonribosomal peptide synthetase P4-B4-NRPS | DAWRFLWSYHHAVVDGWSVPLILKQVLGRYAELGAGEAAPLPGSRFLPFVNWLAARDAREQAEYWKQVLEGIEEPTPIGFASPARGPQAQGQGRRAFVFDAALREQVDRAARRAGVTRASLLTGAWALTLGYAGGGRDVVFGTTLSGRPATLPGVERMVGLFINTVPVRVGMDDDASVSQWLRQLHEQQSERARLGAASLTDIQRWAGYEGGELLSSLFVVENYPVDRTLARGDAGFDVSEFAAAETRTNYPLVGQLIPGEETVLYVDFDASRYDEESIGRLGASFMHLLSQLAAQPDARLGDLTLVDDDEARRLIHDWNATPPVGEGYLLHASIERHAELTPLAPAIIGVDEAMNYRELADETLRTARAVAAAGAKREPVAVLLPRSARAVAAYSGVMRAGCAYVPADPAMPPGRLRDLLATVGYVLTTREHLPMLDGVAARAILIDETPPADVALPDAAPDDLAYVMFTSGSTGKPKGVMITHRAASLTIEVFLRRYEIGASDRLMCVSAAGFDLSVFDFFGAFAAGAAVLLAPESSTIAPAVWLELMTREGATVWESVPAVMELLLLECRQSGRALPPSLKLAMLSGDRVPVGLPAQIRAAATSDPEVLALGGATEGAIWSCWYDTRELASDAAFVPYGRHLPGQRLYVLSSSLQAVPVGVPGDLWIAGAGVALGYLGQPDLTAYRFVDNPFVPGERMYRTGDRARVLADGNLEFLGRVDDQVKIGGFRIEIGEIEAALAAAPGVERGVASVVERDGRRIIAGYVLLLPGASLDLAAVRDALARRLPPYMLPASIMALDSLPLSANGKVDRKRLPDPVVETGAAAAETEAEAALVEIWQGLLGLERVGVRDNFFALGGDSILSIQMASRAAERGLRLSPQQVFRYPTIAELAAEGCAAEEAGAQAEQGEVVGEVRPGPIQAWYLDWPGTDWEQFNQGAYLGLDGVVDAESLIGALQAVAQRHDALRIGWRRDGERWIQASGAGEPVEVKAVDLRGLADAEAALERDAAALQSSLRLGGASLWAARLYRLDEGWRLLWLAHHASVDGVSWRILLEDLWRAYAALSRGEAAAWPAKTVSYQAWSQRLWEWAETLPDSTLSYWREMDAPGMPLPGFNAAEDTVAAESRVSLQWEPETTERWLRQAGEAYRMRPEELLVTALARALRQWTGAKECVLDLEGHGRDGLAGVDVSRTVGWFTSLYPL | Gram-negative bacillus | Inducing apoptosis | GFP assay | NIH 3T3 | Cutaneous T-cell lymphoma | Not found |
| dbacp05782 | Putative nonribosomal peptide synthetase P4-G7-NRPS | MTMARLMTDLADAGVTLRRRGDQLQVQAPQGALDAALVARLREAKEELLRVLDDEGARAAPLAPAQPGEAGDAAALSPGQARLVAATRLGDPAMYNEQAAIELADAVDAEAVARAFAALARRHDILRTVFSDGEPVRQTVLPEPIVTLQAWTVDGDDALRARAADLARLPFAAGAPMWRVDLFSTPERAAVLVLTIHHAIFDRWSMSVLIRDFSAYLALPDAAEAPASGLSYRDYSAWQRRWMASPDYAAQLDAWVDDLAEVDEVPAIRGDRPRPPAMSGRGGTERFEIPADCMDAAAAFSRSRNTTLFTTLFSAFALLQHRYTGEARALTLTPAANRPFQAAEEIAGYFVNLVALATEVGEGDSFGALVDRARDASARAFARQGVPLDAIVERLRARGGPRHEQFAQTVFAFQNVRLPAVRTASGAAVPFDLDSPFARFDLYLSIEGDERGTFAVWQYNTDLYEAATIRQLGEHYLALLRAALASPDADARALPILSAEEEARLRGWGRHELPYRADAAIDRLFRERAADHPGRVALEQGGVRWTYAELDQWSDRAAGALRAAGVEAGAVVGVAGERSPRLLAAFLAVLKAGAAYLPLDPTYPAARLRAMTADAAPALMIIADGLDAGWLGDYAGPVLSLADCEAGVARPLQSEARPAEAESL | Gram-negative bacillus | Inducing apoptosis | GFP assay | NIH 3T3 | Cutaneous T-cell lymphoma | Not found |
| dbacp05793 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | H157 | Lung cancer | IC50 : 843.40 µM |
| dbacp05794 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | H157 | Prostate cancer | IC50 : 843.40 µM |
| dbacp05795 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | H157 | Breast cancer | IC50 : 843.40 µM |
| dbacp05796 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | H157 | Lung cancer | IC50 : 843.40 µM |
| dbacp05797 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | H157 | Prostate cancer | IC50 : 843.40 µM |
| dbacp05798 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | H157 | Breast cancer | IC50 : 843.40 µM |
| dbacp05799 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | H157 | Glioma | IC50 : 843.40 µM |
| dbacp05800 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | MBD-MB-435s | Lung cancer | IC50 : 872.70 µM |
| dbacp05801 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | MBD-MB-435s | Prostate cancer | IC50 : 872.70 µM |
| dbacp05802 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | MBD-MB-435s | Breast cancer | IC50 : 872.70 µM |
| dbacp05803 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | MBD-MB-435s | Glioma | IC50 : 872.70 µM |
| dbacp05804 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | PC-3 | Lung cancer | IC50 : 283.90 µM |
| dbacp05805 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | PC-3 | Prostate cancer | IC50 : 283.90 µM |
| dbacp05806 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | PC-3 | Breast cancer | IC50 : 283.90 µM |
| dbacp05807 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | PC-3 | Glioma | IC50 : 283.90 µM |
| dbacp05808 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | U251-MG | Lung cancer | IC50 : 104.10 µM |
| dbacp05809 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | U251-MG | Prostate cancer | IC50 : 104.10 µM |
| dbacp05810 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | U251-MG | Breast cancer | IC50 : 104.10 µM |
| dbacp05811 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | U251-MG | Glioma | IC50 : 104.10 µM |
| dbacp05812 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | MCF-7 | Lung cancer | IC50 : 109.30 µM |
| dbacp05813 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | MCF-7 | Prostate cancer | IC50 : 109.30 µM |
| dbacp05814 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | MCF-7 | Breast cancer | IC50 : 109.30 µM |
| dbacp05815 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | MCF-7 | Glioma | IC50 : 109.30 µM |
| dbacp05816 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | HMEC-1 | Lung cancer | IC50 : 588.20 µM |
| dbacp05817 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | HMEC-1 | Prostate cancer | IC50 : 588.20 µM |
| dbacp05818 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | HMEC-1 | Breast cancer | IC50 : 588.20 µM |
| dbacp05819 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | HMEC-1 | Glioma | IC50 : 588.20 µM |
| dbacp05822 | R8-BAD | RRRRRRRRGCNLWAAQRYGRELRRMSDEFVD | BH3-only, Sensizers (BAD, HRK, Noxa) | Inducing apoptosis | Not specified | HNSCC 1483 | Head and neck squamous cell carcinomas (HNSCC) | Not found |
| dbacp05823 | R8-BAD | RRRRRRRRGCNLWAAQRYGRELRRMSDEFVD | BH3-only, Sensizers (BAD, HRK, Noxa) | Inducing apoptosis | Not specified | UM-22A | Head and neck squamous cell carcinomas (HNSCC) | Not found |
| dbacp05824 | R8-BAD | RRRRRRRRGCNLWAAQRYGRELRRMSDEFVD | BH3-only, Sensizers (BAD, HRK, Noxa) | Inducing apoptosis | Not specified | UM-22B | Head and neck squamous cell carcinomas (HNSCC) | Not found |
| dbacp05825 | R8-BadBH3 | rrrrrrrrGNLWAAQRYGRELRRMSDEFVDSFKK | Synthetic Peptide | Inducing mitochondrial apoptosis | MTT/MTS assay | SK-N-AS | Brain tumor | 0% apoptosis at 10 µM |
| dbacp05826 | R8-BadBH3 | rrrrrrrrGNLWAAQRYGRELRRMSDEFVDSFKK | Synthetic Peptide | Inducing mitochondrial apoptosis | MTT/MTS assay | SK-N-AS | Brain tumor | 10% apoptosis at 20 µM |
| dbacp05827 | R8-BadBH3 | rrrrrrrrGNLWAAQRYGRELRRMSDEFVDSFKK | Synthetic Peptide | Inducing mitochondrial apoptosis | MTT/MTS assay | SK-N-AS | Brain tumor | 30% apoptosis at 50 µM |
| dbacp05828 | R8-BadBH3 | rrrrrrrrGNLWAAQRYGRELRRMSDEFVDSFKK | Synthetic Peptide | Inducing mitochondrial apoptosis | MTT/MTS assay | NB69 | Brain tumor | 30% apoptosis at 10 µM |
| dbacp05829 | R8-BadBH3 | rrrrrrrrGNLWAAQRYGRELRRMSDEFVDSFKK | Synthetic Peptide | Inducing mitochondrial apoptosis | MTT/MTS assay | NB69 | Brain tumor | 80% apoptosis at 20 µM |
| dbacp05830 | R8-BadBH3 | rrrrrrrrGNLWAAQRYGRELRRMSDEFVDSFKK | Synthetic Peptide | Inducing mitochondrial apoptosis | MTT/MTS assay | NB69 | Brain tumor | 80% apoptosis at 50 µM |
| dbacp05831 | R8-BadBH3 | rrrrrrrrGNLWAAQRYGRELRRMSDEFVDSFKK | Synthetic Peptide | Inducing mitochondrial apoptosis | MTT/MTS assay | NGP | Tumor | 20% apoptosis at 10 µM |
| dbacp05832 | R8-BadBH3 | rrrrrrrrGNLWAAQRYGRELRRMSDEFVDSFKK | Synthetic Peptide | Inducing mitochondrial apoptosis | MTT/MTS assay | NGP | Tumor | > 50% apoptosis at 20 µM |
| dbacp05833 | R8-BadBH3 | rrrrrrrrGNLWAAQRYGRELRRMSDEFVDSFKK | Synthetic Peptide | Inducing mitochondrial apoptosis | MTT/MTS assay | NGP | Tumor | 30% apoptosis at 50 µM |
| dbacp05834 | R8-BadBH3 | rrrrrrrrGNLWAAQRYGRELRRMSDEFVDSFKK | Synthetic Peptide | Inducing mitochondrial apoptosis | MTT/MTS assay | IMR5 | Tumor | 15% apoptosis at 10 µM |
| dbacp05835 | R8-BadBH3 | rrrrrrrrGNLWAAQRYGRELRRMSDEFVDSFKK | Synthetic Peptide | Inducing mitochondrial apoptosis | MTT/MTS assay | IMR5 | Tumor | 20% apoptosis at 20 µM |
| dbacp05836 | R8-BadBH3 | rrrrrrrrGNLWAAQRYGRELRRMSDEFVDSFKK | Synthetic Peptide | Inducing mitochondrial apoptosis | MTT/MTS assay | IMR5 | Tumor | 50% apoptosis at 50 µM |
| dbacp05837 | R8-Bak | RRRRRRRRGCMGQVGRQLAIIGDDINRRY | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | HNSCCs | Head and neck squamous cell carcinomas (HNSCC) | Not found |
| dbacp05838 | R8-Bax | RRRRRRRRGCSTKKLSECLKRIGDELDSnM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | HNSCCs | Head and neck squamous cell carcinomas (HNSCC) | Not found |
| dbacp05839 | R8-BidBH3 | rrrrrrrrGEDIIRNIARHLAQVGDSMDR | Synthetic Peptide | Inducing mitochondrial apoptosis | MTT/MTS assay | SK-N-AS | Brain tumor | 8% apoptosis at 10 µM |
| dbacp05840 | R8-BidBH3 | rrrrrrrrGEDIIRNIARHLAQVGDSMDR | Synthetic Peptide | Inducing mitochondrial apoptosis | MTT/MTS assay | SK-N-AS | Brain tumor | 45% apoptosis at 20 µM |
| dbacp05841 | R8-BidBH3 | rrrrrrrrGEDIIRNIARHLAQVGDSMDR | Synthetic Peptide | Inducing mitochondrial apoptosis | MTT/MTS assay | SK-N-AS | Brain tumor | 65% apoptosis at 50 µM |
| dbacp05842 | R8-BidBH3 | rrrrrrrrGEDIIRNIARHLAQVGDSMDR | Synthetic Peptide | Inducing mitochondrial apoptosis | MTT/MTS assay | NB69 | Brain tumor | 25% apoptosis at 10 µM |
| dbacp05843 | R8-BidBH3 | rrrrrrrrGEDIIRNIARHLAQVGDSMDR | Synthetic Peptide | Inducing mitochondrial apoptosis | MTT/MTS assay | NB69 | Brain tumor | 66% apoptosis at 20 µM |
| dbacp05844 | R8-BidBH3 | rrrrrrrrGEDIIRNIARHLAQVGDSMDR | Synthetic Peptide | Inducing mitochondrial apoptosis | MTT/MTS assay | NB69 | Brain tumor | 68% apoptosis at 50 µM |
| dbacp05845 | R8-BidBH3 | rrrrrrrrGEDIIRNIARHLAQVGDSMDR | Synthetic Peptide | Inducing mitochondrial apoptosis | MTT/MTS assay | NGP | Tumor | 43% apoptosis at 10 µM |
| dbacp05846 | R8-BidBH3 | rrrrrrrrGEDIIRNIARHLAQVGDSMDR | Synthetic Peptide | Inducing mitochondrial apoptosis | MTT/MTS assay | NGP | Tumor | 46% apoptosis at 20 µM |
| dbacp05847 | R8-BidBH3 | rrrrrrrrGEDIIRNIARHLAQVGDSMDR | Synthetic Peptide | Inducing mitochondrial apoptosis | MTT/MTS assay | NGP | Tumor | 79% apoptosis at 50 µM |
| dbacp05848 | R8-BidBH3 | rrrrrrrrGEDIIRNIARHLAQVGDSMDR | Synthetic Peptide | Inducing mitochondrial apoptosis | MTT/MTS assay | IMR5 | Tumor | 23% apoptosis at 10 µM |
| dbacp05849 | R8-BidBH3 | rrrrrrrrGEDIIRNIARHLAQVGDSMDR | Synthetic Peptide | Inducing mitochondrial apoptosis | MTT/MTS assay | IMR5 | Tumor | 35% apoptosis at 20 µM |
| dbacp05850 | R8-BidBH3 | rrrrrrrrGEDIIRNIARHLAQVGDSMDR | Synthetic Peptide | Inducing mitochondrial apoptosis | MTT/MTS assay | IMR5 | Tumor | 55% apoptosis at 50 µM |
| dbacp05851 | R8-BidBH3Alt | rrrrrrrrGEDIIRNIARHAAQVGASMDR | Synthetic Peptide | Inducing mitochondrial apoptosis | MTT/MTS assay | SK-N-AS | Brain tumor | 1% apoptosis at 10 µM |
| dbacp05852 | R8-BidBH3Alt | rrrrrrrrGEDIIRNIARHAAQVGASMDR | Synthetic Peptide | Inducing mitochondrial apoptosis | MTT/MTS assay | SK-N-AS | Brain tumor | 2% apoptosis at 20 µM |
| dbacp05853 | R8-BidBH3Alt | rrrrrrrrGEDIIRNIARHAAQVGASMDR | Synthetic Peptide | Inducing mitochondrial apoptosis | MTT/MTS assay | SK-N-AS | Brain tumor | 3% apoptosis at 50 µM |
| dbacp05854 | R8-BidBH3Alt | rrrrrrrrGEDIIRNIARHAAQVGASMDR | Synthetic Peptide | Inducing mitochondrial apoptosis | MTT/MTS assay | NB69 | Brain tumor | 2% apoptosis at 10 µM |
| dbacp05855 | R8-BidBH3Alt | rrrrrrrrGEDIIRNIARHAAQVGASMDR | Synthetic Peptide | Inducing mitochondrial apoptosis | MTT/MTS assay | NB69 | Brain tumor | 1% apoptosis at 20 µM |
| dbacp05856 | R8-BidBH3Alt | rrrrrrrrGEDIIRNIARHAAQVGASMDR | Synthetic Peptide | Inducing mitochondrial apoptosis | MTT/MTS assay | NB69 | Brain tumor | 5% apoptosis at 50 µM |
| dbacp05857 | R8-BidBH3Alt | rrrrrrrrGEDIIRNIARHAAQVGASMDR | Synthetic Peptide | Inducing mitochondrial apoptosis | MTT/MTS assay | NGP | Tumor | 1% apoptosis at 10 µM |
| dbacp05858 | R8-BidBH3Alt | rrrrrrrrGEDIIRNIARHAAQVGASMDR | Synthetic Peptide | Inducing mitochondrial apoptosis | MTT/MTS assay | NGP | Tumor | 2% apoptosis at 20 µM |
| dbacp05859 | R8-BidBH3Alt | rrrrrrrrGEDIIRNIARHAAQVGASMDR | Synthetic Peptide | Inducing mitochondrial apoptosis | MTT/MTS assay | NGP | Tumor | 3% apoptosis at 50 µM |
| dbacp05860 | R8-BidBH3Alt | rrrrrrrrGEDIIRNIARHAAQVGASMDR | Synthetic Peptide | Inducing mitochondrial apoptosis | MTT/MTS assay | IMR5 | Tumor | 0% apoptosis at 10 µM |
| dbacp05861 | R8-BidBH3Alt | rrrrrrrrGEDIIRNIARHAAQVGASMDR | Synthetic Peptide | Inducing mitochondrial apoptosis | MTT/MTS assay | IMR5 | Tumor | 1% apoptosis at 20 µM |
| dbacp05862 | R8-BidBH3Alt | rrrrrrrrGEDIIRNIARHAAQVGASMDR | Synthetic Peptide | Inducing mitochondrial apoptosis | MTT/MTS assay | IMR5 | Tumor | 2% apoptosis at 50 µM |
| dbacp05863 | RA-V | cyclopeptideRA-V-,cyclo(YAAYAY) | Plant sources | Inducing apoptosis | MTT assay | MCF-7 | Breast cancer | Not found |
| dbacp05864 | RA-V | cyclopeptideRA-V-,cyclo(YAAYAY) | Plant sources | Inducing apoptosis | MTT assay | MDA-MB-231 | Breast cancer | Not found |
| dbacp05865 | RA-V | cyclopeptideRA-V-,cyclo(YAAYAY) | Plant sources | Inducing apoptosis | MTT assay | 4T1 | Breast cancer | Not found |
| dbacp05873 | Radical SAM domain protein | MEAVLYVTRKCNLSCGHCIVDKEDNSDLPTDKVETLASDYPIDRTILSGGEPFLHDNFEELVALVPEPTVLSNGLVLSDEEYVGENSDMLEELNGIQLSVEGKEETTDARRGEGVWDRVMEAHQNLSEIGVESYLRSTYSREMMEEVGELMEFCDAEGISLVLFPEIGKPPLSPTENASFFDYAVEKGVVVATPDFHSYIGEGGECPAARTRISVDVNGEIYPCQFNWDYCLGEVGDEWGLIESRIERFDRTEPVPRTCSRCDFANKCRGCGVADTWSGCPIARGLSHSESPSRRPLKRVQETMNTLEDVGAPRGCHGC | Uncultured archaeon | Apoptosis inducing | MTT assay | MCF-7 | Breast cancer | MIC : 42% ± 8.1 μM |
| dbacp05874 | Radical SAM domain protein | MEAVLYVTRKCNLSCGHCIVDKEDNSDLPTDKVETLASDYPIDRTILSGGEPFLHDNFEELVALVPEPTVLSNGLVLSDEEYVGENSDMLEELNGIQLSVEGKEETTDARRGEGVWDRVMEAHQNLSEIGVESYLRSTYSREMMEEVGELMEFCDAEGISLVLFPEIGKPPLSPTENASFFDYAVEKGVVVATPDFHSYIGEGGECPAARTRISVDVNGEIYPCQFNWDYCLGEVGDEWGLIESRIERFDRTEPVPRTCSRCDFANKCRGCGVADTWSGCPIARGLSHSESPSRRPLKRVQETMNTLEDVGAPRGCHGC | Uncultured archaeon | Apoptosis inducing | MTT assay | U2OS | Osteosarcoma | No significant effect |
| dbacp05877 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Not found | Inducing apoptosis | MTT and LDH assay | H157 | Lung cancer | IC50 : 5.90 µM |
| dbacp05878 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Not found | Inducing apoptosis | MTT and LDH assay | H157 | Prostate cancer | IC50 : 5.90 µM |
| dbacp05879 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Not found | Inducing apoptosis | MTT and LDH assay | H157 | Breast cancer | IC50 : 5.90 µM |
| dbacp05880 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Not found | Inducing apoptosis | MTT and LDH assay | H157 | Glioma | IC50 : 5.90 µM |
| dbacp05881 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Not found | Inducing apoptosis | MTT and LDH assay | MBD-MB-435s | Lung cancer | IC50 : 15.44 µM |
| dbacp05882 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Not found | Inducing apoptosis | MTT and LDH assay | MBD-MB-435s | Prostate cancer | IC50 : 15.44 µM |
| dbacp05883 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Not found | Inducing apoptosis | MTT and LDH assay | MBD-MB-435s | Breast cancer | IC50 : 15.44 µM |
| dbacp05884 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Not found | Inducing apoptosis | MTT and LDH assay | MBD-MB-435s | Glioma | IC50 : 15.44 µM |
| dbacp05885 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Not found | Inducing apoptosis | MTT and LDH assay | PC-3 | Lung cancer | IC50 : 5.79 µM |
| dbacp05886 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Not found | Inducing apoptosis | MTT and LDH assay | PC-3 | Prostate cancer | IC50 : 5.79 µM |
| dbacp05887 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Not found | Inducing apoptosis | MTT and LDH assay | PC-3 | Breast cancer | IC50 : 5.79 µM |
| dbacp05888 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Not found | Inducing apoptosis | MTT and LDH assay | PC-3 | Glioma | IC50 : 5.79 µM |
| dbacp05889 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Not found | Inducing apoptosis | MTT and LDH assay | U251-MG | Lung cancer | IC50 : 16.14 µM |
| dbacp05890 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Not found | Inducing apoptosis | MTT and LDH assay | U251-MG | Prostate cancer | IC50 : 16.14 µM |
| dbacp05891 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Not found | Inducing apoptosis | MTT and LDH assay | U251-MG | Breast cancer | IC50 : 16.14 µM |
| dbacp05892 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Not found | Inducing apoptosis | MTT and LDH assay | U251-MG | Glioma | IC50 : 16.14 µM |
| dbacp05893 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Not found | Inducing apoptosis | MTT and LDH assay | MCF-7) | Lung cancer | IC50 : 20.19 µM |
| dbacp05894 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Not found | Inducing apoptosis | MTT and LDH assay | MCF-7) | Prostate cancer | IC50 : 20.19 µM |
| dbacp05895 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Not found | Inducing apoptosis | MTT and LDH assay | MCF-7) | Breast cancer | IC50 : 20.19 µM |
| dbacp05896 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Not found | Inducing apoptosis | MTT and LDH assay | MCF-7) | Glioma | IC50 : 20.19 µM |
| dbacp05897 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Not found | Inducing apoptosis | MTT and LDH assay | HMEC-1 | Lung cancer | IC50 : 79.50 µM |
| dbacp05898 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Not found | Inducing apoptosis | MTT and LDH assay | HMEC-1 | Prostate cancer | IC50 : 79.50 µM |
| dbacp05899 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Not found | Inducing apoptosis | MTT and LDH assay | HMEC-1 | Breast cancer | IC50 : 79.50 µM |
| dbacp05900 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Not found | Inducing apoptosis | MTT and LDH assay | HMEC-1 | Glioma | IC50 : 79.50 µM |
| dbacp05901 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Gram-negative purple non-sulfur bacteria | Inducing apoptosis | MTT Cell viability assay and Lactate dehydrogenase (LDH) leakage assay | H157 | Lung | IC50 : 5.90 µM |
| dbacp05902 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Gram-negative purple non-sulfur bacteria | Inducing apoptosis | MTT Cell viability assay and Lactate dehydrogenase (LDH) leakage assay | MBD-MB-435s | Melanocyte | IC50 : 15.44 µM |
| dbacp05903 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Gram-negative purple non-sulfur bacteria | Inducing apoptosis | MTT Cell viability assay and Lactate dehydrogenase (LDH) leakage assay | PC-3 | Human prostate carcinoma | IC50 : 5.79 µM |
| dbacp05904 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Gram-negative purple non-sulfur bacteria | Inducing apoptosis | MTT Cell viability assay and Lactate dehydrogenase (LDH) leakage assay | U251-MG | Human glioblastoma astrocytoma | IC50 : 16.14 µm |
| dbacp05905 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Gram-negative purple non-sulfur bacteria | Inducing apoptosis | MTT Cell viability assay and Lactate dehydrogenase (LDH) leakage assay | MCF-7 | Human breast cancer | IC50 : 20.19 µM |
| dbacp05906 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Skin secretions, the pickerel frog, North America | Inducing apoptosis | MTT Cell viability assay and Lactate dehydrogenase (LDH) leakage assay | H157 | Lung cancer | IC50 : 5.90 µM |
| dbacp05907 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Skin secretions, the pickerel frog, North America | Inducing apoptosis | MTT Cell viability assay and Lactate dehydrogenase (LDH) leakage assay | MDA-MB-435S | Breast cancer | IC50 : 15.44 µM |
| dbacp05908 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Skin secretions, the pickerel frog, North America | Inducing apoptosis | MTT Cell viability assay and Lactate dehydrogenase (LDH) leakage assay | PC-3 | Human prostate carcinoma | IC50 : 5.79 µM |
| dbacp05909 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Skin secretions, the pickerel frog, North America | Inducing apoptosis | MTT Cell viability assay and Lactate dehydrogenase (LDH) leakage assay | U251-MG | Glioma | IC50 : 16.14 µM |
| dbacp05910 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Skin secretions, the pickerel frog, North America | Inducing apoptosis | MTT Cell viability assay and Lactate dehydrogenase (LDH) leakage assay | MCF-7 | Breast cancer | IC50 : 20.19 µM |
| dbacp05911 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Skin secretions, the pickerel frog, North America | Inducing apoptosis | MTT Cell viability assay and Lactate dehydrogenase (LDH) leakage assay | HMEC-1 | Glioma | IC50 : 79.50 µM |
| dbacp05928 | Red Sea microbiome peptide | AAEKEFIKYPYPTPLQYQQLATRLKVEKKLVRRW | Red Sea microbiome derived peptide | Apoptosis inducing | MTT/MTS assay | U2OS | Osteosarcoma | Not found |
| dbacp05961 | RGD-mda-7 | MNFQQRLQSLWTLARPFCPPLLATASQMQMVVLPCLGFTLLLWSQVSGAQGQEFHFGPCQVKGVVPQKLWEAFWAVKDTMQAQDNITSARLLQQEVLQNVSDAESCYLVHTLLEFYLKTVFKNYHNRTVEVRTLKSFSTLANNFVLIVSQLQPSQENEMFSIRGDSAHRRFLLFRRAFKQLDVEAALTKALGEVDILLTWMQKFYKL | Derived from wtmda-7/IL-24 by insertion or a glycine residue between Arg(164) and Asp(165). | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | Cell viability(% of control):0.5 at concentration 4 µg/ml |
| dbacp05962 | RGD-mda-7 | MNFQQRLQSLWTLARPFCPPLLATASQMQMVVLPCLGFTLLLWSQVSGAQGQEFHFGPCQVKGVVPQKLWEAFWAVKDTMQAQDNITSARLLQQEVLQNVSDAESCYLVHTLLEFYLKTVFKNYHNRTVEVRTLKSFSTLANNFVLIVSQLQPSQENEMFSIRGDSAHRRFLLFRRAFKQLDVEAALTKALGEVDILLTWMQKFYKL | Derived from wtmda-7/IL-24 by insertion or a glycine residue between Arg(164) and Asp(165). | Apoptosis inducing | MTT/MTS assay | Ket-3 | Tumor | Cell viability(% of control): 0.5 at concentration 8 µg/ml |
| dbacp05963 | RGD-mda-7 | MNFQQRLQSLWTLARPFCPPLLATASQMQMVVLPCLGFTLLLWSQVSGAQGQEFHFGPCQVKGVVPQKLWEAFWAVKDTMQAQDNITSARLLQQEVLQNVSDAESCYLVHTLLEFYLKTVFKNYHNRTVEVRTLKSFSTLANNFVLIVSQLQPSQENEMFSIRGDSAHRRFLLFRRAFKQLDVEAALTKALGEVDILLTWMQKFYKL | Derived from wtmda-7/IL-24 by insertion or a glycine residue between Arg(164) and Asp(165). | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | Apoptotic rate(%): >70% at concentration of 8 µg/ml |
| dbacp05964 | RGD-mda-7 | MNFQQRLQSLWTLARPFCPPLLATASQMQMVVLPCLGFTLLLWSQVSGAQGQEFHFGPCQVKGVVPQKLWEAFWAVKDTMQAQDNITSARLLQQEVLQNVSDAESCYLVHTLLEFYLKTVFKNYHNRTVEVRTLKSFSTLANNFVLIVSQLQPSQENEMFSIRDSAHRRFLLFRRAFKQL | Derived from wtmda-7/IL-24 by insertion or a glycine residue between Arg(164) and Asp(165). | Apoptosis inducing | MTT/MTS assay | Ket-3 | Tumor | Apoptotic rate(%): >50% at concentration of 8 µg/ml |
| dbacp05965 | RGD-tachyplesin | CRGDCGGKWCFRVCYRGICYRRCR | Not found | Inducing apoptosis | Not specified | TSU | Prostate cancer | Not found |
| dbacp05966 | RGD-tachyplesin | CRGDCGGKWCFRVCYRGICYRRCR | Not found | Inducing apoptosis | Not specified | B16 | Prostate cancer | Not found |
| dbacp05967 | RGD-tachyplesin | CRGDCGGKWCFRVCYRGICYRRCR | Not found | Inducing apoptosis | Not specified | Cos-7 | Prostate cancer | Not found |
| dbacp05968 | RGD-tachyplesin | CRGDCGGKWCFRVCYRGICYRRCR | Not found | Inducing apoptosis | Not specified | NIH-3T3 | Prostate cancer | Not found |
| dbacp05969 | RGSALTHLP | RGSALTHLP | Siamese crocodile Leukocyte | Apoptosis inducing | Sulforhodamine B colorimetric assay | HeLa | Cervical cancer | IC50 : 126.24 ± 3.5 μM |
| dbacp05970 | RGSALTHLP | RGSALTHLP | Siamese crocodile Leukocyte | Apoptosis inducing | Sulforhodamine B colorimetric assay | CaSki | Cervical cancer | IC50 : 168.33 ± 1.6 μM |
| dbacp05974 | RP9 | RGSALTHLP | Siamese crocodile leukocyte extract | Apoptosis | Sulforhodamine B colorimetric assay, apoptosis array assay | HeLa | Cervical cancer | IC50 : 126.2 μM |
| dbacp05975 | RP9 | RGSALTHLP | Siamese crocodile leukocyte extract | Apoptosis | Sulforhodamine B colorimetric assay, apoptosis array assay | CaSki | Cervical cancer | IC50 :168.3 μM |
| dbacp05981 | RT2 | NGVQPKYRWWRWWRRWW-NH2 | Siamese crocodile leukocyte | Inducing apoptosis | Sulforhodamine B colorimetric assay | HeLa | Cervical cancer | IC50 : 28.7–53.4 μM |
| dbacp05982 | RT2 | NGVQPKYRWWRWWRRWW-NH2 | Siamese crocodile leukocyte | Apoptosis inducing | Sulforhodamine B colorimetric assay | HeLa | Cervical cancer | IC50 : 28.7–53.4 μM |
| dbacp05983 | RT2 | NGVQPKYRWWRWWRRWW-NH2 | Siamese crocodile leukocyte | Apoptosis inducing | Sulforhodamine B colorimetric assay | HeLa | Cervical cancer | IC50 : 28.7–53.4 μM |
| dbacp05984 | S−24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Not found | Inducing apoptosis | MTT and LDH assay | H157 | Lung cancer | IC50 : 58.18 µM |
| dbacp05985 | S−24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Not found | Inducing apoptosis | MTT and LDH assay | H157 | Prostate cancer | IC50 : 58.18 µM |
| dbacp05986 | S−24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Not found | Inducing apoptosis | MTT and LDH assay | H157 | Breast cancer | IC50 : 58.18 µM |
| dbacp05987 | S−24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Not found | Inducing apoptosis | MTT and LDH assay | H157 | Glioma | IC50 : 58.18 µM |
| dbacp05988 | S−24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Not found | Inducing apoptosis | MTT and LDH assay | MBD-MB-435s | Lung cancer | IC50 : 179.00 µM |
| dbacp05989 | S−24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Not found | Inducing apoptosis | MTT and LDH assay | MBD-MB-435s | Prostate cancer | IC50 : 179.00 µM |
| dbacp05990 | S−24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Not found | Inducing apoptosis | MTT and LDH assay | MBD-MB-435s | Breast cancer | IC50 : 179.00 µM |
| dbacp05991 | S−24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Not found | Inducing apoptosis | MTT and LDH assay | MBD-MB-435s | Glioma | IC50 : 179.00 µM |
| dbacp05992 | S−24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Not found | Inducing apoptosis | MTT and LDH assay | PC-3 | Lung cancer | IC50 : 792.60 µM |
| dbacp05993 | S−24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Not found | Inducing apoptosis | MTT and LDH assay | PC-3 | Prostate cancer | IC50 : 792.60 µM |
| dbacp05994 | S−24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Not found | Inducing apoptosis | MTT and LDH assay | PC-3 | Breast cancer | IC50 : 792.60 µM |
| dbacp05995 | S−24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Not found | Inducing apoptosis | MTT and LDH assay | PC-3 | Glioma | IC50 : 792.60 µM |
| dbacp05996 | S−24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Not found | Inducing apoptosis | MTT and LDH assay | U251-MG | Lung cancer | IC50 : 278.30 µM |
| dbacp05997 | S−24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Not found | Inducing apoptosis | MTT and LDH assay | U251-MG | Prostate cancer | IC50 : 278.30 µM |
| dbacp05998 | S−24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Not found | Inducing apoptosis | MTT and LDH assay | U251-MG | Breast cancer | IC50 : 278.30 µM |
| dbacp05999 | S−24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Not found | Inducing apoptosis | MTT and LDH assay | U251-MG | Glioma | IC50 : 278.30 µM |
| dbacp06000 | S−24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Not found | Inducing apoptosis | MTT and LDH assay | MCF-7 | Lung cancer | IC50 : 316.90 µM |
| dbacp06001 | S−24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Not found | Inducing apoptosis | MTT and LDH assay | MCF-7 | Prostate cancer | IC50 : 316.90 µM |
| dbacp06002 | S−24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Not found | Inducing apoptosis | MTT and LDH assay | MCF-7 | Breast cancer | IC50 : 316.90 µM |
| dbacp06003 | S−24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Not found | Inducing apoptosis | MTT and LDH assay | MCF-7 | Glioma | IC50 : 316.90 µM |
| dbacp06004 | S−24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Not found | Inducing apoptosis | MTT and LDH assay | HMEC-1 | Lung cancer | IC50 : 1185.00 µM |
| dbacp06005 | S−24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Not found | Inducing apoptosis | MTT and LDH assay | HMEC-1 | Prostate cancer | IC50 : 1185.00 µM |
| dbacp06006 | S−24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Not found | Inducing apoptosis | MTT and LDH assay | HMEC-1 | Breast cancer | IC50 : 1185.00 µM |
| dbacp06007 | S−24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Not found | Inducing apoptosis | MTT and LDH assay | HMEC-1 | Glioma | IC50 : 1185.00 µM |
| dbacp06008 | S1 (Ac-KKWRKWLAKK-NH2) | Ac-NAl-NAl-KKWRKWLAKK-NH2 | Not found | Necrosis or apoptosis | MTT assay | PC9 | Human Lung cancer | Not found |
| dbacp06009 | S1 (Ac-KKWRKWLAKK-NH2) | Ac-NAl-NAl-KKWRKWLAKK-NH2 | Not found | Necrosis or apoptosis | MTT assay | PC9-G | Oral cancer | Not found |
| dbacp06010 | S1 (Ac-KKWRKWLAKK-NH2) | Ac-NAl-NAl-KKWRKWLAKK-NH2 | Not found | Necrosis or apoptosis | MTT assay | A549 | Human lung cancer | Not found |
| dbacp06011 | S1 (Ac-KKWRKWLAKK-NH2) | Ac-NAl-NAl-KKWRKWLAKK-NH2 | Not found | Necrosis or apoptosis | MTT assay | C9 | Oral cancer | Not found |
| dbacp06012 | S1 (Ac-KKWRKWLAKK-NH2) | Ac-NAl-NAl-KKWRKWLAKK-NH2 | Not found | Necrosis or apoptosis | MTT assay | OECM-1 | Human lung cancer | Not found |
| dbacp06013 | S1 (Ac-KKWRKWLAKK-NH2) | Ac-NAl-NAl-KKWRKWLAKK-NH2 | Not found | Necrosis or apoptosis | MTT assay | SAS | Oral cancer | Not found |
| dbacp06021 | SALF | Ac-ECKFTVKPYLKRFQVYYKGRMWCPNH2 | Giant tiger prawn | Regulate apoptosis related death receptor/NF-κB signaling pathway | MTT assay | HeLa | Human lung cancer | MIC : 100 µg/ml |
| dbacp06022 | San A-amide | NA | Marine fungus, Wilt of banana | Apoptosis induction | Not specified | HCT-116 | Colon cancer | MIC : 0.98 µg/mL |
| dbacp06023 | Sansalv amide A | NA | Synthetic Peptide | Apoptosis | Cell viability assay | S2-13 | Pancreatic cancer | EC50 : 7.5 µM |
| dbacp06024 | SCAP1 | LANAK | Marine invertebrates | Inducing apoptosis | Not specified | HT-29 | Not specified | IC50 : 90.31 ± 0.45 μM |
| dbacp06025 | SCAP1 | LANAK | Marine invertebrates | Inducing apoptosis | Not specified | HT-29 | Not specified | IC50 : 70.87 ± 0.82 μM |
| dbacp06026 | SCAP1 | LANAK | Marine invertebrates | Inducing apoptosis | Not specified | HT-29 | Not specified | IC50 : 60.21 ± 0.45 μM |
| dbacp06027 | SCH-P10 | DYVP | Marine invertebrates | Inducing apoptosis | MTT assay | DU-145 | Prostate cancer | IC50 : 1.21 mg/mL |
| dbacp06028 | SCH-P10 | DYVP | Marine invertebrates | Inducing apoptosis | MTT assay | PC-3 | Prostate cancer | IC50 : 1.09 mg/mL |
| dbacp06029 | SCH-P9 | LPGP | Marine invertebrates | Inducing apoptosis | MTT assay | DU-145 | Prostate cancer | IC50 : 1.21 mg/mL |
| dbacp06030 | SCH-P9 | LPGP | Marine invertebrates | Inducing apoptosis | MTT assay | PC-3 | Prostate cancer | IC50 : 1.09 mg/mL |
| dbacp06035 | Scolopin-2 | ILKKFMLHRGTKVYKMRTLSKRSH | Chinese red-headed centipede | Regulate caspase-related apoptosis pathways | MTT assay | Hela | Cervical cancer | IC50 : 35 μM |
| dbacp06058 | Sepia ink oligopeptide (SIO) | QPK | Not found | Inducing apoptosis | CCK-8 assay | DU-145 | Prostate cancer | IC50 : < 5 mg/mL |
| dbacp06059 | Sepia ink oligopeptide (SIO) | QPK | Not found | Inducing apoptosis | CCK-8 assay | PC-3 | Prostate cancer | IC50 : < 5 mg/mL |
| dbacp06060 | Sepia ink oligopeptide (SIO) | QPK | Not found | Inducing apoptosis | CCK-8 assay | LNCaP | Prostate cancer | IC50 : < 10 mg/mL |
| dbacp06063 | Shepherdin | KHSSGCAFL | Not found | Inducing apoptosis | MTT assay | HeLa | Cervical carcinoma | IC50 : 25–75 µM |
| dbacp06064 | Shepherdin | KHSSGCAFL | Not found | Inducing apoptosis | MTT assay | PC3 | Prostate adenocarcinoma | IC50 : 25–75 µM |
| dbacp06065 | Shepherdin | KHSSGCAFL | Not found | Inducing apoptosis | MTT assay | p53+/+ HCT116 | Colorectal carcinoma | IC50 : 25–75 µM |
| dbacp06066 | Shepherdin | KHSSGCAFL | Not found | Inducing apoptosis | MTT assay | p53+/+ HCT116 | Colorectal carcinoma | IC50 : 25–75 µM |
| dbacp06067 | Shepherdin (ATP) | RQIKIWFQNRRMKWKKKHSSGCAFL | Not found | Inducing apoptosis | MTT assay | HeLa | Cervical carcinoma | IC50 : 50–75 μM |
| dbacp06068 | Shepherdin (ATP) | RQIKIWFQNRRMKWKKKHSSGCAFL | Not found | Inducing apoptosis | MTT assay | PC3 | Prostate adenocarcinoma | IC50 : 50–75 μM |
| dbacp06069 | Shepherdin (ATP) | RQIKIWFQNRRMKWKKKHSSGCAFL | Not found | Inducing apoptosis | MTT assay | p53+/+ HCT116 | Colorectal carcinoma | IC50 : 50–75 μM |
| dbacp06070 | Shepherdin (ATP) | RQIKIWFQNRRMKWKKKHSSGCAFL | Not found | Inducing apoptosis | MTT assay | p53+/+ HCT116 | Colorectal carcinoma | IC50 : 50–75 μM |
| dbacp06071 | Shepherdin (TAT) | YGRKKRRQRRRKHSSGCAFL | Not found | Inducing apoptosis | MTT assay | HeLa | Cervical carcinoma | IC50 : 50–75 μM |
| dbacp06072 | Shepherdin (TAT) | YGRKKRRQRRRKHSSGCAFL | Not found | Inducing apoptosis | MTT assay | PC3 | Prostate adenocarcinoma | IC50 : 50–75 μM |
| dbacp06073 | Shepherdin (TAT) | YGRKKRRQRRRKHSSGCAFL | Not found | Inducing apoptosis | MTT assay | p53+/+ HCT116 | Colorectal carcinoma | IC50 : 50–75 μM |
| dbacp06074 | Shepherdin (TAT) | YGRKKRRQRRRKHSSGCAFL | Not found | Inducing apoptosis | MTT assay | p53+/+ HCT116 | Colorectal carcinoma | IC50 : 50–75 μM |
| dbacp06079 | Short α-helical peptide | GIIKKIIKKI | Alpha-helical proteins | Cell membrane disruption; Cell apoptosis | MTT/MTS assay | HeLa | Cervical cancer | 99% Cytotoxicity at 4µM approx. |
| dbacp06080 | Short α-helical peptide | GIIKKIIKKIIKKI | Alpha-helical proteins | Cell membrane disruption; Cell apoptosis | MTT/MTS assay | HeLa | Cervical cancer | 95 % Cytotoxicity at 4µM approx. |
| dbacp06081 | Short α-helical peptide | GIIKKIIKKIIKKIIKKI | Alpha-helical proteins | Cell membrane disruption; Cell apoptosis | MTT/MTS assay | HeLa | Cervical cancer | 80% Cytotoxicity at 4µM |
| dbacp06082 | Short α-helical peptide | GIIKKIIKKI | Alpha-helical proteins | Cell membrane disruption; Cell apoptosis | MTT/MTS assay | HL-60 | Leukemia cancer | 100% Cytotoxicity at 4µM approx. |
| dbacp06083 | Short α-helical peptide | GIIKKIIKKIIKKI | Alpha-helical proteins | Cell membrane disruption; Cell apoptosis | MTT/MTS assay | HL-60 | Leukemia cancer | 90% Cytotoxicity at 4µM approx. |
| dbacp06084 | Short α-helical peptide | GIIKKIIKKIIKKIIKKI | Alpha-helical proteins | Cell membrane disruption; Cell apoptosis | MTT/MTS assay | HL-60 | Leukemia cancer | 70% Cytotoxicity at 5µM approx. |
| dbacp06128 | Smac-CPP | AVPIAQKSVSRRRRRRGGRRRR | SMAC | Inducing apoptosis | Not specified | 4T1 | Not found | IC50 : 132 μM |
| dbacp06129 | SmacN7(R)8 | AVPIAQKGGGRRRRRRRRGC | SMAC | Inducing apoptosis | Not specified | H460 | Lung cancer | Not found |
| dbacp06139 | Solute carrier family 15 member 2 | MNPFQKNESKETLFSPVSTEEMLPGPPSPPKKSTPKLFGSSYPLSIAFIVVNEFCERFSYYGMKAVLTLYFLYFLHWNEDTSTSVYHAFSSLCYFTPILGAAIADSWLGKFKTIIYLSLVYVLGHVFKSLGAIPILGGKMLHTILSLVGLSLIALGTGGIKPCVAAFGGDQFEEEHAEARTRYFSVFYLSINAGSLISTFITPMLRGDVKCFGEDCYALAFGIPGLLMVLALVVFAMGSKMYRKPPPEGNIVAQVTKCIWFAICNRFRNRSEDIPKRQHWLDWAAEKYPKHLIMDVKALTRILFLYIPLPMFWALLDQQGSRWTLQANKMDGDLGFFVLQPDQMQVLNPFLVLVFIPLFDLVIYRLISKCGVNFSSLRKMAVGMILACLAFAVAALVEIKINGMIHPQPASQEIFLQVLNLADGEIEVTVQGNRNNPLLVESISSFQNTTHYSKLRLETKSQDLHFHLKYNNLSVHNEYSVEEKNCYQLVVHENGESLSSMLVKDTGIKPANGMTAIRFINTLHKDMNISLDANAPLSVGKDYGVSEYRTVQRGKYPAVHCETEDNVFSLNLGQLDFGTTYLFVITNITNRGLQAWKAEDIPANKLSIAWQLPQYVLVTAAEVMFSVTGLEFSYSQAPSSMKSVLQAAWLLTVAVGNIIVLIVAQFSGLVQWAEFVLFSCLLLVVCLIFSVMGYYYVPLKSEGIHEATEKQIPHIQGnMINLETKNTRL | Mouse | Apoptosis; Cell proliferation | Not specified | Not found | Not found | Not found |
| dbacp06140 | SP22 | ACHWPWCHGWHSACDLPMHPMC | Not found | Inducing apoptosis | Tunnel assay | MCF-7 | Breast cancer | Not found |
| dbacp06141 | SP22 | ACHWPWCHGWHSACDLPMHPMC | Not found | Inducing apoptosis | Tunnel assay | NKM | Stomach cancer | Not found |
| dbacp06142 | SP22 | ACHWPWCHGWHSACDLPMHPMC | Not found | Inducing apoptosis | Tunnel assay | CHO | Ovarian cancer | Not found |
| dbacp06143 | SP22 | ACHWPWCHGWHSACDLPMHPMC | Not found | Inducing apoptosis | Tunnel assay | HEL | Lung cancer | Not found |
| dbacp06183 | t Mastoparan-C(tMP-C, Tat (49-57)-Mastoparan-C) | RKKRRQRRRLNLKALLAVAKKIL | Synthetic construct | Apoptosis inducing | MTT assay | H157 | Non-small cell Lung cancer | IC50 : 2.79 μM |
| dbacp06184 | t Mastoparan-C(tMP-C, Tat (49-57)-Mastoparan-C) | RKKRRQRRRLNLKALLAVAKKIL | Synthetic construct | Apoptosis inducing | MTT assay | MBD-MB-435S | Melanocyte | IC50 : 3.86 μM |
| dbacp06185 | t Mastoparan-C(tMP-C, Tat (49-57)-Mastoparan-C) | RKKRRQRRRLNLKALLAVAKKIL | Synthetic construct | Apoptosis inducing | MTT assay | PC-3 | Human prostate carcinoma | IC50 : 3.86 μM |
| dbacp06186 | t Mastoparan-C(tMP-C, Tat (49-57)-Mastoparan-C) | RKKRRQRRRLNLKALLAVAKKIL | Synthetic construct | Apoptosis inducing | MTT assay | U251-MG | Human glioblastoma astrocytoma | IC50 : 3.36 μM |
| dbacp06187 | t Mastoparan-C(tMP-C, Tat (49-57)-Mastoparan-C) | RKKRRQRRRLNLKALLAVAKKIL | Synthetic construct | Apoptosis inducing | MTT assay | MCF-7 | Human breast cancer | IC50 : 3.70 μM |
| dbacp06192 | Tachyplesin I | KWCFRVCYRGICYRRCR | Hemocytes, Southeast Asia, Japanese horseshoe crab | Apoptosis inducing | Luciferase reporter assay, TUNEL assay | T167 | Squamous cell oral carcinoma | Not found |
| dbacp06193 | Tachyplesin I | KWCFRVCYRGICYRRCR | Hemocytes, Southeast Asia, Japanese horseshoe crab | Apoptosis inducing | Luciferase reporter assay, TUNEL assay | T-409 | Squamous cell oral carcinoma | Not found |
| dbacp06195 | Tat | RKKRRQRRR | HIV-Tat (49-57) | Apoptosis inducing | MTT/MTS assay | HCT-116 | Colon cancer | ~10% cytotoxicity at 100 µM |
| dbacp06199 | Tat-a5 | KAQIRAMECNILGRKKRRQRRR | HIV-Tat (49-57) | Apoptosis inducing | MTT/MTS assay | HCT-116 | Colon cancer | ~80% cytotoxicity at 100 µM |
| dbacp06200 | TAT-Bim (145-165) | RKKRRQ(orn)RRREIWIAQELRRIGDEFNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | EL4 | Mouse T-cell lymphoma | Not found |
| dbacp06201 | TAT-Bim (145-165) | RKKRRQ(orn)RRREIWIAQELRRIGDEFNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Panc-02 | Pancreatic cancer | Not found |
| dbacp06202 | TAT-Bim (145-165) | RKKRRQ(orn)RRREIWIAQELRRIGDEFNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | B16 | Melanoma | Not found |
| dbacp06203 | TAT-CTMP4 | LDPKLMKEEQMSQAQLFTRSFDDGL | Not found | Inducing apoptosis | Not specified | Panc-1 | Pancreatic cancer | TAT-CTMP4 induced a dose-dependent increase in apoptosis as detected by %-TUNEL positive cells and %-active caspase-3 (% active caspase-3 ranged from 31.2 to 61.9 at the highest dose tested (10 µM). |
| dbacp06204 | TAT-CTMP4 | LDPKLMKEEQMSQAQLFTRSFDDGL | Not found | Inducing apoptosis | Not specified | Panc-02 | Pancreatic cancer | TAT-CTMP4 induced a dose-dependent increase in apoptosis as detected by %-TUNEL positive cells and %-active caspase-3 (% active caspase-3 ranged from 31.2 to 61.9 at the highest dose tested (10 µM). |
| dbacp06205 | TAT-CTMP4 | LDPKLMKEEQMSQAQLFTRSFDDGL | Not found | Inducing apoptosis | Not specified | AsPC-1 | Pancreatic cancer | TAT-CTMP4 induced a dose-dependent increase in apoptosis as detected by %-TUNEL positive cells and %-active caspase-3 (% active caspase-3 ranged from 31.2 to 61.9 at the highest dose tested (10 µM). |
| dbacp06206 | TAT-CTMP4 | LDPKLMKEEQMSQAQLFTRSFDDGL | Not found | Inducing apoptosis | Not specified | BxPC-3 | Pancreatic cancer | TAT-CTMP4 induced a dose-dependent increase in apoptosis as detected by %-TUNEL positive cells and %-active caspase-3 (% active caspase-3 ranged from 31.2 to 61.9 at the highest dose tested (10 µM). |
| dbacp06207 | TAT-CTMP4 | LDPKLMKEEQMSQAQLFTRSFDDGL | Not found | Inducing apoptosis | Not specified | CFPAC-1 | Pancreatic cancer | TAT-CTMP4 induced a dose-dependent increase in apoptosis as detected by %-TUNEL positive cells and %-active caspase-3 (% active caspase-3 ranged from 31.2 to 61.9 at the highest dose tested (10 µM). |
| dbacp06208 | TAT-DV3-BH3 | YGRKKRRQRRRGGGLGASWHRPDKGGGGLRRMADDLNAQY | BH3-only, Direct activators (PUMA, Bid) | Inducing apoptosis | CCK-8 assay | HCT116p53–/– | Colon cancer | Survival rate : 32.19 ± 6.42% |
| dbacp06209 | TAT-DV3-BH3 | YGRKKRRQRRRGGGLGASWHRPDKGGGGLRRMADDLNAQY | BH3-only, Direct activators (PUMA, Bid) | Inducing apoptosis | CCK-8 assay | HCT116p53+/+ | Colon cancer | Survival rate : 34.28 ± 8.93% |
| dbacp06210 | TAT-DV3-BH3 | YGRKKRRQRRRGGGLGASWHRPDKGGGGLRRMADDLNAQY | BH3-only, Direct activators (PUMA, Bid) | Inducing apoptosis | CCK-8 assay | GLC-82 | Colon cancer | Survival rate : 63.64 ± 4.80% |
| dbacp06211 | TAT-DV3-BH3 | YGRKKRRQRRRGGGLGASWHRPDKGGGGLRRMADDLNAQY | BH3-only, Direct activators (PUMA, Bid) | Inducing apoptosis | CCK-8 assay | SGC-7901 | Colon cancer | Survival rate : 64.75 ± 33.48% |
| dbacp06212 | TAT-DV3-BH3 | YGRKKRRQRRRGGGLGASWHRPDKGGGGLRRMADDLNAQY | BH3-only, Direct activators (PUMA, Bid) | Inducing apoptosis | CCK-8 assay | MDA-MB-231 | Colon cancer | Survival rate : 69.79 ± 6.71% |
| dbacp06213 | TAT-DV3-BH3 | YGRKKRRQRRRGGGLGASWHRPDKGGGGLRRMADDLNAQY | BH3-only, Direct activators (PUMA, Bid) | Inducing apoptosis | CCK-8 assay | HEK293 | Colon cancer | Survival rate : 115.85 ± 23.03% |
| dbacp06214 | TAT-DV3-BH3 | YGRKKRRQRRRGGGLGASWHRPDKGGGGLRRMADDLNAQY | BH3-only, Direct activators (PUMA, Bid) | Inducing apoptosis | CCK-8 assay | 2BS | Colon cancer | Survival rate : 124.38 ± 22.05% |
| dbacp06215 | TAT-Ras-GAP317-326 | GRKKRRQRRRGGWMWVTNLRTD | Not found | Apoptosis inducing | LDH leakage assay | HeLa | Cervical cancer | 15% apoptosis at 10 µM |
| dbacp06216 | TAT-Ras-GAP317-326 | GRKKRRQRRRGGWMWVTNLRTD | Not found | Apoptosis inducing | LDH leakage assay | HeLa | Cervical cancer | 47% apoptosis at 20 µM |
| dbacp06217 | TAT-Ras-GAP317-326 | GRKKRRQRRRGGWMWVTNLRTD | Not found | Apoptosis inducing | LDH leakage assay | HeLa | Cervical cancer | 72% apoptosis at 30 µM |
| dbacp06218 | TAT-Ras-GAP317-326 | GRKKRRQRRRGGWMWVTNLRTD | Not found | Apoptosis inducing | LDH leakage assay | HeLa | Cervical cancer | 79% apoptosis at 50 µM |
| dbacp06219 | TAT-RasGAP (317-326) From p120RasGAP | GRKKRRQRRRGGWMWVTNLRTD | Not found | Inducing apoptosis | Luciferase assay | HeLa | Breast cancer | Not found |
| dbacp06220 | TAT-RasGAP (317-326) From p120RasGAP | GRKKRRQRRRGGWMWVTNLRTD | Not found | Inducing apoptosis | Luciferase assay | MCF-7 | Human malignant mesothelomia | Not found |
| dbacp06226 | Temporin A | FLPLIGRVLSGIL | Common frog | Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis | MTT/MTS assay | U-943 | Lymphoma cancer | IC50 : 80-90 µg/ml |
| dbacp06301 | Tf-D-LP4 | HAIYPRHSWTWEKKLETAVNLAWTAGNSNKWTWK | VDAC1(voltage-dependent anion channel1) | Inducing apoptosis | Not specified | CLL | Leukemia | IC50 : 1.2 ± 0.1 µM |
| dbacp06302 | Tf-D-LP4 | HAIYPRHSWTWEKKLETAVNLAWTAGNSNKWTWK | VDAC1(voltage-dependent anion channel1) | Inducing apoptosis | Not specified | MEC-1 | Leukemia | IC50 : 1.8 ± 0.2 µM |
| dbacp06303 | Tf-LP4 | HAIYPRHSWTWEKKLETAVNLAWTAGNSNKWTWK | VDAC1(voltage-dependent anion channel1) | Inducing apoptosis | Not specified | CLL | Leukemia | IC50 : 1.7 ± 0.2 µM |
| dbacp06304 | Tf-LP4 | HAIYPRHSWTWEKKLETAVNLAWTAGNSNKWTWK | VDAC1(voltage-dependent anion channel1) | Inducing apoptosis | Not specified | MEC-1 | Leukemia | IC50 : 3.6 ± 0.2 µM |
| dbacp06306 | Tilapia piscidin 4 | FIHHIIGGLFSAGKAIHRLIRRRRR | Not found | Inducing apoptosis | MTT assay | MG63 | Bone cancer | IC50 : 1–5 µM |
| dbacp06307 | TLS peptide | TLSGAFELSRDK | Not found | Inducing apoptosis | Not specified | SKOV3 | Ovarian cancer | Not found |
| dbacp06308 | TO4, human Bax 21-mer (52–72) | QDASTKKLSECLKRIGDELDS | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | Not found | Not specified | Not found |
| dbacp06322 | TP3 | FIHHIIGGLFSVGKHIHSLIHGH | Not found | Inducing apoptosis | MTT assay | MG63 | Bone cancer | 10.02 ± 1.10 μM |
| dbacp06326 | Transactivator of transcript-DV1-Bcl-2, AT-DV1-BH3 | RRRQRRKKRGGGGLGASWHRPDK | Transactivator of transcript-DV1-Bcl-2 TAT-DV1-BH3 | Apoptosis inducing | Cell viability assay, Transwell invasion assay | MDA-MB-231 | Breast cancer | Not specified |
| dbacp06327 | Transactivator of transcript-DV1-Bcl-2, AT-DV1-BH3 | RRRQRRKKRGGGGLGASWHRPDK | Transactivator of transcript-DV1-Bcl-2 TAT-DV1-BH4 | Apoptosis inducing | Cell viability assay, Transwell invasion assay | MCF-7 | Breast cancer | Not specified |
| dbacp06328 | Transactivator of transcript-DV1-Bcl-2, AT-DV1-BH3 | RRRQRRKKRGGGGLGASWHRPDK | Transactivator of transcript-DV1-Bcl-2 TAT-DV1-BH5 | Apoptosis inducing | Cell viability assay, Transwell invasion assay | HEK-293 | Kidney cancer | Not specified |
| dbacp06381 | TT 1 | KIKAVLKVLTT | Venom base | Inducing apoptosis | MTT assay | TT | Thyroid cancer | IC50 : 18.23 ± 2.81 μg/ml |
| dbacp06382 | TT 1 | KIKAVLKVLTT | Venom base | Inducing apoptosis | MTT assay | TT | Thyroid cancer | IC50 : 3.87 ± 0.34 μg/ml |
| dbacp06383 | TT 1 | KIKAVLKVLTT | Venom base | Inducing apoptosis | MTT assay | TT | Thyroid cancer | IC50 : 2.76 ± 0.32 μg/ml |
| dbacp06384 | TubB protein | MTLDSRYANRGGGLYEIDGLAIGHSPPPCSIPGGVQLTATATAEHALKALRAKGLATSDEALPAVRHASGEKAPLSSSQRRMWFLEQLEPGNAAQHLLQSHHIQGPLQVEGLRRALGLMVKRHEALRLVVAIGAAGPEQRVRPEWWPELPLSDLSGVAQADRARALAELARVEAAAPFNLQQGPLFRVRLARLAETEHVLLVTLHHLISDGAWSCEVLIKELAMLYGQHVEGSSPELAPLPVQYRDYAGWEASFAPAGEALEAWWRQRLAGVPTVLELPTEGARPLRQTYRAGRVAITVQPRLRQALEDLAHKEGVSLFALLLTAFTTLLHRYSRQEELVVGWPAPQRPRPELHGLIGYFGTPVALRSRLEPHTRVREALRQLDQEVREANAHAALPFERLVSLLDIARSPSRHPLFQVLFDLLPEQPQPTAGGCAFRPWESFTGLVAYDLTLLLEPRGEGLEGALDYSADLFSEARMQRAATQYLHLLEQLVERPHERLSRLALLTPGEHEALLAGHGLGGPVEGAQVLAHHRFEHQVRLTPHHPALCFGPQVLSYEQLNRRANPLAHRLRRLGAGPDTLVGLCVERSLELPVALLAIWKAGAGFLPLDVNQPRERLAFLLGDASCRILLTQEHLLQRLPPTNAALLCLEREAEALEREPQEDAPHEAGLDNLAYVIHTSGSTGTPKGIAMVHRCLANLVAWQLTHERLGGPSRTLQFASLNFDICYQELFTTWAAGGTVVMVTEEVRRDPARLLEVLEQEQVSRLYLPFIALQQLARVADERGAAPRHLRQLITAGEQLQATPELQRLLSRMPECTLHNQYGPSECHVVTSHDLTREPSRWPRLPPVGRPLAHLRVLLLDGEQQLVPPGVAGEVFLGGPALARGYLGRPEQTADRFVPDPFSREPGARLYRTGDLARLREDGALEFLQRMDAQVKIRGYRIEPGEIEVVLCEHPAVHQAHVRPYVDSAGERRLVAYVAARLEDTDGAETEHVERWRAVWDETYGGPSGTAFDLAGWNDSVRGEPLPPEQMREWVETTVERLMELVPRRVLELGCGSGLLLRRLAPRCESYWGTELSPVAVERLREQLQTGGSPLAQRVRLMAQPADDFSGLPEAGFDTVILNSVTQLFPSVDYLLRVVEGALRVLQPGGTLFIGDVQNLRLFELFHASVALEQASADLEAPALLARTRQRMLLDERLYVDPDFFAALATHFPQLGAVRLHLKRGSGRNEMNRFRYDVELQLAPVAKAGPAQELPELDWRHEGLGLERLERMLAERPAGLVLRNVANARTADEAARLALLRTGNSVGRLRALPAVTSWNPEQLWRLAEAADYTCHVTWSAQDEEGRFDALLMARAAGSSRPAAWLTPPPPPPRPWKSYANQPLAASRRRTLVGVLRSHLEHKLPEYMVPSSFVLLDALPLKPTGKLEVAALPPPEPAQAEQTPGHLAPRTPTERRLAELWRRVLGVHRVGVEDNFFQLGGHSLLATRLLSLIRGELGLELPLRVLFEQPTLAAMAGCLEAQSWSTQAPHPPSASIEEGEL | Aeromonads | Apoptosis and thus cell nucleus fragmentation | Toxicity assay, cell nucleus fragmentation assay (cnf) | L929 | Not specified | MIC : 50 ng/ml |
| dbacp06385 | TubC protein | MSAGALLAHAASLGVRLWVEGERLRFQAPPGVMTPELQSRLGGARHELIALLRQLQPSSQGGSLLAPVARNGRLALSFAQQRLWFQEQLHPEAPANNLTGAVVFTGPLHVAALLGAVAALVRRHEALRTTLGEEGGVPYSLIGEPWQPALEVEALPGATVGERLEQAREVALAESRRRFALETEPHLRVRLLRLAEQQHVLVLSLHHIAADGVGLQVLEQELAALYGALSAGAEPRLPPLPLQVADLADWQRRWVEGEEYQVQLAYWRRQLAGLTPLEVPGDHPRPRIPSMRGAEVRAPLLSAPQAQVLRALGQGEGATLYMTLLAALGVLLQRWTGQHDMAVGSAAANRNRPGLEGILGFLLNIVLLRLDLRGRPRFRELLRQARRVCVEAYAHQELPFEHLVEALQPGSERGDSSLYRVALAVSDTPWMPGHGLKLEGVQAQPLDFPRGVLDLDLHLWVYDTGEGLTGRLEYAVDLYEEPTARRLLEGFRQVLEAVVEAPDRPVPELPVLGEQERHQVLSGWNRTQRPYPREASVHGLFQQRALQAPRAVAVVYGERSLTYGELAERARGLAQGLVARGVRRGDLVALRLERSPEQVESMLAVLQAGAAYVPLDPSYPVQRQEFMLQDSGARLLVHSGPLPFAPQGCATLDLQAWHPAPSDGGEPLPQCSGEDLAYVIYTSGSTGQPKGVAVCHRAMTRLVCNTDYVQLGPEDRVAQASNASFDAATFEVWGALLNGARLVGLATEEAIQARRLAEVLREQRISVLFVTTALFNHVAREQPQAFSTLRYLLFGGEAVDASSVRRVLKQGAPGHLLHVYGPTENTTFSTAWRVEHLAEQAHTVPMGHPIANSRLHVLDEALQPVPVGAMGEVYLGGDGLALGYWRHPEATAERFVPDPHGLEPGGRLYRTGDLARRQADGAVVFAGRVDRQVKLRGFRVEPAEIESHLCEHSEVSAAVVELRGEGALRRLVAYVVPRAGGRPGAEELRTFLRTRLPEYMLPASFSLLEALPLTPNGKVDRSALPESFEEASREQAPVVPPRGPVEALLVDIWREVLGTQRVSVHDDFFDLGGHSLLATRVVSRLREALQVELPLRTLFEAPQLSALAAQVEVLLGHRQLRPPPLVPAVRPPELPLSFAQQRLWFLQQLAPQSTAYQILDAWHVRGRVDVGALERALEQLVRRHEALRTTFEPGGDGVPRQRIHAPAPVPLRQVDLRSHGIAAREEALRWMREQALRPLELDKGPLLRVSLLRLEEAQSLLFLELHHIVGDGWSLSVWSRELSHLYEAALHGAEPGLAPLPVQYADFALWQRGWLQGPVLREELTWWRERLARLAPLRLPADHARPEVQRFNGATYRFTLPGVRVQALRRLGHEHGATLFMVLLAGFNALLARYTGQTDIAIGAPIANRTRGEVEGLIGFFVNTLVLRTRLEGNPSFLELLRRVRETTLEAYAHQELPFERLVEELQPERQANQNPLVQVLLALQNAPREPLRLAGLEAEHLEYLVATTRFDLELHLWEEEEGLSCIAVYDRALYGAGTVERLVGAWCTLLEGVAELPARRVAELPLVPARELRQVPPPSPAAAIETSIGARFSEVARRQPGATAVTQGGRHLTYAELEERSERLARYLAWLGVRAGDRVGLATERTLERIISLLGILKAGAAYVPLDVRQPARRLSLLVQAAGVRTVIAEEQARTVLSGLGQPLTLVDAAQEPASAQQVPALGPERSLGGDMLAYVLFTSGSTGEPKGVCIPHRAVLRLIHEPSYVQLSPREVMLHYAPLEFDASTFEVWGALLNGARLVLVPPEQQSLESLGQELSTQGVTVLWLTAGLFRLMVEEQLKSLRGVRQLLAGGDVLPMPQVRRLREALPECQLINGYGPTESCTFTCCHRVGSPQELGGSVPIGTPIDLGWVSVVDERLQPVPDGAPGELLVGGPGLAWGYLQHPELTAERFIPDPLSRTPGARVYRTGDLVRRREDGTLEFLGRVDHQLKVRGFRIEPGEVEAAVLTHPAVQSAVVVGREGPGGKELVCYAVPRVESSEQGSQQEQRLVHEWESVFDGHMYREAPVGGEPTFNIVGWKSSYTGQPVAVEEMRDWLRHRVERVRGLRPRRILEVGCGTGLMLFALLPHCERYVGTDFSPAALDYVRRYLPPEHPGRVELLHRTADEWSGVAAGSFDAVLLNSVVQYFPSQEYLRQVLARCVEAVEDGGFVFVGDVRSLPLLESFHASVELERAAPSMPLEAWRERVRRAVLEDNELVVDPALFVALAHQHPRVSHVDIELTRGTHPNEMARFRYNAVLHIGPRTPPPASEVPWVDWSTQGLSLDALRARLRQGPPGPLGVAGIPNARVLPAVRAAEALGSTGSARRVEELRRRLSQPGTGAQDPDPFWQLAESLGYTAAVSWSPGRRDGAFDVLFLPATPGMHPRWLGPTPLNRTPPPASARLSSEPRRASLSLRLGSALRAHLQTHLPDFMVPSRFVVLQSLPLTPNGKVDRAALPVPDSRRLESAPLVPPSNELERVLAQVWKEVLGLEEVSREDNFFDVGGHSLLLAQVCSRLEARLGRRLELVTLFRYSSIAALAEHLQAPQELAAAEAQVQRMATERALLQQQAAQRRRAGSKRGAPNDT | Aeromonads | Apoptosis and thus cell nucleus fragmentation | Toxicity assay, cell nucleus fragmentation assay (cnf) | L929 | Not specified | MIC : 50 ng/ml |
| dbacp06386 | TubD protein | MTPSGDEALQSSIALVGMAGRFPGAPDVESFWRNLVAGVESISFFSEEELRQAGVSEQIRRRPEYVPAKGVLEDLELFDAGFFGYSPREASHLDPQQRLLLECSWEALEDAGLRPDQLPGWVGVYVGAGDTSYRFQLLRGHGDPLSGSKDVAGFFGNYPDFLATRVAYKLNLRGPALGIHTACSTSLVSInMACSALRGFECDMALAGGVSLRLPARSGYLYEEGGVASKDGHCRPFDARATGTVTGDGVGVVVLKRLEDALKARDPIHAVIRGWALNNDGASRAGFTAPSVEGQSEVIALAHAAAGISARDITYVEAHGTGTPLGDPIEVAALTRAFRAHTADTAFCTLGAVKSNIGHLDAAAGVAGVIKTVQALRHRLIPPTLHFERPNPALHLEQSPFFVNTQPLPWESPRGPRLAGVSSFGIGGTNAHTLFEEAPPPPASGPTRPNQVLLLSARSTSALEHIAGRLAAHLRRHPDLELADVAFTLQVGRARFPYRRALTCRTLAEAMERLEAPEPRPPEPLAHEGERPPLVMLFPGQGTPLVGTARALHESEPTFRQAVEQCARLLRQTLGLDVREVLFPSAEQEEQARRLAAQTRVAQPALFTLEYALAQTWLGWGLQPQALAGHSLGELVAACLAGVFSLEDALQLVAARGQLMQGCPPGAMLAVPLPEAELAALLGSELCIAAVNGPRACVASGPLPAVEALTAALESRGVSSRRLETSHAFHSASMEACQGPLTTLLRRMRLQAPRLPCVSGLTGRWLTGEEATEPTYWARQLREPVRFSEALETLWSLKEPVLLEVGPGTTLTALARRHPTRPARTQEVASLPVQPDTAVPCIEEAVGELWQAGLELDWSALHAAPRHRAHLPPYPFERQRYWIEPEAAPQPRAQQPTPASLVPPEQPSREALEDWFYVPTWEQAPATSGGGQPLAGPVLAFMDSSGLAEQVLAALWPADSGALLTRVEPAGHYEQLSEHAFRLRPESEEDWDALFQALQSQGRLPRRILHAWALTAEPGPCTPDGEAVLEQGFFSLLRLARALGRHAPERPVQLEVLSSFVHAVGPREPLEPLKATLLGACAVLPLEYPHVQCRTIDVRPGSEPREVLVRSLAAELAAPMGESPVAWRDGQRYVRRATRQRLEASRPLRSLRERGVYLVAGGLGGIGLVLARALAQRARARLALLTHSPFPPREQWEQWLEEAPAHPEPAWRSEADPSERRRTQHRIRCLLELEQLGAEVQVYTADVAEEAAVRSVVEQVHARWGKIHGVLHAAATFDDGVIQLRTHEQSSRALRTKVRGSMVLHEVLASEGLDWFALCSSLASALGSFGQADYCAANAFQDAYAHHLRRQGFTGALALDWGTWRDTGAAMRLVARTRRGGHEKPPTPLTHPLFDCEQREPGGTHWLGLTLRGGEDWVVDEHRLQGVPTLPGVAYLELARAACAQALGAEAVELAELLLLEPLTVPRGESRQVRVVLQPEGQAHALRVESRSEEARGWNEHARGRVRAVPRLAERIQPELLRAACEHEQPVPGEPQEQGPVHAGARWHGLFQWVRRGPRQALAQLALPEPFHGDLERFELHPALMDMATSFAIPGGVPWLAFGYERVLIHGPLPPQVLSHVSLPEESQAGAQQLRLQVRLLDLEGWERVRIDGYLLRPLKPSDASVEPAAPNVEVAVGTPGLLESLGLRRCTRPAPGPRQVEIEVEAAGLNFLDVLGALGMMPALEAEESVLGRECSGRIAAVGEGVSGLRVGDEVLAVAPGCFRSYVLVDESQVVRRPASLGLAEGAAQMVPFATAYFALHTVGRLRRGERILIHAAAGGLGLAAVQLASRTGAEILATAGSEQKREYLRSLGIAHVLDSRSTSFVSEVRERTGGRGVDVVLNSLAGELLLAGLSVLAPHGRFLELGKRDLYADQQVGLRTLARGQTFAAIDFGPHHPDFRAVLEEVATQLTQGQLEPLPTRLFPARQVAEAFSFMARALHIGRVAVSMQGATALPASMTRGSRPAPVAVPPWEDPRLAGGISSEEGAEAFLRALEQGAPQLIISPQDFSSLLRGLGGSQGVREKERLVTGRAAAAEPQALPPSSLEQLIEQVWRKHLGVERVQPTDSFFQLGGDSLLGIQVAADLRRHLGVELPTATLFSHPTLAALAAALRARQGEAAAPTAPAPALVPDPAARFEPFPLTDVQEAYWVGRRSAFELGGVAAHGYFEIESPGLEVERFIQCWRQLLQRHDMLRMVVLPDGRQQVLEQVPEYTPEVVELRGLSPQEAESRRLQLRERMAHQVLRSDRWPLFELVLCRYEGGVRIHMSMDALMLDAWSSAVLRQDFAQLYHEPGRPLEPLAITFRDYVLAERRLREGEAHERARAYWWARLDTLPPPPELPLVKEPSQLEHARFTHREARLEPHRWARLQERARAHGLTPSAACMAAFAEVLARWSRHPRFTLNLTLFQRLPLHPQVDELVGDFTSLVLLEVEAHAASTFAERASRLQAQLWRDLEHGSVSAVQLIRELVRTGRRSPGAIMPVVFTSILSLDARRGPQGSLSFFEGELVYSISQTPQVWLDHGVHEEEGALVLAWDSVEALFPPGMVDDMFHAYQRLLGALAEEEQAWEGELPELLPPAQRELLARYNATQAPRPSGRLEEGFFTQARLHPELPALLAPERTLSYGELARRAQALAARLRELEVQPQELVAIAMHKGWEQATAVLGVLQAAAAYLPLDPEQPPLRLHQLLEEGPARVVLTQSSLLHTVPWPPGVQVIAVDELEPATEAPPLPPRGTPEHLAYVIYTSGSTGKPKGVAIEHRAALNTVVDLNTRFGVGPEDRVLGLSALTFDLSVYDVLGLLGAGGALVLPAAEAEKDPAHWWERLVAGRVTVWNSTPALMLLLVEYAEQRGLKLPAALRLVMLSGDWIPVALPDRIRALGRDVQVVSLGGATEASIWSIAYPIGQVAPQWKSIPYGMPLANQRFHVLDGRLEARPWWVPGELYIGGEGLAREYWRDEPLTATRFIRHPRTGERLYRTGDQGRMLPEGSIEFLGREDLQVKVQGFRVELGEIEAALAQHPALSASVVVARGEPRGVRRLVAYAVPRSGQTPAAGELRRYLAERLPAYMVPSAFVLLESLPRSRNGKIARDQLPEPQQTQGLAAQAAAADPLVERLAALVKEALRLERVEPQDSLLDLGADSVALIRLINRLEAELQFRPRLADIYENPTVQGLATLHQEKTKSQGEGGAPRLTAPRSTLLPAEEWGRFKANRPGLRRFPDGTPEVALPGSGLAPAPEELTALERRRSVRTYSLEPVSHEQLGRLLAPLREWEVQGSRRYLYASAGGLYPVQLYLHLKPGRARGLEPGTWYYDPSTHRLVLLSAGAGLDRRIHDPHQNQAIFDSAAFSLFLIARMGAVEPVYAEHALHFATLEAGLMTQLLDLGAAPSGLGLCHIGDLDFAQARGLFHLEEEHVLLHSLVGGVLPTRGQEAASVPAEGGTEARQLAQLLQQVKTLTPEAARALLEARRGSKGRPHE | Aeromonads | Apoptosis and thus cell nucleus fragmentation | Toxicity assay, cell nucleus fragmentation assay (cnf) | L929 | Not specified | MIC : 50 ng/ml |
| dbacp06387 | TubE protein | MSKLHEELESLAPEQRELLAALMKEQGLDEGALLMPVERKPEGLPLSSAQQRMWFLQQLRPTSPFYNVHAALRLTGKLKVECLVHSLNEFVRRHEPLRTVFPSAGGQPLQRILAPAPAALEQRDLSGVPAQEREAEVYRAVEHAALASFDLEREPPCRFLLVRVEPEEHVLVFATHHIAADGWSLGVFVQELCALYTAAVHAEPPALPPLRLQYADFAAWERSRLKGGRERELLEYWQEQLAGLPDLSTLPPERPRPPLSKQEGATFEFALPPHQVQALRSLAQARRTSLFSVLLAAFQWLLARCAGQDDVALGMPIANRNRKELEGLIGCFASTLVLRAKPSASTAFTSWLAQVSEQLHGALEHQEVPFERLVEVLQPRRRMDRHPLFQIFLAMQQHPLRRAELPGLLLSEFPLRSRVARFDLEFHLWESAQGVEGTLIYDVDLYGQEGVAQLVRRYVSLLEAVAADPTRTLGELAGETLAPPVRKQVLALSECPPLPRPSTAPRTLAEALLQTAERFPTATVSFVQAQGSCTAWTLPELVERARRLQAGLRQWGLRPGDSLVLVLGREEETVEALWACVLAGVAPLVLPAPPARAEASPALSRLRHARQLLGGPRVLTRQEMLPDLARQLQVSPTADILGAVEELRATGGEAPLPPGRMDDVALLNLTSGTTGKAKCAMLTHRNLLVRLEATNVVYESQPLERGLVWLQLHNIGALSEYHLRPLCAGMHTFHAPTEEVLAEPLRWLEWLERYGIAQTWAPSFAYSHLLERLRKVEDRRWSLGGVRVLLSAGEQISAPMVEELMRRLAPSGVREDAFVAAWGMTETASGVTYARRPGTPPRMHTLERASLSGPLRHAAPASPTALRLMDVGAPIAGTALRVVDASGELLSEECVGRIQVRGEMISPGYYGDPKASAALLTADGWLETGDLGFLSEGALTITGRAKDLVIIHGTNFSCYEIESAVEQVEGVAPSSAAAAAVRMLEGSREELAVFFVPTEGLAPQPPASLLSRIRQQVLEQVGVRIDHLIPLEPHQLPRTEGGKLRRSELRARFEAGELRAPQPAPVPSPSRPLEQLIASVWAEVLEHQDIAPEASFFDLGGNSILLVRVERALRARLGLELTLMDLFAYPTVHSLADYLEPRAAQLPAQASPPTQAERRRGMRGAALEQRRTRRQAQRDED | Aeromonads | Apoptosis and thus cell nucleus fragmentation | Toxicity assay, cell nucleus fragmentation assay (cnf) | L929 | Not specified | MIC : 50 ng/ml |
| dbacp06500 | Vigno 5 | GLPLCGETCVGGTCNTPGCSCGWPVCVRN | Viola ignobilis | Apoptosis inducing | MTT assay, AO/EB and DAPI staining assay | HeLa cells | Cervical cancer | IC50 : 2.5 – 10 μM |
| dbacp06501 | Vigno 5 | GLPLCGETCVGGTCNTPGCSCGWPVCVRN | Viola ignobilis | Apoptosis inducing | MTT assay, AO/EB and DAPI staining assay | L929 | Cervical cancer | IC50 : 2.5 – 10 μM |
| dbacp06532 | VS-9 | VKLRSLLCS | Plant sources | Inducing apoptosis | MTT assay | MOLT4 | Leukemia | Not found |
| dbacp06533 | VS-9 | VKLRSLLCS | Plant sources | Inducing apoptosis | MTT assay | K562 | Leukemia | Not found |
| dbacp06534 | wtmda-7/IL-24 | MNFQQRLQSLWTLARPFCPPLLATASQMQMVVLPCLGFTLLLWSQVSGAQGQEFHFGPCQVKGVVPQKLWEAFWAVKDTMQAQDNITSARLLQQEVLQNVSDAESCYLVHTLLEFYLKTVFKNYHNRTVEVRTLKSFSTLANNFVLIVSQLQPSQENEMFSIRDSAHRRFLLFRRAFKQL | Not found | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | Cell viability (% of control):0.5 at concentration 7 µg/ml |
| dbacp06535 | wtmda-7/IL-24 | MNFQQRLQSLWTLARPFCPPLLATASQMQMVVLPCLGFTLLLWSQVSGAQGQEFHFGPCQVKGVVPQKLWEAFWAVKDTMQAQDNITSARLLQQEVLQNVSDAESCYLVHTLLEFYLKTVFKNYHNRTVEVRTLKSFSTLANNFVLIVSQLQPSQENEMFSIRDSAHRRFLLFRRAFKQL | Not found | Apoptosis inducing | MTT/MTS assay | Ket-3 | Tumor | Cell viability (% of control): 0.5 at concentration 8 µg/ml |
| dbacp06536 | wtmda-7/IL-24 | MNFQQRLQSLWTLARPFCPPLLATASQMQMVVLPCLGFTLLLWSQVSGAQGQEFHFGPCQVKGVVPQKLWEAFWAVKDTMQAQDNITSARLLQQEVLQNVSDAESCYLVHTLLEFYLKTVFKNYHNRTVEVRTLKSFSTLANNFVLIVSQLQPSQENEMFSIRDSAHRRFLLFRRAFKQL | Not found | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | Apoptotic rate(%) : > 50% at concentration of 8 µg/ml |
| dbacp06537 | wtmda-7/IL-24 | MNFQQRLQSLWTLARPFCPPLLATASQMQMVVLPCLGFTLLLWSQVSGAQGQEFHFGPCQVKGVVPQKLWEAFWAVKDTMQAQDNITSARLLQQEVLQNVSDAESCYLVHTLLEFYLKTVFKNYHNRTVEVRTLKSFSTLANNFVLIVSQLQPSQENEMFSIRDSAHRRFLLFRRAFKQL | Not found | Apoptosis inducing | MTT/MTS assay | Ket-3 | Tumor | Apoptotic rate(%) : > 30% at concentration of 8 µg/ml |
| dbacp06538 | XD5 | RPEIWYAQELRRNGDEFNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp06539 | XF8 | RPEIWFAQELKRNGDEYNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp06540 | XG10 | RPEIWYAQEIRRFGDEFNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp06541 | XG12 | RPEIWYAQELGRAGDEFNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp06542 | XH11 | RPEIWVAQELKRNGDEFNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Not found | Not found |
| dbacp06544 | YALPAG | YALPAG | Not found | Inducing apoptosis | Not specified | PC-3 | Not found | IC50 : 42.0 mg/ml |
| dbacp06545 | YALPAH | YALPAH | Not found | Inducing apoptosis | Not specified | PC-3 | Not found | IC50 : 11.3 mg/ml |
| dbacp06546 | YALPAR | YALPAR | Not found | Inducing apoptosis | Not specified | PC-3 | Not found | IC50 : 13.1 mg/ml |
| dbacp06547 | YALRAH | YALRAH | Not found | Inducing apoptosis | Not specified | PC-3 | Not found | IC50 : 8.1 mg/ml |
| dbacp06598 | ZXR-1 | FKIGGFIKKLWRSKLA | Venom base | Inducing apoptosis | MTT assay | Hela | Not found | IC50 : 62.6 ± 8.4 µM |
| dbacp06599 | ZXR-1 | FKIGGFIKKLWRSKLA | Venom base | Inducing apoptosis | MTT assay | SACC-83 | Not found | IC50 : 27.9 ± 7.7 µM |
| dbacp06600 | ZXR-1 | FKIGGFIKKLWRSKLA | Venom base | Inducing apoptosis | MTT assay | PC-3 | Not found | IC50 : 69.1 ± 1.6 µM |
| dbacp06601 | ZXR-1 | FKIGGFIKKLWRSKLA | Venom base | Inducing apoptosis | MTT assay | HuH-7 | Not found | IC50 : 77.9 ± 0.9 µM |
| dbacp06602 | ZXR-1 | FKIGGFIKKLWRSKLA | Venom base | Inducing apoptosis | MTT assay | HepG2 | Not found | IC50 : 141.7 ± 12.2 µM |
| dbacp06603 | ZXR-1 | FKIGGFIKKLWRSKLA | Venom base | Inducing apoptosis | MTT assay | 293T | Not found | IC50 : 186.7 ± 13.1 µM |
| dbacp06604 | ZXR-1 | FKIGGFIKKLWRSKLA | Venom base | Inducing apoptosis | MTT assay | WPMY-1 | Not found | IC50 : 283.3 ± 19.0 µM |
| dbacp06605 | αs1-casein f(90_95) | RYLGYL | Bovine milk | Regulation of immune response; Apoptosis inducing | MTT/MTS assay | AZ-97 | Colon cancer | Inhibition at 12 - 15 g/l |
| dbacp06606 | β-Casomorphins 5 f(60_64) | YPFPG | Bovine milk | Regulation of immune response; Apoptosis inducing | MTT/MTS assay | AZ-97 | Colon cancer | Inhibition at 9 - 11 g/l |
| dbacp06656 | LfcinB (21-25)Pal | RWQWRWQWR | LfcinB | Apoptosis inducing | MTT assay | CaCo-2 | Colorectal Cancer | IC50 = 86 μM |
| dbacp06657 | LfcinB (21-25)Pal | RWQWRWQWR | LfcinB | Apoptosis inducing | MTT assay | HT-29 | Colon Cancer | IC50 = 100 μM |
| dbacp06658 | LfcinB (21-25)Pal | RWQWRWQWR | LfcinB | Apoptosis inducing | MTT assay | DU-145 | Prostrate Cancer | IC50 = 40 μM |
| dbacp06659 | Ahx-[Pal] | Ahx-RWQWRWQWR | Synthetic | Apoptosis inducing | MTT assay | HT-29 | Colon Cancer | IC50 = 119 μM |
| dbacp06660 | Ahx-[Pal] | Ahx-RWQWRWQWR | Synthetic | Apoptosis inducing | MTT assay | CaCo-2 | Colorectal Cancer | IC50 = 40 μM |
| dbacp06661 | 9[Orn] [Pal] | RWQWRWQWO | Synthetic | Apoptosis inducing | MTT assay | HT-29 | Colon Cancer | IC50 = 109 μM |
| dbacp06662 | 9[Orn] [Pal] | RWQWRWQWO | Synthetic | Apoptosis inducing | MTT assay | CaCo-2 | Colorectal Cancer | IC50 = 40 μM |
| dbacp06663 | 9[Orn] [Pal] | RWQWRWQWO | Synthetic | Apoptosis inducing | MTT assay | DU-145 | Prostrate Cancer | IC50 = 62 μM |
| dbacp06664 | CH3CO-Ahx-[Pal] | CH3-CO-Ahx-RWQWRWQWR | Synthetic | Apoptosis inducing | MTT assay | CaCo-2 | Colorectal Cancer | IC50 = 31 μM |
| dbacp06665 | 1[dR][Pal] | rWQWRWQWR | Synthetic | Apoptosis inducing | MTT assay | CaCo-2 | Colorectal Cancer | IC50 = 105 μM |
| dbacp06666 | 1[Orn] [Pal] | OWQWRWQWR | Synthetic | Apoptosis inducing | MTT assay | CaCo-2 | Colorectal Cancer | IC50 = 91 μM |
| dbacp06667 | 5[Orn] [Pal] | RWQWOWQWR | Synthetic | Apoptosis inducing | MTT assay | CaCo-2 | Colorectal Cancer | IC50 = 64 μM |
| dbacp06668 | 1[dR] 5[Orn] [Pal] | rWQWOWQWR | Synthetic | Apoptosis inducing | MTT assay | CaCo-2 | Colorectal Cancer | IC50 = 109 μM |
| dbacp06704 | P05 | ADDGRPFPQVIK | Aldolase A fragment | Apoptosis inducing | MTT assay | MG-63 | Bone Cancer | Relative viability = 0.85 at 50 μg/ml |
| dbacp06705 | P05 | ADDGRPFPQVIK | Aldolase A fragment | Apoptosis inducing | MTT assay | U-2 OS | Bone Cancer | Relative viability = 0.98 at 50 μg/ml |
| dbacp06706 | P02 | AEEYEFLTPMEEAPK | Rho GDP Dissociation Inhibitor Alpha fragment | Apoptosis inducing | MTT assay | MG-63 | Bone Cancer | Relative viability = 0.88 at 50 μg/ml |
| dbacp06707 | P02 | AEEYEFLTPMEEAPK | Rho GDP Dissociation Inhibitor Alpha fragment | Apoptosis inducing | MTT assay | U-2 OS | Bone Cancer | Relative viability = 0.93 at 50 μg/ml |
| dbacp06708 | P01 | SETAPAAPAAPAPAEK | Histone H1.4 (H1-4) Fragment | Apoptosis inducing | MTT assay | MG-63 | Bone Cancer | Relative viability = 0.84 at 50 μg/ml |
| dbacp06709 | P01 | SETAPAAPAAPAPAEK | Histone H1.4 (H1-4) Fragment | Apoptosis inducing | MTT assay | U-2 OS | Bone Cancer | Relative viability = 1.13 at 50 μg/ml |
| dbacp06710 | P03 | HVFGESDELIGQK | Triosephosphate Isomerase (TPI) fragment | Apoptosis inducing | MTT assay | MG-63 | Bone Cancer | Relative viability = 1.04 at 50 μg/ml |
| dbacp06711 | P03 | HVFGESDELIGQK | Triosephosphate Isomerase (TPI) fragment | Apoptosis inducing | MTT assay | U-2 OS | Bone Cancer | Relative viability = 0.98 at 50 μg/ml |
| dbacp06712 | P06 | GAGTGGLGLAVEGPSEAK | FLNA (Filamin A) fragment | Apoptosis inducing | MTT assay | MG-63 | Bone Cancer | Relative viability = 0.92 at 50 μg/ml |
| dbacp06713 | P06 | GAGTGGLGLAVEGPSEAK | FLNA (Filamin A) fragment | Apoptosis inducing | MTT assay | U-2 OS | Bone Cancer | Relative viability = 1.17 at 50 μg/ml |
| dbacp06714 | P07 | VEPGLGADNSVVR | FLNA (Filamin A) fragment | Apoptosis inducing | MTT assay | MG-63 | Bone Cancer | Relative viability = 0.96 at 50 μg/ml |
| dbacp06715 | P07 | VEPGLGADNSVVR | FLNA (Filamin A) fragment | Apoptosis inducing | MTT assay | U-2 OS | Bone Cancer | Relative viability = 0.96 at 50 μg/ml |
| dbacp06716 | P08 | NSNLVGAAHEELQQSR | Lamin A/C (LMNA) fragment | Apoptosis inducing | MTT assay | MG-63 | Bone Cancer | Relative viability = 0.92 at 50 μg/ml |
| dbacp06717 | P08 | NSNLVGAAHEELQQSR | Lamin A/C (LMNA) fragment | Apoptosis inducing | MTT assay | U-2 OS | Bone Cancer | Relative viability = 1.06 at 50 μg/ml |
| dbacp06718 | P09 | AAGTLYTYPENWR | Eukaryotic Translation Elongation Factor 1 Gamma (Eef1G) fragment | Apoptosis inducing | MTT assay | MG-63 | Bone Cancer | Relative viability = 0.85 at 50 μg/ml |
| dbacp06719 | P09 | AAGTLYTYPENWR | Eukaryotic Translation Elongation Factor 1 Gamma (Eef1G) fragment | Apoptosis inducing | MTT assay | U-2 OS | Bone Cancer | Relative viability = 1.07 at 50 μg/ml |
| dbacp06720 | P10 | FAAATGATPIAGR | 40S ribosomal protein fragment | Apoptosis inducing | MTT assay | MG-63 | Bone Cancer | Relative viability = 1.08 at 50 μg/ml |
| dbacp06721 | P10 | FAAATGATPIAGR | 40S ribosomal protein fragment | Apoptosis inducing | MTT assay | U-2 OS | Bone Cancer | Relative viability = 1.01 at 50 μg/ml |
| dbacp06735 | NKL-WT | KLKSKLMVVCNKIGLLKSLCRKFVKSH | Trematomus bernacchii | Apoptosis inducing | luciferase-based ATPlite assay | B16-F10 | Skin Cancer | ATP level = 0.753 ± 0.254 at 40 μM |
| dbacp06736 | NKL-MUT | KLKSKLMVVANKIGLLKSLARKFVKSH | Trematomus bernacchii | Apoptosis inducing | luciferase-based ATPlite assay | B16-F10 | Skin Cancer | ATP level = 0.023 ± 0.007 at 40 μM |
| dbacp06749 | mPNC-NLS | QETFSDLWKLLVQRKRQKLMP | Synthetic | p53-mediated apoptosis | MTT assay | A-549 | Lung Cancer | IC50 = 44.9 μM |
| dbacp06750 | mPNC-NLS | QETFSDLWKLLVQRKRQKLMP | Synthetic | p53-mediated apoptosis | MTT assay | U-87 | Brain Tumor | IC50 = 56.9 μM |
| dbacp06751 | mPNC-NLS | QETFSDLWKLLVQRKRQKLMP | Synthetic | p53-mediated apoptosis | Cytotoxicity assay | A-549 | Lung Cancer | IC50 = 45 μM |
| dbacp06754 | 37-mer peptide | TKEQKEQIAKATGLTTKQVRNWYVQLNASIKVCMCSC | Synthetic | Apoptosis inducing | MTT assay | SNU-449 | Liver Cancer | IC50 = 76.4 ± 0.6015 μM |
| dbacp06755 | 37-mer peptide | TKEQKEQIAKATGLTTKQVRNWYVQLNASIKVCMCSC | Synthetic | Apoptosis inducing | MTT assay | HepG-2 | Liver Cancer | IC50 = 33.65 ± 1.09 μM |
| dbacp06756 | 37-mer peptide | TKEQKEQIAKATGLTTKQVRNWYVQLNASIKVCMCSC | Synthetic | Apoptosis inducing | MTT assay | SK-OV-3 | Ovarian cancer | IC50 = 27.45 ± 1.5085 μM |
| dbacp06757 | ATMP5 | THPPTTTTTTTTTTTYTAAPATTT | Synthetic Analog of ATMP1 | Apoptosis inducing | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 64.04 ± 0.021 μg /ml |
| dbacp06758 | ATMP1 | THPPTTTTTTTTTTTYTAAPATTT | Anabas testudineus | Apoptosis inducing | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 8.25 ± 0.14 μg/ml |
| dbacp06759 | p28 | LSTAADMQGVVTDGMASGLDKDYLKPDD | Pseudomonas aeruginosa | Apoptosis inducing | MTT assay | HT-29 | Colon Cancer | IC50 ~ 200 μg/ml |
| dbacp06760 | p28 | LSTAADMQGVVTDGMASGLDKDYLKPDD | Pseudomonas aeruginosa | Apoptosis inducing | MTT assay | CT-26 | Colorectal Cancer | IC50 ~ 150 μg/ml |
| dbacp06761 | RP7 | ATRQPNH | RAGE(receptor for advanced glycation end product) inhibitor | Apoptosis inducing | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 24.5 µM |
| dbacp06762 | RP7 | ATRQPNH | RAGE(receptor for advanced glycation end product) inhibitor | Apoptosis inducing | MTT assay | BT-549 | Breast Cancer | IC50 = 29.9 µM |
| dbacp06793 | CPSA-CPSC-L-ACAN | Not Available | Recombinant Fusion Peptide | Apoptosis inducing | MTT assay | HeLa | Cervical Cancer | IC50 = 63.15 μg/ml |
| dbacp06794 | CM11 | WKLFKKILKVL | Cecropin-Melittin Hybrid Peptide | Apoptosis inducing | MTT assay | Jurkat | Blood Cancer | Survival rate = 47% at 32 μg/ml |
| dbacp06795 | CM11 | WKLFKKILKVL | Cecropin-Melittin Hybrid Peptide | Apoptosis inducing | MTT assay | Raji | Blood Cancer | Survival rate = 51% at 32 μg/ml |
| dbacp06796 | LHRH-BinBC | QHWSYGLRPGGRGPKDAVRAVKGSALLPCIIVHDPNLNNSDKMKFNTYYLLEYKEYWHQLWSQIIPAHQTVKIQERTGISEVVQNSMIEDLNMYIGADFGMYFYLRSSGFKEQITRGLNRPLSQTTTQLGERVEEMEYYNSNDLDVRYVKYALAREFTLKRVNGEIVKNWVAVDYRMAGIQSYPNAPITNPLTLT | Synthetic | Apoptosis inducing | MTT assay | MCF-7 | Breast Cancer | IC50 = 10.96 μM |
| dbacp06797 | LHRH-BinBC | QHWSYGLRPGGRGPKDAVRAVKGSALLPCIIVHDPNLNNSDKMKFNTYYLLEYKEYWHQLWSQIIPAHQTVKIQERTGISEVVQNSMIEDLNMYIGADFGMYFYLRSSGFKEQITRGLNRPLSQTTTQLGERVEEMEYYNSNDLDVRYVKYALAREFTLKRVNGEIVKNWVAVDYRMAGIQSYPNAPITNPLTLT | Synthetic | Apoptosis inducing | LDH leakage assay | MCF-7 | Breast Cancer | 40% LDH efflux at 16 µM |
| dbacp06851 | WP1 | RLLRLMRLRMLLRM | Derived from RLL peptide | Apoptosis inducing | HDAC inhibition assay | HeLa | Cervical Cancer | IC50 = 0.310±0.064 µM |
| dbacp06852 | WP1 | RLLRLMRLRMLLRM | Derived from RLL peptide | Apoptosis inducing | Cell Viability assay | Huh-7 | Liver Cancer | IC50 = 43.74 ± 5.4 μM |
| dbacp06853 | WP1 | RLLRLMRLRMLLRM | Derived from RLL peptide | Apoptosis inducing | Cell Viability assay | HepG-2 | Liver Cancer | IC50 = 52.23 ± 0.9 μM |
| dbacp06854 | WP1 | RLLRLMRLRMLLRM | Derived from RLL peptide | Apoptosis inducing | Cell Viability assay | HT-29 | Colon Cancer | IC50 = 54.6 ± 2.1 μM |
| dbacp06855 | WP2 | RLLRLLRLRRLLRL | Derived from RLL peptide | Apoptosis inducing | HDAC inhibition assay | HeLa | Cervical Cancer | IC50 = 0.446±0.095 µM |
| dbacp06856 | WP2 | RLLRLLRLRRLLRL | Derived from RLL peptide | Apoptosis inducing | Cell Viability assay | Huh-7 | Liver Cancer | IC50 = 28.12 ± 1.5 μM |
| dbacp06857 | WP2 | RLLRLLRLRRLLRL | Derived from RLL peptide | Apoptosis inducing | Cell Viability assay | HepG-2 | Liver Cancer | IC50 = 34.05 ± 0.53 μM |
| dbacp06858 | WP2 | RLLRLLRLRRLLRL | Derived from RLL peptide | Apoptosis inducing | Cell Viability assay | HT-29 | Colon Cancer | IC50 = 42.6 ± 4.0 μM |
| dbacp06864 | AMP-WF3 | FLKSLWRGVKAIFNGARQGYKEHKN | Poecilia Mexicana fish | Apoptosis inducing | MTT assay | Jurkat | Blood Cancer | IC50 = 50 µM |
| dbacp06868 | LfcinB(21-25)Pal | RWQWRWQWR | LfcinB | Apoptosis inducing | MTT assay | MDA-MB-468 | Breast Cancer | IC50 = 72 µM |
| dbacp06869 | LfcinB(21-25)Pal | RWQWRWQWR | LfcinB | Apoptosis inducing | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 103 µM |
| dbacp06870 | LfcinB(21-25)Pal | RWQWRWQWR | LfcinB | Apoptosis inducing | MTT assay | MCF-7 | Breast Cancer | IC50 = 81 µM |
| dbacp06871 | RR-1-RR | RRWQWRWQWRR | Synthetic analogue of LfcinB(21-25)Pal | Apoptosis inducing | MTT assay | MCF-7 | Breast Cancer | IC50 = 58 µM |
| dbacp06872 | RR-1-RR | RRWQWRWQWRR | Synthetic analogue of LfcinB(21-25)Pal | Apoptosis inducing | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 67 µM |
| dbacp06873 | R-1-RR | RWQWRWQWRR | Synthetic analogue of LfcinB(21-25)Pal | Apoptosis inducing | MTT assay | MCF-7 | Breast Cancer | IC50 = 122 µM |
| dbacp06874 | R-1-RR | RWQWRWQWRR | Synthetic analogue of LfcinB(21-25)Pal | Apoptosis inducing | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 95 µM |
| dbacp06875 | RR-1-R | RRWQWRWQWR | Synthetic analogue of LfcinB(21-25)Pal | Apoptosis inducing | MTT assay | MCF-7 | Breast Cancer | IC50 = 68 µM |
| dbacp06876 | RR-1-R | RRWQWRWQWR | Synthetic analogue of LfcinB(21-25)Pal | Apoptosis inducing | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 73 µM |
| dbacp06877 | 1 | WQWRWQW | Synthetic analogue of LfcinB(21-25)Pal | Apoptosis inducing | MTT assay | MCF-7 | Breast Cancer | IC50 = 105 µM |
| dbacp06878 | 1 | WQWRWQW | Synthetic analogue of LfcinB(21-25)Pal | Apoptosis inducing | MTT assay | MDA-MB-231 | Breast Cancer | IC50 > 170 µM |
| dbacp06879 | R-1 | RWQWRWQW | Synthetic analogue of LfcinB(21-25)Pal | Apoptosis inducing | MTT assay | MCF-7 | Breast Cancer | IC50 = 58 µM |
| dbacp06880 | R-1 | RWQWRWQW | Synthetic analogue of LfcinB(21-25)Pal | Apoptosis inducing | MTT assay | MDA-MB-231 | Breast Cancer | IC50 > 150 µM |
| dbacp06881 | 1-R | WQWRWQWR | Synthetic analogue of LfcinB(21-25)Pal | Apoptosis inducing | MTT assay | MCF-7 | Breast Cancer | IC50 = 130 µM |
| dbacp06882 | 1-R | WQWRWQWR | Synthetic analogue of LfcinB(21-25)Pal | Apoptosis inducing | MTT assay | MDA-MB-231 | Breast Cancer | IC50 > 150 µM |
| dbacp06883 | trichoderin A | MDA-P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderma sp. fungus, strain 05FI48 | Apoptosis inducing | PrestoBlue assay | BxPC-3 | Pancreatic Cancer | IC50 = 0.4 μM |
| dbacp06884 | trichoderin A | MDA-P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderma sp. fungus, strain 05FI48 | Apoptosis inducing | CyQUANT Direct assay | PANC-1 | Pancreatic Cancer | IC50 = 0.3 μM |
| dbacp06885 | trichoderin A analogue 4 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | PrestoBlue assay | BxPC-3 | Pancreatic Cancer | IC50 = 0.4 μM |
| dbacp06886 | trichoderin A analogue 12 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | PrestoBlue assay | BxPC-3 | Pancreatic Cancer | IC50 > 1 μM |
| dbacp06887 | trichoderin A analogue 13 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | PrestoBlue assay | BxPC-3 | Pancreatic Cancer | IC50 > 1 μM |
| dbacp06888 | trichoderin A analogue 14 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | PrestoBlue assay | BxPC-3 | Pancreatic Cancer | IC50 = 0.6 μM |
| dbacp06889 | trichoderin A analogue 15 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | PrestoBlue assay | BxPC-3 | Pancreatic Cancer | IC50 = 0.5 μM |
| dbacp06890 | trichoderin A analogue 16 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | PrestoBlue assay | BxPC-3 | Pancreatic Cancer | IC50 = 0.4 μM |
| dbacp06891 | trichoderin A analogue 17 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | PrestoBlue assay | BxPC-3 | Pancreatic Cancer | IC50 = 0.4 μM |
| dbacp06892 | trichoderin A analogue 18 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | PrestoBlue assay | BxPC-3 | Pancreatic Cancer | IC50 = 0.2 μM |
| dbacp06893 | trichoderin A analogue 4 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | CyQUANT Direct assay | PANC-1 | Pancreatic Cancer | IC50 = 0.5 μM |
| dbacp06894 | trichoderin A analogue 12 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | CyQUANT Direct assay | PANC-1 | Pancreatic Cancer | IC50 > 9 μM |
| dbacp06895 | trichoderin A analogue 13 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | CyQUANT Direct assay | PANC-1 | Pancreatic Cancer | IC50 = 6.0 μM |
| dbacp06896 | trichoderin A analogue 14 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | CyQUANT Direct assay | PANC-1 | Pancreatic Cancer | IC50 = 1.8 μM |
| dbacp06897 | trichoderin A analogue 15 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | CyQUANT Direct assay | PANC-1 | Pancreatic Cancer | IC50 = 0.9 μM |
| dbacp06898 | trichoderin A analogue 16 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | CyQUANT Direct assay | PANC-1 | Pancreatic Cancer | IC50 = 0.5 μM |
| dbacp06899 | trichoderin A analogue 17 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | CyQUANT Direct assay | PANC-1 | Pancreatic Cancer | IC50 = 0.6 μM |
| dbacp06900 | trichoderin A analogue 18 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | CyQUANT Direct assay | PANC-1 | Pancreatic Cancer | IC50 = 0.2 μM |
| dbacp06901 | trichoderin A analogue 19 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | CyQUANT Direct assay | PANC-1 | Pancreatic Cancer | IC50 = 0.2 μM |
| dbacp06902 | trichoderin A analogue 19 | MDA-P-AHMOD-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | PrestoBlue assay | BxPC-3 | Pancreatic Cancer | IC50 = 0.1 μM |
| dbacp06904 | LFcin17–30 | FKCRRWQWRMKKLG | Lectoferrin Peptide | Apoptosis inducing | MTT assay | HepG-2 | Liver Cancer | cell viability ~ 50% at 1 µM |
| dbacp06905 | LFcin17–30 | FKCRRWQWRMKKLG | Lectoferrin Peptide | Apoptosis inducing | MTT assay | Jurkat | Blood Cancer | cell viability ~ 70% at 20 µM |
| dbacp06906 | LFampin265–284 | DLIWKLLSKAQEKFGKNKSR | Lectoferrin Peptide | Apoptosis inducing | MTT assay | HepG-2 | Liver Cancer | cell viability ~ 50% at 1 µM |
| dbacp06907 | LFampin265–284 | DLIWKLLSKAQEKFGKNKSR | Lectoferrin Peptide | Apoptosis inducing | MTT assay | Jurkat | Blood Cancer | cell viability ~ 47% at 10 µM |
| dbacp06908 | LFchimera | FKCRRWQWRMKKLG-K-RSKNKGFKEQAKSLLKWILD | Synthetic - Lectoferrin chimera | Apoptosis inducing | MTT assay | HepG-2 | Liver Cancer | cell viability ~ 44% at 10 µM |
| dbacp06909 | LFchimera | FKCRRWQWRMKKLG-K-RSKNKGFKEQAKSLLKWILD | Synthetic - Lectoferrin chimera | Apoptosis inducing | MTT assay | Jurkat | Blood Cancer | cell viability ~ 8% at 20 µM |
| dbacp06917 | KM8 | KLLKINLKALAALAKKIL | Synthetic derivative of Mastoparan | Apoptosis inducing | Not Available | Not Available | Not Available | Not Available |
| dbacp06918 | KM8-Aib | KLLKINLK(Aib)LAALAKKIL | Synthetic derivative of KM8 | Apoptosis inducing | Not Available | Not Available | Not Available | Not Available |
| dbacp06941 | PS14 | PTECQVGTTCKVES | Aphanomyces invadans | Apoptosis inducing | MTT assay | Hep-2 | Larynx Cancer | IC50 = 21 µM |
| dbacp06942 | HTDT-6-2-3-2 | GPLGAGP | Enteromorpha prolifera | Apoptosis inducing | CCK-8 assay | NCI-H-460 | Lung Cancer | IC50 = 0.3686 ± 0.0935 mg/mL |
| dbacp06943 | HTDT-6-2-3-2 | GPLGAGP | Enteromorpha prolifera | Apoptosis inducing | CCK-8 assay | HepG-2 | Liver Cancer | IC50 = 1.2564 ± 0.0548 mg/mL |
| dbacp06944 | HTDT-6-2-3-2 | GPLGAGP | Enteromorpha prolifera | Apoptosis inducing | CCK-8 assay | A-549 | Lung Cancer | IC50 = 0.9867 ± 0.0857 mg/mL |
| dbacp06980 | Ponericin-W1 (11-25), At1 | KLLPSVVGLFKKKKQ | Synthetic | Apoptosis inducing | MTT assay | A-549 | Lung Cancer | IC50 > 100 µM |
| dbacp06981 | Ponericin-W1 (11-25), At1 | KLLPSVVGLFKKKKQ | Synthetic | Apoptosis inducing | MTT assay | HepG-2 | Liver Cancer | IC50 >100 µM |
| dbacp06982 | Ponericin-W1 (11-25) [P4K | KLLKKVVKLFKKKKK | Synthetic | Apoptosis inducing | MTT assay | A-549 | Lung Cancer | IC50 >100 µM |
| dbacp06983 | Ponericin-W1 (11-25) [P4K | KLLKKVVKLFKKKKK | Synthetic | Apoptosis inducing | MTT assay | HepG-2 | Liver Cancer | IC50 >100 µM |
| dbacp06984 | Ponericin-W1 (11-25) [P4K | KLLKKVVKLFKKLLK | Synthetic | Apoptosis inducing | MTT assay | A-549 | Lung Cancer | IC50 = 4.3 µM |
| dbacp06985 | Ponericin-W1 (11-25) [P4K | KLLKKVVKLFKKLLK | Synthetic | Apoptosis inducing | MTT assay | HepG-2 | Liver Cancer | IC50 = 2.2 µM |
| dbacp06986 | At4 | KLLKKLLKLLKKLLK | Synthetic | Apoptosis inducing | MTT assay | A-549 | Lung Cancer | IC50 = 7.2 µM |
| dbacp06987 | At4 | KLLKKLLKLLKKLLK | Synthetic | Apoptosis inducing | MTT assay | HepG-2 | Liver Cancer | IC50 = 2.5 µM |
| dbacp06988 | At5 | KIIKKIIKIIKKIIK | Synthetic | Apoptosis inducing | MTT assay | A-549 | Lung Cancer | IC50 = 3.6 µM |
| dbacp06989 | At5 | KIIKKIIKIIKKIIK | Synthetic | Apoptosis inducing | MTT assay | HepG-2 | Liver Cancer | IC50 = 1.5 µM |
| dbacp06990 | At6 | KVVKKVVKVVKKVVK | Synthetic | Apoptosis inducing | MTT assay | A-549 | Lung Cancer | IC50 > 100 µM |
| dbacp06991 | At6 | KVVKKVVKVVKKVVK | Synthetic | Apoptosis inducing | MTT assay | HepG-2 | Liver Cancer | IC50 = 70.8 µM |
| dbacp06992 | At7 | KIIKKIKKKIKKIIK | Synthetic | Apoptosis inducing | MTT assay | A-549 | Lung Cancer | IC50 = 10.3 µM |
| dbacp06993 | At7 | KIIKKIKKKIKKIIK | Synthetic | Apoptosis inducing | MTT assay | HepG-2 | Liver Cancer | IC50 = 8.8 µM |
| dbacp06994 | At8 | KLLKKLKKKLKKLLK | Synthetic | Apoptosis inducing | MTT assay | A-549 | Lung Cancer | IC50 = 13.4 µM |
| dbacp06995 | At8 | KLLKKLKKKLKKLLK | Synthetic | Apoptosis inducing | MTT assay | HepG-2 | Liver Cancer | IC50 = 8.9 µM |
| dbacp06996 | At9 | KVVKKVKKKVKKVVK | Synthetic | Apoptosis inducing | MTT assay | A-549 | Lung Cancer | IC50 = 100 µM |
| dbacp06997 | At9 | KVVKKVKKKVKKVVK | Synthetic | Apoptosis inducing | MTT assay | HepG-2 | Liver Cancer | IC50 = 51.7 µM |
| dbacp06998 | At10 | IKKIIKIIKKIIKKI | Synthetic | Apoptosis inducing | MTT assay | A-549 | Lung Cancer | IC50 = 4.4 µM |
| dbacp06999 | At10 | IKKIIKIIKKIIKKI | Synthetic | Apoptosis inducing | MTT assay | HepG-2 | Liver Cancer | IC50 = 3.2 µM |
| dbacp07000 | At11 | IIIKKIKKKIKKIII | Synthetic | Apoptosis inducing | MTT assay | A-549 | Lung Cancer | IC50 = 7.9 µM |
| dbacp07001 | At11 | IIIKKIKKKIKKIII | Synthetic | Apoptosis inducing | MTT assay | HepG-2 | Liver Cancer | IC50 = 7.6 µM |
| dbacp07002 | At12 | KIIIKIKKKIKIIIK | Synthetic | Apoptosis inducing | MTT assay | A-549 | Lung Cancer | IC50 = 14.0 µM |
| dbacp07003 | At12 | KIIIKIKKKIKIIIK | Synthetic | Apoptosis inducing | MTT assay | HepG-2 | Liver Cancer | IC50 = 13.4 µM |
| dbacp07017 | D-LAK-120-A | kklalalakkwlalakklalalakk | Synthetic | ROS induction, mitochondria-mediated apoptosis. | MTT assay | A-549 | Lung Cancer | IC50 = 5.55 ± 0.13 μM |
| dbacp07018 | D-LAK-120-A | kklalalakkwlalakklalalakk | Synthetic | ROS induction, mitochondria-mediated apoptosis. | MTT assay | H-358 | Non Small Cell Lung Cancer (NSCLC) | IC50 = 4.00 ± 0.20 μM |
| dbacp07019 | D-LAK-120-A | kklalalakkwlalakklalalakk | Synthetic | ROS induction, mitochondria-mediated apoptosis. | MTT assay | H-1975 | Non Small Cell Lung Cancer (NSCLC) | IC50 between 4.0 and 5.5 μM |
| dbacp07020 | D-LAK-120-A | kklalalakkwlalakklalalakk | Synthetic | ROS induction, mitochondria-mediated apoptosis. | MTT assay | HCC-827 | Lung Adenocarcinoma | IC50 between 4.0 and 5.5 μM |
| dbacp07050 | Temporin-PKE | FLPLIIGALSSLLPKIF | skin secretion of Pelophylax kl. esculentus | Charge-optimized membranolysis induces apoptosis. | MTT assay | U251-MG | Brain Tumor | IC50 = 23.24 μM |
| dbacp07051 | Temporin-PKE | FLPLIIGALSSLLPKIF | skin secretion of Pelophylax kl. esculentus | Charge-optimized membranolysis induces apoptosis. | MTT assay | PC-3 | Prostate Cancer | IC50 = 7.29 μM |
| dbacp07052 | Temporin-PKE | FLPLIIGALSSLLPKIF | skin secretion of Pelophylax kl. esculentus | Charge-optimized membranolysis induces apoptosis. | MTT assay | H-838 | Lung Cancer | IC50 = 16.38 μM |
| dbacp07053 | Temporin-PKE | FLPLIIGALSSLLPKIF | skin secretion of Pelophylax kl. esculentus | Charge-optimized membranolysis induces apoptosis. | MTT assay | HCT-116 | Colorectal Cancer | IC50 = 21.31 μM |
| dbacp07054 | Temporin-PKE | FLPLIIGALSSLLPKIF | skin secretion of Pelophylax kl. esculentus | Charge-optimized membranolysis induces apoptosis. | MTT assay | H-157 | Lung Cancer | IC50 = 17.40 μM |
| dbacp07055 | Temporin-PKE-2K | FLPLIIGKLSSLLPKIF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | U251-MG | Brain Tumor | IC50 = 2.49 μM |
| dbacp07056 | Temporin-PKE-2K | FLPLIIGKLSSLLPKIF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | PC-3 | Prostate Cancer | IC50 = 2.64 μM |
| dbacp07057 | Temporin-PKE-2K | FLPLIIGKLSSLLPKIF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | H-838 | Lung Cancer | IC50 = 3.07 μM |
| dbacp07058 | Temporin-PKE-2K | FLPLIIGKLSSLLPKIF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | HCT-116 | Colorectal Cancer | IC50 = 2.84 μM |
| dbacp07059 | Temporin-PKE-2K | FLPLIIGKLSSLLPKIF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | H-157 | Lung Cancer | IC50 = 2.78 μM |
| dbacp07060 | Temporin-PKE-K12 | FLPLIIGALSSKLPKIF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | U251-MG | Brain Tumor | IC50 = 25.75 μM |
| dbacp07061 | Temporin-PKE-K12 | FLPLIIGALSSKLPKIF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | PC-3 | Prostate Cancer | IC50 = 27.32 μM |
| dbacp07062 | Temporin-PKE-K12 | FLPLIIGALSSKLPKIF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | H-838 | Lung Cancer | IC50 = 22.67 μM |
| dbacp07063 | Temporin-PKE-K12 | FLPLIIGALSSKLPKIF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | HCT-116 | Colorectal Cancer | IC50 = 22.09 μM |
| dbacp07064 | Temporin-PKE-K12 | FLPLIIGALSSKLPKIF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | H-157 | Lung Cancer | IC50 = 24.03 μM |
| dbacp07065 | Temporin-PKE-3K | FLPKIIGKLSSLLPKIF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | U251-MG | Brain Tumor | IC50 = 2.83 μM |
| dbacp07066 | Temporin-PKE-3K | FLPKIIGKLSSLLPKIF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | PC-3 | Prostate Cancer | IC50 = 3.01 μM |
| dbacp07067 | Temporin-PKE-3K | FLPKIIGKLSSLLPKIF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | H-838 | Lung Cancer | IC50 = 0.51 μM |
| dbacp07068 | Temporin-PKE-3K | FLPKIIGKLSSLLPKIF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | HCT-116 | Colorectal Cancer | IC50 = 0.38 μM |
| dbacp07069 | Temporin-PKE-3K | FLPKIIGKLSSLLPKIF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | H-157 | Lung Cancer | IC50 = 3.29 μM |
| dbacp07070 | Temporin-PKE-4K | FLPKIIGKLSSKLPKIF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | U251-MG | Brain Tumor | IC50 = 85.52 μM |
| dbacp07071 | Temporin-PKE-4K | FLPKIIGKLSSKLPKIF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | PC-3 | Prostate Cancer | IC50 = 49.50 μM |
| dbacp07072 | Temporin-PKE-4K | FLPKIIGKLSSKLPKIF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | H-838 | Lung Cancer | IC50 = 35.28 μM |
| dbacp07073 | Temporin-PKE-4K | FLPKIIGKLSSKLPKIF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | HCT-116 | Colorectal Cancer | IC50 = 99.36 μM |
| dbacp07074 | Temporin-PKE-4K | FLPKIIGKLSSKLPKIF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | H-157 | Lung Cancer | IC50 = 27.76 μM |
| dbacp07075 | Temporin-PKE-i | FLPLIIGALSSLLPKiF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | U251-MG | Brain Tumor | IC50 = 4.46 μM |
| dbacp07076 | Temporin-PKE-i | FLPLIIGALSSLLPKiF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | PC-3 | Prostate Cancer | IC50 = 3.35 μM |
| dbacp07077 | Temporin-PKE-i | FLPLIIGALSSLLPKiF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | H-838 | Lung Cancer | IC50 = 5.28 μM |
| dbacp07078 | Temporin-PKE-i | FLPLIIGALSSLLPKiF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | HCT-116 | Colorectal Cancer | IC50 = 3.07 μM |
| dbacp07079 | Temporin-PKE-i | FLPLIIGALSSLLPKiF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | H-157 | Lung Cancer | IC50 = 2.94 μM |
| dbacp07080 | Temporin-PKE-3i | FLPLiiGALSSLLPKiF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | U251-MG | Brain Tumor | IC50 = 120.6 μM |
| dbacp07081 | Temporin-PKE-3i | FLPLiiGALSSLLPKiF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | PC-3 | Prostate Cancer | IC50 = 167 μM |
| dbacp07082 | Temporin-PKE-3i | FLPLiiGALSSLLPKiF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | H-838 | Lung Cancer | IC50 = 193.4 μM |
| dbacp07083 | Temporin-PKE-3i | FLPLiiGALSSLLPKiF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | HCT-116 | Colorectal Cancer | IC50 = 72.06 μM |
| dbacp07084 | Temporin-PKE-3i | FLPLiiGALSSLLPKiF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | H-157 | Lung Cancer | IC50 = 71.18 μM |
| dbacp07097 | K2F6K2 | KKFFFFFFKK | Synthetic | Positive charge–driven membrane disruption apoptosis | CCK-8 assay | A-549 | Lung Cancer | IC50 = 1146.23 ± 346.83 μg/mL |
| dbacp07098 | K3F6K3 | KKKFFFFFFKKK | Synthetic | Positive charge–driven membrane disruption apoptosis | CCK-8 assay | A-549 | Lung Cancer | IC50 = 123.10 ± 35.19 μg/mL |
| dbacp07099 | K4F6K4 | KKKKFFFFFFKKKK | Synthetic | Positive charge–driven membrane disruption apoptosis | CCK-8 assay | A-549 | Lung Cancer | IC50 = 62.64 ± 9.55 μg/mL |
| dbacp07100 | K4F6K4 | KKKKFFFFFFKKKK | Synthetic | Positive charge–driven membrane disruption apoptosis | AnnexinV-FITC/PI double staining assay | A-549 | Lung Cancer | apoptotic cells (early and late) increased from 9.59 ± 1.00% to 43.03 ± 2.13% |
| dbacp07101 | K4F8K4 | KKKKFFFFFFFFKKKK | Synthetic | Positive charge–driven membrane disruption apoptosis | CCK-8 assay | A-549 | Lung Cancer | IC50 = 571.87 ± 66.23 μg/mL |
| dbacp07102 | rScyreprocin | MKEDSNILDKTAKMTKQNKALLFTAGGAAAFMAGYYYYHCNYRNPAPKKSGSTTSQDKTDAQAVQSIPSPSGNKGKESKDPKVKHHHHHH | Recombinant product of Scyreprocin | Membrane disruption triggers ROS-mediated apoptosis | MTS assay | H-460 | Lung Cancer | IC50 = 6.27 µM |
| dbacp07103 | rScyreprocin | MKEDSNILDKTAKMTKQNKALLFTAGGAAAFMAGYYYYHCNYRNPAPKKSGSTTSQDKTDAQAVQSIPSPSGNKGKESKDPKVKHHHHHH | Recombinant product of Scyreprocin | Membrane disruption triggers ROS-mediated apoptosis | MTS assay | HepG-2 | Liver Cancer | IC50 = 441.01 µM |
| dbacp07104 | rScyreprocin | MKEDSNILDKTAKMTKQNKALLFTAGGAAAFMAGYYYYHCNYRNPAPKKSGSTTSQDKTDAQAVQSIPSPSGNKGKESKDPKVKHHHHHH | Recombinant product of Scyreprocin | Membrane disruption triggers ROS-mediated apoptosis | MTS assay | T-24 | Urinary Bladder Cancer | IC50 = 1.94 x 105 µM |
| dbacp07105 | rScyreprocin | MKEDSNILDKTAKMTKQNKALLFTAGGAAAFMAGYYYYHCNYRNPAPKKSGSTTSQDKTDAQAVQSIPSPSGNKGKESKDPKVKHHHHHH | Recombinant product of Scyreprocin | Membrane disruption triggers ROS-mediated apoptosis | MTS assay | DU-145 | Prostate cancer | IC50 = 1158.30 µM |
| dbacp07106 | rScyreprocin | MKEDSNILDKTAKMTKQNKALLFTAGGAAAFMAGYYYYHCNYRNPAPKKSGSTTSQDKTDAQAVQSIPSPSGNKGKESKDPKVKHHHHHH | Recombinant product of Scyreprocin | Membrane disruption triggers ROS-mediated apoptosis | MTS assay | HeLa | Cervical cancer | IC50 = 3.34 x 104 µM |
| dbacp07112 | Galaxamide | (N-Me-L)L(N-Me-L)LL | Galaxaura filamentosa | Cell-cycle arrest induces apoptosis | MTT assay | HepG-2 | Liver Cancer | IC50 = 5.20 ± 0.52 µg/ml |
| dbacp07113 | Galaxamide | (N-Me-L)L(N-Me-L)LL | Galaxaura filamentosa | Cell-cycle arrest induces apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 11.33 ± 2.95 µg/ml |
| dbacp07114 | Galaxamide | (N-Me-L)L(N-Me-L)LL | Galaxaura filamentosa | Cell-cycle arrest induces apoptosis | MTT assay | HeLa | Cervical Cancer | IC50 = 8.53 ± 0.73 µg/ml |
| dbacp07115 | Galaxamide | (N-Me-L)L(N-Me-L)LL | Galaxaura filamentosa | Cell-cycle arrest induces apoptosis | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 8.73 ± 0.29 µg/ml |
| dbacp07116 | Galaxamide | (N-Me-L)L(N-Me-L)LL | Galaxaura filamentosa | Cell-cycle arrest induces apoptosis | MTT assay | A-549 | Lung Cancer | IC50 = 6.99 ± 0.63 µg/ml |
| dbacp07117 | Z-1 | L(N-Me-L)LPL | Synthetic | Cell-cycle arrest induces apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 5.85 ± 1.28 µg/ml |
| dbacp07118 | Z-1 | L(N-Me-L)LPL | Synthetic | Cell-cycle arrest induces apoptosis | MTT assay | HepG-2 | Liver Cancer | IC50 = 7.57 ± 0.17 µg/ml |
| dbacp07119 | Z-1 | L(N-Me-L)LPL | Synthetic | Cell-cycle arrest induces apoptosis | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 17.81 ± 0.6 µg/ml |
| dbacp07120 | Z-1 | L(N-Me-L)LPL | Synthetic | Cell-cycle arrest induces apoptosis | MTT assay | HeLa | Cervical Cancer | IC50 = 11.56 ± 0.65 µg/ml |
| dbacp07121 | Z-1 | L(N-Me-L)LPL | Synthetic | Cell-cycle arrest induces apoptosis | MTT assay | A-549 | Lung Cancer | IC50 = 4.92 ± 0.84 µg/ml |
| dbacp07275 | LCP-2 | WAHT | Laminaria japonica | Mitochondrial apoptosis via p53 activation. | MTT assay | SGC-7901 | Gastric Cancer | IC50 = 116 ± 12.4 μM |
| dbacp07276 | LCP-2 | WAHT | Laminaria japonica | Mitochondrial apoptosis via p53 activation. | MTT assay | MKN-45 | Gastric Cancer | IC50 = 107 ± 11.8 μM |
| dbacp07277 | LCP-2 | WAHT | Laminaria japonica | Mitochondrial apoptosis via p53 activation. | MTT assay | HepG-2 | Gastric Cancer | IC50 = 96.9 ± 9.91 μM |
| dbacp07278 | LCP-2 | WAHT | Laminaria japonica | Mitochondrial apoptosis via p53 activation. | MTT assay | CaCo-2 | Colon Cancer | IC50 = 100 ± 11.6 μM |
| dbacp07279 | LCP-3 | WHLV | Laminaria japonica | Mitochondrial apoptosis via p53 activation. | MTT assay | SGC-7901 | Gastric Cancer | IC50 = 101 ± 10.6 μM |
| dbacp07280 | LCP-3 | WHLV | Laminaria japonica | Mitochondrial apoptosis via p53 activation. | MTT assay | MKN-45 | Gastric Cancer | IC50 = 86.9 ± 9.11 μM |
| dbacp07281 | LCP-3 | WHLV | Laminaria japonica | Mitochondrial apoptosis via p53 activation. | MTT assay | HepG-2 | Gastric Cancer | IC50 = 85.2 ± 9.27 μM |
| dbacp07282 | LCP-3 | WHLV | Laminaria japonica | Mitochondrial apoptosis via p53 activation. | MTT assay | CaCo-2 | Colon Cancer | IC50 = 68.2 ± 7.11 μM |
| dbacp07283 | AtMP1 | THPPTTTTTTTTTTTTTAAPATTT | Anabastestudineus skin mucus fraction 2 | p53-mediated Bax/Bcl-2 apoptosis activation | MTT assay | MCF-7 | Breast Cancer | IC50 = 8.25 ± 0.14 μg/ml |
| dbacp07284 | AtMP1 | THPPTTTTTTTTTTTTTAAPATTT | Anabastestudineus skin mucus fraction 2 | p53-mediated Bax/Bcl-2 apoptosis activation | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 9.35 ± 0.25 μg/ml |
| dbacp07285 | AtMP2 | TGIATSGLATFTLHTGSLAPAT | Anabastestudineus skin mucus fraction 2 | p53-mediated Bax/Bcl-2 apoptosis activation | MTT assay | MCF-7 | Breast Cancer | IC50 = 5.89 ± 0.14 μg/ml |
| dbacp07286 | AtMP2 | TGIATSGLATFTLHTGSLAPAT | Anabastestudineus skin mucus fraction 2 | p53-mediated Bax/Bcl-2 apoptosis activation | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 6.97 ± 0.24 μg/ml |
| dbacp07287 | P264-G274 | PARDVLNTTSG | Parasporin-2Aa1 | h-APN receptor–mediated apoptosis induction. | Sulforhodamine B assay | SW-480 | Colorectal Cancer | EC50 = 90.98 ± 0.75 µM |
| dbacp07288 | P264-G274 | PARDVLNTTSG | Parasporin-2Aa1 | h-APN receptor–mediated apoptosis induction. | Sulforhodamine B assay | SW-620 | Colorectal Cancer | EC50 = 11.28 ± 0.52 µM |
| dbacp07289 | Loop1-PS2Aa | NNETYFNAVKP | Parasporin-2Aa1 | h-APN receptor–mediated apoptosis induction. | Sulforhodamine B assay | SW-480 | Colorectal Cancer | EC50 = 23.76 ± 1.25 µM |
| dbacp07290 | Loop1-PS2Aa | NNETYFNAVKP | Parasporin-2Aa1 | h-APN receptor–mediated apoptosis induction. | Sulforhodamine B assay | SW-620 | Colorectal Cancer | EC50 = 106.2 ± 1.67 µM |
| dbacp07291 | Loop2-PS2Aa | TYFNAVKPPITA | Parasporin-2Aa1 | h-APN receptor–mediated apoptosis induction. | Sulforhodamine B assay | SW-480 | Colorectal Cancer | EC50 = 92.99 ± 0.98 µM |
| dbacp07292 | Loop2-PS2Aa | TYFNAVKPPITA | Parasporin-2Aa1 | h-APN receptor–mediated apoptosis induction. | Sulforhodamine B assay | SW-620 | Colorectal Cancer | EC50 = 15.95 ± 0.69 µM |
| dbacp07293 | Loop1-HCoV-229E | FKPQSGGGKCF | Alphacoronavirus (HCoV-229E) | h-APN receptor–mediated apoptosis induction. | Sulforhodamine B assay | SW-480 | Colorectal Cancer | EC50 = 125.0 ± 1.32 µM |
| dbacp07294 | A4W-GGN5 | FLGWLFKVASK | Gaegurin 5 | h-APN receptor–mediated apoptosis induction. | Sulforhodamine B assay | SW-480 | Colorectal Cancer | EC50 = 98.63 ± 1.17 µM |
| dbacp07295 | A4W-GGN5 | FLGWLFKVASK | Gaegurin 5 | h-APN receptor–mediated apoptosis induction. | Sulforhodamine B assay | SW-620 | Colorectal Cancer | EC50 = 22.07 ± 1.63 µM |
| dbacp07309 | LyeTxI-b | IWLTALKFLGKNLGKLAKQQLAKL | Synthetic | Apoptosis induction and immune modulation. | MTT assay | 4T1 | Breast Cancer | IC50 = 6.5 ± 5.30 µM |
| dbacp07310 | LyeTxI-b | IWLTALKFLGKNLGKLAKQQLAKL | Synthetic | Apoptosis induction and immune modulation. | MTT assay | MCF-7 | Breast Cancer | IC50 = 7.34 ± 3.09 µM |
| dbacp07311 | LyeTxI-b | IWLTALKFLGKNLGKLAKQQLAKL | Synthetic | Apoptosis induction and immune modulation. | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 5.77 ± 0.83 µM |
| dbacp07322 | PCC-1 | KKRKKKAFALKFVVDLI | Poecilocoris lewisi | Sp1 suppression, apoptosis, cell-cycle arrest | MTS assay | SK-Mel-28 | Skin Cancer | IC50 = 50.8 µM |
| dbacp07323 | PCC-1 | KKRKKKAFALKFVVDLI | Poecilocoris lewisi | Sp1 suppression, apoptosis, cell-cycle arrest | MTS assay | G361 | Skin Cancer | IC50 = 57.8 µM |
| dbacp07324 | IK13 | CIIKKIIKKIIKK | Synthetic | Mitochondrial mediated apoptosis | MTT assay | HCT-116 | Colorectal Cancer | IC50 = 29 ± 6 µM |
| dbacp07325 | IK13 | CIIKKIIKKIIKK | Synthetic | Mitochondrial mediated apoptosis | MTT assay | HeLa | Cervical Cancer | IC50 = 47±5 µM |
| dbacp07326 | LK13 | CLLKKLLKKLLKK | Synthetic | Mitochondrial mediated apoptosis | MTT assay | HCT-116 | Colorectal Cancer | IC50 = 23 ± 2 µM |
| dbacp07327 | LK13 | CLLKKLLKKLLKK | Synthetic | Mitochondrial mediated apoptosis | MTT assay | HeLa | Cervical Cancer | IC50 = 83 ± 9 µM |
| dbacp07328 | IR13 | CIIRRIIRRIIRR | Synthetic | Mitochondrial mediated apoptosis | MTT assay | HCT-116 | Colorectal Cancer | IC50 > 100 µM |
| dbacp07329 | IR13 | CIIRRIIRRIIRR | Synthetic | Mitochondrial mediated apoptosis | MTT assay | HeLa | Cervical Cancer | IC50 > 100 µM |
| dbacp07330 | LR13 | CLLRRLLRRLLRR | Synthetic | Mitochondrial mediated apoptosis | MTT assay | HCT-116 | Colorectal Cancer | IC50 = 15.6 ± 1.0 µM |
| dbacp07331 | LR13 | CLLRRLLRRLLRR | Synthetic | Mitochondrial mediated apoptosis | MTT assay | HeLa | Cervical Cancer | IC50 = 26.7 ± 1.3 µM |
| dbacp07332 | CI-15 | CIIKKIIKKIIKKII | Synthetic | Mitochondrial mediated apoptosis | MTT assay | HCT-116 | Colorectal Cancer | IC50 = 7.7 ± 0.2 µM |
| dbacp07333 | CI-15 | CIIKKIIKKIIKKII | Synthetic | Mitochondrial mediated apoptosis | MTT assay | HeLa | Cervical Cancer | IC50 = 2.7 ± 0.5 µM |
| dbacp07334 | GI-15 | LC-Propargyl-GIIKKIIKKIIKKII | Synthetic | Mitochondrial mediated apoptosis | MTT assay | HCT-116 | Colorectal Cancer | IC50 = 13.6 ± 0.2 µM |
| dbacp07335 | GI-15 | LC-Propargyl-GIIKKIIKKIIKKII | Synthetic | Mitochondrial mediated apoptosis | MTT assay | HeLa | Cervical Cancer | IC50 = 16.6 ± 0.8 µM |
| dbacp07347 | GA - 2 | Structure given in figure | Synthetic (glycyrrhetinic acid (GA)-based peptides) | Apoptosis induction, Bax/p53/caspase activation | MTT assay | MCF-7 | Breast Cancer | IC50 = 7.70 ± 1.3 µg/mL |
| dbacp07348 | GA - 2 | Structure given in figure | Synthetic (glycyrrhetinic acid (GA)-based peptides) | Apoptosis induction, Bax/p53/caspase activation | MTT assay | HCT-116 | Colon Cancer | IC50 = 70.30 ± 0.9 µg/mL |
| dbacp07349 | GA - 3 | Structure given in figure | Synthetic (glycyrrhetinic acid (GA)-based peptides) | Apoptosis induction, Bax/p53/caspase activation | MTT assay | MCF-7 | Breast Cancer | IC50 = 5.1 ± 0.7 µg/mL |
| dbacp07350 | GA - 3 | Structure given in figure | Synthetic (glycyrrhetinic acid (GA)-based peptides) | Apoptosis induction, Bax/p53/caspase activation | MTT assay | HCT-116 | Colon Cancer | IC50 = 7.40 ± 0.4 µg/mL |
| dbacp07351 | GA - 4 | Structure given in figure | Synthetic (glycyrrhetinic acid (GA)-based peptides) | Apoptosis induction, Bax/p53/caspase activation | MTT assay | MCF-7 | Breast Cancer | IC50 = 6.10 ± 0.4 µg/mL |
| dbacp07352 | GA - 4 | Structure given in figure | Synthetic (glycyrrhetinic acid (GA)-based peptides) | Apoptosis induction, Bax/p53/caspase activation | MTT assay | HCT-116 | Colon Cancer | IC50 = 73.0 ± 1.4 µg/mL |
| dbacp07353 | GA - 5 | Structure given in figure | Synthetic (glycyrrhetinic acid (GA)-based peptides) | Apoptosis induction, Bax/p53/caspase activation | MTT assay | MCF-7 | Breast Cancer | IC50 = 5.0 ± 0.3 µg/mL |
| dbacp07354 | GA - 5 | Structure given in figure | Synthetic (glycyrrhetinic acid (GA)-based peptides) | Apoptosis induction, Bax/p53/caspase activation | MTT assay | HCT-116 | Colon Cancer | IC50 = 5.2 ± 0.8 µg/mL |
| dbacp07355 | GA - 7 | Structure given in figure | Synthetic (glycyrrhetinic acid (GA)-based peptides) | Apoptosis induction, Bax/p53/caspase activation | MTT assay | MCF-7 | Breast Cancer | IC50 = 3.70 ± 0.2 µg/mL |
| dbacp07356 | GA - 7 | Structure given in figure | Synthetic (glycyrrhetinic acid (GA)-based peptides) | Apoptosis induction, Bax/p53/caspase activation | MTT assay | HCT-116 | Colon Cancer | IC50 = 3.0 ± 1.1 µg/mL |
| dbacp07357 | GA - 7 | Structure given in figure | Synthetic (glycyrrhetinic acid (GA)-based peptides) | Apoptosis induction, Bax/p53/caspase activation | MTT assay | HepG-2 | Liver Cancer | IC50 = 3.30 ± 0.1 µg/mL |
| dbacp07358 | GA - 8 | Structure given in figure | Synthetic (glycyrrhetinic acid (GA)-based peptides) | Apoptosis induction, Bax/p53/caspase activation | MTT assay | MCF-7 | Breast Cancer | IC50 = 6.90 ± 1.1 µg/mL |
| dbacp07359 | GA - 8 | Structure given in figure | Synthetic (glycyrrhetinic acid (GA)-based peptides) | Apoptosis induction, Bax/p53/caspase activation | MTT assay | HCT-116 | Colon Cancer | IC50 = 60.70 ± 0.6 µg/mL |
| dbacp07373 | HPRP-A1 | FKKLKKLFSKLWNWK | N-terminal region of Helicobacter pylori ribosomal protein L1 | Apoptosis induction, p53-mediated cell cycle arrest | MTT assay | CT-26 | Colorectal Cancer | IC50 between 0.5 and 1 µg/mL |
| dbacp07374 | HPRP-A1 | FKKLKKLFSKLWNWK | N-terminal region of Helicobacter pylori ribosomal protein L1 | Apoptosis induction, p53-mediated cell cycle arrest | MTT assay | HT-29 | Colon Cancer | IC50 ~ 0.5 µg/mL |
| dbacp07395 | 17BIPHE2 | GBKRLVQRLKDBLRNLV | Derivative of LL-37 | ERK-mediated apoptosis and mitochondrial disruption | MTT assay | A-549 | Lung Cancer | IC50 = 34.33 µmol |
| dbacp07396 | 17BIPHE2 | GBKRLVQRLKDBLRNLV | Derivative of LL-37 | ERK-mediated apoptosis and mitochondrial disruption | MTT assay | NCI-H-1975 | Lung Cancer | IC50 = 71.42 µmol/L |
| dbacp07401 | NMTP-5 | zffygwyggmekllrggrgerppr | Not Available | NRP1/MDM2 inhibition induces apoptosis | MTT assay | SK-HEP-1 | Liver Cancer | IC50 = 53.84 ± 4.35 µM |
| dbacp07404 | LvHemB1 | DVNFLLHKIYGNIRY | hemocyanin of Litopenaeus vannamei | Mitochondrial targeting induces apoptosis | MTS assay | HeLa | Cervical cancer | 65.1% apoptotic cells at 50 μg/mL |
| dbacp07405 | LvHemB1 | DVNFLLHKIYGNIRY | hemocyanin of Litopenaeus vannamei | Mitochondrial targeting induces apoptosis | MTS assay | EC-109 | Esophageal Cancer | 57.1% apoptotic cells at 50 μg/mL |
| dbacp07406 | LvHemB1 | DVNFLLHKIYGNIRY | hemocyanin of Litopenaeus vannamei | Mitochondrial targeting induces apoptosis | MTS assay | HepG-2 | Liver Cancer | 44.2% apoptotic cells at 50 μg/mL |
| dbacp07407 | LvHemB1 | DVNFLLHKIYGNIRY | hemocyanin of Litopenaeus vannamei | Mitochondrial targeting induces apoptosis | MTS assay | EJ | Bladder Cancer | 89.6% apoptotic cells at 50 μg/mL |
| dbacp07411 | Si1 | (KLAKLAK)2 | Synthetic | Membrane disruption induces cancer apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 124.1 ± 8.12 µM |
| dbacp07412 | Si1 | (KLAKLAK)2 | Synthetic | Membrane disruption induces cancer apoptosis | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 746.5 ± 7.6 µM |
| dbacp07413 | Si3 | KL(Beta-A)KL(Beta-A)AK | Synthetic | Membrane disruption induces cancer apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 176.3 ± 4.66 µM |
| dbacp07414 | Si2 | KL(Beta-A)KL(Beta-A)K | Synthetic | Membrane disruption induces cancer apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 662.9 ± 20.02 µM |
| dbacp07415 | Si2 | KL(Beta-A)KL(Beta-A)K | Synthetic | Membrane disruption induces cancer apoptosis | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 840 ± 21.18 µM |
| dbacp07416 | Si11 | KL(Beta-A)KL(Beta-A)K | Synthetic | Membrane disruption induces cancer apoptosis | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 1087 ± 70.71 µM |
| dbacp07417 | Si11 | KL(Beta-A)KLAK | Synthetic | Membrane disruption induces cancer apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 228.8 ± 7.18 µM |
| dbacp07418 | Si13 | KnLAKnLAK | Synthetic | Membrane disruption induces cancer apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 1704 ± 112 µM |
| dbacp07419 | Si14 | KnLAKnLAK | Synthetic | Membrane disruption induces cancer apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 593.3 ± 60.3 µM |
| dbacp07420 | Si14 | KnLAKnLAK | Synthetic | Membrane disruption induces cancer apoptosis | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 1049 ± 49.77 µM |
| dbacp07421 | Si15 | KnLAKnLAK | Synthetic | Membrane disruption induces cancer apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 140.3 ± 7.12 µM |
| dbacp07422 | Si15 | KnLAKnLAK | Synthetic | Membrane disruption induces cancer apoptosis | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 346.3 ± 7.91 µM |
| dbacp07423 | GP-1 | FKEHGY | Ginseng Leaf Peptide | Mitochondrial apoptosis via p53 activation | MTT assay | CT-26 | Colorectal Cancer | IC50 = 86.4 ± 9.46 µM |
| dbacp07424 | GP-1 | FKEHGY | Ginseng Leaf Peptide | Mitochondrial apoptosis via p53 activation | MTT assay | CaCo-2 | Colon Cancer | IC50 = 104 ± 11.3 µM |
| dbacp07425 | GP-1 | FKEHGY | Ginseng Leaf Peptide | Mitochondrial apoptosis via p53 activation | MTT assay | Colo-320 | Colon Cancer | IC50 = 111 ± 12.0 µM |
| dbacp07426 | GP-2 | EGFHL | Ginseng Leaf Peptide | Mitochondrial apoptosis via p53 activation | MTT assay | CT-26 | Colorectal Cancer | IC50 = 114 ± 12.1 µM |
| dbacp07427 | GP-2 | EGFHL | Ginseng Leaf Peptide | Mitochondrial apoptosis via p53 activation | MTT assay | CaCo-2 | Colon Cancer | IC50 = 154 ± 15.8 µM |
| dbacp07428 | GP-2 | EGFHL | Ginseng Leaf Peptide | Mitochondrial apoptosis via p53 activation | MTT assay | Colo-320 | Colon Cancer | IC50 = 142 ± 14.9 µM |
| dbacp07429 | GP-3 | FSHTYV | Ginseng Leaf Peptide | Mitochondrial apoptosis via p53 activation | MTT assay | CT-26 | Colorectal Cancer | IC50 = 133 ± 12.5 µM |
| dbacp07430 | GP-3 | FSHTYV | Ginseng Leaf Peptide | Mitochondrial apoptosis via p53 activation | MTT assay | CaCo-2 | Colon Cancer | IC50 = 162 ± 17.1 µM |
| dbacp07431 | GP-3 | FSHTYV | Ginseng Leaf Peptide | Mitochondrial apoptosis via p53 activation | MTT assay | Colo-320 | Colon Cancer | IC50 = 149 ± 15.2 µM |
| dbacp07435 | L9H5-1 | LHLLLHLLHHLLHL | Synthetic | Acid-triggered membrane disruption apoptosis | MTT assay | HeLa | Cervical Cancer | IC50 = 5.4 µM |
| dbacp07436 | L8H6 | LHHLLHLLHHLLHL | Synthetic | Acid-triggered membrane disruption apoptosis | MTT assay | HeLa | Cervical Cancer | IC50 = 16.4 µM |
| dbacp07437 | A4K14 - Citropin 1.1 - Sp 7 | GLFAVR8KKVASVS5KGL | Synthetic | Stapled peptide enhances helical apoptosis | CCK-8 assay | C4-2B | Prostate Cancer | IC50 = 10.23 µM |
| dbacp07438 | A4K14 - Citropin 1.1 - Sp 7 | GLFAVR8KKVASVS5KGL | Synthetic | Stapled peptide enhances helical apoptosis | CCK-8 assay | A-549 | Lung Cancer | IC50 = 16.37 µM |
| dbacp07439 | A4K14 - Citropin 1.1 - Sp 7 | GLFAVR8KKVASVS5KGL | Synthetic | Stapled peptide enhances helical apoptosis | CCK-8 assay | U-87 | Brain Tumor | IC50 = 14.72 µM |
| dbacp07440 | A4K14 - Citropin 1.1 - Sp 7 | GLFAVR8KKVASVS5KGL | Synthetic | Stapled peptide enhances helical apoptosis | CCK-8 assay | MCF-7 | Breast Cancer | IC50 = 12.1 µM |
| dbacp07441 | A4K14 - Citropin 1.1 - Sp 6 | GR8FAVIKKS5ASVIKGL | Synthetic | Stapled peptide enhances helical apoptosis | CCK-8 assay | C4-2B | Prostate Cancer | IC50 = 35.84 µM |
| dbacp07442 | A4K14 - Citropin 1.1 - Sp 6 | GR8FAVIKKS5ASVIKGL | Synthetic | Stapled peptide enhances helical apoptosis | CCK-8 assay | A-549 | Lung Cancer | IC50 = 30.19 µM |
| dbacp07443 | A4K14 - Citropin 1.1 - Sp 6 | GR8FAVIKKS5ASVIKGL | Synthetic | Stapled peptide enhances helical apoptosis | CCK-8 assay | U-87 | Brain Tumor | IC50 = 34.49 µM |
| dbacp07444 | A4K14 - Citropin 1.1 - Sp 6 | GR8FAVIKKS5ASVIKGL | Synthetic | Stapled peptide enhances helical apoptosis | CCK-8 assay | MCF-7 | Breast Cancer | IC50 = 23.78 µM |
| dbacp07445 | A4K14 - Citropin 1.1 - Sp 5 | GLFAVIKKVAS5VIKS5L | Synthetic | Stapled peptide enhances helical apoptosis | CCK-8 assay | C4-2B | Prostate Cancer | IC50 = 11.9 µM |
| dbacp07446 | A4K14 - Citropin 1.1 - Sp 5 | GLFAVIKKVAS5VIKS5L | Synthetic | Stapled peptide enhances helical apoptosis | CCK-8 assay | A-549 | Lung Cancer | IC50 = 9.899 µM |
| dbacp07447 | A4K14 - Citropin 1.1 - Sp 5 | GLFAVIKKVAS5VIKS5L | Synthetic | Stapled peptide enhances helical apoptosis | CCK-8 assay | U-87 | Brain Tumor | IC50 = 8.229 µM |
| dbacp07448 | A4K14 - Citropin 1.1 - Sp 5 | GLFAVIKKVAS5VIKS5L | Synthetic | Stapled peptide enhances helical apoptosis | CCK-8 assay | MCF-7 | Breast Cancer | IC50 = 12.42 µM |
| dbacp07449 | A4K14 - Citropin 1.1 - Sp 4 | GLFAVIKKS5ASVS5KGL | Synthetic | Stapled peptide enhances helical apoptosis | CCK-8 assay | C4-2B | Prostate Cancer | IC50 = 8.9 µM |
| dbacp07450 | A4K14 - Citropin 1.1 - Sp 4 | GLFAVIKKS5ASVS5KGL | Synthetic | Stapled peptide enhances helical apoptosis | CCK-8 assay | A-549 | Lung Cancer | IC50 = 10.51 µM |
| dbacp07451 | A4K14 - Citropin 1.1 - Sp 4 | GLFAVIKKS5ASVS5KGL | Synthetic | Stapled peptide enhances helical apoptosis | CCK-8 assay | U-87 | Brain Tumor | IC50 = 7.277 µM |
| dbacp07452 | A4K14 - Citropin 1.1 - Sp 4 | GLFAVIKKS5ASVS5KGL | Synthetic | Stapled peptide enhances helical apoptosis | CCK-8 assay | MCF-7 | Breast Cancer | IC50 = 10.49 µM |
| dbacp07453 | A4K14 - Citropin 1.1 - Sp 3 | GLFAVS5KKVS5SVIKGL | Synthetic | Stapled peptide enhances helical apoptosis | CCK-8 assay | C4-2B | Prostate Cancer | IC50 = 17.89 µM |
| dbacp07454 | A4K14 - Citropin 1.1 - Sp 3 | GLFAVS5KKVS5SVIKGL | Synthetic | Stapled peptide enhances helical apoptosis | CCK-8 assay | A-549 | Lung Cancer | IC50 = 12.11 µM |
| dbacp07455 | A4K14 - Citropin 1.1 - Sp 3 | GLFAVS5KKVS5SVIKGL | Synthetic | Stapled peptide enhances helical apoptosis | CCK-8 assay | U-87 | Brain Tumor | IC50 = 11.93 µM |
| dbacp07456 | A4K14 - Citropin 1.1 - Sp 3 | GLFAVS5KKVS5SVIKGL | Synthetic | Stapled peptide enhances helical apoptosis | CCK-8 assay | MCF-7 | Breast Cancer | IC50 = 11.92 µM |
| dbacp07457 | A4K14 - Citropin 1.1 - Sp 2 | GLFAS5IKKS5ASVIKGL | Synthetic | Stapled peptide enhances helical apoptosis | CCK-8 assay | C4-2B | Prostate Cancer | IC50 = 10.14 µM |
| dbacp07458 | A4K14 - Citropin 1.1 - Sp 2 | GLFAS5IKKS5ASVIKGL | Synthetic | Stapled peptide enhances helical apoptosis | CCK-8 assay | A-549 | Lung Cancer | IC50 = 12.55 µM |
| dbacp07459 | A4K14 - Citropin 1.1 - Sp 2 | GLFAS5IKKS5ASVIKGL | Synthetic | Stapled peptide enhances helical apoptosis | CCK-8 assay | U-87 | Brain Tumor | IC50 = 14.76 µM |
| dbacp07460 | A4K14 - Citropin 1.1 - Sp 2 | GLFAS5IKKS5ASVIKGL | Synthetic | Stapled peptide enhances helical apoptosis | CCK-8 assay | MCF-7 | Breast Cancer | IC50 = 12.65 µM |
| dbacp07461 | A4K14 - Citropin 1.1 - Sp 1 | GS5FAVS5KKVASVIKGL | Synthetic | Stapled peptide enhances helical apoptosis | CCK-8 assay | C4-2B | Prostate Cancer | IC50 = 8.94 µM |
| dbacp07462 | A4K14 - Citropin 1.1 - Sp 1 | GS5FAVS5KKVASVIKGL | Synthetic | Stapled peptide enhances helical apoptosis | CCK-8 assay | A-549 | Lung Cancer | IC50 = 12.48 µM |
| dbacp07463 | A4K14 - Citropin 1.1 - Sp 1 | GS5FAVS5KKVASVIKGL | Synthetic | Stapled peptide enhances helical apoptosis | CCK-8 assay | U-87 | Brain Tumor | IC50 = 11.88 µM |
| dbacp07464 | A4K14 - Citropin 1.1 - Sp 1 | GS5FAVS5KKVASVIKGL | Synthetic | Stapled peptide enhances helical apoptosis | CCK-8 assay | MCF-7 | Breast Cancer | IC50 = 11.26 µM |
| dbacp07465 | ΔM4 | NFFKRIRRAWKRIWKWIYSA | Synthetic | Membrane disruption triggers mitochondrial apoptosis | Not Available | A-375 | Skin Cancer | IC50 = 9.31 μM |
| dbacp07466 | Tachyplesin | KWCFRVCYRGICYIRRCR | Horseshoe crab | Fas activation drives apoptosis/necroptosis | MTT assay | A-549 | Lung Cancer | IC50 = 35 µg/ml |
| dbacp07467 | Tachyplesin | KWCFRVCYRGICYIRRCR | Horseshoe crab | Fas activation drives apoptosis/necroptosis | MTT assay | H-460 | Lung Cancer | IC50 = 25 µg/ml |
| dbacp07475 | Latcripin-7A | MTTESKVKNATTLLHSGKVKERQEGLSALRNIFSQNSSIERFYNVAGRDGRKPSHEIWAPILDGLQTCIRSEKSAFVTAKKSTDVIEKRLAAAAGTYRWFVEKSMMHFAKKTVLEICHFLYREMKVRETLIPSVALDFIKAYECVASHPPHLARLEEDEIEWEE | Lentinula edodes | Cell-cycle arrest, apoptosis, autophagy induction | CCK-8 assay | MCF-7 | Breast Cancer | IC50 = 91 μg/mL |
| dbacp07476 | Latcripin-7A | MTTESKVKNATTLLHSGKVKERQEGLSALRNIFSQNSSIERFYNVAGRDGRKPSHEIWAPILDGLQTCIRSEKSAFVTAKKSTDVIEKRLAAAAGTYRWFVEKSMMHFAKKTVLEICHFLYREMKVRETLIPSVALDFIKAYECVASHPPHLARLEEDEIEWEE | Lentinula edodes | Cell-cycle arrest, apoptosis, autophagy induction | CCK-8 assay | MDA-MB-231 | Breast Cancer | IC50 = 122 μg/mL |
| dbacp07477 | (LLKK)4 linear peptide | LLKKLLKKLLKKLLKK | Synthetic | Apoptosis, drug-resistance reversal, tumor suppression | MTT assay | SK-HEP-1 | Liver Cancer | Cell Viability (%) ~ 14.1 ± 0.8 at 30 µg/mL |
| dbacp07478 | (LLKK)4 linear peptide | LLKKLLKKLLKKLLKK | Synthetic | Apoptosis, drug-resistance reversal, tumor suppression | MTT assay | HCT-116 | Colon Cancer | Cell Viability (%) ~ 10.73 ± 2.4 at 30 µg/mL |
| dbacp07479 | (LLKK)4 linear peptide | LLKKLLKKLLKKLLKK | Synthetic | Apoptosis, drug-resistance reversal, tumor suppression | MTT assay | Bcap-37 | Breast Cancer | Cell Viability (%) ~ 15.07 ± 0.5 at 30 µg/mL |
| dbacp07480 | (LLKK)4 linear peptide | LLKKLLKKLLKKLLKK | Synthetic | Apoptosis, drug-resistance reversal, tumor suppression | MTT assay | PC-3 | Prostate Cancer | Cell Viability (%) ~ 17.1 ± 5.0 at 30 µg/mL |
| dbacp07481 | 2-arm branched peptide | [LLKKLLKK]2kC | Synthetic | Apoptosis, drug-resistance reversal, tumor suppression | MTT assay | SK-HEP-1 | Liver Cancer | Cell Viability (%) ~ 85.7 ± 4.3 at 30 µg/mL |
| dbacp07482 | 2-arm branched peptide | [LLKKLLKK]2kC | Synthetic | Apoptosis, drug-resistance reversal, tumor suppression | MTT assay | HCT-116 | Colon Cancer | Cell Viability (%) ~ 78.6 ± 10.5 at 30 µg/mL |
| dbacp07483 | 2-arm branched peptide | [LLKKLLKK]2kC | Synthetic | Apoptosis, drug-resistance reversal, tumor suppression | MTT assay | Bcap-37 | Breast Cancer | Cell Viability (%) ~ 81.8 ± 8.8 at 30 µg/mL |
| dbacp07484 | 2-arm branched peptide | [LLKKLLKK]2kC | Synthetic | Apoptosis, drug-resistance reversal, tumor suppression | MTT assay | PC-3 | Prostate Cancer | Cell Viability (%) ~ 73.5 ± 2.2 at 30 µg/mL |
| dbacp07485 | 4-arm branched peptide | {[LLKKLLKK]2kC}2 | Synthetic | Apoptosis, drug-resistance reversal, tumor suppression | MTT assay | SK-HEP-1 | Liver Cancer | Cell Viability (%) ~ 31.7 ± 5.1 at 30 µg/mL |
| dbacp07486 | 4-arm branched peptide | {[LLKKLLKK]2kC}2 | Synthetic | Apoptosis, drug-resistance reversal, tumor suppression | MTT assay | HCT-116 | Colon Cancer | Cell Viability (%) ~ 67.6 ± 5.8 at 30 µg/mL |
| dbacp07487 | 4-arm branched peptide | {[LLKKLLKK]2kC}2 | Synthetic | Apoptosis, drug-resistance reversal, tumor suppression | MTT assay | Bcap-37 | Breast Cancer | Cell Viability (%) ~ 51.4 ± 4.2 at 30 µg/mL |
| dbacp07488 | 4-arm branched peptide | {[LLKKLLKK]2kC}2 | Synthetic | Apoptosis, drug-resistance reversal, tumor suppression | MTT assay | PC-3 | Prostate Cancer | Cell Viability (%) ~ 49.0 ± 0.8 at 30 µg/mL |
| dbacp07512 | Dermaseptin-PP | ALWKDMLKGIGKLAGKAALGAVKTLV | Phyllomedusa palliata | Membrane disruption triggers dual apoptosis | MTT assay | H-157 | Lung Cancer | IC50 = 1.55 μM |
| dbacp07513 | Dermaseptin-PP | ALWKDMLKGIGKLAGKAALGAVKTLV | Phyllomedusa palliata | Membrane disruption triggers dual apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 2.92 μM |
| dbacp07514 | Dermaseptin-PP | ALWKDMLKGIGKLAGKAALGAVKTLV | Phyllomedusa palliata | Membrane disruption triggers dual apoptosis | MTT assay | PC-3 | Prostate Cancer | IC50 = 4.15 μM |
| dbacp07515 | Dermaseptin-PP | ALWKDMLKGIGKLAGKAALGAVKTLV | Phyllomedusa palliata | Membrane disruption triggers dual apoptosis | MTT assay | U-251 | Brain Tumor | IC50 = 2.47 μM |
| dbacp07516 | Dermaseptin-PP | ALWKDMLKGIGKLAGKAALGAVKTLV | Phyllomedusa palliata | Membrane disruption triggers dual apoptosis | LDH leakage assay | H-157 | Lung Cancer | 80% LDH release at 10−4 M |
| dbacp07534 | rCT-II | LKCKKLVPLFSKTCPAGKNLCYKMFMVAAPHVPVKRGCIDVCPKSSLLVKYVCCNTDKCN | Naja naja | Apoptosis via intrinsic (mitochondrial) and extrinsic (death receptor) pathways | MTT assay | MCF-7 | Breast Cancer | IC50 = 3.66 µg/mL |
| dbacp07546 | Sur-X | YGRKKRRQRRRKDHRISTFKNWPFLEGCACTPERM | Synthetic | Disrupts XIAP-survivin, induces apoptosis/necroptosis | MTT assay | HCT-116 | Colon Cancer | 20% cell viability at at 20 μM |
| dbacp07547 | Sur-X | YGRKKRRQRRRKDHRISTFKNWPFLEGCACTPERM | Synthetic | Disrupts XIAP-survivin, induces apoptosis/necroptosis | MTT assay | HCT-15 | Colon Cancer | Not Available |
| dbacp07548 | Sur-X | YGRKKRRQRRRKDHRISTFKNWPFLEGCACTPERM | Synthetic | Disrupts XIAP-survivin, induces apoptosis/necroptosis | MTT assay | RKO | Colon Cancer | 25% cell viability at at 20 μM |
| dbacp07549 | Sur-X | YGRKKRRQRRRKDHRISTFKNWPFLEGCACTPERM | Synthetic | Disrupts XIAP-survivin, induces apoptosis/necroptosis | MTT assay | HT-29 | Colon Cancer | Not Available |
| dbacp07578 | R-DIM-P-LF11 | FQWQRNIRKVRPRVKRINRQWQF | Synthetic | Peptides target phosphatidylserine, trigger apoptosis | MTS assay | A-375 | Skin Cancer | LC50 = 125.0 ± 16.8 μM |
| dbacp07579 | R-DIM-P-LF11 | FQWQRNIRKVRPRVKRINRQWQF | Synthetic | Peptides target phosphatidylserine, trigger apoptosis | MTS assay | SBcl2 | Skin Cancer | LC50 = 10.7 ± 0.2 μM |
| dbacp07580 | R-DIM-P-LF11 | FQWQRNIRKVRPRVKRINRQWQF | Synthetic | Peptides target phosphatidylserine, trigger apoptosis | MTS assay | WM164 | Skin Cancer | LC50 = 20.9 ± 3.9 μM |
| dbacp07581 | R-DIM-P-LF11-322 | PFWRIRIRRPRRIRIRWFP | Synthetic | Peptides target phosphatidylserine, trigger apoptosis | MTS assay | A-375 | Skin Cancer | LC50 = 4.2 ± 0.2 μM |
| dbacp07582 | R-DIM-P-LF11-322 | PFWRIRIRRPRRIRIRWFP | Synthetic | Peptides target phosphatidylserine, trigger apoptosis | MTS assay | SBcl2 | Skin Cancer | LC50 = 2.5 ± 0.1 μM |
| dbacp07583 | R-DIM-P-LF11-322 | PFWRIRIRRPRRIRIRWFP | Synthetic | Peptides target phosphatidylserine, trigger apoptosis | MTS assay | WM164 | Skin Cancer | LC50 = 4.7 ± 0.2 μM |
| dbacp07584 | DIM-LF11-322 | PFWRIRIRRPFWRIRIRR | Synthetic | Peptides target phosphatidylserine, trigger apoptosis | MTS assay | A-375 | Skin Cancer | LC50 = 6.3 ± 0.3 μM |
| dbacp07585 | DIM-LF11-322 | PFWRIRIRRPFWRIRIRR | Synthetic | Peptides target phosphatidylserine, trigger apoptosis | MTS assay | SBcl2 | Skin Cancer | LC50 < 1 ± 0.0 μM |
| dbacp07586 | DIM-LF11-322 | PFWRIRIRRPFWRIRIRR | Synthetic | Peptides target phosphatidylserine, trigger apoptosis | MTS assay | WM164 | Skin Cancer | LC50 = 4.6 ± 0.1 μM |
| dbacp07587 | R-DIM-P-LF11-215 | FWRIRIRRPRRIRIRWF | Synthetic | Peptides target phosphatidylserine, trigger apoptosis | MTS assay | A-375 | Skin Cancer | LC50 = 2.7 ± 0.9 μM |
| dbacp07588 | R-DIM-P-LF11-215 | FWRIRIRRPRRIRIRWF | Synthetic | Peptides target phosphatidylserine, trigger apoptosis | MTS assay | SBcl2 | Skin Cancer | LC50 < 1 ± 0.0 μM |
| dbacp07589 | R-DIM-P-LF11-215 | FWRIRIRRPRRIRIRWF | Synthetic | Peptides target phosphatidylserine, trigger apoptosis | MTS assay | WM164 | Skin Cancer | LC50 = 4.6 ± 0.1 μM |
| dbacp07590 | R-DIM-P-LF11-334 | PWRIRIRRPRRIRIWP | Synthetic | Peptides target phosphatidylserine, trigger apoptosis | MTS assay | A-375 | Skin Cancer | LC50 = 6.6 ± 0.3 μM |
| dbacp07591 | R-DIM-P-LF11-334 | PWRIRIRRPRRIRIWP | Synthetic | Peptides target phosphatidylserine, trigger apoptosis | MTS assay | SBcl2 | Skin Cancer | LC50 = 3.4 ± 0.4 μM |
| dbacp07592 | R-DIM-P-LF11-334 | PWRIRIRRPRRIRIWP | Synthetic | Peptides target phosphatidylserine, trigger apoptosis | MTS assay | WM164 | Skin Cancer | LC50 = 5.0 ± 0.1 μM |
| dbacp07593 | R-DIM-LF11-334-LF11-334 | PWRIRIRRRRIRIRWPPWRIRIRR | Synthetic | Peptides target phosphatidylserine, trigger apoptosis | MTS assay | A-375 | Skin Cancer | LC50 < 1 ± 0.1 μM |
| dbacp07594 | R-DIM-LF11-334-LF11-334 | PWRIRIRRRRIRIRWPPWRIRIRR | Synthetic | Peptides target phosphatidylserine, trigger apoptosis | MTS assay | SBcl2 | Skin Cancer | LC50 < 1 ± 0.1 μM |
| dbacp07595 | R-DIM-LF11-334-LF11-334 | PWRIRIRRRRIRIRWPPWRIRIRR | Synthetic | Peptides target phosphatidylserine, trigger apoptosis | MTS assay | WM164 | Skin Cancer | LC50 = 3.6 ± 0.7 μM |
| dbacp07596 | DIM-LF11-339 | RRWFWRRRRWFWRR | Synthetic | Peptides target phosphatidylserine, trigger apoptosis | MTS assay | A-375 | Skin Cancer | LC50 = 4.8 ± 0.4 μM |
| dbacp07597 | DIM-LF11-339 | RRWFWRRRRWFWRR | Synthetic | Peptides target phosphatidylserine, trigger apoptosis | MTS assay | SBcl2 | Skin Cancer | LC50 = 4.7 ± 0.3 μM |
| dbacp07598 | DIM-LF11-339 | RRWFWRRRRWFWRR | Synthetic | Peptides target phosphatidylserine, trigger apoptosis | MTS assay | WM164 | Skin Cancer | LC50 = 3.8 ± 0.3 μM |
| dbacp07644 | Colicin N | HGDNNSKPKPGGNSGNRGNNGDGASAKVGEITITPDNSKPGRYISSNPEYSLLAKLIDAESIKGTEVYTFHTRKGQYVKVTVPDSNIDKMRVDYVNWKGPKYNNKLVKRFVSQFLLFRKEEKEKNEKEALLKASELVSGMGDKLGEYLGVKYKNVAKEVANDIKNFHGRNIRSYNEAMASLNKVLANPKMKVNKSDKDAIVNAWKQVNAKDMANKIGNLGKAFKVADLAIKVEKIREKSIEGYNTGNWGPLLLEVESWIIGGVVAGVAISLFGAVLSFLPISGLAVTALGVIGIMTISYLSSFIDANRVSNINNIISSVIR | Apoptosis via integrin-Akt suppression | MTT assay | H-460 | Lung Cancer | Dose dependent % cell viability resuctuction at 1-15 µM | |
| dbacp07645 | Colicin N | HGDNNSKPKPGGNSGNRGNNGDGASAKVGEITITPDNSKPGRYISSNPEYSLLAKLIDAESIKGTEVYTFHTRKGQYVKVTVPDSNIDKMRVDYVNWKGPKYNNKLVKRFVSQFLLFRKEEKEKNEKEALLKASELVSGMGDKLGEYLGVKYKNVAKEVANDIKNFHGRNIRSYNEAMASLNKVLANPKMKVNKSDKDAIVNAWKQVNAKDMANKIGNLGKAFKVADLAIKVEKIREKSIEGYNTGNWGPLLLEVESWIIGGVVAGVAISLFGAVLSFLPISGLAVTALGVIGIMTISYLSSFIDANRVSNINNIISSVIR | Apoptosis via integrin-Akt suppression | MTT assay | H-292 | Lung Cancer | Dose dependent % cell viability resuctuction at 1-15 µM | |
| dbacp07646 | Colicin N | HGDNNSKPKPGGNSGNRGNNGDGASAKVGEITITPDNSKPGRYISSNPEYSLLAKLIDAESIKGTEVYTFHTRKGQYVKVTVPDSNIDKMRVDYVNWKGPKYNNKLVKRFVSQFLLFRKEEKEKNEKEALLKASELVSGMGDKLGEYLGVKYKNVAKEVANDIKNFHGRNIRSYNEAMASLNKVLANPKMKVNKSDKDAIVNAWKQVNAKDMANKIGNLGKAFKVADLAIKVEKIREKSIEGYNTGNWGPLLLEVESWIIGGVVAGVAISLFGAVLSFLPISGLAVTALGVIGIMTISYLSSFIDANRVSNINNIISSVIR | Apoptosis via integrin-Akt suppression | MTT assay | NCI-H23 | Lung Cancer | Dose dependent % cell viability resuctuction at 1-15 µM | |
| dbacp07647 | AP1-Z1 | FLFSLIPHAISGLISAFK | AcrAP1 from the venom of the Arabian scorpion | Charge–hydrophobicity balance drives apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 7.222 μM |
| dbacp07648 | AP1-Z1 | FLFSLIPHAISGLISAFK | AcrAP1 from the venom of the Arabian scorpion | Charge–hydrophobicity balance drives apoptosis | MTT assay | A-375 | Skin Cancer | IC50 = 9.478 μM |
| dbacp07649 | AP1-Z1 | FLFSLIPHAISGLISAFK | AcrAP1 from the venom of the Arabian scorpion | Charge–hydrophobicity balance drives apoptosis | MTT assay | U-87 | Brain Tumor | IC50 = 10.21 μM |
| dbacp07650 | AP1-Z5a | FLFKLIPKAIKGLIKAFK | Mutant of APR-Z1 | Charge–hydrophobicity balance drives apoptosis | MTT assay | MCF-7 | Breast Cancer | Graph Figure 2A |
| dbacp07651 | AP1-Z5a | FLFKLIPKAIKGLIKAFK | Mutant of APR-Z1 | Charge–hydrophobicity balance drives apoptosis | MTT assay | A-375 | Skin Cancer | Graph Figure 2B |
| dbacp07652 | AP1-Z5a | FLFKLIPKAIKGLIKAFK | Mutant of APR-Z1 | Charge–hydrophobicity balance drives apoptosis | MTT assay | U-87 | Brain Tumor | Graph Figure 2C |
| dbacp07653 | AP1-Z5b | FLFKLIKHAIKGLIKAFK | Mutant of APR-Z1 | Charge–hydrophobicity balance drives apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 1.037 μM |
| dbacp07654 | AP1-Z5b | FLFKLIKHAIKGLIKAFK | Mutant of APR-Z1 | Charge–hydrophobicity balance drives apoptosis | MTT assay | A-375 | Skin Cancer | IC50 = 2.607 μM |
| dbacp07655 | AP1-Z5b | FLFKLIKHAIKGLIKAFK | Mutant of APR-Z1 | Charge–hydrophobicity balance drives apoptosis | MTT assay | U-87 | Brain Tumor | IC50 = 3.115 μM |
| dbacp07656 | AP1-Z3a | FLFSLIKHAIKGLISAFK | Mutant of APR-Z1 | Charge–hydrophobicity balance drives apoptosis | MTT assay | MCF-7 | Breast Cancer | Graph Figure 2A |
| dbacp07657 | AP1-Z3a | FLFSLIKHAIKGLISAFK | Mutant of APR-Z1 | Charge–hydrophobicity balance drives apoptosis | MTT assay | A-375 | Skin Cancer | Graph Figure 2B |
| dbacp07658 | AP1-Z3a | FLFSLIKHAIKGLISAFK | Mutant of APR-Z1 | Charge–hydrophobicity balance drives apoptosis | MTT assay | U-87 | Brain Tumor | Graph Figure 2C |
| dbacp07659 | AP1-Z3b | FLFSLIKHAISKLISAFK | Mutant of APR-Z1 | Charge–hydrophobicity balance drives apoptosis | MTT assay | MCF-7 | Breast Cancer | Graph Figure 2A |
| dbacp07660 | AP1-Z3b | FLFSLIKHAISKLISAFK | Mutant of APR-Z1 | Charge–hydrophobicity balance drives apoptosis | MTT assay | A-375 | Skin Cancer | Graph Figure 2B |
| dbacp07661 | AP1-Z3b | FLFSLIKHAISKLISAFK | Mutant of APR-Z1 | Charge–hydrophobicity balance drives apoptosis | MTT assay | U-87 | Brain Tumor | Graph Figure 2C |
| dbacp07662 | AP1-Z7 | FLFKLIKKAIKKLIKAFK | Mutant of APR-Z1 | Charge–hydrophobicity balance drives apoptosis | MTT assay | MCF-7 | Breast Cancer | Graph Figure 2A |
| dbacp07663 | AP1-Z7 | FLFKLIKKAIKKLIKAFK | Mutant of APR-Z1 | Charge–hydrophobicity balance drives apoptosis | MTT assay | A-375 | Skin Cancer | Graph Figure 2B |
| dbacp07664 | AP1-Z7 | FLFKLIKKAIKKLIKAFK | Mutant of APR-Z1 | Charge–hydrophobicity balance drives apoptosis | MTT assay | U-87 | Brain Tumor | Graph Figure 2C |
| dbacp07665 | AP1-Z9 | FLFKLIKKKIKKLIKKFK | Mutant of APR-Z1 | Charge–hydrophobicity balance drives apoptosis | MTT assay | MCF-7 | Breast Cancer | Graph Figure 2A |
| dbacp07666 | AP1-Z9 | FLFKLIKKKIKKLIKKFK | Mutant of APR-Z1 | Charge–hydrophobicity balance drives apoptosis | MTT assay | A-375 | Skin Cancer | Graph Figure 2B |
| dbacp07667 | AP1-Z9 | FLFKLIKKKIKKLIKKFK | Mutant of APR-Z1 | Charge–hydrophobicity balance drives apoptosis | MTT assay | U-87 | Brain Tumor | Graph Figure 2C |
| dbacp07668 | Longicalycinin A linear analogue 1 | GYPFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 9.66 ± 0.0007 µg/ml |
| dbacp07669 | Longicalycinin A linear analogue 1 | GYPFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 10.45 ± 0.0042 µg/ml |
| dbacp07670 | Longicalycinin A linear analogue 1 | GYPFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 13.29% Cell death at 100 µg/ml |
| dbacp07671 | Longicalycinin A linear analogue 1 | GYPFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 83.02% Cell death at 100 µg/ml |
| dbacp07672 | Longicalycinin A Cyclic analogue 1 | GYPFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 10.2 ± 0.007 µg/ml |
| dbacp07673 | Longicalycinin A Cyclic analogue 1 | GYPFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 11.4 ± 0.0028 µg/ml |
| dbacp07674 | Longicalycinin A Cyclic analogue 1 | GYPFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 69.73% Cell death at 100 µg/ml |
| dbacp07675 | Longicalycinin A Cyclic analogue 1 | GYPFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 71.5% Cell death at 100 µg/ml |
| dbacp07676 | Longicalycinin A linear analogue 2 | LYPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 8.76 ± 0.0035 µg/ml |
| dbacp07677 | Longicalycinin A linear analogue 2 | LYPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 12.33 ± 0 µg/ml |
| dbacp07678 | Longicalycinin A linear analogue 2 | LYPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 71.37% Cell death at 100 µg/ml |
| dbacp07679 | Longicalycinin A linear analogue 2 | LYPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 88.47% Cell death at 100 µg/ml |
| dbacp07680 | Longicalycinin A | FYPFG | Dianthus superbus | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 13.52 µg/ml |
| dbacp07681 | Longicalycinin A | FYPFG | Dianthus superbus | Cyclization enhances apoptosis via lysosomes | MTT assay | DLA cell line | Lung Cancer | CTC50 = 2.62 µM |
| dbacp07682 | Longicalycinin A | FYPFG | Dianthus superbus | Cyclization enhances apoptosis via lysosomes | MTT assay | EAC cell Line | Breast Cancer | CTC50 = 6.17 µM |
| dbacp07683 | Longicalycinin A | FYPFG | Synthetic | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 10.45 ± 0.0042 µg/ml |
| dbacp07684 | Longicalycinin A | FYPFG | Synthetic | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 11.87 ± 0.0021 µg/ml |
| dbacp07685 | Longicalycinin A (Linear) | FYPFG | Synthetic | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 9.18 ± 0.0014 µg/ml |
| dbacp07686 | Longicalycinin A (Linear) | FYPFG | Synthetic | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 9.61 ± 0.0007 µg/ml |
| dbacp07687 | Longicalycinin A linear analogue 14 | PYFFL | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 9.67 ± 0.0007 µg/ml |
| dbacp07688 | Longicalycinin A linear analogue 14 | PYFFL | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 9.12 ± 0.0042 µg/ml |
| dbacp07689 | Longicalycinin A linear analogue 14 | PYFFL | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 13.02% Cell death at 100 µg/ml |
| dbacp07690 | Longicalycinin A linear analogue 14 | PYFFL | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 82.36% Cell death at 100 µg/ml |
| dbacp07691 | Longicalycinin A cyclic analogue 14 | PYFFL | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 10.46 ± 0.0028 µg/ml |
| dbacp07692 | Longicalycinin A cyclic analogue 14 | PYFFL | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 10.92 ± 0.0021 µg/ml |
| dbacp07693 | Longicalycinin A cyclic analogue 14 | PYFFL | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 70.69% Cell death at 100 µg/ml |
| dbacp07694 | Longicalycinin A cyclic analogue 14 | PYFFL | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 52.38% Cell death at 100 µg/ml |
| dbacp07695 | Longicalycinin A linear analogue 3 | GYPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 9.77 ± 0.0007 µg/ml |
| dbacp07696 | Longicalycinin A linear analogue 3 | GYPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 11.4 ± 0 µg/ml |
| dbacp07697 | Longicalycinin A linear analogue 3 | GYPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 82.33% Cell death at 100 µg/ml |
| dbacp07698 | Longicalycinin A linear analogue 3 | GYPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 87.56% Cell death at 100 µg/ml |
| dbacp07699 | Longicalycinin A cyclic analogue 3 | GYPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 9.5 ± 0.0056 µg/ml |
| dbacp07700 | Longicalycinin A cyclic analogue 3 | GYPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 11.28 ± 0.0063 µg/ml |
| dbacp07701 | Longicalycinin A cyclic analogue 3 | GYPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 56.72% Cell death at 100 µg/ml |
| dbacp07702 | Longicalycinin A cyclic analogue 3 | GYPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 28.51% Cell death at 100 µg/ml |
| dbacp07703 | Longicalycinin A linear analogue 4 | AYPFG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 9.53 ± 0.0014 µg/ml |
| dbacp07704 | Longicalycinin A linear analogue 4 | AYPFG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 10.78 ± 0.0021 µg/ml |
| dbacp07705 | Longicalycinin A linear analogue 4 | AYPFG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 27.13% Cell death at 100 µg/ml |
| dbacp07706 | Longicalycinin A linear analogue 4 | AYPFG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 75.91% Cell death at 100 µg/ml |
| dbacp07707 | Longicalycinin A cyclic analogue 4 | AYPFG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 9.77 ± 0.007 µg/ml |
| dbacp07708 | Longicalycinin A cyclic analogue 4 | AYPFG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 11.33 ± 0.0035 µg/ml |
| dbacp07709 | Longicalycinin A cyclic analogue 4 | AYPFG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 71.1% Cell death at 100 µg/ml |
| dbacp07710 | Longicalycinin A cyclic analogue 4 | AYPFG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 52.49% Cell death at 100 µg/ml |
| dbacp07711 | Longicalycinin A linear analogue 5 | FSPFG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 8.99 ± 0.0014 µg/ml |
| dbacp07712 | Longicalycinin A linear analogue 5 | FSPFG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 10.97 ± 0.0049 µg/ml |
| dbacp07713 | Longicalycinin A linear analogue 5 | FSPFG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 76.72% Cell death at 100 µg/ml |
| dbacp07714 | Longicalycinin A linear analogue 5 | FSPFG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 91.52% Cell death at 100 µg/ml |
| dbacp07715 | Longicalycinin A cyclic analogue 5 | FSPFG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 9.45 ± 0.0056 µg/ml |
| dbacp07716 | Longicalycinin A cyclic analogue 5 | FSPFG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 9.98 ± 0.4256 µg/ml |
| dbacp07717 | Longicalycinin A cyclic analogue 5 | FSPFG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 41.37% Cell death at 100 µg/ml |
| dbacp07718 | Longicalycinin A cyclic analogue 5 | FSPFG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 97.74% Cell death at 100 µg/ml |
| dbacp07719 | Longicalycinin A linear analogue 6 | VYPIA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 10.98 ± 0.0014 µg/ml |
| dbacp07720 | Longicalycinin A linear analogue 6 | VYPIA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 12.31 ± 0.0063 µg/ml |
| dbacp07721 | Longicalycinin A linear analogue 6 | VYPIA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 38.64% Cell death at 100 µg/ml |
| dbacp07722 | Longicalycinin A linear analogue 6 | VYPIA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 49.33% Cell death at 100 µg/ml |
| dbacp07723 | Longicalycinin A cyclic analogue 6 | VYPIA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 17.34 ± 0.0014 µg/ml |
| dbacp07724 | Longicalycinin A cyclic analogue 6 | VYPIA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 10.2 ± 0.0021 µg/ml |
| dbacp07725 | Longicalycinin A cyclic analogue 6 | VYPIA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 51.79% Cell death at 100 µg/ml |
| dbacp07726 | Longicalycinin A cyclic analogue 6 | VYPIA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 27.61% Cell death at 100 µg/ml |
| dbacp07727 | Longicalycinin A linear analogue 7 | PYVFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 9.6 ± 0.0007 µg/ml |
| dbacp07728 | Longicalycinin A linear analogue 7 | PYVFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 9.78 ± 0.0212 µg/ml |
| dbacp07729 | Longicalycinin A linear analogue 7 | PYVFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 82.33% Cell death at 100 µg/ml |
| dbacp07730 | Longicalycinin A linear analogue 7 | PYVFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 84.17% Cell death at 100 µg/ml |
| dbacp07731 | Longicalycinin A cyclic analogue 7 | PYVFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 9.21 ± 0.0056 µg/ml |
| dbacp07732 | Longicalycinin A cyclic analogue 7 | PYVFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 12.11 ± 0.0035 µg/ml |
| dbacp07733 | Longicalycinin A cyclic analogue 7 | PYVFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 47.68% Cell death at 100 µg/ml |
| dbacp07734 | Longicalycinin A cyclic analogue 7 | PYVFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 22.86% Cell death at 100 µg/ml |
| dbacp07735 | Longicalycinin A linear analogue 8 | FYPVG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 10.35 ± 0.0014 µg/ml |
| dbacp07736 | Longicalycinin A linear analogue 8 | FYPVG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 12.88 ± 0.0014 µg/ml |
| dbacp07737 | Longicalycinin A linear analogue 8 | FYPVG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 15.35% Cell death at 100 µg/ml |
| dbacp07738 | Longicalycinin A linear analogue 8 | FYPVG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 88.01% Cell death at 100 µg/ml |
| dbacp07739 | Longicalycinin A cyclic analogue 8 | FYPVG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 9.12 ± 0.0007 µg/ml |
| dbacp07740 | Longicalycinin A cyclic analogue 8 | FYPVG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 12.67 ± 0.0028 µg/ml |
| dbacp07741 | Longicalycinin A cyclic analogue 8 | FYPVG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 36.85% Cell death at 100 µg/ml |
| dbacp07742 | Longicalycinin A cyclic analogue 8 | FYPVG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 29.87% Cell death at 100 µg/ml |
| dbacp07743 | Longicalycinin A linear analogue 9 | FYPFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 9.33 ± 0.0007 µg/ml |
| dbacp07744 | Longicalycinin A linear analogue 9 | FYPFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 10.44 ± 0.5536 µg/ml |
| dbacp07745 | Longicalycinin A linear analogue 9 | FYPFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 72.74% Cell death at 100 µg/ml |
| dbacp07746 | Longicalycinin A linear analogue 9 | FYPFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 1.59% Cell death at 100 µg/ml |
| dbacp07747 | Longicalycinin A cyclic analogue 9 | FYPFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 10.67 ± 0 µg/ml |
| dbacp07748 | Longicalycinin A cyclic analogue 9 | FYPFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 10.7 ± 0.0056 µg/ml |
| dbacp07749 | Longicalycinin A cyclic analogue 9 | FYPFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 73.98% Cell death at 100 µg/ml |
| dbacp07750 | Longicalycinin A cyclic analogue 9 | FYPFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 76.25% Cell death at 100 µg/ml |
| dbacp07751 | Longicalycinin A linear analogue 10 | FYPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 10.5 ± 0.0014 µg/ml |
| dbacp07752 | Longicalycinin A linear analogue 10 | FYPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 10.5 ± 0.0007 µg/ml |
| dbacp07753 | Longicalycinin A linear analogue 10 | FYPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 76.72% Cell death at 100 µg/ml |
| dbacp07754 | Longicalycinin A linear analogue 10 | FYPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 92.09% Cell death at 100 µg/ml |
| dbacp07755 | Longicalycinin A cyclic analogue 10 | FYPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 10.28 ± 0 µg/ml |
| dbacp07756 | Longicalycinin A cyclic analogue 10 | FYPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 11.56 ± 0.0028 µg/ml |
| dbacp07757 | Longicalycinin A cyclic analogue 10 | FYPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 72.06% Cell death at 100 µg/ml |
| dbacp07758 | Longicalycinin A cyclic analogue 10 | FYPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 71.27% Cell death at 100 µg/ml |
| dbacp07759 | Longicalycinin A linear analogue 11 | TVPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 9.56 ± 0.0021 µg/ml |
| dbacp07760 | Longicalycinin A linear analogue 11 | TVPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 11.67 ± 0.0014 µg/ml |
| dbacp07761 | Longicalycinin A linear analogue 11 | TVPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 70.28% Cell death at 100 µg/ml |
| dbacp07762 | Longicalycinin A linear analogue 11 | TVPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 88.47% Cell death at 100 µg/ml |
| dbacp07763 | Longicalycinin A cyclic analogue 11 | TVPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 10.36 ± 0 µg/ml |
| dbacp07764 | Longicalycinin A cyclic analogue 11 | TVPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 10.61 ± 0.0007 µg/ml |
| dbacp07765 | Longicalycinin A cyclic analogue 11 | TVPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 72.06% Cell death at 100 µg/ml |
| dbacp07766 | Longicalycinin A cyclic analogue 11 | TVPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 74.89% Cell death at 100 µg/ml |
| dbacp07767 | Longicalycinin A linear analogue 12 | FYPFI | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 11.32 ± 0.0014 µg/ml |
| dbacp07768 | Longicalycinin A linear analogue 12 | FYPFI | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 14.2 ± 0.0014 µg/ml |
| dbacp07769 | Longicalycinin A linear analogue 12 | FYPFI | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 12.06% Cell death at 100 µg/ml |
| dbacp07770 | Longicalycinin A linear analogue 12 | FYPFI | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 81.34% Cell death at 100 µg/ml |
| dbacp07771 | Longicalycinin A cyclic analogue 12 | FYPFI | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 12.37 ± 0.0014 µg/ml |
| dbacp07772 | Longicalycinin A cyclic analogue 12 | FYPFI | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 13.2 ± 0 µg/ml |
| dbacp07773 | Longicalycinin A cyclic analogue 12 | FYPFI | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 63.84% Cell death at 100 µg/ml |
| dbacp07774 | Longicalycinin A cyclic analogue 12 | FYPFI | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 52.72% Cell death at 100 µg/ml |
| dbacp07775 | Longicalycinin A cyclic analogue 15 | PYGFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 10.33 ± 0 µg/ml |
| dbacp07776 | Longicalycinin A cyclic analogue 15 | PYGFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 11.23 ± 0.0007 µg/ml |
| dbacp07777 | Longicalycinin A cyclic analogue 15 | PYGFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 52.33% Cell death at 100 µg/ml |
| dbacp07778 | Longicalycinin A cyclic analogue 15 | PYGFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 27.43% Cell death at 100 µg/ml |
| dbacp07779 | Longicalycinin A linear analogue 16 | FTPFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 11.1 ± 0.0007 µg/ml |
| dbacp07780 | Longicalycinin A linear analogue 16 | FTPFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 12.11 ± 0.0056 µg/ml |
| dbacp07781 | Longicalycinin A linear analogue 16 | FTPFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 15.76% Cell death at 100 µg/ml |
| dbacp07782 | Longicalycinin A linear analogue 16 | FTPFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 88.24% Cell death at 100 µg/ml |
| dbacp07783 | Longicalycinin A cyclic analogue 16 | FTPFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 12.1 ± 0.0007 µg/ml |
| dbacp07784 | Longicalycinin A cyclic analogue 16 | FTPFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 10.4 ± 0.0028 µg/ml |
| dbacp07785 | Longicalycinin A cyclic analogue 16 | FTPFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 42.33% Cell death at 100 µg/ml |
| dbacp07786 | Longicalycinin A cyclic analogue 16 | FTPFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 29.87% Cell death at 100 µg/ml |
| dbacp07787 | Longicalycinin A linear analogue 17 | FSPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 9.33 ± 0.0007 µg/ml |
| dbacp07788 | Longicalycinin A linear analogue 17 | FSPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 11.33 ± 0.0035 µg/ml |
| dbacp07789 | Longicalycinin A linear analogue 17 | FSPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 27.54% Cell death at 100 µg/ml |
| dbacp07790 | Longicalycinin A linear analogue 17 | FSPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 75.68% Cell death at 100 µg/ml |
| dbacp07791 | Longicalycinin A cyclic analogue 17 | FSPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 9.4 ± 0.0014 µg/ml |
| dbacp07792 | Longicalycinin A cyclic analogue 17 | FSPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 11.2 ± 0.0007 µg/ml |
| dbacp07793 | Longicalycinin A cyclic analogue 17 | FSPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 74.53% Cell death at 100 µg/ml |
| dbacp07794 | Longicalycinin A cyclic analogue 17 | FSPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 76.14% Cell death at 100 µg/ml |
| dbacp07795 | Longicalycinin A linear analogue 18 | FSPAG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 10.33 ± 0.0007 µg/ml |
| dbacp07796 | Longicalycinin A linear analogue 18 | FSPAG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 10.2 ± 0.0014 µg/ml |
| dbacp07797 | Longicalycinin A linear analogue 18 | FSPAG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 15.55% Cell death at 100 µg/ml |
| dbacp07798 | Longicalycinin A linear analogue 18 | FSPAG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 56.51% Cell death at 100 µg/ml |
| dbacp07799 | Longicalycinin A cyclic analogue 18 | FSPAG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 9.68 ± 0.0014 µg/ml |
| dbacp07800 | Longicalycinin A cyclic analogue 18 | FSPAG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 9.06 ± 0.0014 µg/ml |
| dbacp07801 | Longicalycinin A cyclic analogue 18 | FSPAG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 46.58% Cell death at 100 µg/ml |
| dbacp07802 | Longicalycinin A cyclic analogue 18 | FSPAG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colon Cancer | 22.8% Cell death at 100 µg/ml |
| dbacp07859 | HN-1 | FALGAVTKLLPSLLCMITRKC | Amolops hainanensis | Apoptosis induction and immune activation | MTT assay | MCF-7 | Breast Cancer | IC50 = 6.9 μM |
| dbacp07860 | HN-1 | FALGAVTKLLPSLLCMITRKC | Amolops hainanensis | Apoptosis induction and immune activation | MTT assay | A-549 | Lung Cancer | Not Available |
| dbacp07861 | HN-1 | FALGAVTKLLPSLLCMITRKC | Amolops hainanensis | Apoptosis induction and immune activation | MTT assay | SGC-7901 | Stomach Cancer | Not Available |
| dbacp07862 | HN-1 | FALGAVTKLLPSLLCMITRKC | Amolops hainanensis | Apoptosis induction and immune activation | MTT assay | MDA-MB-453 | Breast Cancer | Not Available |
| dbacp07863 | HN-1 | FALGAVTKLLPSLLCMITRKC | Amolops hainanensis | Apoptosis induction and immune activation | MTT assay | PC-3 | Prostate Cancer | Not Available |
| dbacp07864 | HN-1 | FALGAVTKLLPSLLCMITRKC | Amolops hainanensis | Apoptosis induction and immune activation | MTT assay | 4T1 | Breast Cancer | Not Available |
| dbacp07879 | Nubein6.8 | LKCNQLIPPFWKTCPKGKNLCYKMTMRAAPMVPVKRGCIDVCPKSSLLIKYMCCNTDKCN | Naja nubiae | DNA damage and apoptosis induction | MTT assay | A-375 | Skin Cancer | EC50 = 0.54 ± 0.04 μM |
| dbacp07880 | Nubein6.8 | LKCNQLIPPFWKTCPKGKNLCYKMTMRAAPMVPVKRGCIDVCPKSSLLIKYMCCNTDKCN | Naja nubiae | DNA damage and apoptosis induction | MTT assay | A-2780 | Ovarian Cancer | EC50 = 1.249 ± 0.06 μM |
| dbacp07881 | Nubein6.8 | LKCNQLIPPFWKTCPKGKNLCYKMTMRAAPMVPVKRGCIDVCPKSSLLIKYMCCNTDKCN | Naja nubiae | DNA damage and apoptosis induction | MTT assay | PANC-1 | Pancreatic Cancer | slight toxicity above 3.7 μM |
| dbacp07889 | H-58 | IKLSKKTKKNLKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | A-549 | Lung Cancer | IC50 = 0.62 ± 0.12 μM |
| dbacp07890 | H-58 | IKLSKKTKKNLKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | HCT-116 | Colon Cancer | IC50 = 1.29 ± 0.08 μM |
| dbacp07891 | H-58 | IKLSKKTKKNLKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | HepG-2 | Liver Cancer | IC50 = 2.13 ± 0.07 μM |
| dbacp07892 | H-57 | IKLSKKTKKNLKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | A-549 | Lung Cancer | IC50 = 0.62 ± 0.12 μM |
| dbacp07893 | H-57 | IKLSKKTKKNLKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | HCT-116 | Colon Cancer | IC50 = 1.29 ± 0.08 μM |
| dbacp07894 | H-57 | IKLSKKTKKNLKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | HepG-2 | Liver Cancer | IC50 = 2.13 ± 0.07 μM |
| dbacp07895 | H-18 | IKLSKKTKKNLKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | A-549 | Lung Cancer | IC50 = 0.89 ± 0.21 μM |
| dbacp07896 | H-18 | IKLSKKTKKNLKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | HCT-116 | Colon Cancer | IC50 = 1.11 ± 0.21 μM |
| dbacp07897 | H-18 | IKLSKKTKKNLKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | HepG-2 | Liver Cancer | IC50 = 1.61 ± 0.21 μM |
| dbacp07898 | H-21 | IKLSKS5TKKS5LKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | A-549 | Lung Cancer | IC50 = 3.26 ± 0.36 μM |
| dbacp07899 | H-21 | IKLSKS5TKKS5LKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | HCT-116 | Colon Cancer | IC50 = 3.05 ± 0.21 μM |
| dbacp07900 | H-21 | IKLSKS5TKKS5LKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | HepG-2 | Liver Cancer | IC50 = 1.50 ± 0.28 μM |
| dbacp07901 | H-20 | IKLSPS5TKKS5LKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | A-549 | Lung Cancer | IC50 = 2.10 ± 0.32 μM |
| dbacp07902 | H-20 | IKLSPS5TKKS5LKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | HCT-116 | Colon Cancer | IC50 = 2.63 ± 0.35 μM |
| dbacp07903 | H-20 | IKLSPS5TKKS5LKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | HepG-2 | Liver Cancer | IC50 = 4.93 ± 0.53 μM |
| dbacp07904 | H-19 | IKLSKETKKNLKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | A-549 | Lung Cancer | IC50 = 1.00 ± 0.36 μM |
| dbacp07905 | H-19 | IKLSKETKKNLKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | HCT-116 | Colon Cancer | IC50 = 1.78 ± 0.35 μM |
| dbacp07906 | H-19 | IKLSKETKKNLKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | HepG-2 | Liver Cancer | IC50 = 1.64 ± 0.36 μM |
| dbacp07907 | H-17 | IKLSKS5TKKS5LKKVLKGAIKGAIAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | A-549 | Lung Cancer | IC50 = 0.96 ± 0.33 μM |
| dbacp07908 | H-17 | IKLSKS5TKKS5LKKVLKGAIKGAIAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | HCT-116 | Colon Cancer | IC50 = 1.49 ± 0.45 μM |
| dbacp07909 | H-17 | IKLSKS5TKKS5LKKVLKGAIKGAIAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | HepG-2 | Liver Cancer | IC50 = 1.64 ± 0.47 μM |
| dbacp07910 | H-16 | IKLSPS5TKKS5LKKVLKGAIKGAIAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | A-549 | Lung Cancer | IC50 = 1.85 ± 0.31 μM |
| dbacp07911 | H-16 | IKLSPS5TKKS5LKKVLKGAIKGAIAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | HCT-116 | Colon Cancer | IC50 = 2.65 ± 0.35 μM |
| dbacp07912 | H-16 | IKLSPS5TKKS5LKKVLKGAIKGAIAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | HepG-2 | Liver Cancer | IC50 = 3.14 ± 0.46 μM |
| dbacp07913 | H-15 | IKLSKS5TKDS5LKKVLKGAIKGAIAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | A-549 | Lung Cancer | IC50 = 2.26 ± 0.24 μM |
| dbacp07914 | H-15 | IKLSKS5TKDS5LKKVLKGAIKGAIAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | HCT-116 | Colon Cancer | IC50 = 2.95 ± 0.25 μM |
| dbacp07915 | H-15 | IKLSKS5TKDS5LKKVLKGAIKGAIAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | HepG-2 | Liver Cancer | IC50 = 2.20 ± 0.27 μM |
| dbacp07916 | H-10 | IKLSPS5TKDS5LKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | A-549 | Lung Cancer | IC50 = 3.59 ± 0.12 μM |
| dbacp07917 | H-10 | IKLSPS5TKDS5LKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | HCT-116 | Colon Cancer | IC50 = 3.51 ± 0.37 μM |
| dbacp07918 | H-10 | IKLSPS5TKDS5LKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | HepG-2 | Liver Cancer | IC50 = 1.50 ± 0.21 μM |
| dbacp07919 | H-5 | IKLSPETKDNLKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | A-549 | Lung Cancer | IC50 = 7.35 ± 0.22 μM |
| dbacp07920 | H-5 | IKLSPETKDNLKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | HCT-116 | Colon Cancer | IC50 = 4.16 ± 0.21 μM |
| dbacp07921 | H-5 | IKLSPETKDNLKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | HepG-2 | Liver Cancer | IC50 = 2.82 ± 0.23 μM |
| dbacp07922 | H-2 | IKLSPS5TKDS5LKKVLKGAIKGAIAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | A-549 | Lung Cancer | IC50 = 4.26 ± 0.52 μM |
| dbacp07923 | H-2 | IKLSPS5TKDS5LKKVLKGAIKGAIAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | HCT-116 | Colon Cancer | IC50 = 3.54 ± 0.72 μM |
| dbacp07924 | H-2 | IKLSPS5TKDS5LKKVLKGAIKGAIAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | HepG-2 | Liver Cancer | IC50 = 1.60 ± 0.24 μM |
| dbacp07925 | oligopeptide 1 | AGAPGG | Sarcophyton glaucum | Selective cytotoxicity, DNA damage, apoptosis | MTT assay | HeLa | Cervical Cancer | EC50 = 8.6 mmol/L |
| dbacp07926 | Phylloseptin-PBa3 | FLSLIPHIVSGVAALANHL | Phyllomedusa burmeisteri | Membrane disruption, apoptosis, selective cytotoxicity | MTT assay | MDA-MB-435S | Breast Cancer | IC50 = 208 µM |
| dbacp07927 | Phylloseptin-PBa3 | FLSLIPHIVSGVAALANHL | Phyllomedusa burmeisteri | Membrane disruption, apoptosis, selective cytotoxicity | MTT assay | H-838 | Lung Cancer | Cell viability ~ 65% at 10-5 M |
| dbacp07928 | B11 | RIRDAIAHGYIVDKV | Litopenaeus vannamei hemocyanin-derived peptide | Mitochondrial dysfunction, caspase-dependent apoptosis | MTS assay | HeLa | Cervical Cancer | Decreased cell viability by 20% at 50 μg/mL |
| dbacp07929 | B11 | RIRDAIAHGYIVDKV | Litopenaeus vannamei hemocyanin-derived peptide | Mitochondrial dysfunction, caspase-dependent apoptosis | MTS assay | HepG-2 | Liver Cancer | Decreased cell viability by 23% at 50 μg/mL |
| dbacp07930 | B11 | RIRDAIAHGYIVDKV | Litopenaeus vannamei hemocyanin-derived peptide | Mitochondrial dysfunction, caspase-dependent apoptosis | MTS assay | EC-109 | Esophageal Cancer | Decreased cell viability by 13% at 50 μg/mL |
| dbacp07931 | myristoyl-CM4 | GRWKIFKKIEKVGQNIRDGIVKAGPAVAVVGQAATI | Bombyx mori | Cell penetration, Mitochondrial dysfunction, Apoptosis pathway activation | MTT assay | MCF-7 | Breast cancer | IC50 = 6 μM |
| dbacp07932 | myristoyl-CM4 | GRWKIFKKIEKVGQNIRDGIVKAGPAVAVVGQAATI | Bombyx mori | Enhanced binding, mitochondrial dysfunction, apoptosis | MTT assay | MDA-MB-231 | Breast cancer | IC50 = 4 μM |
| dbacp07933 | myristoyl-CM4 | GRWKIFKKIEKVGQNIRDGIVKAGPAVAVVGQAATI | Bombyx mori | Enhanced binding, mitochondrial dysfunction, apoptosis | MTT assay | MX-1 | Breast cancer | IC50 = 3 μM |
| dbacp07934 | LyeTx-I-b | IWLTALKFLGKNLGKLAKQQLAKL | Synthetic | Membrane disruption, necroptosis, limited apoptosis | MTT/Resazurin dye assay | U-87-MG | Brain Tumor | IC50 = 29.20 ± 7.96 µM |
| dbacp07935 | LyeTx-I-b | IWLTALKFLGKNLGKLAKQQLAKL | Synthetic | Membrane disruption, necroptosis, limited apoptosis | MTT/Resazurin dye assay | U-373-MG | Brain Tumor | IC50 = 20.94 ± 5.18 µM |
| dbacp07936 | LyeTx-I-b | IWLTALKFLGKNLGKLAKQQLAKL | Synthetic | Membrane disruption, necroptosis, limited apoptosis | MTT/Resazurin dye assay | SH-SY5Y | Brain Tumor | IC50 = 93.80 ± 2.17 µM |
| dbacp07937 | Pantinin-1 | GILGKLWEGFKSIV | Synthetic | Selective binding, membrane disruption, apoptosis | MTS assay | MDA-MB-231 | Breast Cancer | IC50 = 28.5 ± 1.0 µM |
| dbacp07938 | Pantinin-1 | GILGKLWEGFKSIV | Synthetic | Selective binding, membrane disruption, apoptosis | MTS assay | DU-145 | Prostate Cancer | IC50 = 47.5 ± 2.0 µM |
| dbacp07939 | Pantinin-2 | IFGAIWKGISSLL | Synthetic | Selective binding, membrane disruption, apoptosis | MTS assay | MDA-MB-231 | Breast Cancer | IC50 = 12.5 ± 1.0 µM |
| dbacp07940 | Pantinin-2 | IFGAIWKGISSLL | Synthetic | Selective binding, membrane disruption, apoptosis | MTS assay | DU-145 | Prostate Cancer | IC50 = 16.5 ± 1.0 µM |
| dbacp07941 | Pantinin-3 | FLSTIWNGIKSLL | Synthetic | Selective binding, membrane disruption, apoptosis | MTS assay | MDA-MB-231 | Breast Cancer | IC50 = 13.5 ± 2.0 µM |
| dbacp07942 | Pantinin-3 | FLSTIWNGIKSLL | Synthetic | Selective binding, membrane disruption, apoptosis | MTS assay | DU-145 | Prostate Cancer | IC50 = 17.3 ± 1.0 µM |
| dbacp07943 | TC22 | MTVVLLLIVLPLLGGVHSSGIL | Tribolium castaneum | ROS, p53, mitochondrial apoptosis activation | MTT assay | HeLa | Cervical Cancer | Fig 4a |
| dbacp07944 | TC22 | MTVVLLLIVLPLLGGVHSSGIL | Tribolium castaneum | ROS, p53, mitochondrial apoptosis activation | MTT assay | MCF-7 | Breast Cancer | Fig 4a |
| dbacp07951 | S-24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Synthetic Analogue of Ranatuerin-2PLx | R2PLx induces caspase-dependent apoptosis | MTT assay | PC-3 | Prostate Cancer | IC50 = 792.60 µM |
| dbacp07952 | S-24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Synthetic Analogue of Ranatuerin-2PLx | R2PLx induces caspase-dependent apoptosis | MTT assay | H-157 | Lung Cancer | IC50 = 58.18 µM |
| dbacp07953 | S-24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Synthetic Analogue of Ranatuerin-2PLx | R2PLx induces caspase-dependent apoptosis | MTT assay | MDA-MB-435S | Skin Cancer | IC50 = 179.00 µM |
| dbacp07954 | S-24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Synthetic Analogue of Ranatuerin-2PLx | R2PLx induces caspase-dependent apoptosis | MTT assay | U-251-MG | Brain Tumor | IC50 = 278.30 µM |
| dbacp07955 | S-24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Synthetic Analogue of Ranatuerin-2PLx | R2PLx induces caspase-dependent apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 316.90 µM |
| dbacp07985 | R-C16 | RGWFRAMRSIARFIARERLREHL | R-Lycosin-I | Fatty-acid modification enhances peptide apoptosis | CCK-8 assay | A-549 | Lung Cancer | IC50 ~ 5 µM |
| dbacp07986 | SmacN7-Arg8 fused peptide P4 | Ahx-AVPIAQK(KRRRRRRRRRE) | Synthetic | Apoptosis inducing | Cell Titer Blue Cell Viability assay | U-266 | Skin Cancer | Cell viability < 50% at 50 μM |
| dbacp07987 | SmacN7-Arg8 fused peptide P5 | Ahx-(KAVPIAQKE)RRRRRRRR | Synthetic | Apoptosis inducing | Cell Titer Blue Cell Viability assay | U-266 | Skin Cancer | Cell viability < 50% at 50 μM |
| dbacp07988 | SmacN7-Arg8 fused peptide P7 | Ahx-(KAVPIAQKE)GG(KRRRRRRRRE) | Synthetic | Apoptosis inducing | Cell Titer Blue Cell Viability assay | U-266 | Skin Cancer | Cell viability < 50% at 50 μM |
| dbacp08014 | Ec-LDP-hBD1 | MANCVVGYIGERCQYRDLKWWELRGGGGSGGGGSAPAFSVSPASGLSDGQSVSVSVSGAAAGETYYIAQCAPVGGQDACNPATATSFTTDASGAASFSFVVRKSYTGSTPEGTPVGSVDCATAACNLGAGNSGLDLGHVALTFGGGGGSGGGGSDHYNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCKLEHHHHHH | Synthetic | EGFR-targeted defensin induces mitochondrial apoptosis | CCK-8 assay | A-431 | Skin Cancer | IC50 = 1.8 μM |
| dbacp08015 | Ec-LDP-hBD1 | MANCVVGYIGERCQYRDLKWWELRGGGGSGGGGSAPAFSVSPASGLSDGQSVSVSVSGAAAGETYYIAQCAPVGGQDACNPATATSFTTDASGAASFSFVVRKSYTGSTPEGTPVGSVDCATAACNLGAGNSGLDLGHVALTFGGGGGSGGGGSDHYNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCKLEHHHHHH | Synthetic | EGFR-targeted defensin induces mitochondrial apoptosis | CCK-8 assay | A-549 | Lung Cancer | IC50 = 11.9 μM |
| dbacp08016 | Ec-LDP-hBD1 | MANCVVGYIGERCQYRDLKWWELRGGGGSGGGGSAPAFSVSPASGLSDGQSVSVSVSGAAAGETYYIAQCAPVGGQDACNPATATSFTTDASGAASFSFVVRKSYTGSTPEGTPVGSVDCATAACNLGAGNSGLDLGHVALTFGGGGGSGGGGSDHYNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCKLEHHHHHH | Synthetic | EGFR-targeted defensin induces mitochondrial apoptosis | CCK-8 assay | H-460 | Lung Cancer | IC50 = 5.19 μM |
| dbacp08017 | Ec-LDP-hBD1 | MANCVVGYIGERCQYRDLKWWELRGGGGSGGGGSAPAFSVSPASGLSDGQSVSVSVSGAAAGETYYIAQCAPVGGQDACNPATATSFTTDASGAASFSFVVRKSYTGSTPEGTPVGSVDCATAACNLGAGNSGLDLGHVALTFGGGGGSGGGGSDHYNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCKLEHHHHHH | Synthetic | EGFR-targeted defensin induces mitochondrial apoptosis | CCK-8 assay | PG-BE1 | Lung Cancer | IC50 = 31.3 μM |
| dbacp08089 | B1 | KKLFKKILKYLK | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | K-562 | Leukemia Cancer | IC50 = 17.9 ± 1.4 μM |
| dbacp08090 | B1 | KKLFKKILKYLK | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 15.7 ± 1.5 μM |
| dbacp08091 | B1 | KKLFKKILKYLK | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | MCF-7/ADM | Breast Cancer | IC50 = 18.2 ± 1.3 μM |
| dbacp08092 | B1 | KKLFKKILKYLK | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | K-562/ADM | Leukemia Cancer | IC50 = 19.1 ± 2.1 μM |
| dbacp08093 | B2 | KKLFKKILKYLKK | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | K-562 | Leukemia Cancer | IC50 = 33.6 ± 4.2 μM |
| dbacp08094 | B2 | KKLFKKILKYLKK | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 30.8 ± 3.4 μM |
| dbacp08095 | B2 | KKLFKKILKYLKK | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | MCF-7/ADM | Breast Cancer | IC50 = 36.1 ± 6.7 μM |
| dbacp08096 | B2 | KKLFKKILKYLKK | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | K-562/ADM | Leukemia Cancer | IC50 = 39.6 ± 5.7 μM |
| dbacp08097 | B3 | KKLFKKILKYLKKL | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | K-562 | Leukemia Cancer | IC50 = 47.4 ± 12.5 μM |
| dbacp08098 | B3 | KKLFKKILKYLKKL | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 25.3 ± 3.2 μM |
| dbacp08099 | B3 | KKLFKKILKYLKKL | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | MCF-7/ADM | Breast Cancer | IC50 = 28.4 ± 3.1 μM |
| dbacp08100 | B5 | LKKLFKKILKYLK | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | K-562 | Leukemia Cancer | IC50 = 26.5 ± 1.5 μM |
| dbacp08101 | B5 | LKKLFKKILKYLK | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 27.3 ± 2.4 μM |
| dbacp08102 | B5 | LKKLFKKILKYLK | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | MCF-7/ADM | Breast Cancer | IC50 = 28.2 ± 2.7 μM |
| dbacp08103 | B5 | LKKLFKKILKYLK | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | K-562/ADM | Leukemia Cancer | IC50 = 28.3 ± 2.3 μM |
| dbacp08104 | B6 | LKKLFKKILKYLKK | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | K-562 | Leukemia Cancer | IC50 = 19.2 ± 2.3 μM |
| dbacp08105 | B6 | LKKLFKKILKYLKK | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 18.4 ± 1.5 μM |
| dbacp08106 | B6 | LKKLFKKILKYLKK | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | MCF-7/ADM | Breast Cancer | IC50 = 20.7 ± 1.6 μM |
| dbacp08107 | B6 | LKKLFKKILKYLKK | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | K-562/ADM | Leukemia Cancer | IC50 = 22.7 ± 2.3 μM |
| dbacp08108 | B9 | KLKKLFKKILKY | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | K-562 | Leukemia Cancer | IC50 = 60.7 ± 5.4 μM |
| dbacp08109 | B9 | KLKKLFKKILKY | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 38.3 ± 2.5 μM |
| dbacp08110 | B9 | KLKKLFKKILKY | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | MCF-7/ADM | Breast Cancer | IC50 = 30.6 ± 5.7 μM |
| dbacp08111 | B9 | KLKKLFKKILKY | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | K-562/ADM | Leukemia Cancer | IC50 = 83.7 ± 5.3 μM |
| dbacp08112 | FR-15 | FRRFFKWFRRFFKFF | Synthetic | Proline-substituted AMP triggers mitochondrial apoptosis | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 3.15 μM |
| dbacp08113 | FR-15 | FRRFFKWFRRFFKFF | Synthetic | Proline-substituted AMP triggers mitochondrial apoptosis | MTT assay | HeLa | Cervical Cancer | IC50 = 4.9 μM |
| dbacp08114 | FR-15 | FRRFFKWFRRFFKFF | Synthetic | Proline-substituted AMP triggers mitochondrial apoptosis | MTT assay | DLD-1 | Colon Cancer | IC50 = 6.7 μM |
| dbacp08115 | FR-15 | FRRFFKWFRRFFKFF | Synthetic | Proline-substituted AMP triggers mitochondrial apoptosis | MTT assay | HepG-2 | Liver Cancer | IC50 = 2.5 μM |
| dbacp08116 | FR4P | FRRPFKWFRRFFKFF | Analogue of FR-15 | Proline-substituted AMP triggers mitochondrial apoptosis | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 6.3 μM |
| dbacp08117 | FR4P | FRRPFKWFRRFFKFF | Analogue of FR-15 | Proline-substituted AMP triggers mitochondrial apoptosis | MTT assay | HeLa | Cervical Cancer | IC50 = 7.7 μM |
| dbacp08118 | FR4P | FRRPFKWFRRFFKFF | Analogue of FR-15 | Proline-substituted AMP triggers mitochondrial apoptosis | MTT assay | DLD-1 | Colon Cancer | IC50 = 9.4 μM |
| dbacp08119 | FR4P | FRRPFKWFRRFFKFF | Analogue of FR-15 | Proline-substituted AMP triggers mitochondrial apoptosis | MTT assay | HepG-2 | Liver Cancer | IC50 = 2.5 μM |
| dbacp08120 | FR8P | FRRFFKWPRRFFKFF | Analogue of FR-15 | Proline-substituted AMP triggers mitochondrial apoptosis | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 6.4 μM |
| dbacp08121 | FR8P | FRRFFKWPRRFFKFF | Analogue of FR-15 | Proline-substituted AMP triggers mitochondrial apoptosis | MTT assay | HeLa | Cervical Cancer | IC50 = 10.5 μM |
| dbacp08122 | FR8P | FRRFFKWPRRFFKFF | Analogue of FR-15 | Proline-substituted AMP triggers mitochondrial apoptosis | MTT assay | DLD-1 | Colon Cancer | IC50 = 10.8 μM |
| dbacp08123 | FR8P | FRRFFKWPRRFFKFF | Analogue of FR-15 | Proline-substituted AMP triggers mitochondrial apoptosis | MTT assay | HepG-2 | Liver Cancer | IC50 = 4.2 μM |
| dbacp08124 | FR11P | FRRFFKWFRRPFKFF | Analogue of FR-15 | Proline-substituted AMP triggers mitochondrial apoptosis | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 7 μM |
| dbacp08125 | FR11P | FRRFFKWFRRPFKFF | Analogue of FR-15 | Proline-substituted AMP triggers mitochondrial apoptosis | MTT assay | HeLa | Cervical Cancer | IC50 = 11 μM |
| dbacp08126 | FR11P | FRRFFKWFRRPFKFF | Analogue of FR-15 | Proline-substituted AMP triggers mitochondrial apoptosis | MTT assay | DLD-1 | Colon Cancer | IC50 = 12.9 μM |
| dbacp08127 | FR11P | FRRFFKWFRRPFKFF | Analogue of FR-15 | Proline-substituted AMP triggers mitochondrial apoptosis | MTT assay | HepG-2 | Liver Cancer | IC50 = 4.8 μM |
| dbacp08128 | FR4,8P | FRRPFKWPRRFFKFF | Analogue of FR-15 | Proline-substituted AMP triggers mitochondrial apoptosis | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 15.4 μM |
| dbacp08129 | FR4,8P | FRRPFKWPRRFFKFF | Analogue of FR-15 | Proline-substituted AMP triggers mitochondrial apoptosis | MTT assay | HeLa | Cervical Cancer | IC50 = 13.8 μM |
| dbacp08130 | FR4,8P | FRRPFKWPRRFFKFF | Analogue of FR-15 | Proline-substituted AMP triggers mitochondrial apoptosis | MTT assay | DLD-1 | Colon Cancer | IC50 = 15.3 μM |
| dbacp08131 | FR4,8P | FRRPFKWPRRFFKFF | Analogue of FR-15 | Proline-substituted AMP triggers mitochondrial apoptosis | MTT assay | HepG-2 | Liver Cancer | IC50 = 5 μM |
| dbacp08132 | FR8,11P | FRRFFKWPRRPFKFF | Analogue of FR-15 | Proline-substituted AMP triggers mitochondrial apoptosis | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 27 μM |
| dbacp08133 | FR8,11P | FRRFFKWPRRPFKFF | Analogue of FR-15 | Proline-substituted AMP triggers mitochondrial apoptosis | MTT assay | HeLa | Cervical Cancer | IC50 = 18.9 μM |
| dbacp08134 | FR8,11P | FRRFFKWPRRPFKFF | Analogue of FR-15 | Proline-substituted AMP triggers mitochondrial apoptosis | MTT assay | DLD-1 | Colon Cancer | IC50 = 22 μM |
| dbacp08135 | FR8,11P | FRRFFKWPRRPFKFF | Analogue of FR-15 | Proline-substituted AMP triggers mitochondrial apoptosis | MTT assay | HepG-2 | Liver Cancer | IC50 = 15 μM |
| dbacp08136 | Laterosporulin10 (LS10) | ACVNQCPDAIDRFIVKDKGCHGVEKKYYKQVYVACMNGQHLYCRTEGGPCQL | Brevibacillus sp. strain SKDU10 | Apoptosis inducing | MTT assay | MCF-7 | Breast Cancer | 40% cytotoxicity at 5 μM concentration |
| dbacp08137 | Laterosporulin10 (LS10) | ACVNQCPDAIDRFIVKDKGCHGVEKKYYKQVYVACMNGQHLYCRTEGGPCQL | Brevibacillus sp. strain SKDU10 | Apoptosis inducing | LDH leakage assay | MCF-7 | Breast Cancer | >80% LDH release at 15 μM |
| dbacp08138 | Laterosporulin10 (LS10) | ACVNQCPDAIDRFIVKDKGCHGVEKKYYKQVYVACMNGQHLYCRTEGGPCQL | Brevibacillus sp. strain SKDU10 | Apoptosis inducing | MTT assay | HEK-293T | Renal Cancer | 20% cytotoxicity 5 μM concentration |
| dbacp08139 | Laterosporulin10 (LS10) | ACVNQCPDAIDRFIVKDKGCHGVEKKYYKQVYVACMNGQHLYCRTEGGPCQL | Brevibacillus sp. strain SKDU10 | Apoptosis inducing | MTT assay | HT-1080 | Fibrosarcoma | 20% cytotoxicity 5 μM concentration |
| dbacp08140 | Laterosporulin10 (LS10) | ACVNQCPDAIDRFIVKDKGCHGVEKKYYKQVYVACMNGQHLYCRTEGGPCQL | Brevibacillus sp. strain SKDU10 | Apoptosis inducing | MTT assay | HeLa | Cervical Cancer | 20% cytotoxicity 5 μM concentration |
| dbacp08141 | Laterosporulin10 (LS10) | ACVNQCPDAIDRFIVKDKGCHGVEKKYYKQVYVACMNGQHLYCRTEGGPCQL | Brevibacillus sp. strain SKDU10 | Apoptosis inducing | LDH leakage assay | HeLa | Cervical Cancer | ~80% LDH release at 15 μM |
| dbacp08142 | Laterosporulin10 (LS10) | ACVNQCPDAIDRFIVKDKGCHGVEKKYYKQVYVACMNGQHLYCRTEGGPCQL | Brevibacillus sp. strain SKDU10 | Apoptosis inducing | MTT assay | H-1299 | Lung Cancer | 80% cytotoxicity 10 μM concentration |
| dbacp08143 | MccJ25-18-4 | GGAGHVPEYFVGIGTPISFYG-WxEAAYQrFL | Synthetic | Apoptosis inducing | MTT assay | MCF-7 | Breast Cancer | IC50 = 14.2 ± 1.5 μM |
| dbacp08144 | MccJ25-18-4 | GGAGHVPEYFVGIGTPISFYG-WxEAAYQrFL | Synthetic | Apoptosis inducing | MTT assay | MDA-MB-435 | Breast Cancer | IC50 = 20.0 ± 0.5 μM |
| dbacp08145 | MccJ25-18-4 | GGAGHVPEYFVGIGTPISFYG-WxEAAYQrFL | Synthetic | Apoptosis inducing | MTT assay | MDA-MB-435-MDR | Breast Cancer | IC50 = 25.0 ± 0.5 μM |
| dbacp08146 | LfcinB-P13 | KCRRWLKRMKKLG | Synthetic analog of LFcinB | LfcinB-P13 induces liver cancer apoptosis | MTT assay | SMMC-7721 | Liver Cancer | IC50 = 41.8 µg/ml |
| dbacp08253 | Cecropin XJ | APEPRWKIFKKIEKMGRNIRDGIVKAGPAIEVLGSAKAIGK | Larvae of Bombyx mori | CecropinXJ induces apoptosis in HCC | MTT assay | Huh-7 | Liver Cancer | Cell viability = 50% at 50 µmol/l |